



(86) **Date de dépôt PCT/PCT Filing Date:** 2015/03/30
(87) **Date publication PCT/PCT Publication Date:** 2015/10/08
(85) **Entrée phase nationale/National Entry:** 2016/09/23
(86) **N° demande PCT/PCT Application No.:** US 2015/023284
(87) **N° publication PCT/PCT Publication No.:** 2015/153425
(30) **Priorité/Priority:** 2014/04/03 (US61/974,722)

(51) **Cl.Int./Int.Cl. A61K 39/215** (2006.01),
A61P 31/14 (2006.01), **A61P 37/04** (2006.01),
C07K 14/165 (2006.01), **C12N 15/50** (2006.01),
C12N 7/00 (2006.01), **C12N 7/04** (2006.01)
(71) **Demandeur/Applicant:**
BOEHRINGER INGELHEIM VETMEDICA, INC., DE
(72) **Inventeurs/Inventors:**
HERNANDEZ, LUIS ALEJANDRO, US;
IYER, ARUN V., US;
JORDAN, DIANNA M. MURPHY, US;
PATTERSON, ABBY RAE, US;
ROOF, MICHAEL B., US;
VAUGHN, ERIC MARTIN, US;

(54) **Titre : VACCIN CONTRE LE VIRUS DE LA DIARRHEE EPIDEMIQUE PORCINE**
(54) **Title: PORCINE EPIDEMIC DIARRHEA VIRUS VACCINE**

(57) **Abrégé/Abstract:**

The present invention relates to a vaccine for protecting a pig against diseases associated with porcine epidemic diarrhea virus. The vaccine commonly includes inactivated/killed PEDV (e.g., chemically inactivated PED virus), and/or recombinant PEDV antigen and an adjuvant. Methods for protecting pigs against diseases associated with PEDV and methods of producing the porcine epidemic diarrhea virus vaccine are also provided.



(72) **Inventeurs(suite)/Inventors(continued):** VICTORIA, JOSEPH GILBERT, US

(74) **Agent:** LOOPER, YWE J.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 October 2015 (08.10.2015)

(10) International Publication Number
WO 2015/153425 A1

(51) International Patent Classification:
A61K 39/215 (2006.01) C12N 7/00 (2006.01)
C07K 14/165 (2006.01) A61K 39/00 (2006.01)

(21) International Application Number:
PCT/US2015/023284

(22) International Filing Date:
30 March 2015 (30.03.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/974,722 3 April 2014 (03.04.2014) US

(71) Applicant: BOEHRINGER INGELHEIM VET-MEDICA, INC. [US/US]; 2621 North Belt Highway, St. Joseph, Missouri 64506 (US).

(72) Inventors: HERNANDEZ, Luis Alejandro; c/o VP, IP, Legal, Boehringer Ingelheim USA Corp., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368 (US). IYER, Arun V.; c/o VP, IP Legal, Boehringer Ingelheim USA Corp., 900 Ridgebury Rd., P.O. Box 368, Ridgefield, Connecticut 06877-0368 (US). JORDAN, Dianna M. Murphy; c/o VP, IP Legal, Boehringer Ingelheim USA Corp., 900 Ridgebury Rd., P.O. Box 368, Ridgefield, Connecticut 06877-0368 (US). PATTERSON, Abby Rae; c/o VP, IP Legal, Boehringer Ingelheim USA Corp., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368 (US). ROOF, Michael B.; c/o VP, IP Legal, Boehringer Ingelheim USA Corp., 900 Ridgebury Rd., P.O. Box 368, Ridgefield, Connecticut 06877-0368 (US). VAUGHN, Eric Martin; c/o VP, IP Legal, Boehringer Ingelheim USA Corp., 900 Ridgebury Rd., P.O. Box 368,

Ridgefield, Connecticut 06877-0368 (US). VICTORIA, Joseph Gilbert; c/o VP, IP Legal, Boehringer Ingelheim USA Corp., 900 Ridgebury Rd., P.O. Box 368, Ridgefield, Connecticut 06877-0368 (US).

(74) Agents: MORRIS, Michael P. et al.; BOEHRINGER INGELHEIM PHARMACEUTICALS, INC., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: PORCINE EPIDEMIC DIARRHEA VIRUS VACCINE

(57) Abstract: The present invention relates to a vaccine for protecting a pig against diseases associated with porcine epidemic diarrhea virus. The vaccine commonly includes inactivated/killed PEDV (e.g., chemically inactivated PED virus), and/or recombinant PEDV antigen and an adjuvant. Methods for protecting pigs against diseases associated with PEDV and methods of producing the porcine epidemic diarrhea virus vaccine are also provided.

WO 2015/153425 A1

PORCINE EPIDEMIC DIARRHEA VIRUS VACCINE

SEQUENCE LISTING

[0001] This application contains a sequence listing in accordance with 37 C.F.R. 1.821 – 1.825. The sequence listing accompanying this application is hereby incorporated by reference in its entirety.

BACKGROUND OF THE INVENTION

Field of the Invention:

[0002] The present invention relates to a porcine epidemic diarrhea virus (PEDV) vaccine specific to the isolates currently endemic in the United States which are capable of reducing clinical signs of disease caused by PEDV. Due to the high mortality (up to 100%) in less than 10 day old piglets, the disease is of economic concern to the U.S. swine industry.

Description of the Related Art:

[0003] The porcine epidemic diarrhea virus is an enveloped, positive-sense single-stranded RNA virus that causes acute diarrhea, vomiting, and dehydration in pigs. It was first identified in Europe but has become increasingly problematic in many Asian countries, including Korea, China, Japan, the Philippines, and Thailand. In April of 2013, PEDV emerged in U.S. swine in the Midwest, swiftly spreading across the country. By October 2013, PEDV was detected in swine herds in 18 States. The economic impact of PEDV infection has already been substantial. North American isolates of PEDV have been identified (Huang, et al. 2013; Stevenson et al. 2013), however no fully licensed vaccine is commercially available in the United States. Accordingly, there is a continuing need to develop vaccines capable of protecting pigs against disease associated with PEDV. It would be advantageous to develop a vaccine that is effective against emerging North American PEDV strains which could be administered via a mucosal route (oral or intranasal) as well as via parenteral methods (e.g., intramuscularly, subcutaneously or intravenously).

[0004] PEDV is a member of the subfamily *Coronavirinae* of genus *Alphacoronavirus* (Bridgen et al. 1993) and was first identified in England in 1971 and

later in other countries, such as Belgium, China, Hungary, Italy, Japan, Korea, and Thailand (Oldham J. 1972; Pensaert and De Bouck P. 1978; Chen et al. 2008; Nagy et al. 1996; Martelli et al. 2008; Takahashi et al. 1983; Chae et al. 2000; and Puranaveja et al. 2009). Other members of this family include Porcine Respiratory Coronavirus (PRCV), Hemagglutinating Encephalomyelitis Coronavirus (PHE), and Transmissible Gastroenteritis Virus (TGEV). Although PEDV and TGEV viruses are related and the clinical signs are very similar, there is no immune cross-protection.

[0005] PEDV is an enveloped virus possessing approximately a 28 kb, positive-sense, single stranded RNA genome, with a 5' cap and a 3' polyadenylated tail. (Pensaert and De Bouck P. 1978). The genome comprises a 5' untranslated region (UTR), a 3' UTR, and at least seven open reading frames (ORFs) that encode four structural proteins (spike (S), envelope (E), membrane (M), and nucleocapsid (N)) and three non-structural proteins (replicases 1a and 1b and ORF3); these are arranged on the genome in the order 5' –replicase (1a/1b)-S-ORF3-E-M-N-3' (Oldham J. 1972; and Bridgen et al. 1993). The first three emergent North American PEDV genomic sequences characterized, Minnesota MN (GenBank: KF468752.1), Iowa IA1 (GenBank: KF468753.1), and Iowa IA2 (GenBank: KF468754.1), have the same size of 28,038 nucleotides (nt), excluding the polyadenosine tail and share the genome organization with the prototype PEDV CV777 strain (GenBank: AF353511.1). These three North American PEDV sequences shared 99.8 to 99.9% nucleotide identities. In particular, strains MN and IA2 had only 11 nucleotide differences across the entire genome.

[0006] The PEDV S protein is a type I glycoprotein composed of 1,383 amino acids (aa). The S protein can be divided into S1 (1-789 aa) and S2 (790-1,383 aa) domains based on its homology with S protein of other coronaviruses (Chang et al; 2002; Cruz et al, 1994; Godet, et al 1994; Jackwood et al. 2001; Sturman and Holmes; 1984; and Sun et al. 2008). The S protein in coronaviruses is a surface antigen, where it plays a role in regulating interactions with host cell receptor glycoproteins to mediate viral entry, and stimulating induction of neutralizing antibodies in the natural host. Thus the S glycoprotein is a primary target for the development of effective vaccines against PEDV.

[0007] The PEDV M protein is the most abundant envelope component playing an important role in the viral assembly process and also induces antibodies that neutralize the virus. Likewise the PEDV N protein, which binds to virion RNA providing a structural basis for the nucleocapsid, may also be important for induction of cell-mediated immunity (Saif, L. 1993).

[0008] The only accessory gene in PEDV is ORF3. While accessory genes are generally maintained in field strains, alteration of ORF3 is thought to influence virulence; cell culture adaptation has been used to alter the ORF3 gene in order to reduce virulence (Song et al. 2003). In fact, through investigation of the ORF3 gene, researchers have charted the emergence of new genogroups of PEDV in immunized swine herds in China since 2006. Phylogenic studies of these strains and the geographical reemergence of PEDV in China have demonstrated that those field strains causing devastating enteric disease differ genetically in ORF3 from the European strains and vaccine strains (Park et al. 2011).

[0009] It is well know that different strains of PEDV do exist with varying levels of virulence. During the 1980s and 1990s, PEDV was prevalent throughout Europe, in countries such as Belgium, England, Germany, France, the Netherlands, and Switzerland. The frequency of reported cases in Europe subsequently tapered off and/or the disease caused by PEDV was not of sufficient economic importance to start commercial development of a vaccine (Song and Park 2012). While outbreaks of PEDV have been documented in China since the 1980s, variant strains of PEDV emerging since 2010 associated with large-scale outbreaks of diarrhea have been more acute and severe. Thus the trial of vaccine development was mainly accomplished in Asian countries (Song and Park 2012). Variants emerging since 2010 have been reported as having 80-90% morbidity and 50-90% mortality in suckling piglets (Bi et al. 2012; Pan et al. 2012; and Li et al. 1012). Recent evidence suggests that the emerging virulent forms of PEDV in China may be a result of evolution of the live vaccine strains (Chen et al. 2010).

[0010] As an enteric disease affecting the pig's intestine, PEDV spreads via fecal-oral exposure. Contaminated trucks and equipment are frequent sources of infection to naïve animals. The clinical signs of PEDV infection are similar to transmissible gastroenteritis virus (TGEV) infection (Pijpers et al. 1993). In pigs three weeks of age and younger, clinical signs (including acute watery, diarrhea, vomiting, and dehydration) can be seen as soon as 24 hours after PEDV

infection leading to to 100% mortality.can appear . PEDV-infected feeder and grower pigs, as well as sows and boars, can develop diarrhea and vomiting. The animals can also show signs of anorexia and can be lethargic. The full impact on older pigs is yet to be determined, but reduced feed efficiency, additional days to market, and the susceptibility of infected animals to secondary infections is likely. For sows, reduced body condition may negatively impact reproductive performance. Reports have indicated that there are signs that PEDV could become endemic in North American herds, resulting in persistent diarrhea and other challenges.

[0011] The gross and histological changes in the gut of animals infected with PEDV are similar in the United States as those observed in China; essentially the virus destroys the villi of a pig's intestine so that there is a failure to absorb nutrients. Huang et al. 2012 reported that animals succumbing to the disease in the Minnesota and Iowa outbreaks had gross pathological lesions confined to the small intestine and that the small intestine was characterized by thin translucent walls distended with yellow fluid. Histological evaluations revealed regions of small intestines with villus blunting and fusion and minimal lymphoblastic infiltration of the villi of the lamia propria.

[0012] Huang et al. 2013 characterized three different strains of PEDV from outgoing outbreaks in the United States – one from Minnesota and two from Iowa, designated MN (GenBank accession No: KF468752) and IA1 (GenBank accession No: KF468753) and IA2 (GenBank accession No: KF48754), respectively. Huang's phylogenic survey grouped PEDV strains as falling into two distinct genogroups, designated genogroup 1 (G1) and genogroup 2 (G2). The significant changes in the N-terminal domain (NTD) of the spike gene differentiated genogroup 1 and 2. Huang et al. 2013 suggests that the second deletion region (DR2) in the N-terminal domain (NTD) appears to have a higher degree of antigenic change than DR1, suggesting that the emerging North American strains may be less “antigenically” related to the G1a vaccine strains.

[0013] Genogroup 1 includes at least three clusters 1a, 1b, and R. Subgroup 1a includes the early European, Chinese, and Korean isolates, e.g., prototype CV777 strain (Belgium, 1978, GenBank: AF353511.1) and strains LZC (Gansu, China, 2006; GenBank: EF185992) and SM98 (Korea, 1998; GenBank: GU937797.1). Subgroup 1b contains five strains—one from South

Korea (the DR13 attenuated vaccine strain, GenBank: JQ023162.1) and the others from China linked by the common “genetic signature” 8-aa deletion in nsp3 and the large ORF3 deletion at the C terminus. Group “R” is associated with recombinants of the other genogroups. However, the newly emergent PEDV strains, including those arising in China since 2010 and in North America since 2013, belong to genogroup G2a. The Chinese strain AH2012 (GenBank accession no: KC210145) and the North American strains share several unique nucleotides changes and are clustered together in genogroup 2a. Nucleotide identity to AH2012 for strains MN and IA2 was 99.6% and for strain IA1 was 99.5% . Researchers have speculated that an AH2012-like virus was possibly transmitted to the eastern China regions and then transported to the United States and is most likely the closest ancestor to the North American strains. Members of the genogroup 2a share only approximately 96.9% similarity to the prototype PEDV strain CV777 of genogroup 1a (Bridgen, et al. 1993; Huang et al. 2013; GenBank: AF353511.1). As such, the attenuated PEDV vaccines based on the historical CV777-derived G1a strains or DR13-derived G1b strains may be antigenically less related to the newly emergent Chinese and North American G2a PEDV strains and therefore may be poor vaccine candidates.

[0014] A closely related North American isolate US/Colorado/2013 (GenBank Accession No: KF272920.1) has also been reported by Marthaler et al, 2013. Like the North American isolates above, the complete PEDV genome of CO/13 has a nucleotide identity of 96.5 to 99.5% with other complete PEDV genomes available in GenBank, with the highest nucleotide identity (99.5%) with Chinese strain AH2012 (GenBank Accession No. KC210145). It is a member of the 2a genogroup. Comparison of the complete genome of CO/13 to that of PEDV reference strain CV777, demonstrates that CO/13 contains a 1-nt insertion (at position 48) and deletions of 5 nucleotides in the 5' UTR (at positions 73 and 83 to 86). This North American virus exhibits increased divergence within S1 at genomic positions 20,696 and 21,125 sharing only 82% nucleotide identity with several insertions/deletions.

[0015] Several PEDV vaccines, which differ in their genomic sequence, mode of delivery, and efficacy, have been developed. A cell culture adaptation of the European CV777 strain has been used in Asian countries where the PEDV outbreaks have been severe. These have been in use since the 1990s.

[0016] In the early 1980s Japanese researchers isolated a causative PED virus strain 83P-5 from the diarrhea of an infected pig. Kusanagi et al. 1989 isolated and adapted the strain in Vero cells. An attenuated virus vaccine of cell culture adapted PEDV (P-5V) (83P-5) has been used in Japan in sows since 1997. The 100th-passaged 83P-5 strain was licensed for use as an attenuated PEDV vaccine in Japan by Nisseiken Co., Ltd. (Sato et al. 2011). It has been reported that adaptation and attenuation of the 83P-5 strain showed mutations in the extra-cellular portion of the S protein with sequence similarity to that of the attenuated DR13 strain (Sato et al. 2011; See Strain 83P-5 Spike gene sequence at 100th passage, GenBank: AB548621.1). Although this later Japanese vaccine is considered efficacious, not all sows were able to pass immunity to their piglets (Usami et al. 1998). The Japanese strains and the European strains are members of genogroup G1a or G1b. As discussed above these attenuated vaccine strains are less related to the divergent North American strains than the newly emergent Chinese strains of genogroup 2a.

[0017] Oral vaccination with an attenuated Korean PEDV strain, DR13 (passage level 100) (GenBank: JQ023162.1), a member of genogroup G1b, has been shown to be efficacious as a vaccine. The viral strain was licensed and used as an oral vaccine in South Korea since 2004, and registered and commercialized in the Philippines in 2011 (Song and Park 2012). However, it has been reported that attenuated DR13 does not significantly alter the duration of virus shedding in challenged piglets – an indication that immune protection is incomplete. Moreover, oral immunization with highly attenuated PEDV only conferred protection at very high doses of vaccine (Song and Park 2012).

[0018] Other known vaccines include SUISHOT® PT-100 (ChoongAng Vaccine Laboratories, South Korea) a combination killed PEDV and TGEV vaccine, and SUISHOT® PED a killed PEDV vaccine. The strain and subtypes offered through ChoonAng Vaccine Laboratories are unknown. Also Komipharm International Co., another South Korean company, offers a series of killed, live, and combination vaccines marketed under the tradename PRO-VAC® which include the PEDV strain SM98P of genogroup G1a. Qilu Animal Health Products Factory of China, also markets a combination killed vaccine in China containing PEDV and TGEV whose strain and subtypes are unknown.

[0019] Therefore, what is needed is a PEDV vaccine specific to the isolates currently endemic in North America which is capable of reducing the clinical signs of disease caused by PEDV, and inducing protective immunity in immunized animals, including the reduction of viral shedding in immunized animals.

SUMMARY OF THE INVENTION

[0020] The present invention provides immunogenic compositions, vaccines, and related methods that overcome deficiencies in the art. The present invention relates to immunogenic compositions which include inactivated/killed and/or recombinant forms of an enveloped (+) single-stranded RNA virus, porcine epidemic diarrhea virus, or PEDV. In particular, the application provides a vaccine for protecting pigs against diseases associated with North American isolates of PEDV. The present PEDV isolate BI1251-125-10 (herein referred to as “125-10”) (SEQ ID NO:1 and SEQ ID NO:15) is a virulent North American RNA virus strain with a genetic profile similar to those of other North American PEDVs reported of genogroup 2a.

[0021] Immunogenic compositions and vaccines of the invention comprise inactivated/killed PEDV (e.g., chemically inactivated PEDV isolate 125-10 (SEQ ID NO:1 and SEQ ID NO:15)) and typically also includes an adjuvant. The vaccine may also include other components, such as preservative(s), antimicrobial agents, stabilizer(s), for example a stabilizer that can increase the shelf-life of the vaccine, emulsions, and antigens against other porcine pathogens.

[0022] Immunogenic compositions and vaccines of the invention comprise a Spike antigen, expressed in one non-limiting example in insect cells via a recombinant baculovirus expressing a modified PEDV Spike protein (e.g., modified Spike nucleic acid sequence (SEQ ID NO:8) encoding amino acid sequence (SEQ ID NO: 9)) and typically also includes an adjuvant. The vaccine may also include other components, such as preservative(s), stabilizer(s) and antigens against other porcine pathogens.

[0023] A preferred spike nucleic acid sequence suitable for use in the invention is a polynucleotide encoding a Spike polypeptide, said polynucleotide having at least at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, more preferably at least 90%, 91%, 92%,

93%, or 94%, and most preferably at least 95%, 96%, 96.1%, 96.2%, 96.3%, 96.4%, 96.5%, 96.6%, 96.7%, 96.8%, 96.9%, 97%, 97.1%, 97.2%, 97.3%, 97.4%, 97.5%, 97.6%, 97.7%, 97.8%, 97.9%, 98%, 98.1%, 98.2%, 98.3%, 98.4%, 98.5%, 98.6%, 98.7%, 98.8%, 98.9%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 99.99% sequence identity to SEQ ID NO: 2, 6, 8, and/or 13. “As used herein, it is in particular understood that the term “sequence identity to SEQ ID NO:X” or “identical SEQ ID NO:X”, respectively, is equivalent to the term “sequence identity with the sequence of SEQ ID NO:X over the length of SEQ ID NO: X” or “identical to the sequence of SEQ ID NO:X over the length of SEQ ID NO: X”, respectively, wherein in this context “X” is any integer selected from 1, 2, 6, 8, 13, and 15.”

[0024] A preferred spike polypeptide suitable for use in the invention is the polypeptide having the sequence set out in SEQ ID NO:3, 7, 9 and/or 14 having at least 80% homology with SEQ ID NO:3, 7, 9 and/or 14, for example at least 85% homology with SEQ ID NO:3, 7, 9 and/or 14, such as a least 85% homology with SEQ ID NO:3, 7, 9 and/or 14, such as at least 90% homology with SEQ ID NO:3, 7, 9 and/or 14, for example at least 95%, at least 98% or at least 99% homology with SEQ ID NO:3, 7, 9 and/or 14.

[0025] The terms “vaccine” and “immunogenic composition” are defined herein in a broad sense to refer to any type of biological agent in an administrable form capable of stimulating an immune response in an animal inoculated with the vaccine. Vaccines in general may be based on either the virus itself (e.g, killed/inactivated or attenuated) or an immunogenic (antigenic) component of the virus. In one embodiment of the invention, the vaccine (immunogenic composition) preferably includes the viral agent in a killed/inactivated form or an antigenic portion of the virus presented as a sub-unit vaccine. Herein, the term “protection” when used in reference to a vaccine refers to the amelioration (either partial or complete) of any of the symptoms associated with the disease or condition in question. Thus, protection of pigs from PEDV by the present vaccines generally results in a diminishing of virus shedding and/or one or more of the clinical symptoms associated with infection by PEDV (e.g., acute watery diarrhea, acute vomiting, dehydration, anorexia, lethargy, depression, and high mortality in pigs less than 10 days old).

[0026] Those of skill in the art will understand that the compositions used herein may incorporate known injectable, physiologically acceptable sterile solutions. For preparing a ready-to-use solution for parenteral injection or infusion, aqueous isotonic solutions, e.g. saline or plasma protein solutions, are readily available. In addition, the immunogenic and vaccine compositions of the present invention can include veterinary-acceptable carriers, diluents, isotonic agents, stabilizers, or adjuvants.

[0027] Methods of the invention include, but are not limited to, a method of provoking an immune response against a PEDV infection in a subject comprising the step of administering to the subject an immunogenic composition comprising an inactivated/killed PEDV, attenuated PEDV, and/or Spike antigen. Preferably, the immune response is provoked against more than one serotype, or strain of PEDV. Compositions of the invention may be used to prevent a PEDV infection. Preferably, such immune response reduces the incidence of or severity of one or more clinical signs associated with or caused by the infection with one or more PEDV serotypes.

[0028] Herein, suitable subjects and subjects in need to which compositions of the invention may be administered include animals in need of prophylactic treatment for a viral associated infection, disease, or condition. Animals in which the immune response is stimulated by use of compositions or methods of the invention include livestock, such as swine, bovines, poultry (e.g., chickens, ducks, geese, or turkeys) goats, and sheep, and domestic animals, such as mice, rabbits, dogs, cats, and horses. Preferred animals include porcine, murids, equids, lagomorphs, and bovids. Most preferably, an immune response is stimulated in pigs.

[0029] The invention also provides a method of reducing the incidence of or severity of one or more clinical signs associated with or caused by PEDV infection, comprising the step of administering an immunogenic composition of the invention that comprises inactivated/killed PEDV vaccine and/or in combination with a Spike antigen as provided herewith and preferably a carrier molecule, such that the incidence of or the severity of a clinical sign of the PEDV infection is reduced by at least 10%, preferably at least 20%, even more preferred at least 30%, even more preferred at least 50%, even more preferred at least 70%, most preferred 100% relative to a subject that has not received the immunogenic composition as provided herewith. Such clinical signs include watery diarrhea, vomiting, and dehydration. Any of these clinical

signs may result from an infection with PEDV having the genogroup of 2a or any other PEDV genogroup including G1a, G1b, or G2b

[0030] In one embodiment, the present immunogenic compositions include a chemically inactivated form of PEDV. Vaccines which include chemically inactivated PEDV (SEQ ID NO:1 or SEQ ID NO:15) virus are particularly desirable. A variety of chemical inactivating agents known to those skilled in the art may be employed to inactivate the virus. Ethylenimine and related derivatives, such as binary ethylenimine (“BEI”) and acetythylenimine, are examples of suitable chemical inactivating agents for use in inactivating the PED virus. Other chemical inactivating agents, e.g., beta-propiolactone or aldehydes (such as formaldehyde and glutaraldehyde), can also be used to inactivate the virus.

[0031] The present immunogenic compositions and/or vaccines generally include an adjuvant which desirably may have bioadhesive properties, particularly where the virus is designed to be capable of intranasal administration. Examples of suitable adjuvants include cross-linked olefinically unsaturated carboxylic acid polymers, such as cross-linked acrylic acid polymers. As used herein the term “cross-linked acrylic acid polymer” refers to polymer and copolymers formed from a monomer mixture which includes acrylic acid as the predominant monomer in the mixture. Examples of suitable cross-linked acrylic acid polymers include those commercially available under the tradenames CARBOPOL® 934P and CARBOPOL® 971 (available from B.F.Goodrich Co., Cleveland, Ohio). One particularly suitable adjuvant for use in the present vaccines is a cross-linked acrylic acid polymer having a Brookfield viscosity of no more than about 20,000 cPs (as measured at 20 rpm as a 1.0 wt. % aqueous solution at pH 7.5). Where a bioadhesive adjuvant is desired, it may be advantageous to utilize an adjuvant which has a bioadhesive property of at least about 50 dynes/cm² as measured between two pieces of freshly excised rabbit stomach tissue (as determined by the procedure described in U.S. Pat. No. 4,615,697).

[0032] The present invention also relates to a method of immunizing a subject, comprising administering to a subject any of the immunogenic compositions as described herein.

[0033] The term "immunizing" relates to an active immunization by the administration of an immunogenic composition to a subject to be immunized, thereby causing an immunological response against the antigen included in such immunogenic composition.

[0034] Preferably, immunization results in lessening of the incidence of the particular PEDV infection in a herd or in the reduction in the severity of clinical signs caused by or associated with the particular PEDV infection.

[0035] Further, the immunization of a subject in need with the immunogenic compositions as provided herewith, results in preventing infection of a subject by PEDV infection. Even more preferably, immunization results in an effective, long-lasting, immunological-response against PEDV infection. It will be understood that the said period of time will last more than 2 months, preferably more than 3 months, more preferably more than 4 months, more preferably more than 5 months, more preferably more than 6 months. It is to be understood that immunization may not be effective in all subjects immunized.

[0036] Preferably, a herd of subjects is envisaged in this context which normally, i.e. without immunization, would develop clinical signs normally caused by or associated with a PEDV infection. Whether the subjects of a herd are effectively immunized can be determined without further ado by the person skilled in the art. Preferably, the immunization shall be effective if clinical signs in at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, still more preferably in at least 95% and most preferably in 100% of the subjects of a given herd are lessened in incidence or severity by at least 10%, more preferably by at least 20%, still more preferably by at least 30%, even more preferably by at least 40%, still more preferably by at least 50%, even more preferably by at least 60%, still more preferably by at least 70%, even more preferably by at least 80%, still more preferably by at least 90%, still more preferably by at least 95% and most preferably by 100% in comparison to subjects that are either not immunized or immunized with an immunogenic composition that was available prior to the present invention but subsequently infected by the particular PEDV.

[0037] Methods for preventing clinical signs caused by PEDV in a subject in need, or methods of protecting pigs against diseases associated with PEDV include administering an immunogenic composition and/or vaccine containing inactivated /killed PEDV and/or Spike

antigen to the pigs. The vaccine can be administered using a variety of methods including intranasal, oral and/or parenteral (e.g., intramuscular) administration. In one embodiment of the method, for example, the inactivated PEDV containing vaccine is administered intramuscularly one or more times (e.g., at intervals of 2–4 weeks). In another embodiment of the method, for example, the inactivated PEDV containing vaccine is administered orally one or more times (e.g., at intervals of 2–4 weeks). In an alternative embodiment oral administration can be followed by and/or precede administration of the vaccine at least once, intramuscularly (e.g., 2–4 weeks after and/or before the parenteral administration of vaccine). Ideally, all pigs in a given herd are vaccinated at the prescribed intervals in order to protect against the spread of symptoms of the disease.

[0038] A method of producing an inactivated/killed PEDV vaccine is also provided. The method typically includes inoculating simian cells with PED virus, e.g., with PED virus SEQ ID NO:1 or SEQ ID NO:15. The inoculated simian cells are incubated, generally at least until CPE is observed (commonly after 24 to 120 hours at 37° C.), and then the PEDvirus is harvested from the incubated cells (e.g., by decanting and filtering the culture fluids). The harvested virus-containing fluids can be treated with a chemical inactivating agent, such as binary ethylenimine, to form inactivated/killed PED virus. Typically, the inactivated virus is further processed, e.g., by concentration and blending with other components, to produce a commercial formulation. For example, the fluids containing the inactivated virus may be concentrated and blended with an adjuvant and/or antigen(s) to one or more other porcine pathogens.

[0039] A method of producing a recombinantly expressed Spike antigen vaccine generated in insect cells via a recombinant baculovirus expressing a modified PEDV Spike protein is also provided. The method in one exemplary embodiment includes cloning the PEDV Spike coding sequence (SEQ ID NO:7) modified to remove the PEDV Spike signal peptide, transmembrane domain, and c-terminal domain into a vector (VSVG-PEDVS-VSVG DNA Sequence (SEQ ID NO:8)) and co-transfect Sf9 insect cells. For the inactivated recombinant PEDV material, PEDV baculoviral harvest was inactivated for 24 hours using 5mM BEI, clarified and 0.45µm filtered. Typically, the inactivated virus is further processed, e.g., by concentration and blending with other components, to produce a commercial formulation. For example, the fluids containing the

inactivated virus may be concentrated and blended with an adjuvant and/or antigen(s) to one or more other porcine pathogens.

[0040] The present application is also directed to a kit which includes in combination, (1) a dispenser capable of administering a vaccine to a pig; and (2) a chemically inactivated PEDV and/or recombinant Spike antigen containing vaccine capable of protecting against diseases associated with PEDV. The kit may include a dispenser which is capable of dispensing its contents as droplets, e.g., as aerosol, atomized spray and/or liquid droplets, and a form of the vaccine which is capable of protecting against diseases associated with PEDV, for example when administered intranasally and/or intramuscularly.

[0041] Throughout this application, the text refers to various embodiments of the present compositions and/or related methods. The various embodiments described are meant to provide a variety of illustrative examples and should not be construed as descriptions of alternative species. Rather, it should be noted that the descriptions of various embodiments provided herein may be of overlapping scope. The embodiments discussed herein are merely illustrative and are not meant to limit the scope of the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

[0042] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

[0043] FIG. 1 DNA Alignment of PEDV 1251-125-10 (125-10) genome (SEQ ID NO:1) and closest Chinese PEDV strain AH2012 (GenBank Accession No: KC210145) (SEQ ID NO:10).

[0044] FIG. 2 DNA Alignment of PEDV 1251-125-10 (125-10) genome (SEQ ID NO:1) and closest North American PEDV strain Colorado 2013 (GenBank Accession No: KF272920) (SEQ ID NO:11).

[0045] FIG. 3 Amino Acid Sequence Alignment of PEDV 1251-125-10 (125-10) spike protein (SEQ ID NO:14) aligned and closest GenBank sequence corresponding to North American Colorado strain (GenBank Accession No: AGO58924) (SEQ ID NO:12).

[0046] FIG. 4 Graphical representation of Anti-PEDV-IgG ELISA data (Group least square mean $\pm$ standard error anti-PEDV-IgG S:P ratios for D-1, 14, 28 and 49).

[0047] FIG. 5 Graphical representation of Anti-PEDV-IgA ELISA data (Group least square mean $\pm$ standard error anti-PEDV-IgA S:P ratios for D-1, 14, 28 and 49).

DETAILED DESCRIPTION

[0048] The invention provides immunogenic compositions including inactivated/killed, forms of PEDV and/or recombinantly expressed PEDV-Spike antigen. The vaccines are designed for protecting swine against diseases associated with PEDV. The vaccines typically include a chemically inactivated form of PEDV and those which include chemically inactivated/ killed PEDV virus are particularly desirable. In another embodiment the vaccines include a recombinant expressed Spike antigen generated, for example, in insect cells via a recombinant baculovirus expressing a modified PEDV Spike protein.

[0049] One embodiment of the invention can be a vaccine comprising one or more antigens of PEDV genotype 2a. In a preferred embodiment PEDV is of North American origin. More preferably, the PEDV of North American genotype is any PEDV encoded by SEQ ID NO:1, or comprising the sequence of SEQ ID NO:1, and/or comprises the RNA equivalent of SEQ ID NO:1; which sequence is at least 99% identical with the SEQ ID NO:1, and/or is at least 99% identical with the RNA equivalent of SEQ ID. NO:1; which spike protein is encoded by nucleic acid sequences of SEQ ID NO:2, 6, 8, or 13; which spike protein is encoded by a nucleic acid sequence that is at least 90% identical with the SEQ ID NO:2, 6, 8, or 13; that is encoded by SEQ ID NO:15; or which sequence is at least 99% identical SEQ ID NO:15.

[0050] In other embodiments of the invention, the vaccine is a recombinant vaccine or a killed vaccine. In exemplary embodiments of the invention, PEDV is chemically inactivated, for example, by treatment with a chemical inactivating agent which includes a compound selected from the group consisting of ethylenimine, binary ethylenimine, acetythylenimine and mixtures

thereof. In a preferred embodiment, PEDV is chemically inactivated by treatment with binary ethylenimine.

[0051] In yet other embodiments of the invention, the vaccine further comprises an adjuvant. In a preferred embodiment, the adjuvant is an EMULSIGEN® based oil-in-water emulsion.

[0052] In one embodiment of the invention, the vaccine is recombinant vaccine. In a preferred embodiment, such a recombinant vaccine comprises one or more immunogenic components selected from the group consisting of an isolated nucleic acid encoding an antigen of PEDV spike protein, wherein the recombinant Spike polypeptide has at least 90% homology with SEQ ID NO:3, 7, 9 or 14; a vector comprising the isolated nucleic acid of a); the recombinant PEDV Spike protein encoded by the nucleic acid of a); and/or any combination thereof. Optionally, such a recombinant vaccine comprises a pharmaceutical acceptable carrier and/or excipient. In one embodiment the excipient is one or more adjuvants. Preferably, the adjuvant is an EMULSIGEN® oil-in-water emulsion-based adjuvant.

[0053] In yet another aspect of the invention, the recombinant vaccine further comprises one or more additional antigens, for example, the additional antigen can be structural protein M, E, or N of a PEDV.

[0054] In another embodiment, the recombinant vaccine comprises an immunogenic component that can be an isolated nucleic acid, a vector, a recombinant PEDV Spike protein, and/or a combination of at least two of the later.

[0055] Embodiments of the invention also include methods of preventing clinical signs and/or for protecting a pig against diseases associated with PEDV, comprising administering to such pig any of the killed/inactivated and/or recombinant vaccines described herein. For example the administered vaccine comprises one or more antigens of PEDV of genotype 2a. In a preferred embodiment PEDV is of North American origin. More preferably, PEDV) of North American genotype is any PEDV encoded by or comprising the sequence of SEQ ID NO:1; which sequence is at least 99% identical with the SEQ ID NO:1; which spike protein is encoded

by nucleic acid sequences of SEQ ID NO:2, 6, 8, or 13; and/or which spike protein is encoded by a nucleic acid sequence at least 90% identical with the SEQ ID NO:2, 6, 8, or 13.

[0056] In another embodiment the method includes administration of a vaccine comprising one or more immunogenic components selected from the group consisting of a PEDV that is encoded by SEQ ID NO:1, or comprising the sequence of SEQ ID NO:1, and/or comprises the RNA equivalent (SEQ ID NO:16); which sequence is at least 99% identical with the SEQ ID NO:1, and/or is at least 99% identical with the RNA equivalent (SEQ ID NO:15); which spike protein is encoded by nucleic acid sequences of SEQ ID NO:2, 6, 8, or 13; which spike protein is encoded by a nucleic acid sequence that is at least 90% identical with the SEQ ID NO:2, 6, 8, or 13; that is encoded by SEQ ID NO:15; or which sequence is at least 99% identical SEQ ID NO:15.

[0057] In another embodiment the method includes administration of a vaccine comprising one or more immunogenic components selected from the group consisting of an isolated nucleic acid encoding an antigen of PEDV spike protein, wherein the recombinant Spike polypeptide has at least 90% homology with SEQ ID NO:3, 7, 9 or 14; a vector comprising the isolated nucleic acid of a); the recombinant PEDV Spike protein encoded by the nucleic acid of a); and any combination thereof.

[0058] Yet another embodiment of the invention includes a kit for vaccinating a pig against diseases associated with PEDV comprising: a dispenser capable of administering a vaccine to a pig; and a PEDV vaccine as described herein.

[0059] An embodiment of the invention includes a method of producing a porcine epidemic diarrhea vaccine according to claim 5 comprising: (a) inoculating simian cells with PEDV; (b) incubating the inoculated simian cells; (c) harvesting PEDV from the incubated cells; and (d) treating the harvested cells with a chemical inactivating agent, preferably with a compound selected from the group consisting of ethylenimine, binary ethylenimine, acetythylenimine or a mixture thereof to form inactivated PEDV vaccine. In a preferred embodiment, the method comprises a (PEDV comprising a sequence that is encoded by SEQ ID NO:1, or comprising the sequence of SEQ ID NO:1, and/or comprises the RNA equivalent of SEQ ID NO:1; which sequence is at least 99% identical with the SEQ ID NO:1, and/or is at least

99% identical with the RNA equivalent of SEQ ID. NO:1; which spike protein is encoded by nucleic acid sequences of SEQ ID NO:2, 6, 8, or 13; which spike protein is encoded by a nucleic acid sequence that is at least 90% identical with the SEQ ID NO:2, 6, 8, or 13; that is encoded by SEQ ID NO:15; or which sequence is at least 99% identical SEQ ID NO:15.

[0060] In one embodiment, the method includes PEDV of genogroup 2a comprising SEQ ID NO:1 and or SEQ ID NO:15. In alternative embodiments of the method, the inoculated simian cells are Vero cells. In a preferred embodiment of the method the chemical inactivating agent includes binary ethylenimine. The method can further comprise adding an adjuvant to the PEDV vaccine, preferably, the adjuvant is an EMULSIGEN® oil-in-water emulsion-based adjuvant.

[0061] Another embodiment of the invention includes a method of producing a recombinant vaccine comprising: expressing one or more antigens of PEDV in a host cell; and harvesting one or more antigens from PEDV-expressing cells. In one such embodiment the method can include one or more antigens comprising an isolated nucleic acid encoding an antigen of PEDV spike protein, wherein the recombinant Spike polypeptide has at least 90% homology with SEQ ID NO:3, 7, 9 or 14; a vector comprising the isolated nucleic acid of a); the recombinant PEDV Spike protein encoded by the nucleic acid of a); and any combination thereof. In one exemplary embodiment, one or more antigens of PEDV are expressed by a recombinant baculovirus vector. The method can include one or more antigens of PEDV expressed in insect cells. One embodiment further comprises the addition of an adjuvant to the PEDV vaccine, preferably wherein the adjuvant is an EMULSIGEN® oil-in-water emulsion-based adjuvant.

[0062] In more general terms, a variety of chemical inactivating agents known to those skilled in the art may be employed to inactivate the virus. Ethylenimine and related derivatives, such as binary ethylenimine (BEI) and acetythylenimine, are examples of suitable chemical inactivating agents for use in inactivating the PED virus. Other chemical inactivating agents, e.g., beta-propiolactone, aldehydes (such as formaldehyde) and/or detergents (e.g., Tween® detergent, Triton® X, or alkyl trimethylammonium salts) can also be used to inactivate the virus. The inactivation can be performed using standard methods known to those of skill in the art.

Samples can be taken at periodic time intervals and assayed for residual live virus. Monitoring of cytopathic effect on an appropriate cell line and/or fluorescent staining with an appropriate specific monoclonal or polyclonal antibody can be used to detect the presence of residual live virus.

[0063] Inactivation with BEI can be accomplished by combining a stock BEI solution (e.g., a solution formed by adding 0.1–0.2 M 2-bromo-ethylamine hydrobromide to 0.1–0.2 N aqueous NaOH) with viral fluids to a final concentration of about 1–5 mM BEI. Inactivation is commonly performed by holding the BEI-virus mixture at 35–40° C. (e.g., 37° C.) with constant mixing for 24–72 hours. Virus inactivation can be halted by the addition of sodium thiosulfate solution to a final concentration in excess of the BEI concentration (e.g., addition of sodium thiosulfate at 17% of the volume of BEI to neutralize excess BEI) followed by mixing.

[0064] The present immunogenic compositions usually include an adjuvant and, if desired, one or more emulsifiers such as Tween® detergent incorporated with the inactivated/killed PEDV. Suitable adjuvants include, for example, vitamin E acetate solubilisate, aluminum hydroxide, aluminum phosphate or aluminum oxide, (mineral) oil emulsions, non-ionic detergents, squalene and saponins. Other adjuvants which may be used include an oil based adjuvants such as Freund's complete adjuvant (FCA), and Freund's incomplete adjuvant (FIA). It has been found that cross-linked olefinically unsaturated carboxylic acid polymers, such as CARBOPOL® 971 polymer, are particularly suitable adjuvants for use in the present inactivated PEDV immunogenic compositions.

[0065] Examples for suitable oil-in water emulsions are EMULSIGEN® based adjuvants, such as EMULSIGEN® (an oil-in-water emulsion), EMULSIGEN-D® (an oil-in-water) with dimethyldioctadecylammonium bromide (DDA)), EMULSIGEN-P® (an oil-in-water) with a proprietary immunostimulant), EMULSIGEN-75® (a double adjuvant comprised of an oil-in-water) with a cross-linked polymer), and EMULSIGEN® -BCL (an oil-in-water emulsion that is free of animal origin components). (MVP Technologies, Inc. Omaha, Nebr., USA).

Pharmaceutical/vaccine compositions that comprise inactivated PEDV or recombinant PEDV proteins, have been effectively adjuvanted with oil-in water emulsions, preferably with such EMULSIGEN®-based adjuvants, more preferably with EMULSIGEN® (an oil-in-water

emulsion that is free of animal origin components) and EMULSIGEN® -BCL (an oil-in-water emulsion that is free of animal origin components).

[0066] It is generally advantageous to formulate the present compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of the active material calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of inactivated/killed PEDV, and/or recombinantly expressed PEDV antigen are dictated by and depend on among other factors (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved; (b) the limitations inherent in the art of compounding such active material for the treatment of disease; and (c) the manner of intended administration of the dosage unit form.

[0067] The principal active ingredient is typically compounded for convenient and effective administration in effective amounts with a suitable pharmaceutically acceptable carrier in dosage unit form as disclosed herein. A unit dosage form can, for example, contain the PEDV antigen in amounts ranging from 1 to about 5 relative potency units ("RPU"). This amount of the antigen is generally present in from about 1 to about 25/ml of carrier. In the case of compositions containing supplementary active ingredients, the dosages are determined by reference to the usual dose and manner of administration of the supplementary active ingredients.

[0068] The present vaccines typically include inactivated PEDV formulated with a pharmaceutically acceptable carrier. The pharmaceutical forms suitable for injectable use commonly include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The formulation should desirably be sterile and fluid to the extent that easy syringability exists. The dosage form should be stable under the conditions of manufacture and storage and typically is preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like), suitable mixtures thereof and vegetable oils. One possible carrier is a physiological salt solution. The proper

fluidity of the solution can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabenes, chlorobutanol, phenol, sorbic acid, thimerosal (sodium ethylmercuri-thiosalicylate), deomycin, gentamicin and the like. In many cases it may be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions, if desired, can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

[0069] Sterile injectable solutions may be prepared by incorporating the inactivated virus in the desired amount in an appropriate solvent with various other ingredients as enumerated above, as required, followed by filtered sterilization. Generally, dispersions can be prepared by incorporating the various active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and the freeze-drying technique which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0070] It may also be advantageous to add a stabilizer to the present compositions to improve the stability of inactivated virus. Suitable stabilizers include, for example, glycerol/EDTA, carbohydrates (such as sorbitol, mannitol, trehalose, starch, sucrose, dextran or glucose), proteins (such as albumin or casein) and protein degradation products (e.g., partially hydrolyzed gelatin). If desired, the formulation may be buffered by methods known in the art, using reagents such as alkali metal phosphates, e.g., sodium hydrogen phosphate, sodium dihydrogen phosphate, potassium hydrogen phosphate and/or potassium dihydrogen phosphate. Other solvents, such as ethanol or propylene glycol, can be used to increase solubility of ingredients in the vaccine formulation and/or the stability of the solution. Further additives which can be used in the present formulation include conventional antioxidants and conventional chelating agents, such as ethylenediamine tetraacetic acid (EDTA).

[0071] The compositions and methods of the present invention may be illustrated by the following examples, which are presented to illustrate the present invention and to assist in teaching one of ordinary skill how to make and use the same. These examples are not intended in any way to narrow or otherwise limit the scope of the present invention.

[0072] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA technology, protein chemistry and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, *Molecular Cloning: A Laboratory Manual*, Vols. I, II and III, Second Edition (1989); *DNA Cloning*, Vols. I and II (D. N. Glover ed. 1985); *Oligonucleotide Synthesis* (M. J. Gait ed. 1984); *Nucleic Acid Hybridization* (B. D. Hames & S. J. Higgins eds. 1984); *Animal Cell Culture* (R. K. Freshney ed. 1986); *Immobilized Cells and Enzymes* (IRL press, 1986); Perbal, B., *A Practical Guide to Molecular Cloning* (1984); the series, *Methods In Enzymology* (S. Colowick and N. Kaplan eds., Academic Press, Inc.); *Protein purification methods – a practical approach* (E.L.V. Harris and S. Angal, eds., IRL Press at Oxford University Press); and *Handbook of Experimental Immunology*, Vols. I-IV (D. M. Weir and C. C. Blackwell eds., 1986, Blackwell Scientific Publications).

[0073] It is to be understood that this invention is not limited to particular DNA, RNA, polypeptide sequences, or process parameters as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only, and is not intended to be limiting. It must be noted that, as used in this specification and the appended claims, the singular forms "a", "an" and "the" include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to "an antigen" includes a mixture of two or more antigens; reference to "an excipient" includes mixtures of two or more excipients, and the like.

Definitions:

[0074] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs at the time of filing. The meaning and scope of terms should be clear; however, in the

event of any latent ambiguity, definitions provided herein take precedent over any dictionary or extrinsic definition. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Herein, the use of “or” means “and/or” unless stated otherwise. Furthermore, the use of the term “including”, as well as other forms such as “includes” and “included” is not limiting. All patents and publications referred to herein are incorporated by reference herein.

[0075] “Protection against disease”, “protective immunity”, “functional immunity” and similar phrases, means a response against a disease or condition generated by administration of one or more therapeutic compositions of the invention, or a combination thereof, that results in fewer deleterious effects than would be expected in a non-immunized subject that has been exposed to disease or infection. That is, the severity of the deleterious effects of the infection are lessened in a vaccinated subject. Infection may be reduced, slowed, or possibly fully prevented, in a vaccinated subject. Herein, where complete prevention of infection is meant, it is specifically stated. If complete prevention is not stated then the term includes partial prevention.

[0076] Herein, “reduction of the incidence and/or severity of clinical signs” or “reduction of clinical symptoms” means, but is not limited to, reducing the number of infected subjects in a group, reducing or eliminating the number of subjects exhibiting clinical signs of infection, or reducing the severity of any clinical signs that are present in one or more subjects, in comparison to wild-type infection. For example, it should refer to any reduction of pathogen load, pathogen shedding, reduction in pathogen transmission, or reduction of any clinical sign symptomatic of PEDV. Preferably these clinical signs are reduced in one or more subjects receiving the therapeutic composition of the present invention by at least 10% in comparison to subjects not receiving the composition and that become infected. More preferably clinical signs are reduced in subjects receiving a composition of the present invention by at least 20%, preferably by at least 30%, more preferably by at least 40%, and even more preferably by at least 50%.

[0077] The term “increased protection” herein means, but is not limited to, a statistically significant reduction of one or more clinical symptoms which are associated with infection by an infectious agent, preferably PEDV, respectively, in a vaccinated group of subjects vs. a non-vaccinated control group of subjects. The term “statistically significant reduction of clinical

symptoms” means, but is not limited to, the frequency in the incidence of at least one clinical symptom in the vaccinated group of subjects is at least 10%, preferably 20%, more preferably 30%, even more preferably 50%, and even more preferably 70% lower than in the non-vaccinated control group after the challenge with the infectious agent.

[0078] “Long-lasting protection” shall refer to “improved efficacy” that persists for at least 3 weeks, but more preferably at least 3 months, still more preferably at least 6 months. In the case of livestock, it is most preferred that the long lasting protection shall persist until the average age at which animals are marketed for meat.

[0079] An “immunogenic or immunological composition” refers to a composition of matter that comprises at least one porcine epidemic diarrhea virus, or immunogenic portion thereof, that elicits an immunological response in the host of a cellular or antibody-mediated immune response to the composition. In a preferred embodiment of the present invention, an immunogenic composition induces an immune response and, more preferably, confers protective immunity against one or more of the clinical signs of a PEDV infection.

[0080] The immunogenic composition as used herein also refers to a composition that comprises any of the PEDV Spike proteins described herein. According to a further embodiment, such immunogenic composition further comprises at least a portion of a viral vector expressing said PEDV Spike protein, preferably of a recombinant baculovirus. Moreover, the immunogenic composition can comprise i) any of the PEDV proteins described above, preferably in concentrations described above, ii) at least a portion of the viral vector expressing said PEDV Spike protein, preferably of a recombinant baculovirus, and iii) a portion of the cell culture supernatant.

[0081] Thus according to one aspect, the present invention relates to a method for reducing the percentage of PEDV infections in a herd of pigs comprising the step administering to said pig(s) an effective amount of PEDV Spike antigen or an immunogenic composition comprising PEDV antigen, wherein the PEDV antigen is recombinant PEDV Spike antigen, preferably a baculovirus expressed PEDV Spike protein. Preferably those recombinant or baculovirus expressed PEDV Spike having the sequence as described herein.

[0082] An "immune response" or "immunological response" means, but is not limited to, the development of a cellular and/or antibody-mediated immune response to the composition or vaccine of interest. Usually, an immune or immunological response includes, but is not limited to, one or more of the following effects: the production or activation of antibodies, B cells, helper T cells, suppressor T cells, and/or cytotoxic T cells, directed specifically to an antigen or antigens included in the composition or vaccine of interest. Preferably, the host will display either a therapeutic or a protective immunological (memory) response such that resistance to new infection will be enhanced and/or the clinical severity of the disease reduced. Such protection will be demonstrated by either a reduction in number of symptoms, severity of symptoms, or the lack of one or more of the symptoms associated with the infection of the pathogen, a delay in the onset of viremia, reduced viral persistence, a reduction in the overall viral load and/or a reduction of viral excretion.

[0083] As used herein, "a pharmaceutical- or veterinary-acceptable carrier" includes any and all solvents, dispersion media, coatings, adjuvants, stabilizing agents, diluents, preservatives, antibacterial and antifungal agents, isotonic agents, adsorption delaying agents, and the like. In some preferred embodiments, and especially those that include lyophilized immunogenic compositions, stabilizing agents for use in the present invention include stabilizers for lyophilization or freeze-drying.

[0084] In some embodiments, the immunogenic composition of the present invention contains an adjuvant. "Adjuvants" as used herein, can include aluminum hydroxide and aluminum phosphate, saponins *e.g.*, Quil A, QS-21 (Cambridge Biotech Inc., Cambridge MA), GPI-0100 (Galenica Pharmaceuticals, Inc., Birmingham, AL), water-in-oil emulsion, oil-in-water emulsion, water-in-oil-in-water emulsion.

[0085] The emulsion can be based in particular on light liquid paraffin oil (European Pharmacopeia type); isoprenoid oil such as squalane or squalene; oil resulting from the oligomerization of alkenes, in particular of isobutene or decene; esters of acids or of alcohols containing a linear alkyl group, more particularly plant oils, ethyl oleate, propylene glycol di-(caprylate/caprate), glyceryl tri-(caprylate/caprate) or propylene glycol dioleate; esters of branched fatty acids or alcohols, in particular isostearic acid esters. The oil is used in

combination with emulsifiers to form the emulsion. The emulsifiers are preferably nonionic surfactants, in particular esters of sorbitan, of mannide (*e.g.* anhydromannitol oleate), of glycol, of polyglycerol, of propylene glycol and of oleic, isostearic, ricinoleic or hydroxystearic acid, which are optionally ethoxylated, and polyoxypropylene-polyoxyethylene copolymer blocks, in particular the Pluronic products, especially L121. *See* Hunter *et al.* The Theory and Practical Application of Adjuvants (Ed. Stewart-Tull, D. E. S.), John Wiley and Sons, NY, pp51-94 (1995) and Todd *et al.* Vaccine 15:564-570 (1997). Exemplary adjuvants are the SPT emulsion described on page 147 of “Vaccine Design, The Subunit and Adjuvant Approach” edited by M. Powell and M. Newman, Plenum Press, 1995, and the emulsion MF59 described on page 183 of this same book.

[0086] Examples for suitable oil-in water emulsions are EMULSIGEN® based adjuvants, such as EMULSIGEN® (an oil-in-water emulsion o/w), EMULSIGEN-D® (an oil-in-water (o/w) with dimethyldioctadecylammonium bromide (DDA)), EMULSIGEN-P® (an oil-in-water (o/w) with a proprietary immunostimulant), EMULSIGEN-75® (a double adjuvant comprised of an oil-in-water (o/w) with a cross-linked polymer), and EMULSIGEN® -BCL (an oil-in-water emulsion that is free of animal origin components). (MVP Laboratories, Inc. Omaha, Nebr., USA). Pharmaceutical/vaccine compositions that comprise inactivated PEDV or recombinant PEDV proteins, have been effectively adjuvanted with oil-in water emulsions, preferably with such EMULSIGEN®-based adjuvants, more preferably with EMULSIGEN® (an oil-in-water emulsion o/w) and/or EMULSIGEN® -BCL (an oil-in-water emulsion that is free of animal origin components).

[0087] Examples of suitable adsorbent aluminum hydroxide gels for use in veterinary vaccines include REHYDRAGEL®, REHYDRAGEL-CG®; REHYDRAGEL-LV; REHYDRAGEL-HPA; REHYDRAPHOS (General Chemical, Berkeley Heights, New Jersey, USA)?

[0088] A further instance of an adjuvant is a compound chosen from the polymers of acrylic or methacrylic acid and the copolymers of maleic anhydride and alkenyl derivative. Advantageous adjuvant compounds are the polymers of acrylic or methacrylic acid which are cross-linked, especially with polyalkenyl ethers of sugars or polyalcohols. These compounds are

known by the term carbomer (Phameuropa Vol. 8, No. 2, June 1996). Persons skilled in the art can also refer to U.S. Pat. No. 2,909,462 which describes such acrylic polymers cross-linked with a polyhydroxylated compound having at least 3 hydroxyl groups, preferably not more than 8, the hydrogen atoms of at least three hydroxyls being replaced by unsaturated aliphatic radicals having at least 2 carbon atoms. The preferred radicals are those containing from 2 to 4 carbon atoms, e.g. vinyls, allyls and other ethylenically unsaturated groups. The unsaturated radicals may themselves contain other substituents, such as methyl. The products sold under the name CARBOPOL.RTM. (also known as polyacrylic acid); (BF Goodrich, Ohio, USA) are particularly appropriate. They are cross-linked with an allyl sucrose or with allyl pentaerythritol. Among them, there may be mentioned CARBOPOL.RTM. 974P (also known as polyacrylic acid), CARBOPOL.RTM. 934P (also known as polyacrylic acid) and CARBOPOL.RTM. 971P (also known as polyacrylic acid). Most preferred is the use of CARBOPOL.RTM. 971P (also known as polyacrylic acid). Among the copolymers of maleic anhydride and alkenyl derivative, the copolymers EMA (Monsanto) which are copolymers of maleic anhydride and ethylene. The dissolution of these polymers in water leads to an acid solution that will be neutralized, preferably to physiological pH, in order to give the adjuvant solution into which the immunogenic, immunological or vaccine composition itself will be incorporated.

[0089] Further suitable adjuvants include, but are not limited to, the RIBI adjuvant system (Ribi Inc.), Block co-polymer (CytRx, Atlanta Ga.), SAF-M (Chiron, Emeryville Calif.), monophosphoryl lipid A, Avridine lipid-amine adjuvant, heat-labile enterotoxin from E. coli (recombinant or otherwise), cholera toxin, or muramyl dipeptide among many others.

[0090] It is expected that an adjuvant can be added in an amount of about 100 μ g to about 10 mg per dose, preferably in an amount of about 100 μ g to about 10 mg per dose, more preferably in an amount of about 500 μ g to about 5 mg per dose, even more preferably in an amount of about 750 μ g to about 2.5 mg per dose, and most preferably in an amount of about 1 mg per dose. Alternatively, the adjuvant may be at a concentration of about 0.01 to 50%, preferably at a concentration of about 2% to 30%, more preferably at a concentration of about 5% to 25%, still more preferably at a concentration of about 7% to 22%, and most preferably at a concentration of 10% to 20% by volume of the final product.

[0091] “Diluents” can include water, saline, dextrose, ethanol, glycerol, and the like. Isotonic agents can include sodium chloride, dextrose, mannitol, sorbitol, and lactose, among others. Stabilizers include albumin and alkali salts of ethylenediaminetetraacetic acid, among others.

[0092] “Isolated” means altered “by the hand of man” from its natural state, *i.e.*, if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or polypeptide naturally present in a living organism is not “isolated,” but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is “isolated”, as the term is employed herein.

[0093] “Safety” refers to the absence of adverse consequences in a vaccinated animal following vaccination, including but not limited to: potential reversion of a viral-based vaccine to virulence, clinically significant side effects such as persistent, systemic illness or unacceptable inflammation at the site of vaccine administration.

[0094] The terms “vaccination” or “vaccinating” or variants thereof, as used herein means, but is not limited to, a process which includes the administration of an immunogenic composition of the invention that, when administered to an animal, elicits, or is able to elicit—directly or indirectly—, an immune response in the animal against PEDV.

[0095] “Mortality”, in the context of the present invention, refers to death caused by PEDV infection, and includes the situation where the infection is so severe that an animal is euthanized to prevent suffering and provide a humane ending to its life.

[0096] Herein, “effective dose” means, but is not limited to, an amount of antigen that elicits, or is able to elicit, an immune response that yields a reduction of clinical symptoms in an animal to which the antigen is administered.

[0097] As used herein, the term “effective amount” means, in the context of a composition, an amount of an immunogenic composition capable of inducing an immune response that reduces the incidence of or lessens the severity of infection or incident of disease in an animal. Particularly, an effective amount refers to colony forming units (CFU) per dose. Alternatively, in the context of a therapy, the term “effective amount” refers to the amount of a therapy which is

sufficient to reduce or ameliorate the severity or duration of a disease or disorder, or one or more symptoms thereof, prevent the advancement of a disease or disorder, cause the regression of a disease or disorder, prevent the recurrence, development, onset, or progression of one or more symptoms associated with a disease or disorder, or enhance or improve the prophylaxis or treatment of another therapy or therapeutic agent.

[0098] “Sequence Identity” as it is known in the art refers to a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, namely a reference sequence and a given sequence to be compared with the reference sequence. Sequence identity is determined by comparing the given sequence to the reference sequence after the sequences have been optimally aligned to produce the highest degree of sequence similarity, as determined by the match between strings of such sequences. Upon such alignment, sequence identity is ascertained on a position-by-position basis, e.g., the sequences are “identical” at a particular position if at that position, the nucleotides or amino acid residues are identical. The total number of such position identities is then divided by the total number of nucleotides or residues in the reference sequence to give % sequence identity. Sequence identity can be readily calculated by known methods, including but not limited to, those described in Computational Molecular Biology, Lesk, A. N., ed., Oxford University Press, New York (1988), Biocomputing: Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York (1993); Computer Analysis of Sequence Data, Part I, Griffin, A.M., and Griffin, H. G., eds., Humana Press, New Jersey (1994); Sequence Analysis in Molecular Biology, von Heinge, G., Academic Press (1987); Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M. Stockton Press, New York (1991); and Carillo, H., and Lipman, D., SIAM J. Applied Math., 48: 1073 (1988), the teachings of which are incorporated herein by reference. Preferred methods to determine the sequence identity are designed to give the largest match between the sequences tested. Methods to determine sequence identity are codified in publicly available computer programs which determine sequence identity between given sequences. Examples of such programs include, but are not limited to, the GCG program package (Devereux, J., et al. Nucleic Acids Research, 12(1):387 (1984)), BLASTP, BLASTN and FASTA (Altschul, S. F. et al. J. Molec. Biol., 215:403-410 (1990)). The BLAST programs are publicly available from NCBI and other sources (BLAST Manual, Altschul, S. et al. NCVI NLM NIH Bethesda, MD 20894,

Altschul, S. F. et al. J. Molec. Biol., 215:403-410 (1990), the teachings of which are incorporated herein by reference). These programs optimally align sequences using default gap weights in order to produce the highest level of sequence identity between the given and reference sequences. As an illustration, by a polynucleotide having a nucleotide sequence having at least, for example, 85%, preferably 90%, even more preferably 95% "sequence identity" to a reference nucleotide sequence, it is intended that the nucleotide sequence of the given polynucleotide is identical to the reference sequence except that the given polynucleotide sequence may include up to 15, preferably up to 10, even more preferably up to 5 point mutations per each 100 nucleotides of the reference nucleotide sequence. In other words, in a polynucleotide having a nucleotide sequence having at least 85%, preferably 90%, even more preferably 95% identity relative to the reference nucleotide sequence, up to 15%, preferably 10%, even more preferably 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 15%, preferably 10%, even more preferably 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. Analogously, by a polypeptide having a given amino acid sequence having at least, for example, 85%, preferably 90%, even more preferably 95% sequence identity to a reference amino acid sequence, it is intended that the given amino acid sequence of the polypeptide is identical to the reference sequence except that the given polypeptide sequence may include up to 15, preferably up to 10, even more preferably up to 5 amino acid alterations per each 100 amino acids of the reference amino acid sequence. In other words, to obtain a given polypeptide sequence having at least 85%, preferably 90%, even more preferably 95% sequence identity with a reference amino acid sequence, up to 15%, preferably up to 10%, even more preferably up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 15%, preferably up to 10%, even more preferably up to 5% of the total number of amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or the carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either

individually among residues in the reference sequence or in the one or more contiguous groups within the reference sequence. Preferably, residue positions which are not identical differ by conservative amino acid substitutions. However, conservative substitutions are not included as a match when determining sequence homology.

[0099] A “conservative substitution” refers to the substitution of an amino acid residue or with another amino acid residue having similar characteristics or properties including size, hydrophobicity, etc., such that the overall functionality does not change significantly.

[0100] “Sequence homology”, as used herein, refers to a method of determining the relatedness of two sequences discounting conservative substitutions. To determine sequence homology, two or more sequences are optimally aligned, and gaps are introduced if necessary. In other words, to obtain a polypeptide having 95% sequence homology with a reference sequence, 85%, preferably 90%, even more preferably 95% of the amino acid residues in the reference sequence must match or comprise a conservative substitution with another amino acid, or a number of amino acids up to 15%, preferably up to 10%, even more preferably up to 5% of the total amino acid residues, not including conservative substitutions, in the reference sequence may be inserted into the reference sequence. Preferably the homolog sequence comprises at least a stretch of 50, even more preferred of 100, even more preferred of 250, even more preferred of 500 amino acids.

[0101] The terms "sequence identity" or "percent identity" are used interchangeably herein. For the purpose of this invention, it is defined here that in order to determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid for optimal alignment with a second amino or nucleic acid sequence). The amino acid or nucleotide residues at corresponding amino acid or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid or nucleotide residue as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity=number of identical positions/total number of positions (i.e. overlapping positions) x 100). Preferably, the two

sequences are the same length. When sequence identity is used in reference to proteins it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (e.g., charge or hydrophobicity) and therefore do not change the functional properties of the molecule. When sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Sequences that differ by such conservative substitutions are said to have "sequence similarity" or "similarity."

[0102] A sequence comparison may be carried out over the entire lengths of the two sequences being compared or over fragment of the two sequences. Typically, the comparison will be carried out over the full length of the two sequences being compared. However, sequence identity may be carried out over a region of, for example, twenty, fifty, one hundred or more contiguous amino acid residues.

[0103] The skilled person will be aware of the fact that several different computer programs are available to determine the homology between two sequences. For instance, a comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid or nucleic acid sequences is determined using the Needleman and Wunsch (J. Mol. Biol. (48): 444-453 (1970)) algorithm which has been incorporated into the GAP program in the Accelrys GCG software package (available at <http://www.accelrys.com/products/gcg/>), using either a Blosum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. The skilled person will appreciate that all these different parameters will yield slightly different results but that the overall percentage identity of two sequences is not significantly altered when using different algorithms.

[0104] The protein sequences or nucleic acid sequences of the present invention can further be used as a "query sequence" to perform a search against public databases to, for example, to identify other family members or related sequences. Such searches can be performed using the BLASTN and BLASTP programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403-

10. BLAST protein searches can be performed with the BLASTP program, score=50, wordlength=3 to obtain amino acid sequences homologous to protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (1997) Nucleic Acids Res. 25(17): 3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., BLASTP and BLASTN) can be used. See the homepage of the National Center for Biotechnology Information at <http://www.ncbi.nlm.nih.gov/>.

[0105] The claimed PEDV of the invention shall also encompass variants of the PEDV isolate 1251-125-10 ("125-10") and variants of sub-fragments thereof. Such variants have essentially the same immunological properties as characteristic of the Oklahoma strain (SEQ ID NO 1 and 15). The term "having essentially the same immunological properties" encompass (but is not restricted to) that said variants are essentially effective in treating or preventing the clinical signs caused by PEDV as described below or in improving the efficacy parameters as described below.

[0106] The term "variant" with respect to sequence SEQ ID NO:1, 2, 3, 6, 7, 8, 9, 14 and 15 (e.g., a polypeptide or nucleic acid sequence) is intended to mean substantially similar sequences. For nucleotide sequences comprising an open reading frame, variants include those sequences that, because of the degeneracy of the genetic code, encode the identical amino acid sequence of the native protein. Variant nucleotide sequences also include synthetically derived nucleotide sequences, such as those generated, for example, by using site-directed mutagenesis and for open reading frames, encode the native protein, as well as those that encode a polypeptide having amino acid substitutions relative to the native protein for the purposes of codon optimization. Generally, nucleotide sequence variants of the invention will have at least at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, more preferably at least 90%, 91%, 92%, 93%, or 94%, and most preferably at least 95%, 96%, 96.1%, 96.2%, 96.3%, 96.4%, 96.5%, 96.6%, 96.7%, 96.8%, 96.9%, 97%, 97.1%, 97.2%, 97.3%, 97.4%, 97.5%, 97.6%, 97.7%, 97.8%, 97.9%, 98%, 98.1%, 98.2%, 98.3%, 98.4%, 98.5%, 98.6%, 98.7%, 98.8%, 98.9%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.99% sequence identity compared to a reference sequence using one of the alignment programs described using standard parameters.

[0107] The term “genogroup” as it is known in the art refers to related viruses within a genus; which may be further subdivided into genetic clusters. Identified genogroups of PEDV include group G1, comprising subgroups G1a, G1b, R (attenuated/adapted); and G2, comprising subgroups G2a, and G2b. Members of the G2a genogroup include the Chinese strain AH2012 (GenBank accession no: KC210145) and the North American strains, sharing several unique nucleotides changes. Strains MN and IA2 had 99.6% and strain IA1 had 99.5% nucleotide identity with AH2012, respectively. Researchers have speculated that an AH2012-like virus was possibly transmitted to the eastern China regions and then transported to the United States and is the most likely closest ancestor to the North American strains. Members of the genogroup 2a share only approximately 96.9% similarity to the prototype PEDV strain CV777 of genogroup 1a (Bridgen, et al. 1993; Huang et al. 2013; GenBank: AF353511.1). As such, the attenuated PEDV vaccines based on the historical CV777-derived G1a strains or DR13-derived G1b strains may be antigenically less related to the newly emergent Chinese and North American G2a PEDV strains.

[0108] A closely related North American isolate US/Colorado/2013 (GenBank Accession No: KF272920.1) has also been reported by Marthaler et al. 2013. Like the North American isolates above the complete PEDV genome of CO/13 has a nucleotide identity of 96.5 to 99.5% with other complete PEDV genomes available in GenBank, with the highest nucleotide identity (99.5%) with Chinese strain AH2012 (GenBank Accession No. KC210145). Chinese strain AH2012 is a member of the 2a genogroup. Comparison of the complete genome of North American isolate CO/13 to that of PEDV reference strain CV777, shows that CO/13 contains a 1-nucleotide insertion (at position 48) and deletions of 5 nucleotides in the 5' UTR (at positions 73 and 83 to 86), while the spike gene contains insertions of 16 nucleotides (positions 20804, 20810 to 20820, 20843, and 21053 to 21055) and deletions of 7 nucleotides (positions 20853 and 21118 to 21124).

[0109] The term “PEDV of North American origin” means a PEDV isolate comprising SEQ ID NO:1 and/or SEQ ID NO:15, and/or any PEDV isolates having at least 99% sequence identity to SEQ ID NO:1, and/or is at least 99% identical with the RNA equivalent of SEQ ID. NO:1, and/or a PEDV isolate in which a Spike protein is encoded by SEQ ID NO:13, and/or any PEDV isolate in which a Spike protein has at least 98% sequence identity to SEQ ID:13, and/ or

any PEDV isolate in which the expressed Spike protein has at least 90% homology with SEQ ID NO:14.

[0110] The term “clade” as it is known in the art refers to a group consisting of an ancestor and all its descendants, a single "branch" in a phylogenetic tree. The ancestor may be, as an example an individual, a population or a species. A genogroup can include multiple clades, for example AH2012 is in a different clade than the North American isolates.

[0111] According to a further embodiment, the present invention also relates to a vector that comprises any of such nucleic acid molecules as described herein. In other words, the present invention relates to a vector, that includes the coding sequence of any such Spike, M, E, N PEDV protein, or part thereof. Preferably, said vector is an expression vector, which allows the expression of any such Spike, M, E, and/or N PEDV protein or part of the protein. Vectors according to the invention are those which are suitable for the transfection or infection of bacterial, yeast or animal cells, in vitro or in vivo.

[0112] Vectors and methods for making and/or using vectors (or recombinants) for expression can be by or analogous to the methods disclosed in: U.S. Pat. Nos. 4,603,112, 4,769,330, 5,174,993, 5,505,941, 5,338,683, 5,494,807, 4,722,848, 5,942,235, 5,364,773, 5,762,938, 5,770,212, 5,942,235, 382,425, PCT publications WO 94/16716, WO 96/39491, WO 95/30018; Paoletti, "Applications of pox virus vectors to vaccination: An update," PNAS USA 93: 11349-11353, October 1996; Moss, "Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety," PNAS USA 93: 11341-11348, October 1996; Smith et al., U.S. Pat. No. 4,745,051(recombinant baculovirus); Richardson, C. D. (Editor), Methods in Molecular Biology 39, "Baculovirus Expression Protocols" (1995 Humana Press Inc.); Smith et al., "Production of Human Beta Interferon in Insect Cells Infected with a Baculovirus Expression Vector", Molecular and Cellular Biology, December, 1983, Vol. 3, No. 12, p. 2156-2165; Pennock et al., "Strong and Regulated Expression of Escherichia coli B-Galactosidase in Infect Cells with a Baculovirus vector, "Molecular and Cellular Biology March 1984, Vol. 4, No. 3, p. 406; EPA0 370 573; U.S. application No. 920,197, filed Oct. 16, 1986; EP Patent publication No. 265785; U.S. Pat. No. 4,769,331 (recombinant herpesvirus); Roizman, "The function of herpes simplex virus genes: A primer for genetic engineering of novel vectors," PNAS USA

93:11307-11312, October 1996; Andreansky et al., "The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors," PNAS USA 93: 11313-11318, October 1996; Robertson et al., "Epstein-Barr virus vectors for gene delivery to B lymphocytes", PNAS USA 93: 11334-11340, October 1996; Frolov et al., "Alphavirus-based expression vectors: Strategies and applications," PNAS USA 93: 11371-11377, October 1996; Kitson et al., J. Virol. 65, 3068-3075, 1991; U.S. Pat. Nos. 5,591,439, 5,552,143; WO 98/00166; allowed U.S. application Ser. Nos. 08/675,556, and 08/675,566 both filed Jul. 3, 1996 (recombinant adenovirus); Grunhaus et al., 1992, "Adenovirus as cloning vectors," Seminars in Virology (Vol. 3) p. 237-52, 1993; Ballay et al. EMBO Journal, vol. 4, p. 3861-65, Graham, Tibtech 8, 85-87, April, 1990; Prevec et al., J. Gen Virol. 70, 42434; PCT WO 91/11525; Felgner et al. (1994), J. Biol. Chem. 269, 2550-2561, Science, 259: 1745-49, 1993; and McClements et al., "Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease", PNAS USA 93: 11414-11420, October 1996; and U.S. Pat. Nos. 5,591,639, 5,589,466, and 5,580,859, as well as WO 90/11092, WO93/19183, WO94/21797, WO95/11307, WO95/20660; Tang et al., Nature, and Furth et al., Analytical Biochemistry, relating to DNA expression vectors, *inter alia*. See also WO 98/33510; Ju et al., Diabetologia, 41: 736-739, 1998 (lentiviral expression system); Sanford et al., U.S. Pat. No. 4,945,050; Fischbach et al. (Intracel); WO 90/01543; Robinson et al., Seminars in Immunology vol. 9, pp. 271-283 (1997), (DNA vector systems); Szoka et al., U.S. patent No. 4,394,448 (method of inserting DNA into living cells); McCormick et al., U.S. Pat. No. 5,677,178 (use of cytopathic viruses); and U.S. Pat. No. 5,928,913 (vectors for gene delivery); as well as other documents cited herein.

[0113] Preferred viral vectors include baculovirus such as BaculoGold (BD Biosciences Pharmingen, San Diego, Calif.), in particular provided that the production cells are insect cells. Although the baculovirus expression system is preferred, it is understood by those of skill in the art that other expression systems will work for purposes of the present invention, namely the expression of HG into the supernatant of a cell culture. Such other expression systems may require the use of a signal sequence in order to cause H5 expression into the media.

Effective Dose:

[0114] The compounds described herein can be administered to a subject at therapeutically effective doses to prevent PEDV-associated diseases. The dosage will depend upon the host receiving the vaccine as well as factors such as the size, weight, and age of the host.

[0115] The precise amount of immunogenic composition of the invention to be employed in a formulation will depend on the route of administration and the nature of the subject (e.g., age, size, stage/level of disease), and should be decided according to the judgment of the practitioner and each subject's circumstances according to standard clinical techniques. An effective immunizing amount is that amount sufficient to treat or prevent a PEDV infectious disease in a subject.

[0116] Immunogenicity of a composition can be determined by monitoring the immune response of test subjects following immunization with the composition by use of any immunoassay known in the art. Generation of a humoral (antibody) response and/or cell-mediated immunity may be taken as an indication of an immune response. Test subjects may include animals such as pigs, mice, hamsters, dogs, cats, rabbits, cows, horses, sheep, poultry (e.g. chickens, ducks, geese, and turkeys), and humans.

[0117] The immune response of the test subjects can be analyzed by various approaches such as: the reactivity of the resultant immune serum to the immunogenic conjugate, as assayed by known techniques, e.g., enzyme linked immunosorbent assay (ELISA), immunoblots, immunoprecipitations, virus neutralization, etc.; or, by protection of immunized hosts from infection by the pathogen and/or attenuation of symptoms due to infection by the pathogen in immunized hosts as determined by any method known in the art, for assaying the levels of an infectious disease agent, e.g., the viral levels (for example, by culturing of a sample from the subject), or other technique known in the art. The levels of the infectious disease agent may also be determined by measuring the levels of the antigen against which the immunoglobulin was directed. A decrease in the levels of the infectious disease agent or an amelioration of the symptoms of the infectious disease indicates that the composition is effective.

[0118] The therapeutics of the invention can be tested in vitro for the desired therapeutic or prophylactic activity, prior to in vivo use in animals. For example, in vitro assays that can be used to determine whether administration of a specific therapeutic is indicated include in vitro

cell culture assays in which appropriate cells from a cell line or cells cultured from a subject having a particular disease or disorder are exposed to or otherwise administered a therapeutic, and the effect of the therapeutic on the cells is observed.

[0119] Alternatively, the therapeutic may be assayed by contacting the therapeutic to cells (either cultured from a subject or from a cultured cell line) that are susceptible to infection by the infectious disease agent but that are not infected with the infectious disease agent, exposing the cells to the infectious disease agent, and then determining whether the infection rate of cells contacted with the therapeutic was lower than the infection rate of cells not contacted with the therapeutic. Infection of cells with an infectious disease agent may be assayed by any method known in the art.

[0120] In addition, the therapeutic can be assessed by measuring the level of the molecule against which the antibody is directed in the animal model or human subject at suitable time intervals before, during, or after therapy. Any change or absence of change in the amount of the molecule can be identified and correlated with the effect of the treatment on the subject. The level of the molecule can be determined by any method known in the art.

[0121] After vaccination of an animal to PEDV using the methods and compositions of the present invention, any binding assay known in the art can be used to assess the binding between the resulting antibody and the particular molecule. These assays may also be performed to select antibodies that exhibit a higher affinity or specificity for the particular antigen.

Administration to a Subject:

[0122] Preferred routes of administration include but are not limited to intranasal, oral, intradermal, and intramuscular. The skilled artisan will recognize that compositions of the invention may also be administered in one, two or more doses, as well as, by other routes of administration. For example, such other routes include subcutaneously, intracutaneously, intravenously, intravascularly, intraarterially, intraperitoneally, intrathecally, intratracheally, intracutaneously, intracardially, intralobally, intramedullary, intrapulmonarily, and intravaginally. Depending on the desired duration and effectiveness of the treatment, the compositions according to the invention may be administered once or several times, also

intermittently, for instance on a daily basis for several days, weeks or months and in different dosages.

[0123] The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventors to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

EXAMPLES

EXAMPLE 1: Isolation and Production of Inactivated PEDV Strain

[0124] To produce the porcine epidemic diarrhea virus vaccine, killed virus, a master seed culture of a PEDV (isolate) was first produced. From this master seed, a culture of PEDV was grown and then inactivated. The inactivated virus culture was then mixed with an adjuvant in order to produce the porcine epidemic diarrhea virus vaccine. The following method was used to produce the porcine epidemic diarrhea virus vaccine.

[0125] Animals or tissues from animals exhibiting extreme diarrhea were acquired in 2013. Homogenates from mucosal scrapings were generated from these animals filtered through a 0.2 micron syringe filter and the filtrate was used to inoculate African Green Monkey kidney cells (VERO). Virus was grown in the presence of PEDV maintenance media containing modified MEM, porcine trypsin, tryptose phosphate broth, yeast extract and HEPES buffer. Virus growth was evaluated and visualized by checking for characteristic syncytia formation and fusion of cell monolayer. CPE positive material was subjected to sequencing using Illumina-based MiSeq technology.

[0126] In order to produce the PEDV master seed virus culture ("PEDV MSV"), porcine epidemic diarrhea virus strain (isolate) (PEDV isolate) was isolated in BI VERO cells and passed a total nineteen times in BI VERO cells and then virus was grown in 2013 EU VERO cells till

passage 30. The 30th passage of the virus was diluted and put down as the master seed virus designated PEDV KV-1251-125-10-OK.

[0127] From the master seed virus, a culture of PEDV (KV-1251-125-10-OK, to be referred to herein as “125-10”) was produced by infecting 2013 EU VERO cells with PEDV KV-1251-125-10-OK MSV in PEDV maintenance media containing modified Minimal Essential Media, porcine trypsin (10 μ g/ml), tryptose phosphate broth (0.3%), yeast extract (0.02%) and 1M HEPES buffer (2.5%) The 2013 EU VERO cells were typically infected with the PEDV (125-10) MSV at a minimum dose of 10⁴ TCID₅₀ /850cm² roller bottle. Such cultures can be grown in sterile disposable roller bottles or on microcarrier beads. The culture was incubated at 36° C.±2° C. for 24 to 48 hours until cytopathic effect (“CPE”) was observed. Typically, characteristic syncytia can be seen within 12 hours of infection, syncytia expand and cell monolayer fuses from 24-48 hours followed by sloughing of cells. During incubation, the culture was monitored for PEDV induced CPE to ensure a pure PEDV strain. If atypical CPE was observed or any macroscopic or microscopic evidence of contamination existed, the culture was discarded. Pure virus culture was aseptically harvested into sterile polypropylene carboys. Virus was freeze thawed to release cell associated virions and was clarified by centrifugation or by filtration through filters of 0.45 microns followed by 0.2 microns. Bulk virus harvest fluids were tested to ensure the absence of mycoplasma prior to inactivation. Harvested fluids which were not immediately inactivated were stored at -70° C. or below.

[0128] The volume of harvested fluids is determined and the temperature of the fluids is brought to 36 ± 2°C. A 0.4 M solution of 2-bromoethylethylamine (BEA) is mixed with a stock solution of 0.3 N NaOH to generate a binary ethyleneimine (BEI) stock solution which is then added to the harvest fluids to give a final concentration of BEI of 5 mM. The fluids are stirred continuously for a minimum of 24hours. A 1.0 M sodium thiosulfate solution to give a final minimum concentration of 5 mM is added to neutralize any residual BEI. The inactivated fluids can be stored at -70 ± 3°C for long term storage or at 4 ± 3°C for short term.

[0129] After treatment with BEI, the culture was tested for its ability to induce CPE typical of PEDV to ensure inactivation of the virus. This task was accomplished by passing the BEI treated viral fluids over Vero cells and checking the Vero cells for any viral infection. The BEI

treated culture fluids were typically stored at -70° C or below until the inactivation assay had been completed.

[0130] The inactivated virus was formulated as an adjuvanted vaccine by thoroughly blending the inactivated PEDV culture with adjuvant EMULSIGEN®-BCL at a 20% inclusion rate to form a bulk serial. The bulk serial was maintained at 2–8° C. until being transferred into vials containing either one or ten doses (@2.0 ml per dose).

EXAMPLE 2: Genome Sequence Analysis of PEDV Isolate 1251-125-10 “125-10”

[0131] **Sample preparation and analysis:** Prior to extraction virus tissue culture supernatants were pre-treated with a cocktail of DNase and RNase to remove residual host cell genomic nucleic acids. Viral genomic RNA was then extracted from the nuclease-treated samples using the Qiagen viral RNA extraction kit (Cat #52906). Post extraction, samples were again treated with DNase to further enrich for viral genomic RNA. Subsequently, viral genomic RNA was converted to double stranded cDNA (ds cDNA) through randomly primed reverse transcription and Klenow fragment treatment. The ds cDNA products were then used to generate a library for Illumina MiSeq-based sequencing using the NextEraXT library preparation kit (Cat #FC-131-1024). Each sample was barcoded with unique tags on both the 5'- and 3'-ends to minimize the chances of bioinformatic mis-binning. This library was run on the MiSeq using the 500-cycle kit (Cat # MS-102-2003) and data was analyzed using a combination of NextGene (version 2.3.4) and Sequencher software (version 5.1). High quality sequences were selected as those containing a median Q-score of greater than 25 and trimmed with a cut-off of no more than three uncalled bases at 3'-end or 3-consecutive bases with Q-score measuring less than 16. The sequences were then assembled *de novo* using criteria of 85% or greater match over a 35bp stretch to generate a putative PEDV full genome for each strain. The putative complete genome sequence for each was then verified by template-based alignment to verify single nucleotide polymorphisms (SNP) or variable small insertions/deletions.

[0132] For sample 1251-125-10, a total of 570,253 sequences were generated with an average length of 136bp after trimming of low quality data. Of those sequences; 484,247 (84.9%) assembled into a single contig 27,995bp long which through BLASTn analysis revealed strong identity to the single-stranded RNA alphacoronavirus PEDV. A total of 11 positions

exhibited polymorphism at either a single nucleotide or a small insertion/deletion, these positions are listed in Table 1.

[0133] Table 1: Polymorphic Residues in Isolate 1251-125-10 “125-10”

Position	Residue Frequencies	Gene
3,315	T (51%) A (49%)	ORF1A/B
3,423 - 3,426	DEL (50%) TTA (50%)	ORF1A/B
9,425	C (64%) T (36%)	ORF1A/B
10,136	T (52%) A (48%)	ORF1A/B
14,416	A (69%) G (31%)	ORF1A/B
18,179	C (73%) T (27%)	ORF1A/B
19,100	C (73%) T (27%)	ORF1A/B
23,101	G (63%) A (37%)	Spike
25,057	T (59%) 10bp INS (41%)	Spike
25,165-25,169	TTATG (74%) DEL (26%)	ORF3
27,510	C (73%) T (27%)	ORF3

[0134] The putative complete/near-complete PEDV genome of 1251-125-10 (**SEQ ID NO:1**) was aligned to the closest Chinese AH2012 (GenBank Accession No: KC210145) and North American Colorado 2013 isolate (GenBank Accession No: AGO58924) of PEDV (See **FIG. 1** and **FIG. 2**). The identities to both isolates exceed 99.2% indicating very close relation to both strains, both in genogroup 2a.

[0135] Next, the immunogenic spike protein sequence was examined for protein identity/similarity to the larger GenBank repository of PEDV spike proteins. Again, the closest GenBank isolate submitted was derived from the North American Colorado 2013 strain deposited by the University of Minnesota Veterinary diagnostic laboratory (GenBank Accession No: AGO58924) exhibiting over 99.5% identity (1380/1386 identical amino acids) (**FIG. 3**). Of the 6 amino acid changes, 1 was due to the polymorphism at position 23,101 which would encode either CGA (Arg) in the majority or CAA (Gln) in minority at position 838. The North American Colorado 2013 strain contains a Gln at this position.

EXAMPLE 3: Method of Monitoring Inactivation of Viruses

[0136] Each lot of PEDV virus or pool is tested for inactivation by passage in VERO cells. Seventy five cm² of 24 hour cell culture are inoculated with 2.0 mL of inactivated PEDV fluids and maintained at $36 \pm 3^{\circ}\text{C}$ for 48 hours. One flask of VERO cells remains uninoculated. For positive virus controls one culture of VERO cells is inoculated with a positive control PEDV. At the end of the incubation period, the cell monolayers are examined for CPE typical of PEDV. The material is frozen and thawed three times and then 2ml of each material is inoculated onto one day old VERO cells. The culture should be maintained at $37 \pm 2^{\circ}\text{C}$ for 48 hours. Following the second passage, a third passage is performed. After incubation and passage, the absence of virus-infected cells in the BEI treated viral fluids as determined by lack of immunofluorescence staining constitutes a satisfactory inactivation test. The control cells inoculated with the positive control virus shall show CPE typical of PEDV and the uninoculated flask shall show no evidence of PEDV CPE.

EXAMPLE 4:

Construction of a Recombinant Baculoviruses Coding for and Expressing PEDV Spike Antigens

[0137] The BaculoDisplay-Spike antigen was generated in insect cells via a recombinant baculovirus expressing a modified PEDV Spike protein. Briefly, the nucleic acid sequence (SEQ ID NO:2) encoding the PEDV Spike protein (SEQ ID NO:3) was cloned from a diagnostic sample using specific primers (Forward primer: SEQ ID NO:4 and Reverse primer:

SEQ ID NO:5). The cloned PEDV Spike coding sequence was modified to remove the PEDV Spike signal peptide, transmembrane domain, and c-terminal domain (SEQ ID NO:6). These domains were replaced with the equivalent domains from the Vesicular stomatitis virus G protein (VSVG) by overlap extension PCR. The VSVG-PEDVS-VSVG coding sequence (SEQ ID NO:8) was transferred into a baculovirus transfer vector (pVL1393) using complementary restriction sites. The pVL1393 vector containing the VSVG-PEDV-VSVG Spike coding sequence expressing the modified Spike protein (SEQ ID NO:9) was used to co-transfect Sf9 insect cells along with FlashBAC ULTRA baculovirus DNA. Recombinant baculovirus were amplified and checked for PEDV Spike protein expression by IFA and Western blot using PEDV-specific serum. The PEDV Spike protein was shown to co-pellet with the baculovirus particles after a 100,000g centrifugation step, suggesting that it was associated with the baculovirus.

EXAMPLE 5:

Preparation of Pharmaceutical Compositions (Vaccines) Comprising PEDV Spike Antigens:

[0138] For the inactivated PEDV material, PEDV viral harvest was inactivated for a minimum of 24 hours using 5mM BEI, clarified and 0.45µm filtered.

[0139] After neutralization various adjuvants were added and the following vaccine/pharmaceutical compositions were generated.

EXAMPLE 6:

Inoculation of Pigs with Inactivated PEDV and Baculovirus Spike Vaccine and assessment of the serological response

[0140] The purpose of the study was to demonstrate immunogenicity of an inactivated PEDV virus for protection of vaccinated pigs. The vaccine used in the study included inactivated PED virus and a BaculoDisplay-Spike (Baculo-S) protein construct. Both the inactivated PEDV vaccine and the BaculoDisplay-Spike (Baculo-S) protein vaccines were adjuvanted with EMULISGEN®-BCL. A previous challenge study had shown a strong positive correlation

between clinical protection and the IgA and IgG responses detected in the blood 21 days following challenge with PEDV (De Arriba et al. 2002). Therefore, the serological response of each of the prototype vaccines was assessed by IgG and IgA ELISA analysis. In addition, a virus neutralizing assay was done on the sera.

[0141] Experimental Design: Experiments were designed to evaluate the serological response to two prototype PEDV vaccines.

[0142] Eighteen pigs (28 $\pm$ 7 days of age at D-1) were randomized into three treatment groups (See Table 2) and housed in a single room for the duration of the study. The animals were intramuscularly vaccinated on D0, 14 and 28 with either a placebo or one of the two PEDV prototype vaccines. Pigs were monitored for clinical signs daily from D0 through D49. Rectal temperatures and injection sites were monitored to evaluate the vaccines' safety from D0-D4, D14-18, and D28-D32. Fecal, oral and nasal swabs and serum were taken from the piglets on D-1, 3, 14, 17, 28, 31 and 49. The serum samples taken on D-1, 14, 28 and 49 were screened by ELISA for anti-PEDV-IgG and by FFN assay for the presence of neutralizing antibodies. Fecal samples and serum collected on D-1, D3, 17 and 31 were evaluated by PCR to confirm that neither prototype was able to replicate in the pig. Fecal samples from D14, 28 and 49 were stored at -70°C for potential future evaluation. On D49, animals were humanely euthanized and necropsied.

[0143] Table 2. Summary of experimental design

Group (name)	n	Vaccine	Volume/Dose
1 (BEI-VH)	7	BEI inactivated PEDV viral harvest adjuvanted with EMULSIGEN®-BCL (20% v/v)	2ml/5.6 log TCID ₅₀
2 (Baculo-S)	7	BaculoDisplay-Spike protein adjuvanted with EMULSIGEN®-BCL(20% v/v)	1ml/ 866µg/ml total protein
3 (Control)	4	Placebo	2ml

[0144] Prototype vaccines: Tables 4a and b describe the prototype vaccines. For the placebo treatment, 2ml of Production PBS was administered. The BaculoDisplay-Spike antigen

was generated in insect cells via a recombinant baculovirus expressing a modified PEDV Spike protein. Briefly, the coding sequence for the PEDV Spike protein was cloned from a diagnostic sample using specific primers. The cloned PEDV Spike coding sequence was modified to remove the PEDV Spike signal peptide, transmembrane domain, and c-terminal domain (SEQ ID NO:7). These domains were replaced with the equivalent domains from the Vesicular stomatitis virus G protein (VSVG) by overlap extension PCR (SEQ ID NO:8). The VSVG-PEDVS-VSVG coding sequence was transferred into a baculovirus transfer vector (pVL1393) using complementary restriction sites. The pVL1393 vector containing the VSVG-PEDV-VSVG Spike coding sequence was used to co-transfect Sf9 insect cells along with FlashBAC ULTRA baculovirus DNA. Recombinant baculovirus were amplified and checked for PEDV Spike expression by IFA and Western blot using PEDV-specific serum. The PEDV Spike protein was shown to co-pellet with the baculovirus particles after a 100,000g centrifugation step, suggesting that it was associated with the baculovirus. For the inactivated PEDV material, PEDV viral harvest was inactivated for 24 hours using 5mM BEI, clarified and 0.45µm filtered.

[0145] Table 4a. Summary of PEDV prototype vaccine material – Inactivated viral harvest

Material:	0.45µm filtered, BEI inactivated porcine epidemic disease virus p7 on BI-Vero (production grade trypsin); 5.3 log TCID ₅₀ /ml
Testing of vaccine material	BEI inactivated material was passed once in BI-Veros at various dilutions. Lack of viral growth was confirmed by IFA using anti-PEDV polyclonal sera. Sterility of the formulated vaccine was determined by inoculating a blood agar plate and a MacConkey agar plate with 50µl of material. Plates were incubated aerobically and anaerobically for 48hrs. No growth was noted following incubation. The sterility testing was done for each of the prepared vaccine batches (D0, D14 and D28).
Formulation:	42 ml of BEI inactivated material was divided into three 14ml aliquots. One aliquot was thawed in a 37°C waterbath on D0, 14 and 28. On each of the vaccination days, 3.5ml of EMULSIGEN®-BCL (MVP) was added to 14ml of inactivated material slowly over 1 minute while stirring. The mixture was stirred for 10min, transferred to a vaccine bottle, than stored at 4°C.

[0146] **Table 4b. Summary of the PEDV prototype vaccine material – BaculoDisplay-Spike**

Material:	BaculoFBU/PEDVS p2
Testing of vaccine material	Sterility of the formulated vaccine was determined by inoculating a blood agar plate and a MacConkey agar plate with 50µl of material. Plates were incubated aerobically and anaerobically for 48hrs. No growth was noted following incubation. The sterility testing was done for each of the prepared vaccine batches (D0, D14 and D28).
Formulation:	27 ml of BaculoDisplay-Spike protein was divided into three 9ml aliquots and stored at 4°C. On D0, 14 and 28, 2.0ml of EMULSIGEN®-BCL (MVP) was added to 8.0ml of material slowly over 1 minute while stirring. Mixture was stirred for 10min then stored at 4°C.

[00100] PEDV vaccination: On D0, 14 and 28, the Investigator or designee administered the vaccine material to all pigs. Each pig received 2ml of the BEI inactivated PEDV vaccine, 1 ml of the BaculoDisplay-Spike prototype or 2ml of the placebo intramuscularly using a sterile needle and syringe appropriate for their age. On D0 and D28, the vaccine was given in the right neck musculature and on D14 it was given in the left neck musculature.

[0147] Tissue collection: Pigs were evaluated for macroscopic lesions. Abnormalities were recorded on the necropsy form. Fresh samples of small intestine and colon and fixed sections of lung, heart, spleen, kidney, small intestine, colon and liver were collected. Fresh samples were stored at BIVI-Ames at -70°C for a minimum of six months after the completion of the study. Fixed sections were stored at BIVI-Ames at room temperature for a minimum of six months after the completion of the study.

[0148] Viral assays: PEDV RT-PCR: Samples were screened by RT-PCR as described in Table 3. The quantitative one-step RT-PCR kit (ISCRIP™ One-Step RT-PCR kit for probes; BioRad, cat no. 170-8895) was used for the assay. Sequence information for the primers, probe and ultramer are as follows: PEDV-qPCR-probe, 5'-6-FAM/ACAGAGCCTGTGTTGGTGTATAGTAACAT-3'BHQ_1 (SEQ ID NO: 16); PEDV-qPCR-F, 5'-TATAGTGGGTGTTATTTCTAGTT-3' (SEQ ID NO: 17); PEDV-qPCR-R, 5'-

GCCAATACTGCCAGATTTACA-3' (SEQ ID NO: 18), PEDV-ultramer, 5'-TGATGATATAGTGGGTGTTATTTCTAGTTTGTCTAGCTCCACTTTTAACAGTACTAGG GAGTTGCCTGGTTTCTTCTACCATTTCTAATGATGGCTCTAATTGTACAGAGCCTGTGT TGGTGTATAGTAACATAGGTGTTTGTAAATCTGGCAGTATTGGCTATGTCCCAT-3' (SEQ ID NO: 19). Real-time RT-PCR was carried out in a 25µl reaction containing 2µl of extracted total nucleic acid, 0.75µl of probe (4µM), 0.5µl of each primer (10µM), 12.5µl of 2X RT-PCR mix, 0.5µl ISCRIP™ reverse transcriptase and 8.25µl of DEPC-treated water. The reaction took place using a CFX96 real-time PCR detection system (BioRad) under the following conditions: initial reverse transcription at 50°C for 30min, followed by initial denaturation at 95°C for 5 min, 40 cycles of denaturation at 95°C for 15s and annealing and extension at 57°C for 30s. The optical data were analyzed using CFX Manager software (version 2.1, BioRad). For each determination, the threshold lines were automatically calculated using the regression setting for cycle threshold (Ct) determination mode. Baseline subtraction was done automatically using the baseline subtracted mode. Curves with baseline end values of less than 10 were manually corrected. Samples were run in single reactions and quantitative amounts were determined using an ultramer-based standard curve and reported as genomic copies per microliter (gc/µl). Samples with no detection following 40 cycles were considered negative.

[0149] Anti-PEDV-IgG ELISA: Samples were screened by ELISA as described in Table 3. For the assay, plates were coated with 4ng/µl of PEDV-1251-125-2 for one hour at 37°C. Following washing, wells were coated with 100µl of a 1:100 diluted serum sample (for the IgG assay) and incubated for one hour at 37°C. Following washing, wells were blocked with 0.05% non-fat milk and incubated for one hour at 37°C. Following washing, wells were coated with 100µl of a 1:10,000 dilution of horse-radish peroxidase (HRP)-conjugated-goat-anti-swine-IgG and incubated for one hour at 37°C. Following washing, the plate was developed with 3,5,3',5'-tetramethylbenzidine for 5 minutes and the reaction was stopped with 2 M H₂SO₄ before optical density (OD) measurement at 450nm. Samples were run in duplicate wells and results are reported as the average sample to positive (S:P) ratio. As no cut-off values for positive versus negative interpretation have been generated for either of the ELISA assays, samples with S:P ratios greater than the sum of two standard deviations higher plus the highest control group mean were considered positive (S:P ratio > 0.28 or > 0.16 for the IgG assay).

[0150] **PEDV Fluorescent focus assay:** The PEDV FFN assay was run consisted of a duplicate serum dilution series screened in a 96-well plate format by a virus neutralization assay using a cell culture adapted PEDV stain. Titers were reported as the greatest serum dilution showing a 90% reduction of fluorescent foci in comparison to the negative control. For each sample, duplicate well titers were averaged.

[0151] **Statistical analysis of data:** Data analysis was performed using JMP 9.0.3 (SAS Institute, Inc., Cary, North Carolina, USA) by the Monitor. For all analysis, a p-value less than 0.05 was considered significant. For repeated measures of data (serology), a multiple analysis of variance was performed using time as the repeated variable in the model. If a significant p-value was noted, a one-way ANOVA was performed using group as the independent factor; separate analyses were done for each day. If a significant p-value was noted; pair-wise differences between group means were evaluated using Wilcoxon adjusted pairwise comparisons.

[0152] **Serology:** PEDV Fluorescent focus neutralization (FFN) assay: See Table 5 for individual animal results. All animals in the BEI-VH group showed four-fold increases in neutralizing titers, while only two of seven animals in Group 2 had a similar response. The control animals had no detectable neutralizing titers.

[0153] **Table 5. PEDV Fluorescent focus neutralization assay results for study D-1, 14, 28 and 49. Highlighted cells indicate titers greater than 0.**

Animal no.	PEDV group	Study day			
		-1	14	28	49
131	BEI-VH	0	0	80	120
132		0	0	60	80
134		0	0	40	80
142		0	0	160	80
143		0	0	80	160
146		0	0	30	60
148		0	0	40	160
133	Baculo-S	0	0	20	0
135		0	0	0	0
136		0	0	0	0
139		0	0	0	0
141		0	0	0	0
144		0	0	0	40
145		0	0	0	120
137	Control	0	0	0	0
138		0	0	0	0
140		0	0	0	0
147		0	0	0	0

[0154] **Anti-PEDV-IgG ELISA:** Sample to positive (S:P) ratios for individual animals are listed in Table 6 below. All animals in Group 1 (BEI-VH) had a detectable IgG response by D28 that was at least two standard deviations higher in comparison to mean S:P ratios of the control group. In contrast, only two animals in Group 2 (Baculo-S) had detectable IgG responses and only after receiving three doses of the vaccine. Group least square mean S:P ratios $\pm$ standard error are presented in **FIG 4**. By D28, animals in Group 1 (BEI-VH) had significantly higher S:P ratios in comparison to Group 2 and Group 3 ($p < 0.01$, Wilcoxon adjusted pairwise comparisons).

[0155] **Table 6. Individual anti-PEDV-IgG S:P ratios for D-1, 14, 28 and 49.**

Highlighted values indicate S:P ratios at least two standard deviations greater than the mean S:P ratios of the control group on D49.

Animal no.	PEDV group	Study days			
		D-1	D14	D28	D49
131	BEI-VH	0.078995	0.119838	0.452301	0.93054393
132		0.085278	0.126571	0.317992	0.58200837
134		0.069569	0.183124	0.328033	0.65230126
142		0.057002	0.094704	0.392887	0.62552301
143		0.049372	0.150808	0.351464	0.59874477
146		0.048923	0.079443	0.296653	0.65104603
148		0.069569	0.130162	0.498326	0.75774059
133	Baculo-S	0.066427	0.093806	0.086611	0.13807531
135		0.058348	0.109964	0.156904	0.28410042
136		0.04623	0.09605	0.094142	0.18995816
139		0.054309	0.067325	0.093305	0.18158996
141		0.051167	0.061041	0.079916	0.14937238
144		0.061041	0.14632	0.138075	0.34644351
145		0.042639	0.064183	0.079916	0.20292887
137	Control	0.05386	0.071364	0.135146	0.21464435
138		0.050269	0.062837	0.082427	0.21631799
140		0.048923	0.060144	0.089121	0.18661088
147		0.064632	0.090664	0.127615	0.25941423

[0156] **PEDV viremia/shedding:** To assess the potential for shedding and viremia following vaccination, serum and fecal samples were screened by RT-PCR for the presence of PEDV RNA on the fourth day following each vaccination (D3, D18 and D31). No PEDV RNA was detected in any of the samples.

[0157] **Conclusions:** Based on the combined serological data (IgG and FFN) of the above study, three doses of the PEDV Spike protein expressed by the BaculoDisplay method given at 866µg per dose and adjuvanted with EMULSIGEN®-BCL was not able to generate a consistent serological response. In this case, the lack of response indicates that the vaccine was either not sufficiently immunogenic (i.e. protein was not delivered in sufficient quantity or a non-suitable

adjuvant was used) or that the confirmation of the recombinant Spike protein was not similar to the wildtype virus.

[0158] Conversely, the anti-PEDV IgG and FFN serological data does suggest that two or three doses of the BEI inactivated PEDV viral harvest given at 5.6 log/dose and adjuvanted with EMULSIGEN®-BCL was able to consistently elicit a serological response in naïve swine. However, the average anti-PEDV-IgG S:P ratio in vaccinated animals was lower in comparison to animals administered feedback material. Specifically, the average anti-PEDV-IgG S:P ratio ($\pm$ standard deviation) in 45 animals from one herd administered feedback material prior to sampling was found to be 0.90 ± 0.20 in comparison to 0.69 ± 0.12 in vaccinated animals (data not shown). In addition, via personal communications with Dr. Eric Nelson, FFN titers in five of seven of the vaccinated animals in this study were below titers typically seen following feedback administration.

EXAMPLE 7:

Efficacy BEI Inactivated PEDV (Three Dose, Various Adjuvants)

(Study 2013131) – Troy Kaiser

[0159] The following study evaluated whether a vaccination with three 2-mL doses of a killed PEDV vaccine could elicit an immune response when administered to pigs three weeks of age at 14 day intervals. The primary outcome was serology tested by fluorescent focus neutralization (FFN).

[0160] Study groups included: T01 = PBS (n=10); T02 = 6.04 log TCID₅₀/ml BEI PEDV + 20% EMULSIGEN®-BCL (n=18); T03 = 6.04 log TCID₅₀/ml BEI PEDV + 10% EMULSIGEN-D® (n=20); T04 = 6.04 log TCID₅₀/ml BEI PEDV + 15% REHYDRAGEL®; T05 = 6.04 log TCID₅₀/ml BEI PEDV + 5% S:P oil (n=20).

[0161] Table 7. Vaccine Formulations and Controls

Treatment		Description
T01	Negative Control (NC)	Phosphate Buffered Saline (1x)
T02	Experimental Vaccine (EV)	PEDv at 6.04 log ₁₀ TCID ₅₀ /mL inactivated with binary ethyleneimine, adjuvanted with 20% EMULSIGEN®-BCL
T03	Experimental Vaccine (EV)	PEDv at 6.04 log ₁₀ TCID ₅₀ /mL inactivated with binary ethyleneimine, adjuvanted with 10% EMULSIGEN-D®
T04	Experimental Vaccine (EV)	PEDv at 6.04 log ₁₀ TCID ₅₀ /mL inactivated with binary ethyleneimine, adjuvanted with 15% REHYDRAGEL®
T05	Experimental Vaccine (EV)	PEDv at 6.04 log ₁₀ TCID ₅₀ /mL inactivated with binary ethyleneimine, adjuvanted with 5% S:P oil

[0162]

On D0, pigs were administered the 2-mL treatment intramuscularly in the right neck. A second treatment was administered on D14 in the left neck, and a third treatment was administered on D28 in the right neck for all groups. Blood samples were collected on D-1, D13, D27, D42, and D49. Serum was tested for PEDV neutralizing antibodies using FFN.

[0163] Serology: Seroconversion occurred in 11.2% of pigs after two vaccinations and 55.6% of pigs when vaccinated three times with PEDV vaccine adjuvanted with 20% Emulsigen BCL (T02; Table 8). The geometric mean titer for seropositive pigs $\geq 1:20$ for all treatment groups are presented below in Table 8. The frequency distribution of titers by treatment group of all pigs is presented in Table 9.

[0164] **Table 8. Proportion of seropositive pigs and geometric mean titer by group for pigs responding serologically**

Group	Pigs with $\geq 1:20$ Response	Geometric Mean Titer
T01	0/10 (0%)	Not applicable
T02	10/18 (55.6%)	1:45.9
T03	6/20 (30%)	1:44.8
T04	2/20 (10%)	1:40.0
T05	2/20 (10%)	1:56.6

[0165] **Table 9. Frequency distribution of titers by group**

Group	n	PEDv Neutralizing Antibodies*						
		<1:20	1:20	1:28	1:40	1:80	1:113	1:160
T01	10	10 (100%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
T02	18	8 (44.4%)	2 (11.1%)	1 (5.6%)	4 (22.2%)	1 (5.6%)	1 (5.6%)	1 (5.6%)
T03	20	14 (70.0%)	1 (5.0%)	1 (5.0%)	2 (10.0%)	1 (5.0%)	1 (5.0%)	0 (0.0%)
T04	20	18 (90.0%)	1 (5.0%)	0 (0.0%)	0 (0.0%)	1 (5.0%)	0 (0.0%)	0 (0.0%)
T05	20	18 (90.0%)	0 (0.0%)	0 (0.0%)	1 (5.0%)	1 (5.0%)	0 (0.0%)	0 (0.0%)

*Maximum titer on D42 or D49

[0166] **Conclusions:** Seroconversion occurred in 11.2% of T02 pigs after two doses and seroconversion occurred in 55.6% of pigs when vaccinated three times with the experimental vaccine formulated with 6.04 log₁₀ TCID₅₀/mL PEDv inactivated with binary ethyleneimine and adjuvanted with 20% Emulsigen BCL. The data collected from this study indicate that this experimental vaccine elicited an immune response that supports a claim of reasonable expectation of efficacy.

EXAMPLE 8:

Efficacy of Baculovirus Vaccines (Two Dose, Various Adjuvants)

(Study 2014236) Kara Claxton

[0167] The following study evaluated the serological response to vaccination with two 2-mL doses of a killed Porcine Epidemic Diarrhea Virus (PEDv) Vaccine, or a baculovirus construct vaccine, as measured after administration of either vaccine to pigs at three weeks of

age. The primary outcome was serology tested by fluorescent focus neutralization (FFN) for serum samples collected following vaccination in the treated pigs.

[0168] The study groups included: T01 = PBS (n=10); T02 = 6.93 log TCID₅₀/ml BEI PEDV + 20% EMULSIGEN®-BCL (n=20); T03 = Baculovirus with PEDV Spike Ag (n=9); 6x Concentrated Baculovirus with PEDV Spike Ag (n=10); Trypsin Baculovirus with PEDV Spike Ag (n=10); and Killed Positive Control vaccine conditionally licensed (POS CON) (n=10). On D0, pigs were administered the 2-mL treatment intramuscularly in the right neck. A second treatment was administered on D14 in the left neck for T01-T05 and on D21 for T06.

[0169] **Table 10: Vaccine Formulation and Controls**

Treatment		Description
T01	Negative Control (NC)	Saline (PBS 1x)
T02	Experimental Vaccine (EV)	Porcine epidemic diarrhea virus at 6.93 log ₁₀ TCID ₅₀ /mL PEDv inactivated with BEI, adjuvanted with 20% Emulsigen BCL.
T03	EV	Recombinant baculovirus with PEDv Spike glycoprotein displayed in the viral envelope.*
T04	EV	Recombinant baculovirus with PEDv Spike glycoprotein displayed in the viral envelope.* The clarified inactivated material was concentrated ~6X prior to formulation.
T05	EV	Recombinant baculovirus with PEDv Spike glycoprotein displayed in the viral envelope.* Recombinant PEDv Spike-Display Baculovirus was produced in insect cells with 10µg/mL trypsin added during infection.
T06	Positive Control (PC)	iPED+ (Harris vaccine – Conditionally Licensed)

BEI = binary ethyleneimine

*The PEDV Spike signal sequence and C-terminal tail were replaced with the baculovirus gp64 equivalent. Recombinant PEDv Spike-Display Baculovirus was produced in insect cells. Infected cultures were harvested and clarified by centrifugation and 0.2-µm filtration. Clarified harvest material was inactivated with 5mM BEI for 72 hours at 37°C then clarified by centrifugation and 0.2-µm filtration.

[0170] **Serology:** Seroconversion post-vaccination (D28 & D35) occurred in 20% of pigs vaccinated with PEDv vaccine adjuvanted with 20% Emulsigen BCL (T02; [0171]1) and 60% of pigs vaccinated with trypsin-grown PEDV SPIKE- baculovirus (T05; [0171]1). The geometric

mean titer for seropositive pigs $\geq 1:20$ for all treatment groups are presented below in [0171]1. The frequency distribution of titers by treatment group of all pigs is presented in Table 12.

[0171] **Table 11: Proportion of seropositive pigs and geometric mean titer by group for pigs responding serologically**

Group	Pigs with $\geq 1:20$ Response	Geometric Mean Titer
T01	0/10 (0%)	Not applicable
T02	4/20 (20%)	1:30.7
T03	0/9 (0%)	Not applicable
T04	0/10 (0%)	Not applicable
T05	6/10 (60%)	1:35.5
T06	7/10 (70%)	1:41.9

[0172] **Table 12: Frequency distribution of titers by group**

Group	n	PEDv Neutralizing Antibodies*							
		<1:20	1:20	1:28	1:40	1:57	1:80	1:113	1:160
T01	10	10 (100%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
T02	20	16 (80%)	1 (5%)	2 (10%)	0 (0.0%)	1 (5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
T03	9	9 (100%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
T04	10	10 (100%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
T05	10	4 (40%)	2 (20%)	2 (20%)	1 (10%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (10%)
T06	10	3 (30%)	2 (20%)	2 (20%)	0 (0.0%)	0 (0.0%)	2 (20%)	1 (10%)	0 (0.0%)

[0173] **Conclusion:** Seroconversion occurred in 20% of T02 pigs after two administrations of the experimental vaccine formulated with $6.93 \log_{10}$ TCID₅₀/mL PEDV inactivated with BEI and adjuvanted with 20% Emulsigen BCL. Seroconversion occurred in 60% of T05 pigs after two administrations of the experimental recombinant trypsin grown-baculovirus vaccine formulated with PEDV Spike glycoprotein.

EXAMPLE 9:**Efficacy Study****POC Efficacy (Study 2014030)—Abby Patterson**

[0174] The below study was designed to assess the efficacy of killed vaccine and other prototype vaccines in sows. The primary outcome parameter is piglet mortality following challenge with porcine epidemic diarrhea virus (PEDV). The secondary outcome parameter was dam serology. Other parameters measured included: clinical signs (including ISL) in sows following vaccination; PEDV shedding in sows following vaccination (via qRT-PCR); clinical signs in piglets; and PEDV serology in piglets

[0175] At four and two weeks pre-farrow (D0 and D14), each gestating dam was administered 2 mL of one of the following treatments by three routes (intramuscular, intranasal and oral): T01 (negative control, NC) phosphate buffered saline; T02 (BEI-VH) adjuvanted with 20% Emulsigen BCL; T03 (strict control, SC) served as non-vaccinated/non-challenged control. Eight animals were used per group, excluding T06 which had four animals. On D35 or D36, pigs were challenged orally with 1 mL of 2.0 log₁₀ TCID₅₀/mL PEDV viral harvest. Clinical signs (vomiting and diarrhea) in dams and pigs were observed daily during the challenge phase. Serum was collected from dams at four- and two-weeks pre-farrow (D0 and D14), the day prior to piglet challenge (D34 or D35) and the day of off-test (D57).

[0176] On D0 and D14, the PEDV prototype vaccines were administered to the sows. At each vaccination, the sows received a total of 6 mL of vaccine where 2 mL were administered by intramuscular, intranasal and oral route. For the intramuscular administration route, a 2 mL injection was given into the musculature of the neck below the ear. The side of the neck for administration was alternated for the initial and booster vaccination. For the oral administration route, 2 ml were delivered over the caudal oropharynx using an 8Fr polypropylene catheter (2.7mm diameter by 254mm length) attached to a syringe. For the intranasal route, 1 ml was injected into each nare using a 4.5 inch catheter attached to a syringe.

[0177] Table 13: Experimental Vaccine and Control Product

Treatment	Group	Serial #	Description
T01	NC	2842-182-D	1X Phosphate Buffered Saline; Gibco catalog no. 10010-023; Lot no.1510272
T02	BEI-VH	2842-182-E	KV-1251-125-10-OK, 0.2µm filtered, passage MSV+5, 6.04 log TCID ₅₀ /mL. Viral harvest was inactivated with 5mM BEI for 72hr at 37°C. For formulation, Emulsigen BCL (MVP lot no. 17006, manufacture date 2/11/11) was added at a 20% inclusion rate.

[0178] Table 14: Challenge Material

PEDV Challenge Strain:	Isolate id. 1251-140-4; passage 5
Challenge preparation:	Propagated in Vero cells
Dose of Challenge material:	1 mL at 2.0 log ₁₀ TCID ₅₀ /mL
Testing of Challenge Material:	Challenge virus was titrated prior to administration on 2013 EU Vero cells (5.03 TCID ₅₀ /ml) and diluted to 2 log TCID ₅₀ /mL.
Method of Administration:	Oral administration (by syringe) with pigs manually restrained.

[0179] Vaccine efficacy: Pig mortality: Pig mortality following challenge with a virulent PEDV isolate was the primary outcome parameter used to assess vaccine efficacy. A summary of mortality by group during the challenge period is listed below. With 55% mortality and all litters affected in T01 (NC), the challenge was considered sufficiently virulent. In comparison to T01 (NC), T02 (BEI-VH) demonstrated a numerical reduction in pig mortality with a PF (95% CI) of 0.20 (-0.550, 0.586). The reduction was not statistically significant as the 95% CI (-0.550, 0.586) included zero.

[0180] Extra-binomial variation was evident in this study, resulting in a wide confidence interval for T02 (BEI-VH) PF when utilizing the underlying binomial distribution. Mortality varied greatly among litters within a group, including ranging from 0% to 100% for T02 (BEI-VH).

[0181] An intestinal sample or intestinal content was taken at the time necropsy and tested by qRT-PCR to detect PEDV antigen. Of samples tested from animals during the time of peak mortality, PEDV was detected in 55.5% of samples.

[0182] **Table 15:**

Group	Proportion Mortality Estimate	Standard Error	Prevented Fraction*	95% Confidence interval	Median Mortality	Minimum %/ Maximum %
NC	0.55	0.11	.	.	52.78	12.50 / 100.00
BEI-VH	0.44	0.10	0.20	(-0.550, 0.586)	34.29	0.00 / 100.00

*Based on T01 (NC) proportion affected.

**NC=Not Calculated. Confidence Interval possible for T02 (BEI-VH) based on study design

[0183] **Sow serology:** Fluorescent Focus Neutralizing (FFN) assay: The FFN assay was used to assess the dam virus neutralizing response following vaccination and challenge. Geometric mean titers listed by group are presented below for days on which blood was collected from sows.

[0184] Following two doses of vaccine, 2/8 (25%) of sows in T02 (BEI-VH) had detectable levels of neutralizing antibody. Detectable levels of neutralizing antibody were not observed in any of the other groups.

[0185] Following lateral exposure to PEDV, all sows in exposed treatment groups had detectable levels of neutralizing antibody. Animals in T03 (SC) group remained seronegative throughout the trial. The geometric mean titer on D57 (approximately 21 days post-exposure) indicated that vaccination resulted in numerically higher titers in comparison to T01 (NC). Sows in T02 (BEI-VH) group had a GMT of 613, which is an approximately three-fold higher titer in comparison to the GMT of 200 for sows in T01 (NC) ($p=0.005$). As multiple samples in T02 (BEI-VH) group had detectable neutralizing antibodies at the highest dilution tested (1:640), these results likely represent a conservative estimate of the differences between groups.

[0186] **Table 16:**

Treatment	Group	Geometric Mean Titer*			
		Study Day**			
		D0	D14	D34 or D35	D57
T01	NC	<20	<20	<20	200
T02	BEI-VH	<20	<20	15	613
T03	SC	<20	<20	<20	<20

Where all values were <20, geometric mean titer is presented as <20. Otherwise, values of <20 were set to 10 for GMT calculation

**D57 GMT for T01 (NC) and T02 (BEI-VH) are back-transformed Least-Squares Means

[0187] **S1-based ELISA data:** An S1-based ELISA was used to assess the dam's response to the PEDV-spike protein following vaccination and challenge. Assay results for colostrum, milk and serum are listed by group for days on which samples were collected.

[0188] At the time of pig challenge, sows in T02 (BEI-VH) had significantly higher geometric mean titer in serum as compared to sows in T01 (NC) ($p=0.0005$). Following exposure to PEDV, a larger significant difference was noted between the two groups ($p<0.0001$).

[0189] Significant differences in geometric mean titers of anti-PEDV IgA in colostrum and in milk were not observed between T02 (BEI-VH) and T04 (NC).

[0190] Table 17:

Treatment	Group	Geometric Mean Titer*			
		Study Day			
		D27 through D32: Colostrum	D34 or D35: Serum	D57: Serum	D57: Milk
T01	NC	0.186	0.098	0.504	0.220
T02	BEI-VH	0.139	0.256	1.499	0.244
T03	SC	0.134	0.125	0.164	0.088

* GMT for T01 (NC) and T02 (BEI-VH) are back-transformed Least-Squares Means

[0191] **Pig serology**: Serum was collected at the time of necropsy from pigs to evaluate the presence of neutralizing antibodies. The table below presents the geometric mean FFN titers of positive pigs by group. The table also includes the frequency of detection expressed as the number of pigs with a GMT greater than or equal to 20 over the number of animals tested. Testing was performed on all available samples. Samples from numerous pigs were unable to be obtained due to the time difference between death and necropsy.

[0192] Descriptive statistics for FFN titers by mortality status (Died: Yes/No) and group (Overall) are listed below. Overall, a similar proportion of pigs in the vaccinated groups seroconverted (or had maternal antibodies) regardless of time of necropsy. However, in T01 (NC), a higher percentage of pigs that died prior to off test had titers (88%) in comparison to pigs that lived for the duration of the study (43%).

[0193] When looking at the overall pig titers by group, the proportion mortality estimate was inversely related to the overall group FFN percentage for T02 (BEI-VH).

[0194] Table 18:

Group	Pigs (Died = yes)	Pigs (Died = no)	Overall	Proportion Mortality Estimate
NC	55 (28/32; 88%)	33 (9/21; 43%)	63 (37/53; 59%)	0.55
BEI-VH	44 (23/42; 55%)	50 (9/16; 56%)	64 (32/58; 55%)	0.44

* GMT (no. animals titer ≥ 20 / total pigs tested; percentage); note that serum was not obtained from all pigs

[0195] Clinical observations following challenge: Pig fecal scores: Descriptive statistics for the duration of abnormal fecal observations in pigs, by group and mortality status (Died: Yes/No), are listed below. Overall, the median duration of abnormal fecal scores in pigs with the same mortality status was similar among groups. In animals that died or were euthanized, there was a numerically shorter median duration of abnormal fecal scores. This trend was most evident in T01 (NC) pigs and is likely secondary to the fact that the majority of these animals died within the first week following challenge.

[0196] Table 19:

Duration (days) abnormal fecal score						
Died	Group	# pigs	Median	Minimum	Maximum	Std Dev
No	NC	32	5.5	3.5	7.0	0.8
	BEI-VH	42	6.0	4.5	8.5	0.8
Yes	NC	39	2.3	0.5	6.0	1.3
	BEI-VH	33	4.3	2.0	6.0	1.4

[0197] The severity of fecal scores in pigs is summarized in the frequency table below. In all treatment groups a high portion of pigs (>91%) presented with a fecal score of 2 during at least one observation following challenge.

[0198] Table 20:

Group	Maximum Fecal Score			
	0	1	2	Total
NC	1 1.41	5 7.04	65 91.55	71
BEI-VH	1 1.33	0 0.00	74 98.67	75
Total	2	5	139	146

[0199] Conclusions: A 20% reduction in pig mortality was observed in T02 (BEI-VH) as compared to T01 (NC) group. Three routes of administration were attempted in this study. Although 3 routes were used, there is no expectation that routes other than IM contributed to the efficacy of T02 (BEI-VH) based on the adjuvant and vaccine formulation. Overall the inactivated PEDV adjuvanted with 20% EMULSIGEN-BCL® vaccine with a minimum pre-inactivation titer of 6.04 log TCID₅₀/ml appears to induce better immune responses in the piglets and sows. The preferred vaccination schedule is IM route of administration for piglets 3 weeks of age or older, three 2 ml doses at 2-week intervals. Clinical signs in sows following vaccination were not observed in T02 (BEI-VH) and were limited in the other treatment groups. The use of vaccination did not appear to affect the percentage of pigs born live (data not shown).

[0200] Dam serology was evaluated as a secondary parameter by two separate assays (focus fluorescent neutralization, S1-based ELISA). Both assays indicated a significant increase in titer in T02 (BEI-VH) following vaccination and exposure as compared to T01 (NC). Due to known limitations of the FFN assay, samples were also tested by an S1-based ELISA. This ELISA was chosen as the S1 domain of the spike protein is expected to contain neutralizing epitopes.

[0201] Following lateral exposure to PEDV, all animals in exposed treatment groups had detectable levels of neutralizing antibody. Sows in T02 (BEI-VH) had approximately three-fold higher titers in comparison to the T01 (NC) animals. This is evidence that use of the vaccine stimulated an initial primary response and resulted in a greater secondary response following

exposure to the challenge virus. As multiple samples in T02 (BEI-VH) group had detectable neutralizing antibodies at the highest dilution tested (1:640), these results likely represent a conservative estimate of the differences between groups.

[0202] Table 21: Pig mortality and sow serological data are summarized below.

Treatment	Group	FFN (Sow serum, D21)	IgG ELISA (Sow serum, D21)	Pig Mortality (%)	Prevented Fraction (pig mortality)
T01	NC	200	0.504	55%	.
T02	BEI-VH	613	1.499	44%	0.20
T03	SC	<20	0.164	NA	NA

[0203] All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the following claims.

[0204] The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

1. Bridgen A, Duarte M, Tobler K, Laude H, Ackermann M. 1993. Sequence determination of the nucleocapsid protein gene of the porcine epidemic diarrhoea virus confirms that this virus is a coronavirus related to human coronavirus 229E and porcine transmissible gastroenteritis virus. J. Gen. Virol. 74 (Pt 9):1795–1804.
2. Duarte M, Gelfi J, Lambert P, Rasschaert D, Laude H. 1993. Genome organization of porcine epidemic diarrhoea virus. Adv. Exp. Med. Biol. 342:55–60

3. Tobler K, Bridgen A, Ackermann M. 1993. Sequence analysis of the nucleocapsid protein gene of porcine epidemic diarrhoea virus. *Adv. Exp. Med. Biol.* 342:49–54.
4. Oldham J. 1972. Letter to the editor. *Pig Farming* 1972(October suppl):72–73.
5. Pensaert MB, de Bouck P. 1978. A new coronavirus-like particle associated with diarrhea in swine. *Arch. Virol.* 58:243–247.
6. Chen JF, Sun DB, Wang CB, Shi HY, Cui XC, Liu SW, Qiu HJ, Feng L. 2008. Molecular characterization and phylogenetic analysis of membrane protein genes of porcine epidemic diarrhea virus isolates in China. *Virus Genes* 36:355–364.
7. Nagy B, Nagy G, Meder M, Mocsári E. 1996. Enterotoxigenic *Escherichia coli*, rotavirus, porcine epidemic diarrhoea virus, adenovirus and calici-like virus in porcine postweaning diarrhoea in Hungary. *Acta Vet. Hung.* 44:9–19.
8. Martelli P, Lavazza A, Nigrelli AD, Merialdi G, Alborali LG, Pensaert MB. 2008. Epidemic of diarrhoea caused by porcine epidemic diarrhoea virus in Italy. *Vet. Rec.* 162:307–310.
9. Takahashi K, Okada K, Ohshima K. 1983. An outbreak of swine diarrhea of a new-type associated with coronavirus-like particles in Japan. *Nippon Juigaku Zasshi* 45:829–832.
10. Chae C, Kim O, Choi C, Min K, Cho WS, Kim J, Tai JH. 2000. Prevalence of porcine epidemic diarrhoea virus and transmissible gastroenteritis virus infection in Korean pigs. *Vet. Rec.* 147:606–608
11. Puranaveja S, Poolperm P, Lertwatcharasarakul P, Kesdaengsakonwut S, Boonsoongnern A, Urairong K, Kitikoon P, Choojai P, Kedkovid R, Teankum K, Thanawongnuwech R. 2009. Chinese-like strain of porcine epidemic diarrhea virus, Thailand. *Emerg. Infect. Dis.* 15:1112–1115.
12. Stevenson GW, Hoang H, Schwartz KJ, Burrough ER, Sun D, Madson D, Cooper VL, Pillatzki A, Gauger P, Schmitt BJ, Koster LG, Killian ML, Yoon KJ. 2013. Emergence of porcine epidemic diarrhea virus in the United States: clinical signs, lesions, and viral genomic sequences. *J. Vet. Diagn. Invest.* 25:649–654.
13. Kim SH, Kim IJ, Pyo HM, Tark DS, Song JY, Hyun BH. 2007. Multiplex real-time RT-PCR for the simultaneous detection and quantification of transmissible gastroenteritis virus and porcine epidemic diarrhea virus. *J. Virol. Methods* 146:172–177.
14. Hofmann M, Wyler R. 1988. Propagation of the virus of porcine epidemic diarrhea in cell culture. *J. Clin. Microbiol.* 26:2235–2239.
15. Marthaler D, Jiang Y, Otterson T, Goyal S, Rossow K, Collins J. 2013. Complete genome sequence of porcine epidemic diarrhea virus strain USA/Colorado/2013 from the United States. *Genome Announc.* 1(4):e00555-13.10.1128/genomeA.00555-13
16. Song D, Park B. 2012. Porcine epidemic diarrhoea virus: a comprehensive review of molecular epidemiology, diagnosis, and vaccines. *Virus Genes* 44:167–175.
17. Huang YW, Dickerman AW, Piñeyro P, Li L, Fang L, Kiehne R, Opriessnig T, Meng XJ. 2013. Origin, evolution, and genotyping of emergent porcine epidemic diarrhea virus strains in the United States. *mBio* 4(5):e00737-13.

18. Bi J, Zeng S, Xiao S, Chen H, Fang L. 2012. Complete genome sequence of porcine epidemic diarrhea virus strain AJ1102 isolated from a suckling piglet with acute diarrhea in China. *J. Virol.* 86:10910–10911.
19. Chen J, Wang C, Shi H, Qiu HJ, Liu S, Shi D, Zhang X, Feng L. 2011. Complete genome sequence of a Chinese virulent porcine epidemic diarrhea virus strain. *J. Virol.* 85:11538–11539.
20. Chen J, Liu X, Shi D, Shi H, Zhang X, Feng L. 2012. Complete genome sequence of a porcine epidemic diarrhea virus variant. *J. Virol.* 86:3408.10.1128/JVI.07150-11
21. Fan H, Zhang J, Ye Y, Tong T, Xie K, Liao M. 2012. Complete genome sequence of a novel porcine epidemic diarrhea virus in south China. *J. Virol.* 86:10248–10249.
22. Gao Y, Kou Q, Ge X, Zhou L, Guo X, Yang H. 2013. Phylogenetic analysis of porcine epidemic diarrhea virus field strains prevailing recently in China. *Arch. Virol.* 158:711–715.
23. Li B, Liu H, He K, Guo R, Ni Y, Du L, Wen L, Zhang X, Yu Z, Zhou J, Mao A, Lv L, Hu Y, Yu Y, Zhu H, Wang X. 2013. Complete genome sequence of a recombinant porcine epidemic diarrhea virus strain from eastern China. *Genome Announc.* 1(2):e00105-13.10.1128/genomeA.00105-13
24. Luo Y, Zhang J, Deng X, Ye Y, Liao M, Fan H. 2012. Complete genome sequence of a highly prevalent isolate of porcine epidemic diarrhea virus in south China. *J. Virol.* 86:9551–9551.
25. Wang XM, Niu BB, Yan H, Gao DS, Huo JY, Chen L, Chang HT, Wang CQ, Zhao J. 2013. Complete genome sequence of a variant porcine epidemic diarrhea virus strain isolated in central China. *Genome Announc.* 1(1):e00243-12.10.1128/genomeA.00243-12
26. Wei ZY, Lu WH, Li ZL, Mo JY, Zeng XD, Zeng ZL, Sun BL, Chen F, Xie QM, Bee YZ, Ma J-Y. 2012. Complete genome sequence of novel porcine epidemic diarrhea virus strain GD-1 in China. *J. Virol.* 86:13824–13825.
27. Zhao M, Sun Z, Zhang Y, Wang G, Wang H, Yang F, Tian F, Jiang S. 2012. Complete genome sequence of a Vero cell-adapted isolate of porcine epidemic diarrhea virus in eastern China. *J. Virol.* 86:13858–13859.
28. S.H. Chang, J.L. Bae, T.J. Kang, J. Kim, G.H. Chung, C.W. Lim, H. Laude, M.S. Yang, Y.S. Jang. 2002. Identification of the epitope region capable of inducing neutralizing antibodies against the porcine epidemic diarrhea virus. *Mol. Cells* **14**, 295 – 299.
29. D.J. Cruz, C.J. Kim, H.J. Shin. 2008. The GPRLQPY motif (SEQ ID NO: 20) located at the carboxy-terminal of the spike protein induces antibodies that neutralize Porcine epidemic diarrhea virus. *Virus Res.* **132**, 192 – 196.
30. M. Godet, J. Grosclaude, B. Delmas, H. Laude. 1994. Major receptor-binding and neutralization determinants are located within the same domain of the transmissible gastroenteritis virus (coronavirus) spike protein. *J. Virol.* **68**, 8008 – 8016.
31. M.W. Jackwood, D.A. Hilt, S.A. Callison, C.W. Lee, H. Plaza, E. Wade. 2001. Spike glycoprotein cleavage recognition site analysis of infectious bronchitis virus. *Avian Dis.* **45**, 366 – 372.

32. L.S. Sturman, K.V. Holmes. 1984 Proteolytic cleavage of peplomeric glycoprotein E2 of MHV yields two 90K subunits and activates cell fusion. *Adv. Exp. Med. Biol.* **173**, 25 – 35.
33. D. Sun, L. Feng, H. Shi, J. Chen, X. Cui, H. Chen, S. Liu, Y. Tong, Y. Wang, G. Tong. 2008. Identification of two novel B cell epitopes on porcine epidemic diarrhea virus spike protein. *Vet. Microbiol.* **131**, 73 – 81.
34. S.J. Park, H.J. Moon, J.S. Yang, C.S. Lee, D.S. Song, B.K. Kang, B.K. Park. 2007. Sequence analysis of the partial spike glycoprotein gene of porcine epidemic diarrhea viruses isolated in Korea. *Virus Genes* 35, 321–332.
35. L.J. Saif. 1993. Coronavirus immunogens. *Vet. Microbiol.* 285–297.
36. S.J. Park, H.K. Kim, D.S. Song, H.J. Moon, B.K. Park. 2011 Molecular characterization and phylogenetic analysis of porcine epidemic diarrhea virus (PEDV) field isolates in Korea. *Arch. Virol.* 156, 577–585.
37. D.S. Song, J.S. Yang, J.S. Oh, J.H. Han, B.K. Park. Differentiation of a Vero cell adapted porcine epidemic diarrhea virus from Korean field strains by restriction fragment length polymorphism analysis of ORF 3. 2003. *Vaccine* 21, 1833–1842.
38. D.S. Song, J.S., B.K. Park. 2012 Porcine epidemic diarrhoea virus: a comprehensive review of molecular epidemiology, diagnosis, and vaccines. *Virus Genes* 44, 167-175.
39. J.F. Chen, D.B. Sun, C.B. Wang, H.Y. Shi, X.C. Cui, S.W. Liu, H.J. Qiu, L. Feng. 2008. Molecular characterization and phylogenetic analysis of membrane protein genes of porcine epidemic diarrhea virus isolates in China. *Virus Genes* 36, 355–364.
40. L. Yuan, S.Y. Kang, L.A. Ward, T.L. To, L.J. Saif. 1998 Antibody-secreting cell responses and protective immunity assessed in gnotobiotic pigs inoculated orally or intramuscularly with inactivated human rotavirus. *J. Virol.* 72, 330–338.
41. C.H. Kweon, B.J. Kwon, J.G. Lee, G.O. Kwon, Y.B. Kang. 1999. Derivation of attenuated porcine epidemic diarrhea virus (PEDV) as vaccine candidate. *Vaccine* **17**, 2546–2553.
42. Y. Usami, O. Yamaguchi, K. Kumanomido, Y. Matsumura. 1998. Antibody response of pregnant sows to porcine epidemic diarrhea virus live vaccine and maternally-derived antibodies of the piglets. *J. Jpn. Vet. Med. Assoc.* **51**, 652–655.
43. L.A. Ward, L. Yuan, B.I. Rosen, T.L. To, L.J. Saif. 1996. Development of mucosal and systemic lymphoproliferative responses and protective immunity to human group A rotaviruses in a gnotobiotic pig model. *Clin. Diagn. Lab. Immunol.* **3**, 342–350.
44. A. Pijpers, A.P. van Nieuwstadt, C. Terpstra, J.H. Verheijden. 1993. Porcine epidemic diarrhoea virus as a cause of persistent diarrhoea in a herd of breeding and finishing pigs. *Vet. Rec.* 132, 129–131.
45. T. Sato, Takeyama, N., Katsumata, A., Tuchiya, K., Kodama, T., Kusanagi, K. 2011. Mutations in the spike gene of porcine epidemic diarrhea virus associated with growth adaptation in vitro and attenuation of virulence in vivo. *Virus Genes*, 43, 1, 72.
46. Park, S.J., Kim, H.K., Song, D.S., An, D.J. and Park, B.K. 2012. Complete genome sequences of a Korean virulent porcine epidemic diarrhea virus and its attenuated counterpart J. *Virol.* 86 (10), 5964 .

47. Kusanagi K, Kuwahara H, Katoh T, Nunoya T, Ishikawa Y, Samejima T, Tajima M. 1992. Isolation and serial propagation of porcine epidemic diarrhea virus in cell cultures and partial characterization of the isolate. J Vet Med Sci. 1992 Apr;54(2):313-8.
48. Hofmann M, Wyler R. 1988. Propagation of the virus of porcine epidemic diarrhea in cell culture. J Clin Microbiol. Nov;26(11):2235-9.
49. de Arriba ML, Carvajal A, Pozo J, Rubio P. 2002. Mucosal and Systemic Isotype-specific Antibody Responses and Protection in Conventional Pigs Exposed to Virulent or Attenuated Porcine Epidemic Diarrhoea Virus. Vet Immunol Immunopathol. 85(1-2): p. 85-97.

CLAIMS

What is claimed is:

1. A vaccine comprising one or more antigens of porcine epidemic diarrhea virus (PEDV) of genotype 2a.
2. The vaccine according to claim 1, wherein the porcine epidemic diarrhea virus (PEDV) is of North American origin.
3. The vaccine according to claim 2, wherein the porcine epidemic diarrhea virus (PEDV) of North American genotype is any PEDV:
 - a) that is encoded by SEQ ID NO:1, and/or comprises the sequence of SEQ ID NO:1 and/or comprises the RNA equivalent of SEQ ID NO:1;
 - b) which sequence is at least 99% identical with SEQ ID NO:1 and/or is at least 99% identical with the RNA equivalent of SEQ ID. NO:1 ;
 - c) which spike protein is encoded by nucleic acid sequences of SEQ ID NO:2, 6, 8, or 13;
 - d) which spike protein is encoded by a nucleic acid sequence that is at least 90% identical with the SEQ ID NO:2, 6, 8, or 13;
 - e) that is encoded by SEQ ID NO:15; or
 - f) which sequence is at least 99% identical SEQ ID NO:15.
4. The vaccine of claim 1, wherein the vaccine is recombinant vaccine or a killed vaccine.
5. The vaccine of claim 1, wherein the vaccine is killed vaccine.
6. The vaccine according to claim 5, wherein the porcine epidemic diarrhea virus (PEDV) is any PEDV:
 - a) that is encoded by SEQ ID NO:1 and/or or comprises the sequence of SEQ ID NO:1, and/or comprises the RNA equivalent of SEQ ID NO:1;
 - b) which sequence is at least 99% identical with SEQ ID NO:1, and/or is at least 99% identical with the RNA equivalent of SEQ ID NO:1,

- c) which spike protein is encoded by nucleic acid sequences of SEQ ID NO:2, 6, 8, or 13;
 - d) which spike protein is encoded by a nucleic acid sequence that is at least 90% identical with the SEQ ID NO:2, 6, 8, or 13;
 - e) that is encoded by SEQ ID NO:15; and/or
 - f) which sequence is at least 99% identical SEQ ID NO:15.
7. The vaccine of claim 5, wherein the porcine epidemic diarrhea virus (PEDV) is chemically inactivated.
 8. The vaccine of claim 7, wherein the porcine epidemic diarrhea virus (PEDV) is chemically inactivated by treatment with a chemical inactivating agent which includes a compound selected from the group consisting of ethylenimine, binary ethylenimine, acetythylenimine and mixtures thereof.
 9. The vaccine of claim 8, wherein the porcine epidemic diarrhea virus (PEDV) is chemically inactivated by treatment with binary ethylenimine.
 10. The vaccine of claim 5, wherein the vaccine further comprises an adjuvant.
 11. The vaccine of claim 10, wherein the adjuvant is an EMULSIGEN® oil-in-water emulsion-based adjuvant.
 12. The vaccine of claim 6, wherein the porcine epidemic diarrhea virus (PEDV) comprises SEQ ID NO:1, and/or comprises the RNA equivalent of SEQ ID NO:1.
 13. The vaccine of claim 4, wherein the vaccine is recombinant vaccine.
 14. The vaccine of claim 13, wherein such recombinant vaccine comprises one or more immunogenic components selected from the group consisting of :
 - a) an isolated nucleic acid encoding an antigen of porcine epidemic diarrhea virus (PEDV) spike protein, wherein the recombinant Spike polypeptide has at least 90% homology with SEQ ID NO:3, 7, 9 or 14,
 - b) a vector comprising the isolated nucleic acid of a),

- c) the recombinant PEDV Spike protein encoded by the nucleic acid of a), and
 - d) any combination thereof.
- 15. The vaccine of claim 13, wherein such vaccine comprises a pharmaceutical acceptable carrier and/or excipient.
 - 16. The vaccine of claim 15, wherein the excipient is one or more adjuvants.
 - 17. The vaccine of claim 16, wherein the adjuvant is an EMULSIGEN® oil-in-water emulsion-based adjuvant.
 - 18. The vaccine of claim 13, wherein the vaccine further comprises one or more additional antigens.
 - 19. The vaccine of claim 18, wherein the additional antigen is structural protein M, E, or N of a porcine epidemic diarrhea virus (PEDV).
 - 20. The vaccine of claim 14, wherein an immunogenic component is the isolated nucleic acid.
 - 21. The vaccine of claim 14, wherein an immunogenic component is the vector.
 - 22. The vaccine of claim 14, wherein an immunogenic component is the recombinant porcine epidemic diarrhea virus (PEDV) Spike protein.
 - 23. The vaccine of claim 14 wherein an immunogenic component is a combination.
 - 24. A method for protecting a pig against diseases associated with porcine epidemic diarrhea virus (PEDV), comprising administering to such pig the vaccine of claim 1.
 - 25. A method for protecting a pig against diseases associated with porcine epidemic diarrhea virus (PEDV), comprising administering to such pig the vaccine of claim 5.
 - 26. A method for protecting a pig against diseases associated with porcine epidemic diarrhea virus (PEDV), comprising administering to such pig the vaccine of claim 13.
 - 27. The method of 24, wherein such vaccine comprises one or more immunogenic components selected from the group consisting of:
 - a) that is encoded by SEQ ID NO:1, and/or comprises the sequence of SEQ ID NO:1, and/or comprises the RNA equivalent of SEQ ID NO:1;

- b) which sequence is at least 99% identical with the SEQ ID NO:1, and/or is at least 99% identical with the RNA equivalent of SEQ ID. NO:1;
 - c) which Spike protein is encoded by nucleic acid sequences of SEQ ID NO:2, 6, 8, or 13;
 - d) which Spike protein is encoded by a nucleic acid sequence that is at least 90% identical with the SEQ ID NO:2, 6, 8, or 13;
 - e) that is encoded by SEQ ID NO:15; and
 - f) which sequence is at least 99% identical SEQ ID NO:15.
28. The method of 25, wherein such vaccine comprises one or more immunogenic components selected from the group consisting of:
- a) that is encoded by or comprises the sequence of SEQ ID NO:1,
 - b) which sequence is at least 99% identical with the SEQ ID NO:1,
 - c) which spike protein is encoded by nucleic acid sequences of SEQ ID NO:2, 6, 8, or 13, and
 - d) which spike protein is encoded by a nucleic acid sequence that is at least 90% identical with the SEQ ID NO:2, 6, 8, or 13.
29. The method of claim 26, wherein such recombinant vaccine comprises one or more immunogenic components selected from the group consisting of :
- a) an isolated nucleic acid encoding an antigen of porcine epidemic diarrhea virus (PEDV) spike protein, wherein the recombinant Spike polypeptide has at least 90% homology with SEQ ID NO:3, 7, 9 or 14,
 - b) a vector comprising the isolated nucleic acid of a),
 - c) the recombinant PEDV Spike protein encoded by the nucleic acid of a), and
 - d) any combination thereof.
30. A kit for vaccinating a pig against diseases associated with porcine epidemic diarrhea virus (PEDV) comprising:
- a) a dispenser capable of administering a vaccine to a pig; and

- b) the vaccine according to claim 1.
31. A kit for vaccinating a pig against diseases associated with porcine epidemic diarrhea virus (PEDV) comprising:
- a) a dispenser capable of administering a vaccine to a pig; and
 - b) the vaccine according to claim 5.
32. A kit for vaccinating a pig against diseases associated with porcine epidemic diarrhea virus (PEDV) comprising:
- a) a dispenser capable of administering a vaccine to a pig; and
 - b) the vaccine according to claim 13.
33. A method of producing a porcine epidemic diarrhea vaccine according to claim 5 comprising:
- (a) inoculating simian cells with the porcine epidemic diarrhea virus (PEDV);
 - (b) incubating the inoculated simian cells;
 - (c) harvesting porcine epidemic diarrhea virus (PEDV) from the incubated cells; and
 - (d) treating the harvested cells with a chemical inactivating agent, preferably with a compound selected from the group consisting of ethylenimine, binary ethylenimine, acetylenimine or a mixture thereof to form inactivated PEDV vaccine.
34. The method of claim 33, wherein the porcine epidemic diarrhea virus (PEDV) comprises:
- a) a sequence that is encoded by or comprises the sequence of SEQ ID NO:1,
 - b) a sequence that is at least 99% identical with the SEQ ID NO:1,
 - c) a spike protein that is encoded by nucleic acid sequences of SEQ ID NO:2, 6, 8, or 13,
 - d) a spike protein that is encoded by a nucleic acid sequence that is at least 90% identical with the SEQ ID NO:2, 6, 8, or 13.
35. The method of claim 34, wherein the porcine epidemic diarrhea virus (PEDV) of genogroup 2a comprises SEQ ID NO:1 and/or the RNA equivalent of SEQ ID NO:1.

36. The method of claim 33, wherein the simian cells are Vero cells.
37. The method of claim 33, wherein the chemical inactivating agent includes binary ethylenimine.
38. The method of claim 33, further comprising adding an adjuvant to the porcine epidemic diarrhea virus (PEDV) vaccine.
39. The method of claim 38, further comprising adding an adjuvant to the with a porcine epidemic diarrhea virus (PEDV) vaccine wherein the adjuvant is an EMULSIGEN® oil-in-water emulsion-based adjuvant.
40. A method of producing a recombinant vaccine of claim 13 comprising:
- a) expressing the one or more antigens of porcine epidemic diarrhea virus (PEDV) in a host cell, and
 - b) harvesting the one or more antigens of porcine epidemic diarrhea virus (PEDV) cells.
41. The method of claim 40, wherein the one or more antigens comprises:
- a) an isolated nucleic acid encoding an antigen of porcine epidemic diarrhea virus (PEDV) spike protein, wherein the recombinant Spike polypeptide has at least 90% homology with SEQ ID NO:3, 7, 9 or 14,
 - b) a vector comprising the isolated nucleic acid of a),
 - c) the recombinant PEDV Spike protein encoded by the nucleic acid of a), and
 - d) any combination thereof.
42. The method of claim 40, wherein recombinant the one or more antigens of porcine epidemic diarrhea virus (PEDV) is expressed by a recombinant baculovirus vector.
43. The method of claim 42, wherein recombinant the one or more antigens of porcine epidemic diarrhea virus (PEDV) is expressed in insect cells.
44. The method of claim 43, further comprising adding an adjuvant to the porcine epidemic diarrhea virus (PEDV) vaccine.

45. The method of claim 44, further comprising adding an adjuvant to the with a porcine epidemic diarrhea virus (PEDV) vaccine wherein the adjuvant is an EMULSIGEN® oil-in-water emulsion-based adjuvant.
46. The vaccine according to claim 1, wherein one or more antigens of porcine epidemic diarrhea virus (PEDV) of genotype 2 is a porcine epidemic diarrhea virus (PEDV) of genotype 2a.
47. One or more antigens of porcine epidemic diarrhea virus (PEDV) of genotype 2a for use as a medicament, wherein the one or more antigens of PEDV is preferably selected from the group consisting of: a PEDV of genotype 2a, wherein said PEDV is optionally the PEDV of any one of claims 2, 3, or of any one of claims 6 to 9; one or more immunogenic components of PEDV of genotype 2a, wherein said one or more immunogenic components of PEDV is optionally the one or more immunogenic components of any one of claims 27 to 29, or 46.
48. The vaccine of any one of claims 1 to 23, or 46 for use in a method for protecting a pig against diseases associated with porcine epidemic diarrhea virus (PEDV).
49. Use of one or more antigens of porcine epidemic diarrhea virus (PEDV) of genotype 2a for the preparation of a medicament for protecting a pig against diseases associated with porcine epidemic diarrhea virus (PEDV), wherein the one or more antigens of PEDV is preferably selected from the group consisting of: a PEDV of genotype 2a, wherein said PEDV is optionally the PEDV of any one of claims 2, 3, or of any one of claims 6 to 9, one or more immunogenic components of PEDV of genotype 2a, wherein said one or more immunogenic components of PEDV is optionally the one or more immunogenic components of any one of claims 27 to 29, or 46.

1/66

FIG. 1

PEDV 1251-125-10 (125-10) near-complete genome (SEQ ID NO:1) aligned to closest Chinese PEDV G2a strain: AH2012 (GenBank Accn #: KC210145) (nucleotides 45-28031 of SEQ ID NO:10).

125_10	1	GACTCTTGTCTACTCAATTCAACTAAACGAAATTCCTTGTCTTCCGGCCGCATGTCCAT	60
AH2012	45	GACTCTTGTCTACTCAATTCAACTAAACGAAATT--TTGTCTTCCGGCCGCATGTCCAT	102
125_10	61	GCTGCTGGAAGCTGACGTGGAATTTTATTAGGTTTGCTTAAGTAGCCATCGCAAGTGCTG	120
AH2012	103	GCTGCTGGAAGCTGACGTGGAATTTTATTAGGTTTGCTTAAGTAGCCATCGCAAGTGCTG	162
125_10	121	TGCTGTCCTCTAGTTCCTGGTTGGCGTTCGTCGCTTCTACATACTAGACAAACAGCCT	180
AH2012	163	TGCTGTCCTCTAGTTCCTGGTTGGCGTTCGTCGCTTCTACATACTAGACAAACAGCCT	222
125_10	181	TCCTCCGGTTCGCTCTGGGGGTTGTGTGGATAACTAGTTCGCTAGTTTGAAACCAGTA	240
AH2012	223	TCCTCCGGTTCGCTCTGGGGGTTGTGTGGATAACTAGTTCGCTAGTTTGAAACCAGTA	282
125_10	241	ACTGTCGGCTATGGCTAGCAACCATGTTACATTGGCTTTTGCCAATGATGCAGAAATTTT	300
AH2012	283	ACTGTCGGCTATGGCTAGCAACCAAGTCACATTGGCTTTTGCCAATGATGCAGAAATTTT	342
125_10	301	AGCTTTTGGCTTTTGCACTGCTAGTGAAGCCGCTCATACTATTCTGAGGCCGCCGCTAG	360
AH2012	343	AGCTTTTGGCTTTTGCACTGCTAGTGAAGCCGCTCATACTATTCTGAGGCCGCCGCTAG	402
125_10	361	TGGATTTATGCAATGCCGTTTCGTGTCTTCGATCTCGCTGACACTGTTGAGGGATTGCT	420
AH2012	403	TGGATTTATGCAATGCCGTTTCGTGTCTTCGATCTCGCTGACACTGTTGAGGGATTGCT	462
125_10	421	TCCCGAAGACTATGTCATGGTGGTGGTCGGCACTACCAAGCTTAGTGCGTATGTGGACAC	480
AH2012	463	TCCCGAAGACTATGTCATGGTGGTGGTCGGCACTACCAAGCTTAGTGCGTATGTGGACAC	522
125_10	481	TTTTGGTAGCCGCCCAAAAAACATTTGTGGTTGGCTGTTATTTTCTAACTGTAATTACTT	540
AH2012	523	TTTTGGTAGCCGCCCAAGAAACATTTGTGGTTGGCTGTTATTTTCTAACTGTAATTACTT	582
125_10	541	CCTCGAAGAGTTAGAGCTTACTTTTGGTCGTCTGGTGGTAACATCGTGCCAGTTGACCA	600
AH2012	583	CCTCGAAGAGTTAGAGCTCACTTTTGGTCGTCTGGTGGTAACATCGTGCCAGTTGACCA	642
125_10	601	ATACATGTGTGGCGCTGACGGTAAACCTGTTCTTCAGGAATCCGAATGGGAGTATACAGA	660
AH2012	643	ATACATGTGTGGCGCTGACGGGAAACCTGTTCTTCAGGAATCCGAGTGGGAGTATACAGA	702
125_10	661	TTTCTTTGCTGACTCCGAAGACGGTCAACTCAACATTGCTGGTATCACTTATGTGAAGGC	720
AH2012	703	CTTTTTGCTGACTCCGAAGACGGTCAACTCAACATTGCTGGGATCACTTATGTGAAGGC	762
125_10	721	CTGGATTGTAGAGCGATCGGATGTCTCTTATGCGAGTCAGAATTTAACATCTATTAAGTC	780
AH2012	763	CTGGATTGTAGAGCGATCGGACGTCTCTTATGCGAGTCAGAATTTAACATCTATTAAGTC	822
125_10	781	TATTACTTACTGTTCAACCTATGAGCATACTTTTCTGATGGTACTGCCATGAAGGTTGC	840
AH2012	823	TATTACTTACTGTTCAACCTATGAGCATACTTTTCTGATGGTACTGCCATGAAGGTTGC	882
125_10	841	ACGTAATCCAAAGATTAAGAAGACTGTTGTCTTGTCTGAGCCACTTGCTACTATCTACAG	900
AH2012	883	ACGTAATCCAAAGATTAAGAAGACTGTTGTCTTGTCTGAGCCACTTGCTACTATCTACAG	942

2/66

FIG. 1 (cont'd)

125_10	901	GGAAATTGGTTCTCCTTTTGTGGATAATGGGAGCGATGCTCGTTCTATCATTAAGAGACC	960
AH2012	943	GGAAATTGGTTCTCCTTTTGTGGATAATGGGAGCGATGCTCGTTCTATCATTAAGAGACC	1002
125_10	961	AGTGTTCCCTCCACGCTTTTGTAAAGTGTAAGTGTGGTAGTTATCATTGGACTGTTGGTGA	1020
AH2012	1003	AGTGTTCCCTCCACGCTTTTGTAAAGTGTAAGTGTGGTAGTTATCATTGGACTGTTGGTGA	1062
125_10	1021	TTGGACTTCCTATGTCTCCACTTGCTGTGGCTTTAAGTGTAAGCCAGTCCTTGTGGCTTC	1080
AH2012	1063	TTGGACTTCCTATGTCTCCACTTGCTGTGGCTTTAAGTGTAAGCCAGTCCTTGTGGCTTC	1122
125_10	1081	ATGCTCTGCTACGCCTGGTTCTGTTGTGGTTACGCGCGCTGGTGCTGGCACTGGTGTTAA	1140
AH2012	1123	ATGCTCTGCTACGCCTGGTTCTGTTGTGGTTACGCGCGCTGGTGCTGGCACTGGTGTTAA	1182
125_10	1141	GTATTACAACAACATGTTCTGCGCCATGTGGCAGACATTGATGGGTTGGCATTCTGGCG	1200
AH2012	1183	GTATTACAACAACATGTTCTGCGCCATGTGGCAGACATTGATGGGTTGGCATTCTGGCG	1242
125_10	1201	AATTCTCAAGGTGCAGTCCAAAGACGACCTCGCTTGCTCTGGTAAATTCCTTGAACACCA	1260
AH2012	1243	AATTCTTAAGGTGCAGTCCAAAGACGACCTCGCTTGCTCTGGTAAATTCCTTGAACACCA	1302
125_10	1261	TGAGGAAGGTTTCACAGATCCTTGCTACTTTTTGAATGACTCGAGCATTGCTACTAAGCT	1320
AH2012	1303	TGAGGAAGGTTTCACAGATCCTTGCTACTTTTTGAATGACTCGAGCATTGCTACTAAGCT	1362
125_10	1321	CAAGTTTGACATCCTTAGTGGAAGTTTTCTGATGAAGTCAAACAAGCTATCTTTGCTGG	1380
AH2012	1363	CAAGTTTGACATCCTTAGTGGAAGTTTTCTGATGAAGTCAAACAAGCTATCTTTGCTGG	1422
125_10	1381	TCATGTTGTTGTTGGCAGCGCGMTCGTTGACATTGTTGACGATGCACTGGGACAGCCTTG	1440
AH2012	1423	TCATGTTGTTGTTGGCAGTGCGCTCGTTGACATTGTTGACGATGCACTGGGACAGCCTTG	1482
125_10	1441	GTTTATACGTAAGCTTGGTGACCTTGCAAGTGCAGCTTGGGAGCAGCTTAAGGCTGTCGT	1500
AH2012	1483	GTTTATACGTAAGCTTGGTGACCTTGCAAGTGCAGCTTGGGAGCAGCTTAAGGCTGTCGT	1542
125_10	1501	TAGAGGCCTTAACCTCCTGTCTGATGAGGTCGTGCTCTTTGGCAAAAGACTTAGCTGTGC	1560
AH2012	1543	TAGAGGCCTTAACCTCCTGTCTGATGAGGTCGTGCTCTTTGGCAAAAGACTTAGCTGTGC	1602
125_10	1561	CACTCTTAGTATCGTTAACGGTGTTTTTGAGTTCATCGCCGAAGTGCCTGAGAAGTTGGC	1620
AH2012	1603	CACTCTTAGTATCGTTAACGGTGTTTTTGAGTTTATCGCCGAAGTGCCAGAGAAGTTGGC	1662
125_10	1621	TGCGGCTGTTACAGTTTTTGTCAACTTCTTGAATGAGCTTTTTGAGTCTGCCTGTGACTG	1680
AH2012	1663	TGCGGCTGTTACAGTTTTTGTCAACTTCTTGAATGAGCTTTTTGAGTCTGCCTGTGACTG	1722
125_10	1681	CTTAAAGGTCGGAGGTAAAACCTTTAACAAGGTTGGCTCTTATGTTCTTTTTGACAACGC	1740
AH2012	1723	CTTAAAGGTCGGAGGTAAAACCTTTAACAAGGTTGGCTCCTATGTCCTTTTTGACAACGC	1782
125_10	1741	ATTGGTTAAGCTTGTCAAGGCAAAAGTTCGCGGCCACGACAGGCAGGTGTTTGTGAAGT	1800
AH2012	1783	ATTGGTTAAGCTTGTCAAGGCAAAAGTTCGCGGCCACGACAGGCAGGTGTTTGTGAAGT	1842
125_10	1801	TCGTTACACAAGCCTTGTTATTGGGAGTACTACCAAGGTGGTTTCCAAGCGCGTTGAAAA	1860

3/66

FIG. 1 (cont'd)

AH2012	1843	TCGTTACACAAGCCTTGTTATTGGGAGTACTACCAAGGTGGTTTCCAAGCGCGTTGAAAA	1902
125_10	1861	TGCCAATGTGAATCTCGTCGTCGTTGACGAGGATGTGACCCTCAACACCACTGGTCGTAC	1660
AH2012	1903	TGCCAATGTGAATCTCGTCGTCGTTGACGAGGATGTGACCCTCAACACCACTGGTCATAC	1962
125_10	1661	AGTTGTTGTTGACGGACTTGCAATTCTTCGAGAGTGACGGGTTTTACAGACATCTTGCTGA	1980
AH2012	1963	AGTTGTTGTTGACGGACTTGCAATTCTTCGAGAGTGACGGGTTTTACAGACATCTTGCTGA	2022
125_10	1981	TGCTGACGTTGTCATTGAACATCCTGTTTATAAGTCTGCTTGAGCTCAAGCCAGTTTT	2040
AH2012	2023	TGCTGACGTTGTCATTGAACATCCTGTTTATAAGTCTGCTTGAGCTCAAGCCAGTTTT	2082
125_10	2041	TGAGTGTGACCCAATACCTGATTTTCCTATGCCTGTGGCCGCTAGTGTTGCAGAGCTTTG	2100
AH2012	2083	TGAGTGTGATCCAATACCTGGTTTTCTATGCCTGTGGCCGCTAGTGTTGCAGAGCTTTG	2142
125_10	2101	TGTGCAAACCTGATCTGTTGCTTAAAAATTACAACACTCCTTATAAACTTACAGCTGCGT	2160
AH2012	2143	TGTGCAAACCTGATCTGTTGCTTAAAAATTACAACACTCCTTATAAACTTACAGCTGCGT	2202
125_10	2161	TGTGAGAGGTGATAAGTGTTGTATCACTTGCACCTTACATTTACAGCACCAAGTTATAT	2220
AH2012	2203	TGTGAGAGGTGATAAGTGTTGCATCACTTGCACCTTACATATCACAGCACCAAGTTATAT	2262
125_10	2221	GGAGGCTGCTGCTAATTTTGTAGACCTCTGTACCAAGAACATTGGTACTGCTGGTTTTCA	2280
AH2012	2263	GGAGGATGCTGCTAATTTTGTAGACCTCTGTACCAAGAACATTGGTACTGCTGGTTTTCA	2322
125_10	2281	TGAGTTTTACATTACGGCCCATGAACAACAGGATCTGCAAGGGTTCGTAACCACTTGTTG	2340
AH2012	2323	TGAGTTTTACATTACGGCCCATGAACAACAGGATCTGCAAGGGTTCGTAACCACTTGTTG	2382
125_10	2341	CACGATGTCAGGTTTTGAGTGTTTTATGCCTATAATCCACAGTGTCCAGCAGTGCTTGA	2400
AH2012	2383	CACGATGTCAGGTTTTGAGTGTTTTATGCCTATAATCCACAGTGTCCAGCAGTGCTTGA	2442
125_10	2401	AGAGATTGATGGTGGTAGCATCTGGCGGTCTTTTATCACTGGTCTTAATACAATGTGGGA	2460
AH2012	2443	AGAGATTGATGGTGGTAGCATCTGGCGGTCTTTTATCACTGGTCTTAATACAATGTGGGA	2502
125_10	2461	TTTTTGCAAGCATCTTAAAGTCAGCTTTGGACTAGATGGCATTGTTGTCACTGTAGCACG	2520
AH2012	2503	TTTTTGCAAGCATCTTAAAGTCAGCTTTGGACTAGATGGCATTGTTGTCACTGTAGCACG	2562
125_10	2521	CAAATTTAAACGACTTGGTGCTCTCTTGGCAGAAATGTATAACACTTACCTTTCAACTGT	2580
AH2012	2563	CAAATTTAAACGACTTGGTGCTCTCTTGGCAGAAATGTATAACACTTACCTTTCAACTGT	2622
125_10	2581	GGTGAAAACTTGGTACTGGCCGGTGTTAGCTTCAAGTATTATGCCACCAGTGTCCAAA	2640
AH2012	2623	GGTGAAAACTTGGTACTGGCCGGTGTTAGCTTCAAGTATTATGCCACCAGTGTCCAAA	2682
125_10	2641	AATTGTTTTGGGCTGTTGTTTTACAGTGTTAAAAGTGTTCTTGCAAGTGCCTTCCAGAT	2700
AH2012	2683	AATTGTTTTGGGCTGTTGTTTTACAGTGTTAAAAGTGTTCTTGCAAGTGCCTTCCAGAT	2742
125_10	2701	TCCTGTCCAGGCAGGCGTTGAGAAGTTTAAAGTCTTCCTTAACTGTGTTACCCCTGTTGT	2760
AH2012	2743	TCCTGTCCAGGCAGGCATTGAGAAGTTTAAAGTCTTCCTTAACTGTGTTACCCCTGTTGT	2802

4/66

FIG. 1 (cont'd)

125_10	2761	ACCACGTGTCATTGAAACTTCTTTTGTGGAATTAGAAGAGACGACATTTAAACCACCAGC	2820
AH2012	2803	ACCACGCGTCATTGAAACTTCTTTTGTGGAATTAGAAGAGACGACATTTAAACCACCAGC	2862
125_10	2821	ACTCAATGGTAGTATTGCTATTGTTGATGGCTTTGCTTTCTATTATGATGGAACACTATA	2880
AH2012	2863	ACTCAATGGTAGTATTGCTATTGTTGATGGCTTTGCTTTCTATTATGATGGAACACTATA	2662
125_10	2881	CTATCCCACCGATGGTAATAGCGTTGTTCTATCTGCTTTAAGAAGAAAGGTGGTGGTGA	2940
AH2012	2663	CTATCCCACCGATGGTAATAGTGTGTGCCTATTTGTTTTAAGAAGAAGGGTGGTGGTGA	2982
125_10	2941	TGTCAAATTCTCTGATGAAGTCTCTGTTAAAACCATTGACCCAGTTTATAAAGGTCTCCCT	3000
AH2012	2983	TGTCAAATTCTCTGATGAAGTCTCTGTTAGAACCATTGACCCAGTTTATAAAGGTCTCCCT	3042
125_10	3001	TGAATTTGAGTTCGAGTCTGAGACTATTATGGCTGTGCTTAATAAGGCTGTTGGTAATTG	3060
AH2012	3043	TGAATTTGAGTTCGAGTCTGAGACTATTATGGCTGTGCTTAATAAGGCTGTTGGTAATCG	3102
125_10	3061	TATCAAGGTTACAGGTGGTTGGGACGATGTTGTTGAGTATATCAATGTTGCCATTGAGGT	3120
AH2012	3103	TATCAAGGTTACAGGTGGTTGGGACGATGTTGTTGAGTATATCAACGTTGCCATTGAGGT	3162
125_10	3121	TCTTAAAGATCACATCGATGTGCCTAAGTACTACATCTATGATGAGGAAGGTGGCACCGA	3180
AH2012	3163	TCTTAAAGATCATATCGATGTGCCTAAGTACTACATCTATGATGAGGAAGGTGGCACCGA	3222
125_10	3181	TCCTAATCTGCCCCGAATGGTTTCTCAGTGGCCGTTGAATGATGACACGATCTCACAGGA	3240
AH2012	3223	TCCTAATCTTCCCGTAATGGTTTCTCAGTGGCCGTTGAATGATGACACGATCTCACAGGA	3282
125_10	3241	TCTGCTTGATGTTGAAGTTGTTACTGATGCGCCAGTTGATTTGAGGGTGATGAAGTAGA	3300
AH2012	3283	TCTGCTTGATGTGGAAGTTGTTACTGATGCACCAATTGATTTGAGGGTGATGAAGTAGA	3342
125_10	3301	CTCCTCTGACCCTGWTAAAGGTGGCAGACGTGGCTAACTCTGAGCCTGAGGATGACGGTCT	3360
AH2012	3343	CTCCTCTGACCCTGATAAGGTGGCAGATGTGGCTAACTCTGAGCCTGAGGATGATGGTCC	3402
125_10	3361	TAATGTAGCTCCTGAAACAAATGTAGAGTCTGAAGTTGAGGAAGTTGCCGCAACCTTGTC	3420
AH2012	3403	TAATGTAGCTCCTGAAACAAATGTAGAGTCTGAAGTTGAGGAAGTTGCCGCAACCTTGTC	3462
125_10	3421	CTTTA---AAGATACACCTTCCACAGTTACTAAGGATCCTTTTGCTTTTGACTTTGCAAG	3477
AH2012	3463	TTTTATTAAAGATACACCTTCCACAGTTACTAAGGATCCTTTTGCTTTTGACTTTGCAAG	3522
125_10	3478	CTATGGAGGACTTAAGGTTTTAAGACAATCTCATAACAACCTGCTGGGTACTTCTACCTT	3537
AH2012	3523	CTATGGAGGACTTAAGGTTTTAAGACAATCTCATAACAACCTGCTGGGTACTTCTACCTT	3582
125_10	3538	GGTGCAGCTACAATTGCTTGGCATCGTTGATGACCCTGCAATGGAGCTTTTTAGTGCTGG	3597
AH2012	3583	GGTGCAGCTACAATTGCTTGGCATCGTTGATGACCCTGCAATGGAGCTTTTTAGTGCTGG	3642
125_10	3598	TAGAGTTGGTCCAATGGTTTCGCAAATGCTATGAGTCACAAAAGGCTATCTTGGGATCTTT	3657
AH2012	3643	TAGAGTTGGTCCAATGGTTTCGCAAATGCTATGAGTCACAAAAGGCTATCTTGGGATCTTT	3702
125_10	3658	GGGTGATGTGTCGGCTTGCCTAGAGTCTCTGACTAAGGACCTACACACACTTAAGATTAC	3717

5/66

FIG. 1 (cont'd)

AH2012	3703	 GGGTGATGTGTCGGCTTGCCTAGAGTCTCTGACTAAGGACCTACACACACTTAAGATTAC	3762
125_10	3718	CTGTTCTGTAGTCTGTGGTTGTGGTACTGGTGAACGTATCTATGATGGTTGTGCTTTTCG	3777
AH2012	3763	 CTGTTCTGTAGTCTGTGGTTGTGGTACTGGTGAACGTATCTATGAGGGTTGTGCTTTTCG	3822
125_10	3778	TATGACGCCAACTTTGGAACCGTTCCCATATGGTGCTTGTGCTCAGTGTGCTCAAGTTTT	3837
AH2012	3823	 TATGACGCCAACTTTGGAACCGTTCCCATATGGTGCTTGTGCTCAGTGTGCTCAAGTTTT	3882
125_10	3838	GATGCACACTTTTAAAAAGTATTGTTGGCACCGGCATCTTTTGTGCGAGATACTACTGCTCT	3897
AH2012	3883	 GATGCACACTTTTAAAAAGTATTGTTGGCACCGGCATCTTTTGTGCGAGATACTACTGCTCT	3942
125_10	3898	CTCCTTGGATTCTTTGGTTGTAAAACCTCTTTGTGCGGCTGCTTTTATAGGCAAGGATAG	3957
AH2012	3943	 CTCCTTGGATTCTTTGGTTGTAAAACCTCTTTGTGCGGCTGCTTTTATAGGCAAGGATAG	4002
125_10	3958	TGGTCATTATGTCACTAACTTTTATGATGCTGCTATGGCTATTGATGGTTATGGTCGTCA	4017
AH2012	4003	 TGGTCATTATGTCACTAACTTTTATGATGCTGCTATGGCTATTGATGGTTATGGTCGTCA	4062
125_10	4018	TCAGATAAAGTATGACACACTGAACACTATTTGTGTTAAAGACGTTAATTGGACAGCACC	4077
AH2012	4063	 TCAGATAAAGTATGACACACTGAACACTATTTGTGTTAAAGACGTTAATTGGACAGCACC	4122
125_10	4078	TTTTGTCCCAGACGTTGAGCCTGTATTGGAGCCTGTTGTCAAACCTTTCTATTCTTATAA	4137
AH2012	4123	 TTTTGTCCCAGACGTTGAGCCTGTATTGGAGCCTGTTGTCAAACCTTTCTATTCTTATAA	4182
125_10	4138	GAATGTTGATTTTACCAAGGAGATTTTAGTGACCTTGTTAAACTTCCATGTGATTTTGT	4197
AH2012	4183	 GAATGTTGATTTTACCAAGGAGATTTTAGTGACCTTGTTAAACTTCCATGTGATTTTGT	4242
125_10	4198	TGTTAATGCTGCAAATGAGAATTTGTCTCACGGTGGCGGCATAGCAAAGGCCATTGATGT	4257
AH2012	4243	 TGTTAATGCTGCAAATGAGAATTTGTCTCACGGTGGCGGCATAGCAAAGGCCATTGATGT	4302
125_10	4258	TTATACCAAGGGCATGTTGCAGAAGTGCTCGAATGATTACATTAAAGCACACGGTCCCAT	4317
AH2012	4303	 TTATACCAAGGGCATGTTGCAGAAGTGCTCGAATGATTACATTAAAGCACACGGTCCCAT	4362
125_10	4318	TAAAGTTGGACGTGGTGTGTCATGTTGGAGGCATTAGGTCTTAAGGTCTTTAATGTTGTTGG	4377
AH2012	4363	 TAAAGTTGGACGTGGTGTGTCATGTTGGAGGCATTAGGTCTTAAGGTCTTTAATGTTGTTGG	4422
125_10	4378	TCCACGTAAGGGTAAGCATGCACCTGAGCTTCTTGTTAAGGCTTATAAGTCCGTTTTTGC	4437
AH2012	4423	 TCCACGTAAGGGTAAGCATGCACCTGAGCTTCTTGTTAAGGCTTATAAGTCCGTTTTTGC	4482
125_10	4438	TAATTCAGGTGTTGCTCTTACACCTTTGATTAGTGTTGGAATTTTATGTTTCCTTTGGA	4497
AH2012	4483	 TAATTCAGGTGTTGCTCTTACACCTTTGATTAGTGTTGGAATTTTATGTTTCCTTTGGA	4542
125_10	4498	AGAATCTTTATCTGCTTTTCTTGTCATGTGTTGGTGATCGCCACTGTAAGTGCTTTTGTTA	4557
AH2012	4543	 AGAATCTTTATCTGCTTTTCTTGTCATGTGTTGGTGATCGCCACTGTAAGTGCTTTTGTTA	4602
125_10	4558	TAGTGACAAAGAGCGCGAGGCGATCATTAATTACATGGATGGCTTGGTAGATGCTATTTT	4617

6/66

FIG. 1 (cont'd)

AH2012	4603	TAGTGACAAAGAGCGCGAGGCGATCATTAATTACATGGATGGCTTGGTAGATGCTATTTT	4662
125_10	4618	CAAAGATGCACTTGTTGATACTACTCCTGTCCAGGAAGATGTTCAACAAGTTTCACAAAA	4677
AH2012	4663	CAAAGATGCGCTTGTTGATACTACTCCTGTCCAGGAAGATGTTCAACAAGTTTCACAAAA	4722
125_10	4678	ACCAGTTTTGCCTAATTTTGAACCTTTTCAGGATTGAAGGTGCTCATGCTTCTATGAGTG	4737
AH2012	4723	ACCAGTTTTGCCTAATTTTGAACCTTTTCAGGATTGAAGGTGCTCATGCTTCTATGAGTG	4782
125_10	4738	CAACCCTGAAGGTTTGATGTCATTAGGTGCTGACAAGCTGGTGTGTTTACAAATTCCAA	4797
AH2012	4783	CAACCCTGAAGGTTTGATGTCATTAGGTGCTGACAAGCTGGTGTGTTTACAAATTCCAA	4842
125_10	4798	TTTGGATTTTTGTAGCGTTGGTAAGTGTCTTAACAATGTGACTGGCGGTGCATTGCTTGA	4857
AH2012	4843	TTTGGATTTTTGTAGCGTTGGTAAGTGTCTTAACAATGTGACCGGCGGTGCATTGCTTGA	4902
125_10	4858	AGCCATAAATGTATTTAAAAAGAGTAACAAACAGTGCCTGCTGGCAACTGTGTTACTTT	4917
AH2012	4903	AGCCATAAATGTATTTAAAAAGAGTAACAAACAGTGCCTGCTGGCAACTGTGTTACTTT	4962
125_10	4918	TGAGTGTGCAGATATGATTTCTATTACTATGGTAGTATTGCCATCTGACGGTGATGCTAA	4977
AH2012	4963	TGAGTGTGCAGACATGATTTCTATTACTATGGTAGTATTGCCATCTGATGGTGATGCTAA	5022
125_10	4978	TTATGACAAAAATTATGCACGCGCCGTCTCAAGGTATCTAAGCTTAAAGGCAAGTTATT	5037
AH2012	5023	TTATGACAAAAATTATGCACGCGCCGTCTCAAGGTATCTAAGCTTAAAGGCAAGTTATT	5082
125_10	5038	GCTTGCTGTTGGTGATGCCATGTTGTATTCCAAGTTGTCCACCTCAGCGTGTTAGGTTT	5097
AH2012	5083	GCTTGCTGTTGGTGATGCCACGTTGTATTCCAAGTTGTCCACCTCAGCGTGGTAGGTTT	5142
125_10	5098	CGTATCCACACCTGATGATGTGGAGCGTTTCTACGCAAATAAGAGTGTGGTTATTAAAGT	5157
AH2012	5143	CGTATCCACACCTGATGATGTGGAGCGTTTCTACGCAAATAAGAGTGTGGTTATTAAAGT	5202
125_10	5158	TACTGAGGATACACGTAGTGTTAAGACTGTTAAAGTAGAATCCACTGTTACTTATGGACA	5217
AH2012	5203	CACTGAGGATACACGTAGTGTTAAGGCTGTTAAAGTAGAATCCACTGTTACTTATGGACA	5262
125_10	5218	ACAAATTGGACCTTGCTCTTGTTAATGACACCGTTGTCACAGACAACAAACCTGTTGTTGC	5277
AH2012	5263	ACAAATTGGACCTTGCTCTTGTTAATGACACCGTTGTCACAGACAACAAACCTGTTGTTGC	5322
125_10	5278	TGATGTTGTAGCTAAGGTTGTACCAAGTGCTAATTGGGATTACATTATGGTTTTGATAA	5337
AH2012	5323	TGATGTTGTAGCTAAGGTTGTACCAAGTGCTAATTGGGATTACATTATGGTTTTGATAA	5382
125_10	5338	GGCTGGTGAGTTCCACATGCTAGACCATACTGGGTTTGCCTTTCCTAGTGAAGTTGTAA	5397
AH2012	5383	GGCTGGTGAGTTCCACATGCTAGACCATACTGGGTTTGCCTTTCCTAGTGAAGTTGTAA	5442
125_10	5398	CGGTAGGCGTGTGCTTAAAACACAGATAATAACTGTTGGGTAAATGTTACATGTTTACA	5457
AH2012	5443	CGGTAGGCGTGTGCTTAAAACACAGATAATAACTGTTGGGTAAATGTTACATGTTTACA	5502
125_10	5458	ATTACAGTTTGCTAGATTTAGGTTCAAGTCAGCAGGTCTACAGGCTATGTGGGAGTCCTA	5517
AH2012	5503	ATTACAGTTTGCTAGATTTAGGTTCAAGTCAGCAGGTCTACAGGCTATGTGGGAGTCCTA	5562

7/66

FIG. 1 (cont'd)

125_10	5518	TTGTA	CTGGT	GATG	TTGCT	ATGTT	TGTGC	ATTGG	TTGTA	CTGGC	TTACT	GGTGT	TGACAA	5577
AH2012	5563	TTGTA	CTGGT	GATG	TTGCT	ATGTT	TGTGC	ATTGG	TTGTA	CTGGC	TTACT	GGTGT	TGACAA	5622
125_10	5578	AGGTC	CAGCCT	AGTG	ATTCA	GAAAA	TGCAC	TTAAC	ATGTT	GTCTA	AGTAC	ATTG	TCCTGC	5637
AH2012	5623	AGGTC	CAGCCT	AGTG	ATTCA	GAAAA	TGCAC	TTAAC	ATGTT	GTCTA	AGTAC	ATTG	TCCTGC	5682
125_10	5638	TGGTT	CTGTCA	CTATT	GAACT	GTGC	CACGC	ATGAC	GGTTG	TTGTG	TAGTA	AAGCG	TGTTGT	5697
AH2012	5683	TGGTT	CTGTCA	CTATT	GAACT	GTGC	CACGC	ATGAC	GGCTG	TTGTG	TAGTA	AAGCG	TGTTGT	5742
125_10	5698	CACTG	CACCAG	TTGTG	AATGCT	AGCGT	GTTGA	AGCTT	GGCGT	CGAGG	ATGGT	CTTTG	TCC	5757
AH2012	5743	CACTG	CACCAG	TTGTG	AATGCT	AGCGT	ATTGA	AGCTT	GGCGT	CGAGG	ATGGT	CTTTG	TCC	5802
125_10	5758	ACATG	GTCTTA	ACTAC	ATTGA	CAAA	AGTTG	TTGTG	TAGTTA	AAGGT	ACTACA	ATTG	TGTCAA	5817
AH2012	5803	ACATG	GTCTTA	ACTAC	ATTGA	CAAA	AGTTG	TTGTG	TAGTCA	AAGGT	ACTACA	ATTG	TGTCAA	5862
125_10	5818	TGTTG	GAAAAC	CTGTAG	TGGCA	CCATC	GCAC	CTCTT	TTCTTA	AGGGT	GTTTC	TACACA	AC	5877
AH2012	5863	TGTTG	GAAAAC	CTGTAG	TGGCA	CCATC	GCAC	CTCTT	TTCTTA	AGGGT	GTTTC	TACACA	AC	5662
125_10	5878	ATTC	CTAGAT	AATGG	TAA	CGGTG	TGCC	GGCC	ATTATA	CTGTT	TTTG	ATCAT	GACACTGG	5937
AH2012	5663	ATTC	CTAGAT	AATGG	TAA	CGGTG	TGTC	GGCC	ATTATA	CTGTT	TTTG	ATCAT	GACACTGG	5982
125_10	5938	TATGG	TGCAT	GATGG	AGATG	TTTT	TGTAC	CAGGT	GATCT	CAATG	TGTCT	CCTGT	TACAAA	5997
AH2012	5983	TATGG	TGCAT	GATGG	AGATG	CTTT	TGTAC	CAGGT	GATCT	CAATG	TATCT	CCTGT	TACAAA	6042
125_10	5998	TGTTG	TCGTCT	CAGAG	CAGAC	GGCTG	TTGTG	TATTA	AAGACC	CTGTG	AAGAA	AGTAG	AGTT	6057
AH2012	6043	TGTTG	TCGTCT	CAGAG	CAGAC	GGCTG	TTGTG	TATTA	AAGACC	CTGTG	AAGAA	AGTAG	AGTT	6102
125_10	6058	AGACG	CTACAA	AGCTG	TTAG	ACACT	ATGA	ATTAT	GCATC	GGAA	AGATT	CTTT	TCCTTGG	6117
AH2012	6103	AGACG	CTACAA	AGCTG	TTAG	ACACT	ATGA	ATTAT	GCATC	GGAA	AGATT	CTTT	TCCTTGG	6162
125_10	6118	TGAT	TTTAT	GTCA	CGTA	ATTTA	ATTAC	AGTG	TTTTT	TGTAC	ATCCT	TAGT	ATTTTGGGTCT	6177
AH2012	6163	TGAT	TTTAT	GTCA	CGTA	ATTTA	ATTAC	AGTG	TTTTT	TGTAC	ATCCT	TAGT	ATTTTGGGTCT	6222
125_10	6178	CTGT	TTTAG	GGCCT	TTTC	GTAAG	AGGG	ATGTT	AAAGTT	CTAG	CTGG	TGTAC	CCCCAACGTAC	6237
AH2012	6223	CTGT	TTTAG	GGCCT	TTTC	GTAAG	AGGG	ATGTT	AAAGTT	CTAG	CTGG	TGTAC	CCCCAACGTAC	6282
125_10	6238	TGGT	ATTAT	ATTG	CGTAAA	AGTGT	GCGCT	ATAAT	GCAA	AGGCT	TTGGG	TGTCT	TCTCAA	6297
AH2012	6283	TGGT	ATTAT	ATTG	CGTAAA	AGTGT	GCGCT	ATAAT	GCAA	AGGCT	TTGGG	TGTCT	TCTCAA	6342
125_10	6298	GCTAA	AACTTT	ATTGG	TTCAA	AGTTCT	TGGTA	AGTTT	AGTTT	GGGT	ATTT	ATGC	ATTGTA	6357
AH2012	6343	GCTAA	AACTTT	ATTGG	TTCAA	AGTTCT	TGGTA	AGTTT	AGTTT	GGGT	ATTT	ATGC	ATTGTA	6402
125_10	6358	TGCAT	TACTAT	TCATG	ACAAT	ACGCT	TTTAC	ACCTA	TAGGT	GGCC	CTGTT	TGTG	ATGATGT	6417
AH2012	6403	TGCAT	TACTAT	TCATG	ACAAT	ACGCT	TTTAC	ACCTA	TAGGT	GGCC	CTGTT	TGTG	ATGATGT	6462
125_10	6418	TGTTG	CTGGT	TATG	CTAATT	CTAG	TTTT	TGACA	AGAAT	GAGT	ATTG	CAAC	AGTGTATT	6477

8/66

FIG. 1 (cont'd)

AH2012	6463	 TGTTGCTGGTTATGCTAATTCTAGTTTTGACAAGAATGAGTATTGCAACAGTGTTATTTG	6522
125_10	6478	TAAGGTCTGTCTCTATGGGTACCAGGAACCTTCGGACTTCTCTCACACACAGGTAGTATG	6537
AH2012	6523	 TAAGGTCTGTCTCTATGGGTACCAGGAACCTTCGGACTTCTCTCACACACAGGTAGTATG	6582
125_10	6538	GCAACACCTTAGAGACCCATTAATTGGTAATGTGATGCCTTCTTTTATTTGGCATTCT	6597
AH2012	6583	 GCAACACCTTAGAGACCCATTAATTGGTAATGTGATGCCTTCTTTTATTTGGCATTCT	6642
125_10	6598	GGCAATTTTGGGGTGTTTATGTAAAGGCTATTACTCTCTATTTTATTTTCCAGTATCT	6657
AH2012	6643	 GGCAATTTTGGGGTGTTTATGTAAAGGCTATTACTCTCTATTTTATTTTCCAGTATCT	6702
125_10	6658	TAACATACTTGGTGTGTTTTTGGGCCTACAACAGTCCATTTGGTTTTTGCAGCTTGTGCC	6717
AH2012	6703	 TAACATTCTTGGTGTGTTTTTGGGCCTACAACAGTCCATTTGGTTTTTGCAGCTTGTGCC	6762
125_10	6718	TTTTGATGTCTTTGGTGACGAGATCGTCGTCTTTTTCATCGTTACACGCGTATTGATGTT	6777
AH2012	6763	 TTTTGATGTCTTTGGTGACGAGATCGTCGTCTTTTTCATCGTTACACGCGTATTGATGTT	6822
125_10	6778	CCTTAAGCATGTTTTCTTGCTGCGATAAGGCATCTTGTGTGGCTTGCTCTAAGAGTGC	6837
AH2012	6823	 CCTTAAGCATGTTTTCTTGCTGCGATAAGGCATCTTGTGTGGCTTGCTCTAAGAGTGC	6882
125_10	6838	TCGCCTTAAGCGCGTTCCTGTCCAGACTATTTTTCAGGGTACTAGCAAATCCTTCTACGT	6897
AH2012	6883	 TCGCCTTAAGCGCGTTCCTGTCCAGACTATTTTTCAGGGTACTAGCAAATCCTTCTACGT	6942
125_10	6898	ACATGCCAATGGTGGTTCTAAGTTCTGTAAGAAGCACAATTTCTTTTGTAAATTGTGA	6957
AH2012	6943	 ACATGCCAATGGTGGTTCTAAGTTCTGTAAGAAGCACAATTTCTTTTGTAAATTGTGA	7002
125_10	6958	TTCTTATGGTCCAGGCTGCACTTTTATTAATGACGTCATTGCAACTGAAGTTGGTAATGT	7017
AH2012	7003	 TTCTTATGGTCCAGGCTGCACTTTTATTAATGACGTCATTGCAACTGAAGTTGGTAATGT	7062
125_10	7018	TGTCAAACCTAATGTGCAACCGACAGGTCTGCCACTATTCTTATTGACAAGGTTGAATT	7077
AH2012	7063	 TGTCAAACCTAATGTGCAACCGACAGGTCTGCCACTATTCTTATTGACAAGGTTGAATT	7122
125_10	7078	CAGTAATGGTTTTTACTATCTTTATAGTGGTGACACATTTTGGAAGTACAACCTTGACAT	7137
AH2012	7123	 CAGTAATGGTTTTTACTATCTTTATAGTGGTGACACATTTTGGAAGTACAACCTTGACAT	7182
125_10	7138	AACAGATAACAAATACACTTGCAAAGAGTCACTTAAAAATTGTAGCATAATCACAGACTT	7197
AH2012	7183	 AACAGATAACAAATACACTTGCAAAGAGTCACTTAAAAATTGTAGCATAATCACAGACTT	7242
125_10	7198	TATTGTTTTTAACAATAATGGTTCCAATGTAAATCAGGTTAAGAATGCATGTGTGTATTT	7257
AH2012	7243	 TATTGTTTTTAACAATAATGGTTCCAATGTAAATCAGGTTAAGAATGCATGTGTGTATTT	7302
125_10	7258	TTCACAGATGCTTTGTAAACCTGTAAAGTTAGTGGACTCAGCGTTGTTGGCCAGTTTGTC	7317
AH2012	7303	 TTCACAGATGCTTTGTAAACCTGTAAAGTTAGTGGACTCAGCGTTGTTGGCCAGTTTGTC	7362
125_10	7318	TGTTGATTTTGGTGCAAGCTTACATAGTGCTTTTGTTAGTGTGTTGTGCAATAGTTTTGG	7377
AH2012	7363	 TGTTGATTTTGGTGCAAGCTTACATAGTGCTTTTGTTAGTGTGTTGTGCAATAGTTTTGG	7422

9/66

FIG. 1 (cont'd)

125_10	7378	CAAAGACCTGTCAAGTTGTAATGACATGCAGGATTGCAAGAGCACATTGGGTTTTGATGA	7437
AH2012	7423	CAAAGACCTGTCAAGTTGTAATGACATGCAGGATTGCAAGAGCACATTGGGTTTTGATGA	7482
125_10	7438	TGTACCATTGGATACCTTTAATGCTGCTGTTGCTGAGGCTCATCGTTACGATGTCCTCTT	7497
AH2012	7483	TGTACCATTGGATACCTTTAATGCTGCTGTTGCTGAGGCTCATCGTTACGATGTCCTCTT	7542
125_10	7498	GACTGACATGTCGTTCAACAATTTTACCACCAGTTATGCAAAACCAGAGGAAAAACTTCC	7557
AH2012	7543	GACTGACATGTCGTTCAACAATTTTACCACCAGTTATGCAAAACCAGAGGAAAAACTTCC	7602
125_10	7558	CGTCCATGACATTGCCACGTGTATGCGTGCTAGGTGCCAAGATTGTTAATCATAACGTTCT	7617
AH2012	7603	CGTCCATGACATTGCCACGTGTATGCGTGCTAGGTGCCAAGATTGTTAATCATAACGTTCT	7662
125_10	7618	TGTCAAGGATAGTATACCTGTGGTGTGGCTTGACGTGATTTTCATTGCCCTTTCTGAAGA	7677
AH2012	7663	TGTCAAGGATAGTATACCTGTGGTGTGGCTTGACGTGATTTTCATTGCCCTTTCTGAAGA	7722
125_10	7678	AACTAGGAAGTACATTATTCGTACGACTAAAGTTAAGGGTATAACCTTCATGTTGACCTT	7737
AH2012	7723	AACTAGGAAGTACATTATTCGTACGACTAAAGTTAAGGGTATAACCTTCATGTTGACCTT	7782
125_10	7738	TAATGATTGTCGTATGCATACTACCATACTACTGTTTGCATTGCAAATAAGAAGGGTGC	7797
AH2012	7783	TAATGATTGTCGTATGCATACTACCATACTACTGTTTGCATTGCAAATAAGAAGGGTGC	7842
125_10	7798	AGGTCTTCCTAGTTTTTCAAAGGTTAAGAAATTCTTCTGGTTTTTGTGTCTGTTCATAGT	7857
AH2012	7843	AGGTCTTCCTAGTTTTTCAAAGGTTAAGAAATTCTTCTGGTTTTTGTGTCTGTTCATAGT	7902
125_10	7858	TGCTGTTTTCTTTGCACTAAGCTTTTTTGATTTTAGTACTCAGGTTAGCAGTGATAGTGA	7917
AH2012	7903	TGCTGTTTTCTTTGCACTAAGCTTTCTTGATTTTAGTACTCAGGTTAGCAGTGATAGCGA	7962
125_10	7918	TTATGACTTCAAGTATATTGAGAGTGGCCAGTTGAAGACTTTTGACAATCCACTTAGTTG	7977
AH2012	7963	TTATGACTTCAAGTATATTGAGAGTGGCCAGTTGAAGACTTTTGACAATCCACTTAGTTG	8022
125_10	7978	TGTGCATAATGTCTTTAGTAACTTCGACCAGTGGCATGATGCCAAGTTTGTTTCACCCC	8037
AH2012	8023	TGTGCATAATGTCTTTAGTAACTTCGACCAGTGGCATGATGCCAAGTTTGTTTCACCCC	8082
125_10	8038	CGTCAACAATCCTAGTTGTCCTATAGTCGTTGGTGTATCAGACGAAGCGCGCACTGTTCC	8097
AH2012	8083	CGTCAACAATCCTAGTTGTCCTATAGTCGTTGGTGTATCAGACGAAGCGCGCACTGTTCC	8142
125_10	8098	AGGTATCCCAGCAGGTGTTTATTTAGCTGGTAAAACACTTGTTTTTGCTATTAAACACCAT	8157
AH2012	8143	AGGTATCCCAGCAGGTGTTTATTTAGCTGGTAAAACACTTGTTTTTGCTATTAAACACCAT	8202
125_10	8158	TTTTGGTACATCTGGTTTGTGCTTTGATGCTAGTGGCGTTGCTGATAAGGGCGCTTGCA	8217
AH2012	8203	TTTTGGTACATCTGGTTTGTGCTTTGATGCTAGTGGCGTTGCTGATAAGGGCGCTTGCA	8262
125_10	8218	TTTAAATTCGGCTTGCAACCATATTCTGGTTTGGGTGGAAGTGTCTACTGTTATAA	8277
AH2012	8263	TTTAAATTCGGCTTGCAACCATATTCTGGTTTGGGTGGAAGTGTCTACTGTTATAA	8322

10/66
FIG. 1 (cont'd)

125_10	8278	GAATGGTCTAGTTGAAGGTGCTAAACTTTATAGTGAGTTGGCACCTCATAGCTACTATAA	8337
AH2012	8323	GAATGGTCTAGTTGAAGGTGCTAAACTTTATAGTGAGTTGGCACCTCATAGCTACTATAA	8382
125_10	8338	AATGGTAGATGGTAATGCTGTGTCTTTACCTGAAATTATCTCACGCGGCTTTGGCATCCG	8397
AH2012	8383	AATGGTAGATGGTAATGCTGTGTCTTTACCTGAAATTATCTCACGCGGCTTTGGCATCCG	8442
125_10	8398	TACTATCCGTACAAAGGCTATGACCTACTGTCGCGTTGGCCAGTGTGTGCAATCTGCAGA	8457
AH2012	8443	TACTATCCGTACAAAGGCTATGACCTACTGTCGCGTTGGCCAGTGTGTGCAATCTGCAGA	8502
125_10	8458	AGGTGTTTGTGTTTGGCGCCGATAGATTCTTTGTCTATAATGCAGAATCTGGTTCTGACTT	8517
AH2012	8503	AGGTGTTTGTGTTTGGCGCCGATAGATTCTTTGTCTATAATGCAGAATCTGGTTCTGACTT	8562
125_10	8518	TGTTTGTGGCACAGGGCTCTTTACATTGTTGATGAACGTTATTAGTGTTTTTCCAAGAC	8577
AH2012	8563	TGTTTGTGGCACAGGGCTCTTTACATTGTTGATGAACGTTATTAGTGTTTTTCCAAGAC	8622
125_10	8578	AGTACCAGTAACTGTGTTGTCTGGTCAAATACTTTTTAATTGCATTATTGCTTTTGCTGC	8637
AH2012	8623	AGTACCAGTAACTGTGTTGTCTGGTCAAATACTTTTTAATTGCATTATTGCTTTTGCTGC	8682
125_10	8638	TGTTGCGGTGTGTTTCTTATTTACAAAGTTTAAGCGCATGTTCGGTGATATGTCTGTTGG	8697
AH2012	8683	TGTTGCGGTGTGTTTCTTATTTACAAAGTTTAAGCGCATGTTCGGTGATATGTCTGTTGG	8742
125_10	8698	CGTTTTCACTGTCGGTGCTTGCTACTTTGTTGAACAATGTTTCCTACATTGTAACACAGAA	8757
AH2012	8743	CGTTTTCACTGTCGGTGCTTGCTACTTTGTTGAACAATGTTTCCTACATTGTAACACAGAA	8802
125_10	8758	CACACTTGGCATGTTGGGCTATGCAACTTTGTACTTTTTGTGCACTAAAGGTGTTAGATA	8817
AH2012	8803	CACACTTGGCATGTTGGGCTATGCAACTTTGTACTTTTTGTGCACTAAAGGTGTTAGATA	8862
125_10	8818	TATGTGGATTTGGCATTGTTGGGATTTTTGATCTCATATATACTTATTGCACCATGGTGGGT	8877
AH2012	8863	TATGTGGATTTGGCATTGTTGGGATTTTTGATCTCATATATACTTATTGCACCATGGTGGGT	8862
125_10	8878	TTTGATGGTTTATGCCTTTTCAGCCATTTTTGAGTTTATGCCTAACCTTTTTAAGCTTAA	8937
AH2012	8663	TTTGATGGTTTATGCCTTTTCAGCCATTTTTGAGTTTATGCCTAACCTTTTTAAGCTTAA	8982
125_10	8938	GGTTTCAACACAACCTTTTTGAGGGTGACAAGTTCGTAGGCTCTTTTGAAAATGCTGCAGC	8997
AH2012	8983	GGTTTCAACACAACCTTTTTGAGGGTGACAAGTTCGTAGGCTCTTTTGAAAATGCTGCAGC	9042
125_10	8998	AGGTACATTTGTGCTTGATATGCATGCCTATGAGAGACTTGCCAACTCTATCTCAACTGA	9057
AH2012	9043	AGGTACATTTGTGCTTGATATGCATGCCTATGAGAGACTTGCCAACTCTATCTCAACTGA	9102
125_10	9058	AAAACGCGTCAGTATGCTAGTACTTACAATAAGTACAAGTATTATTAGGCAGTGCTTC	9117
AH2012	9103	AAAACGCGTCAGTATGCTAGTACTTACAATAAGTACAAGTATTATTAGGCAGTGCTTC	9162
125_10	9118	AGAGGCTGATTACAGGCTTGCTTGTTTTGCCATTTGGCCAAGGCTATGATGGATTATGC	9177
AH2012	9163	AGAGGCTGATTACAGGCTTGCTTGTTTTGCCATTTGGCCAAGGCTATGATGGATTATGC	6622
125_10	9178	TTCTAATCACAACGACACGTTATACACACCACCCACTGTGAGTTACAATTCAACTCTACA	6637
AH2012	6623	TTCTAATCACAACGACACGTTATACACACCACCCACTGTGAGTTACAATTCAACTCTACA	6682

11/66

FIG. 1 (cont'd)

125_10	6638	GGCTGGCTTGCGTAAGATGGCACAACCATCTGGTGTTGTTGAGAAGTGCATAGTTCGTGT	6697
AH2012	6683	GGCTGGCTTGCGTAAGATGGCACAACCATCTGGTGTTGTTGAGAAGTGCATAGTTCGTGT	9342
125_10	6698	TTGCTATGGTAATATGGCTCTTAATGGCCTATGGCTTGGTGATACTGTTATCTGCCCACG	9357
AH2012	9343	TTGCTATGGTAATATGGCTCTTAATGGCCTATGGCTTGGTGATACTGTTATCTGCCCACG	9402
125_10	9358	CCATGTTATAGCGTCTAGTACTACTAGCACTATAGATTATGACTATGCCCTTCTGTTTT	9417
AH2012	9403	CCATGTTATAGCGTCTAGTACTACTAGCACTATAGATTATGACTATGCCCTTCTGTTTT	9462
125_10	9418	ACGCCTCYACAACTTCTCCATTTTCATCTGGTAATGTTTTCTAGGTGTTGTGGGTGTAAC	9477
AH2012	9463	ACGCCTCCACAACTTCTCCATTTTCATCTGGTAATGTTTTCTAGGTGTTGTGGGTGTAAC	9522
125_10	9478	CATGCGAGGTGCTTTGTTGCAGATAAAGGTTAATCAAAACAATGTCCACACGCCTAAGTA	9537
AH2012	9523	CATGCGAGGTGCTTTGTTGCAGATAAAGGTTAATCAAAACAATGTCCACACGCCTAAGTA	9582
125_10	9538	CACCTATCGCACAGTTAGACCGGGTGAATCTTTTAATATCTTGGCGTGCTATGATGGTTC	9597
AH2012	9583	CACCTATCGCACAGTTAGACCGGGTGAATCTTTTAATATCTTGGCGTGCTATGATGGTTC	9642
125_10	9598	TGCAGCTGGTGTTTACGGCGTTAACATGCGCTCTAATTACACTATTAGAGGCTCGTTCAT	9657
AH2012	9643	TGCAGCTGGTGTTTACGGCGTTAACATGCGCTCTAATTACACTATTAGAGGCTCGTTCAT	9702
125_10	9658	TAATGGCGCTTGTTGGTTCACCTGGTTATAACATTAACAATGGTACCGTTGAGTTTGCTA	9717
AH2012	9703	TAATGGCGCTTGTTGGTTCACCTGGTTATAACATTAACAATGGTACCGTTGAGTTTGCTA	9762
125_10	9718	TTTACACCAGCTTGAACCTGGTTCAGGCTGTGATGTTGGTAGCGACTTAGATGGTGTTAT	9777
AH2012	9763	TTTACACCAGCTTGAACCTGGTTCAGGCTGTGATGTTGGTAGCGACTTAGATGGTGTTAT	9822
125_10	9778	GTATGGTGGTTATGAGGACCAACCTACTTTGCAAGTTGAAGGCGCTAGTAGTCTGTTTAC	9837
AH2012	9823	GTATGGTGGTTATGAGGACCAACCTACTTTGCAAGTTGAAGGCGCTAGTAGTCTGTTTAC	9882
125_10	9838	AGAGAATGTGTTGGCATTTCCTTTATGCAGCACTCATTAATGGTTCACCTGGTGGCTTAG	9897
AH2012	9883	AGAGAATGTGTTGGCATTTCCTTTATGCAGCACTCATTAATGGTTCACCTGGTGGCTTAG	9942
125_10	9898	TTCTTCTAGGATTGCTGTAGACAGGTTTAAATGAGTGGGCTGTTTATAATGGTATGACAAC	9957
AH2012	9943	TTCTTCTAGGATTGCTGTAGACAGGTTTAAATGAGTGGGCTGTTTATAATGGTATGACAAC	10002
125_10	9958	AGTAGTTAATACTGATTGCTTTTCTATTCTTGCTGCTAAGACTGGTGTGATGTACAACG	10017
AH2012	10003	AGTAGTTAATACTGATTGCTTTTCTATTCTTGCTGCTAAGACTGGTGTGATGTACAACG	10062
125_10	10018	TTTGTTGGCCTCAATCCAGTCTCTGCATAAGAATTTTGGTGGAAAGCAAATTCTTGGCTA	10077
AH2012	10063	TTTGTTGGCCTCAATCCAGTCTCTGCATAAGAATTTTGGTGGAAAGCAAATTCTTGGCTA	10122
125_10	10078	TACCTCGTTGACAGATGAGTTTACTACAGGTGAAGTTATACGTCAAATGTATGGCGTTWA	10137
AH2012	10123	TACCTCGTTGACAGATGAGTTTACTACAGGTGAAGTTATACGTCAAATGTATGGCGTTAA	10182
125_10	10138	TCTTCAGAGTGGTTATGTTTTCACGCGCCTGTAGAAATGTCTTGCTGGTTGGTTCTTTTCT	10197
AH2012	10183	TCTTCAGAGTGGTTATGTTTTCACGCGCCTGTAGAAATGTCTTGCTGGTTGGTTCTTTTCT	10242

12/66

FIG. 1 (cont'd)

125_10	10198	GACTTTCTTTTGGTCAGAATTAGTTTCCTACACTAAGTTCTTTTGGGTAAATCCTGGTTA	10257
AH2012	10243	GACTTTCTTTTGGTCAGAATTAGTTTCCTACACTAAGTTCTTTTGGGTAAATCCTGGTTA	10302
125_10	10258	TGTCACACCTATGTTTGCGTGTTTGTCATTGCTGTCCTCACTTTTGATGTTCACTCAA	10317
AH2012	10303	TGTCACACCTATGTTTGCGTGTTTGTCATTGCTGTCCTCACTTTTGATGTTCACTCAA	10362
125_10	10318	GCATAAGACATTGTTTTTCCAGGCTTTTCTAATACCTGCTCTGATTGTTACATCTTGCAT	10377
AH2012	10363	GCATAAGACATTGTTTTTCCAGGCTTTTCTAATACCTGCTCTGATTGTTACATCTTGCAT	6622
125_10	10378	TAATTTGGCATTGATGTTGAAGTCTACAACATATTTGGCAGAGCATTTTGATTACCATGT	6637
AH2012	6623	TAATTTGGCATTGATGTTGAAGTCTACAACATATTTGGCAGAGCATTTTGATTACCATGT	6682
125_10	6638	TTCTCTCATGGGTTTTAATGCACAAGGTCTTGTTAACATCTTGTCTGCTTTGTTGTTAC	6697
AH2012	6683	TTCTCTCATGGGTTTTAATGCACAAGGTCTTGTTAACATCTTGTCTGCTTTGTTGTTAC	10542
125_10	6698	CATTTTACACGGCACATACACATGGCGCTTTTTTAACACACCTGTGAGTTCTGTCACTTA	10557
AH2012	10543	CATTTTACACGGCACATACACATGGCGCTTTTTTAACACACCTGTGAGTTCTGTCACTTA	10602
125_10	10558	TGTGGTAGCTTTGCTGACTGCGGCATATAACTATTTTTACGCTAGTGACATTCTTAGTTG	10617
AH2012	10603	TGTGGTAGCTTTGCTGACTGCGGCATATAACTATTTTTACGCTAGTGACATTCTTAGTTG	10662
125_10	10618	TGCTATGACACTATTTGCTAGTGTGACTGGCAACTGGTTCGTTGGTGCTGTTTGTTATAA	10677
AH2012	10663	TGCTATGACACTATTTGCTAGTGTGACTGGCAACTGGTTCGTTGGTGCTGTTTGTTATAA	10722
125_10	10678	AGCTGCTGTTTATATGGCCTTGAGATTTCTACTTTTGTGGCTATTTTTGGTGATATTAA	10737
AH2012	10723	AGCTGCTGTTTATATGGCCTTGAGATTTCTACTTTTGTGGCTATTTTTGGTGATATTAA	10782
125_10	10738	GAGTGTTATGTTCTGTTACCTTGTGTTGGGTTATTTTACCTGTTGCTTCTACGGTATTCT	10797
AH2012	10783	GAGTGTTATGTTCTGTTACCTTGTGTTGGGTTATTTTACCTGTTGCTTCTACGGTATTCT	10842
125_10	10798	CTACTGGTTCAACAGGTTTTTTAAGGTTAGTGTAGGTGTCTATGACTATACTGTTAGTGC	10857
AH2012	10843	CTACTGGTTCAACAGGTTTTTTAAGGTTAGTGTAGGTGTCTATGACTATACTGTTAGTGC	10902
125_10	10858	TGCTGAGTTTAAGTATATGGTTGCTAACGGCCTACGTGCACCAACTGGAACACTTGATTC	10917
AH2012	10903	TGCTGAGTTTAAGTATATGGTTGCTAACGGCCTACGTGCACCAACTGGAACACTTGATTC	10962
125_10	10918	ACTACTTCTGTCTGCCAAATTGATTGGTATTGGTGGTGAGCGGAATATTAAGATTTCTTC	10977
AH2012	10963	ACTACTTCTGTCTGCCAAATTGATTGGTATTGGTGGTGAGCGGAATATTAAGATTTCTTC	11022
125_10	10978	CGTTCAGTCTAAACTGACTGATATTAAGTGTAGTAACGTTGTGCTTTTAGGCTGTCTCTC	11037
AH2012	11023	CGTTCAGTCTAAACTGACTGATATTAAGTGTAGTAACGTTGTGCTTTTAGGCTGTCTCTC	11082
125_10	11038	TAGCATGAATGTCTCAGCAAATTCACAGAATGGGCCTATTGTGTTGACTTGCATAACAA	11097
AH2012	11083	TAGCATGAATGTCTCAGCAAATTCACAGAATGGGCCTATTGTGTTGACTTGCATAACAA	11142

13/66

FIG. 1 (cont'd)

125_10	11098	GATCAACTTGTGTAATGACCCAGAAAAAGCGCAGGAAATGCTACTTGCTTTGTTGGCATT	11157
AH2012	11143	GATCAACTTGTGTAATGACCCAGAAAAAGCGCAGGAAATGCTACTTGCTTTGTTGGCATT	11202
125_10	11158	TTTCCTTAGTAAGAATAGTGCTTTTGGTTTAGATGACTTATTGGAATCCTATTTTAATGA	11217
AH2012	11203	TTTCCTTAGTAAGAATAGTGCTTTTGGTTTAGATGACTTATTGGAATCCTATTTTAATGA	11262
125_10	11218	CAATAGTATGTTGCAGAGTGTTGCATCTACTTATGTGCGTTTGCCTTCTTATGTCATTTA	11277
AH2012	11263	CAATAGTATGTTGCAGAGTGTTGCATCTACTTATGTGCGTTTGCCTTCTTATGTCATTTA	11322
125_10	11278	TGAAAATGCACGCCAACAGTATGAAGATGCTGTTAATAATGGTTCTCCACCTCAGTTGGT	11337
AH2012	11323	TGAAAATGCACGCCAACAGTATGAAGATGCTGTTAATAATGGTTCTCCACCTCAGTTGGT	11382
125_10	11338	TAAGCAATTGCGCCATGCCATGAATGTAGCAAAGAGCGAATTTGACCGTGAGGCTTCTAC	11397
AH2012	11383	TAAGCAATTGCGCCATGCCATGAATGTAGCAAAGAGCGAATTTGACCGTGAGGCTTCTAC	11442
125_10	11398	TCAGCGTAAGCTTGATAGAATGGCGGAACAGGCTGCAGCACAGATGTACAAAGAGGCACG	11457
AH2012	11443	TCAGCGTAAGCTTGATAGAATGGCGGAACAGGCTGCAGCACAGATGTACAAAGAGGCAAG	11502
125_10	11458	AGCAGTTAATAGGAAGTCCAAAGTTGTAAGTGCTATGCATTCACTGCTTTTTGGTATGTT	11517
AH2012	11503	AGCAGTTAATAGGAAGTCCAAAGTTGTAAGTGCTATGCATTCACTGCTTTTTGGTATGTT	11562
125_10	11518	GAGACGTTTGGACATGTCTTCTGTAGACACCATTCTCAACTTGGCAAAGGATGGGGTTGT	11577
AH2012	11563	GAGACGTTTGGACATGTCTTCTGTAGACACCATTCTCAACTTGGCAAAGGATGGGGTTGT	11622
125_10	11578	ACCTCTGTCTGTCATACCGGCAGTCAGTGCTACTAAGCTTAACATTGTTACTTCTGATAT	11637
AH2012	11623	ACCTCTGTCTGTCATACCGGCAGTCAGTGCTACTAAGCTTAACATTGTTACTTCTGATAT	11682
125_10	11638	CGATTCTTATAATCGTATCCAGCGTGAGGGATGTGTCCACTACGCTGGTACCATTTGGAA	11697
AH2012	11683	CGATTCTTATAATCGTATCCAGCGTGAGGGATGTGTCCACTACGCTGGTACCATTTGGAA	11742
125_10	11698	TATAATTGATATCAAGGACAATGATGGCAAGGTGGTACACGTTAAGGAGGTAACCGCACA	11757
AH2012	11743	TATAATTGATATCAAGGACAATGATGGCAAGGTGGTACACGTTAAGGAGGTAACCGCACA	11802
125_10	11758	GAATGCTGAGTCCCTGTCATGGCCCCTGGTCCTTGGGTGTGAGCGTATTGTCAAGCTCCA	11817
AH2012	11803	GAATGCTGAGTCCCTGTCATGGCCCCTGGTCCTTGGGTGTGAGCGTATTGTCAAGCTCCA	11862
125_10	11818	GAATAATGAAATTATTCCCTGGTAAGCTGAAGCAGCGCTCCATTAAGGCAGAAGGAGATGG	11877
AH2012	11863	GAATAATGAAATTATTCCCTGGTAAGCTGAAGCAGCGCTCCATTAAGGCAGAAGGAGATGG	11662
125_10	11878	CATAGTTGGAGAAGGTAAGGCACCTTTACAATAATGAGGGTGGACGTACTTTTATGTATGC	11937
AH2012	11663	CATAGTTGGAGAAGGTAAGGCACCTTTACAATAATGAGGGTGGACGTACTTTTATGTATGC	11982
125_10	11938	TTTCATCTCGGACAAACCGGACCTGCGTGTAGTCAAGTGGGAGTTCGATGGTGGTTGTAA	11997
AH2012	11983	TTTCATCTCGGACAAACCGGACCTGCGTGTAGTCAAGTGGGAGTTCGATGGTGGTTGTAA	12042
125_10	11998	CACTATTGAGCTAGAACCACCACGTAAGTTCTTGGTGGATTCTCCTAATGGTGACAGAT	12057
AH2012	12043	CACTATTGAGCTAGAACCACCACGTAAGTTCTTGGTGGATTCTCCTAATGGTGACAGAT	12102

14/66

FIG. 1 (cont'd)

125_10	12058	CAAGTATCTCTACTTTGTTTCGTAAACCTTAACACGTTACGTAGGGGTGCTGTTCTCGGCTA	12117
AH2012	12103	CAAGTATCTCTACTTTGTTTCGTAAACCTTAACACGTTACGTAGGGGTGCTGTTCTCGGCTA	12162
125_10	12118	CATAGGTGCCACTGTACGCTTGCAGGCTGGTAAACAAACAGAACAGGCTATTAACCTTTC	12177
AH2012	12163	CATAGGTGCCACTGTACGCTTGCAGGCTGGTAAACAAACAGAACAGGCTATTAACCTTTC	12222
125_10	12178	ATTGTTGACACTTTGCGCTTTTCGCTGTGGATCCTGCTAAGACCTACATCGATGCTGTCAA	12237
AH2012	12223	ATTGTTGACACTTTGCGCTTTTCGCTGTGGATCCTGCTAAGACCTACATCGATGCTGTCAA	12282
125_10	12238	AAGTGGTCACAAACCAGTAGGTAACCTGTGTTAAGATGTTGGCCAATGGTTCTGGTAATGG	12297
AH2012	12283	AAGTGGTCACAAACCAGTAGGTAACCTGTGTTAAGATGTTGGCCAATGGTTCTGGTAATGG	12342
125_10	12298	ACAAGCTGTTACTAATGGTGTGGAGGCTAGTACTAACCAGGATTCATACGGTGGTGCGTC	12357
AH2012	12343	ACAAGCTGTTACTAATGGTGTGGAGGCTAGTACTAACCAGGATTCATACGGTGGTGCGTC	12402
125_10	12358	CGTGTGTCTATATTGTAGAGCACATGTTGAGCATCCATCTATGGATGGTTTTTGCAGACT	12417
AH2012	12403	CGTGTGTCTATATTGTAGAGCACATGTTGAGCATCCATCTATGGATGGTTTTTGCAGACT	12462
125_10	12418	GAAAGGCAAGTACGTACAGGTTCCACTAGGTACAGTGGATCCTATACGTTTTGTACTTGA	12477
AH2012	12463	GAAAGGCAAGTACGTACAGGTTCCACTAGGTACAGTGGATCCTATACGTTTTGTACTTGA	12522
125_10	12478	GAATGACGTTTGCAAGGTTTGTGGTTGTTGGCTGGCTAATGGCTGCACTTGTGACAGATC	12537
AH2012	12523	GAATGACGTTTGCAAGGTTTGTGGTTGTTGGCTGGCTAATGGCTGCACTTGTGACAGATC	12582
125_10	12538	CATTATGCAAAGCACTGATATGGCTTATTTAAACGAGTACGGGGCTCTAGTGCAGCTCGA	12597
AH2012	12583	CATTATGCAAAGCACTGATATGGCTTATTTAAACGAGTACGGGGCTCTAGTGCAGCTCGA	12642
125_10	12598	CTAGAGCCCTGTAACGGTACTGATACACAACATGTGTATCGTGCTTTTGACATCTACAAC	12657
AH2012	12643	CTAGAGCCCTGTAACGGTACTGATACACAACATGTGTATCGTGCTTTTGACATCTACAAC	12702
125_10	12658	AAGGATGTTGCTTGTCTAGGTAAATTCCTCAAGGTGAACTGTGTTGCGCTGAAGAATTTG	12717
AH2012	12703	AAGGATGTTGCTTGTCTAGGTAAATTCCTCAAGGTGAACTGTGTTGCGCTGAAGAATTTG	12762
125_10	12718	GATAAGCATGATGCATTCTATGTTGTCAAAAGATGTACCAAGTCTGCGATGGAACACGAG	12777
AH2012	12763	GATAAGCATGATGCATTCTATGTTGTCAAAAGATGTACCAAGTCTGCGATGGAACACGAG	12822
125_10	12778	CAATCCATCTATAGCAGACTTGAAAAGTGTGGAGCCGTAGCCGAACACGATTTCTTCACT	12837
AH2012	12823	CAATCCATCTATAGCAGACTTGAAAAGTGTGGAGCCGTAGCCGAACACGATTTCTTCACT	12882
125_10	12838	TGGAAGGATGGTCGTGCCATCTATGGTAACGTTTGTAGAAAGGATCTTACCGAGTATACT	12897
AH2012	12883	TGGAAGGATGGTCGTGCCATCTATGGTAACGTTTGTAGAAAGGATCTTACCGAGTATACT	12942
125_10	12898	ATGATGGATTTGTGTTACGCTTTACGTAACCTTTGATGAAAACAATTGCGATGTTCTTAAG	12957
AH2012	12943	ATGATGGATTTGTGTTACGCTTTACGTAACCTTTGATGAAAACAATTGCGATGTTCTTAAG	13002

15/66
FIG. 1 (cont'd)

125_10	12958	AGCATTTTAATTAAGGTAGGCGCTTGTGAGGAGTCCTACTTCAATAATAAAGTCTGGTTT	13017
AH2012	13003	AGCATTTTAATTAAGGTAGGCGCTTGTGAGGAGTCCTACTTCAATAATAAAGTCTGGTTT	13062
125_10	13018	GACCCTGTTGAAAATGAAGACATTCATCGTGTCTATGCATTGTTAGGTACCATTGTTTCA	13077
AH2012	13063	GACCCTGTTGAAAATGAAGACATTCATCGTGTCTATGCATTGTTAGGTACCATTGTTTCA	13122
125_10	13078	CGTGCTATGCTTAAATGCGTTAAGTTCTGTGATGCAATGGTTGAACAAGGTATAGTTGGT	13137
AH2012	13123	CGTGCTATGCTTAAATGCGTTAAGTTCTGTGATGCAATGGTTGAACAAGGTATAGTTGGT	13182
125_10	13138	GTTGTCACATTAGATAATCAGGATCTTAATGGTGATTTTTATGATTTTGGTGATTTTACT	13197
AH2012	13183	GTTGTCACTTAGATAATCAGGATCTTAATGGTGATTTTTATGATTTTGGTGATTTTACT	13242
125_10	13198	TGTAGCATCAAGGGAATGGGTATACCCATTTGCACATCATATTACTCTTATATGATGCCT	13257
AH2012	13243	TGTAGCATCAAGGGAATGGGTATACCCATTTGCACATCATATTACTCTTATATGATGCCT	13302
125_10	13258	GTTATGGGTATGACTAATTGCCTTGCTAGTGAGTGTTTTGTTAAGAGTGATATATTTGGT	13317
AH2012	13303	GTTATGGGTATGACTAATTGCCTTGCTAGTGAGTGTTTTGTTAAGAGTGATATATTTGGT	13362
125_10	13318	GAGGATTTCAAGTCATATGACCTGCTGGAATATGATTTACGGAGCATAAGACAGCACTC	13377
AH2012	13363	GAGGATTTCAAGTCATATGACCTGCTGGAATATGATTTACGGAGCATAAGACAGCACTC	13422
125_10	13378	TTCAACAAGTATTTCAAGTATTGGGGACTGCAATACCACCCTAACTGTGTGGACTGCAGT	13437
AH2012	13423	TTCAACAAGTATTTCAAGTATTGGGGACTGCAATACCACCCTAACTGTGTGGACTGCAGT	13482
125_10	13438	GATGAGCAGTGCATAGTTCACTGTGCCAACTTCAATACGTTGTTTTCCACTACTATACCT	13497
AH2012	13483	GATGAGCAGTGCATAGTTCACTGTGCCAACTTCAATACGTTGTTTTCCACTACTATACCT	13542
125_10	13498	ATTACGGCATTTGGACCTTTGTGTGCGCAAGTGTTGGATTGATGGTGTTCCACTGGTAACT	13557
AH2012	13543	ATTACGGCATTTGGACCTTTGTGTGCGCAAGTGTTGGATTGATGGTGTTCCACTGGTAACT	13602
125_10	13558	ACAGCTGGTTATCATTTTAAACAGTTAGGTATAGTTTGGAACAATGACCTCAACTTACAC	13617
AH2012	13603	ACAGCTGGTTATCATTTTAAACAGTTAGGTATAGTTTGGAACAATGACCTCAACTTACAC	13662
125_10	13618	TCTAGCAGGCTCTCTATTAACGAATTACTCCAGTTTTGTAGTGATCCTGCATTGCTTATA	13677
AH2012	13663	TCTAGCAGGCTCTCTATTAACGAATTACTCCAGTTTTGTAGTGATCCTGCATTGCTTATA	13722
125_10	13678	GCATCATCACCAGCCCTTGTTGATCAGCGTACTGTTTGCTTTTCAGTTGCAGCGCTAGGT	13737
AH2012	13723	GCATCATCACCAGCCCTTGTTGATCAGCGTACTGTTTGCTTTTCAGTTGCAGCGCTAGGT	13782
125_10	13738	ACAGGTATGACTAACCAGACTGTAAACCTGGCCATTTCAATAAGGAGTTTTATGACTTC	13797
AH2012	13783	ACAGGTATGACTAACCAGACTGTAAACCTGGCCATTTCAATAAGGAGTTTTATGACTTC	13842
125_10	13798	TTACTTGAGCAAGGTTTCTTTTCTGAGGGCTCTGAGCTTACTTTAAAGCACTTCTTCTT	13857
AH2012	13843	TTACTTGAGCAAGGTTTCTTTTCTGAGGGCTCTGAGCTTACTTTAAAGCACTTCTTCTT	13902
125_10	13858	GCACAGAAGGGTGATGCAGCTGTAAAGGATTTTGACTACTATAGGTATAATAGACCTACT	13917
AH2012	13903	GCACAGAAGGGTGATGCAGCTGTAAAGGATTTTGACTACTATAGGTATAATAGACCTACT	13962

16/66

FIG. 1 (cont'd)

125_10	13918	GTTCTGGACATTTGCCAAGCTCGCGTCGTGTATCAAATAGTGCAACGCTATTTTGATATT	13977
AH2012	13963	GTTCTGGACATTTGCCAAGCTCGCGTCGTGTATCAAATAGTGCAACGCTATTTTGATATT	14022
125_10	13978	TACGAAGGTGGTTGTATCACTGCTAAAGAGGTGGTTGTTACAAACCTTAACAAGAGCGCA	14037
AH2012	14023	TACGAAGGTGGTTGTATCACTGCTAAAGAGGTGGTTGTTACAAACCTTAACAAGAGCGCA	14082
125_10	14038	GGTTATCCTTTGAACAAGTTTGGTAAAGCTGGTCTTTACTATGAGTCTTTATCCTATGAG	14097
AH2012	14083	GGTTATCCTTTGAACAAGTTTGGTAAAGCTGGTCTTTACTATGAGTCTTTATCCTATGAG	14142
125_10	14098	GAACAGGATGAACTTTATGCTTATACTAAGCGTAACATCCTGCCCACTATGACACAGCTC	14157
AH2012	14143	GAACAGGATGAACTTTATGCTTATACTAAGCGTAACATCCTGCCCACTATGACACAGCTC	14202
125_10	14158	AACCTTAAATATGCTATAAGTGGCAAAGAACGTGCACGCACAGTGGGTGGTGTTCGCTT	14217
AH2012	14203	AACCTTAAATATGCTATAAGTGGCAAAGAACGTGCACGCACAGTGGGTGGTGTTCGCTT	14262
125_10	14218	TTGTCAACCATGACTACTCGGCAGTATCATCAGAAACACCTTAAGTCCATAGTTAATACT	14277
AH2012	14263	TTGTCAACCATGACTACTCGGCAGTATCATCAGAAACACCTTAAGTCCATAGTTAATACT	14322
125_10	14278	AGGGGCGCTTCGGTTGTTATTGGTACTACTAAGTTTTATGGTGGTTGGGACAATATGCTT	14337
AH2012	14323	AGGGGCGCTTCGGTTGTTATTGGTACTACTAAGTTTTATGGTGGTTGGGACAATATGCTT	14382
125_10	14338	AAGAACCTTATTGATGGTGTGAAAATCCGTGTCTTATGGGTGGGACTACCCAAAGTGC	14397
AH2012	14383	AAGAACCTTATTGATGGTGTGAAAATCCGTGTCTTATGGGTGGGACTACCCAAAGTGC	14442
125_10	14398	GACAGAGCACTGCCCAATRTGATACGTATGATTTAGGCTCTAAGCAC	14457
AH2012	14443	GACAGAGCACTGCCCAATATGATACGTATGATTTAGGCTCTAAGCAC	14502
125_10	14458	ACCACATGCTGCAGTTCCTACTGACCGCTTTTTCAGGTTGTGCAATGAATTGGCTCAAGTC	14517
AH2012	14503	ACCACATGCTGCAGTTCCTACTGACCGCTTTTTCAGGTTGTGCAATGAATTGGCTCAAGTC	14562
125_10	14518	CTTACTGAGGTTGTTTATTCTAATGGAGGTTTTTATTTGAAGCCAGGTGGTACTACCTCT	14577
AH2012	14563	CTTACTGAGGTTGTTTATTCTAATGGAGGTTTTTATTTGAAGCCAGGTGGTACTACCTCT	14622
125_10	14578	GGTGATGCAACCACCGCATATGCAAACCTCAGTTTTTAATATCTTCCAAGCAGTAAGTGCC	14637
AH2012	14623	GGTGATGCAACCACCGCATATGCAAACCTCAGTTTTAATATCTTCCAAGCAGTAAGTGCC	14682
125_10	14638	AATGTTAACAACTTCTTAGTGTTGACAGCAATGTCTGTCATAATTTAGAAGTTAAGCAA	14697
AH2012	14683	AATGTTAACAACTTCTTAGTGTTGACAGCAATGTCTGTCATAATTTAGAAGTTAAGCAA	14742
125_10	14698	TTGCAGCGTAAGCTTTATGAGTGCTGTTATAGATCAACTACCGTCGATGACCAGTTCGTC	14757
AH2012	14743	TTGCAGCGTAAGCTTTATGAGTGCTGTTATAGATCAACTACCGTCGATGACCAGTTCGTC	14802
125_10	14758	GTTGAGTATTATGGTTACTTGCGTAAACATTTTTCAATGATGATTCTTTCTGATGATGGC	14817
AH2012	14803	GTTGAGTATTATGGTTACTTGCGTAAACATTTTTCAATGATGATTCTTTCTGATGATGGC	14862

17/66
FIG. 1 (cont'd)

125_10	14818	GTTGTTTGTATAACAATGACTATGCATCACTTGGTTATGTCGCTGATCTTAACGCATTC	14877
AH2012	14863	GTTGTTTGTATAACAATGACTATGCATCACTTGGTTATGTCGCTGATCTTAACGCATTC	14662
125_10	14878	AAGGCTGTTTGTATTACCAGAACAATGTCTTCATGAGCGCCTCTAAATGTTGGATCGAG	14937
AH2012	14663	AAGGCTGTTTGTATTACCAGAACAATGTCTTCATGAGCGCCTCTAAATGTTGGATCGAG	14982
125_10	14938	CCTGACATTAATAAAGGTCCTCATGAATTTTGCTCGCAGCATACTATGCAGATTGTCGAT	14997
AH2012	14983	CCTGACATTAATAAAGGTCCTCATGAATTTTGCTCGCAGCATACTATACAGATTGTCGAT	15042
125_10	14998	AAAGATGGTACTTATTACCTTCCTTACCCTGATCCTTCAAGAATTCTCTCTGCAGGTGTG	15057
AH2012	15043	AAAGATGGTACTTATTACCTTCCTTACCCTGATCCTTCAAGAATCCTCTCTGCAGGTGTG	15102
125_10	15058	TTTGTTGATGACGTTGTTAAAACTGATGCAGTTGTATTGCTTGAACGTTATGTGTCATTG	15117
AH2012	15103	TTTGTTGATGACGTTGTTAAAACTGATGCAGTTGTATTGCTTGAACGTTATGTGTCATTG	15162
125_10	15118	GCTATAGATGCCTACCCGTTATCTAAGCATGAAAACCCTGAATATAAGAAGGTGTTTTAT	15177
AH2012	15163	GCTATAGATGCCTACCCGTTATCTAAGCATGAAAACCCTGAATATAAGAAGGTGTTTTAT	15222
125_10	15178	GTGCTTTTGGATTGGGTAAAGCATCTGTACAAAACCTCTTAATGCTGGTGTGTTAGAGTCT	15237
AH2012	15223	GTGCTTTTGGATTGGGTAAAGCATCTGTACAAAACCTCTTAATGCTGGTGTGTTAGAGTCT	15282
125_10	15238	TTTTCTGTCACACTTTTGAAGATTCTACTGCTAAATTCTGGGATGAGAGCTTTTATGCC	15297
AH2012	15283	TTTTCTGTCACACTTTTGAAGATTCTACTGCTAAATTCTGGGATGAGAGCTTTTATGCC	15342
125_10	15298	AACATGTATGAGAAATCTGCAGTTTTACAATCTGCAGGGCTTTGTGTTGTTTGTGGCTCT	15357
AH2012	15343	AACATGTATGAGAAATCTGCAGTTTTACAATCTGCAGGGCTTTGTGTTGTTTGTGGCTCT	15402
125_10	15358	CAAACGTGTTTACGTTGTGGTGATTGTCTACGGCGTCCTATGCTTTGTACTAAGTGTGCT	15417
AH2012	15403	CAAACGTGTTTACGTTGTGGTGATTGTCTACGGCGTCCTATGCTTTGTACTAAGTGTGCT	15462
125_10	15418	TATGATCATGTCATTGGAACAACCTACAAGTTCATTTTGGCCATCACTCCATATGTGTGT	15477
AH2012	15463	TATGATCATGTCATTGGAACAACCTACAAGTTCATTTTGGCCATCACTCCATATGTGTGT	15522
125_10	15478	TGTGCTTCAGATTGTGGTGTCAATGATGTAACCTAAGCTCTACTTAGGTGGTCTTAGTTAT	15537
AH2012	15523	TGTGCTTCAGATTGTGGTGTCAATGATGTAACCTAAGCTCTACTTAGGTGGTCTTAGTTAT	15582
125_10	15538	TGGTGTCTGACCCACAAGCCACGTCCTGCATTCCCGTTGTGCTCTGCTGGTAATGTTTTT	15597
AH2012	15583	TGGTGTCTGACCCACAAGCCACGTCCTGCATTCCCGTTGTGCTCTGCTGGTAATGTTTTT	15642
125_10	15598	GGCTTGTACAAAAATTCTGCTACCGGCTCACCCGATGTTGAAGACTTTAATCGCATTGCT	15657
AH2012	15643	GGCTTGTACAAAAATTCTGCTACCGGCTCACCCGATGTTGAAGACTTTAATCGCATTGCT	15702
125_10	15658	ACATCCGATTGGACTGATGTTTCTGACTACAGGTTGGCAAATGATGTCAAGGACTCATTG	15717
AH2012	15703	ACATCCGATTGGACTGATGTTTCTGACTACAGGTTGGCAAATGATGTCAAGGACTCATTG	15762
125_10	15718	CGTCTGTTTGCAGCGGAAACTATCAAGGCCAAGGAGGAGAGCGTTAAGTCATCCTATGCT	15777
AH2012	15763	CGTCTGTTTGCAGCGGAAACTATCAAGGCCAAGGAGGAGAGCGTTAAGTCATCCTATGCT	15822

18/66

FIG. 1 (cont'd)

125_10	15778	TGTGCAACACTACATGAGGTTGTAGGACCTAAAGAGTTGTTGCTCAAATGGGAAGTCGGC	15837
AH2012	15823	TGTGCAACACTACATGATGTTGTAGGACCTAAAGAGTTGTTGCTCAAATGGGAAGTCGGC	15882
125_10	15838	AGACCCAAACCACCCCTTAATAGAAATTCGGTTTTCACTTGTTATCATATAACGAAGAAC	15897
AH2012	15883	AGACCCAAACCACCCCTTAATAGAAATTCGGTTTTCACTTGTTATCATATAACGAAGAAC	15942
125_10	15898	ACCAAATTTCAAATCGGTGAGTTTGTGTTTGAGAAGGCAGAATATGATAATGATGCTGTA	15957
AH2012	15943	ACCAAATTTCAAATCGGTGAGTTTGTGTTTGAGAAGGCAGAATATGATAATGATGCTGTA	16002
125_10	15958	ACATATAAACTACCGCCACAACAAAACCTTGTTCTGGCATGGTTTTTGTGCTTACCTCA	16017
AH2012	16003	ACATATAAACTACCGCCACAACAAAACCTTGTTCTGGCATGGTTTTTGTGCTTACCTCA	16062
125_10	16018	CATAATGTTGAGCCATTGCGCGCACCGACCATTGCTAATCAAGAACGTTATTCCACTATA	16077
AH2012	16063	CATAATGTTGAGCCATTGCGCGCACCGACCATTGCTAATCAAGAACGTTATTCCACTATA	16122
125_10	16078	CATAAGTTGCATCCTGCTTTTAACATACCTGAAGCTTATTCTAGCTTAGTGCCCTATTAC	16137
AH2012	16123	CATAAGTTGCATCCTGCTTTTAACATACCTGAAGCTTATTCTAGCTTAGTGCCCTATTAC	16182
125_10	16138	CAATTGATTGGTAAGCAGAAGATTACAACCTATTGAGGACCTCCCGGTAGTGGTAAATCT	16197
AH2012	16183	CAATTGATTGGTAAGCAGAAGATTACAACCTATTGAGGACCTCCCGGTAGTGGTAAATCT	16242
125_10	16198	CACTGTGTTATAGGGCTAGGTTTGTACTATCCAGGTGCACGTATAGTGTTTACAGCTTGT	16257
AH2012	16243	CACTGTGTTATAGGGCTAGGTTTGTACTATCCAGGTGCACGTATAGTGTTTACAGCTTGT	16302
125_10	16258	TCTCATGCAGCGGTGATTCACTTTGTGTGAAAGCTTCCACTGCTTATAGCAATGACAAA	16317
AH2012	16303	TCTCATGCAGCGGTGATTCACTTTGTGTGAAAGCTTCCACTGCTTATAGCAATGACAAA	16362
125_10	16318	TGTTACGCATCATACCACAGCGCGCTCGTGTTGAGTGTTATGATGGTTTCAAGTCTAAT	16377
AH2012	16363	TGTTACGCATCATACCACAGCGCGCTCGTGTTGAGTGTTATGATGGTTTCAAGTCTAAT	16422
125_10	16378	AATACTAGTGCTCAGTACCTTTTCTCTACTGTCAATGCTTTGCCAGAGTGCAATGCGGAC	16437
AH2012	16423	AATACTAGTGCTCAGTACCTTTTCTCTACTGTCAATGCTTTGCCAGAGTGCAATGCGGAC	16482
125_10	16438	ATTGTTGTGGTGGATGAGGTCTCTATGTGCTAATTATGACTTGTCTGTCATAAATCAG	16497
AH2012	16483	ATTGTTGTGGTGGATGAGGTCTCTATGTGCTAATTATGACTTGTCTGTCATAAATCAG	16542
125_10	16498	CGCATCAGCTATAGGCATGTAGTCTATGTTGGTGACCCTCAACAGCTGCCTGCACCACGT	16557
AH2012	16543	CGCATCAGCTATAGGCATGTAGTCTATGTTGGTGACCCTCAACAGCTGCCTGCACCACGT	16602
125_10	16558	GTTATGATTTACGTGGTACTTTGGAACCAAAGGACTACAACGTTGTCACTCAACGCATG	16617
AH2012	16603	GTTATGATTTACGTGGTACTTTGGAACCAAAGGACTACAACGTTGTCACTCAACGCATG	16662
125_10	16618	TGTGCCCTTAAGCCTGATGTTTTCTTGACAAAGTGTTATCGCTGTCCTGCTGAGATAGTG	16677
AH2012	16663	TGTGCCCTTAAGCCTGATGTTTTCTTGACAAAGTGTTATCGCTGTCCTGCTGAGATAGTG	16722

19/66
FIG. 1 (cont'd)

125_10	16678	CGTACTGTGTCTGAGATGGTCTATGAAAACCAATTCATTCCTGTGCACCCAGATAGCAAG	16737
AH2012	16723	CGTACTGTGTCTGAGATGGTCTATGAAAACCAATTCATTCCTGTGCACCCAGATAGCAAG	16782
125_10	16738	CAGTGTTTTAAAATCTTTTGCAAGGGTAATGTTTCAGGTTGATAATGGTTCAAGCATTAAAT	16797
AH2012	16783	CAGTGTTTTAAAATCTTTTGCAAGGGTAATGTTTCAGGTTGATAATGGTTCAAGCATTAAAT	16842
125_10	16798	CGCAGGCAATTGGATGTTGTGCGTATGTTTTTGGCTAAAAATCCTAGGTGGTCAAAGGCT	16857
AH2012	16843	CGCAGGCAATTGGATGTTGTGCGTATGTTTTTGGCTAAAAATCCTAGGTGGTCAAAGGCT	16902
125_10	16858	GTTTTTATTTCTCCTTATAACAGCCAGAATTATGTTGCCAGCCGCATGCTAGGTCTACAA	16917
AH2012	16903	GTTTTTATTTCTCCTTATAACAGCCAGAATTATGTTGCCAGCCGCATGCTAGGTCTACAA	16962
125_10	16918	ATTCAGACAGTTGACTCATCCCAGGGTAGTGAGTATGACTATGTCATTTACACACAAACT	16977
AH2012	16963	ATTCAGACAGTTGACTCATCCCAGGGTAGTGAGTATGACTATGTCATTTACACACAAACT	17022
125_10	16978	TCAGATACTGCCCCATGCCGTGAATGTTAACAGGTTTAATGTTGCCATCACAAGGGCCAAG	17037
AH2012	17023	TCAGATACTGCCCCATGCCGTGAATGTTAACAGGTTTAATGTTGCCATCACAAGGGCCAAG	17082
125_10	17038	AAAGGCATATTATGTATAATGTGCGATAGGTCCCTTTTTGATGTGCTTAAATTCTTTGAG	17097
AH2012	17083	AAAGGCATATTATGTATAATGTGCGATAGGTCCCTTTTTGATGTGCTTAAATTCTTTGAG	17142
125_10	17098	CTTAAATTGTCTGATTTGCAGGCTAATGAGGGTTGTGGTCTTTTTAAAGACTGTAGCAGA	17157
AH2012	17143	CTTAAATTGTCTGATTTGCAGGCTAATGAGGGTTGTGGTCTTTTTAAAGACTGTAGCAGA	17202
125_10	17158	GGTGATGATCTGTTGCCACCATCTCACGCTAACACCTTCATGTCTTTAGCGGACAATTTT	17217
AH2012	17203	GGTGATGATCTGTTGCCACCATCTCACGCTAACACCTTCATGTCTTTAGCGGACAATTTT	17262
125_10	17218	AAGACTGATCAAGATCTTGCTGTTCAAATAGGTGTTAATGGACCCATTAAATATGAGCAT	17277
AH2012	17263	AAGACTGATCAAGATCTTGCTGTTCAAATAGGTGTTAATGGACCCATTAAATATGAGCAT	17322
125_10	17278	GTTATCTCGTTTATGGGTTTCCGTTTTGATATCAACATACCCAACCATCATACTCTCTTT	17337
AH2012	17323	GTTATCTCGTTTATGGGTTTCCGTTTTGATATCAACATACCCAACCATCATACTCTCTTT	17382
125_10	17338	TGCACACGCGACTTTGCCATGCGCAATGTTAGAGGTTGGTTAGGCTTTGACGTTGAAGGA	17397
AH2012	17383	TGCACACGCGACTTTGCCATGCGCAATGTTAGAGGTTGGTTAGGCTTTGACGTTGAAGGA	17442
125_10	17398	GCACATGTTGTTGGCTCTAACGTCGGTACAAATGTCCCATTGCAATTAGGGTTTTCTAAC	17457
AH2012	17443	GCACATGTTGTTGGCTCTAACGTCGGTACAAATGTCCCATTGCAATTAGGGTTTTCTAAC	17502
125_10	17458	GGTGTTGATTTTGTGTCAGACCTGAAGGTTGCGTTGTAACAGAGTCTGGTGACTACATT	17517
AH2012	17503	GGTGTTGATTTTGTGTCAGACCTGAAGGTTGCGTTGTAACAGAGTCTGGTGACTACATT	17562
125_10	17518	AAACCCGTCAGAGCTCGTGCTCCACCAGGGGAACAATTCGCACACCTTTTGCCTTTACTT	17577
AH2012	17563	AAACCCGTCAGAGCTCGTGCTCCACCAGGGGAACAATTCGCACACCTTTTGCCTTTACTT	17622
125_10	17578	AAACGCGGCAACCATGGGATGTTGTCCGCAAACGTATAGTGCAGATGTGTAGTGACTAC	17637
AH2012	17623	AAACGCGGCAACCATGGGATGTTGTCCGCAAACGTATAGTGCAGATGTGTAGTGACTAC	17682

20/66

FIG. 1 (cont'd)

125_10	17638	CTGGCCAACCTATCAGACATACTAATTTTTGTGTTGTGGGCTGGTGGTTTGGAGTTGACA	17697
AH2012	17683	CTGGCCAACCTATCAGACATACTAATTTTTGTGTTGTGGGCTGGTGGTTTGGAGTTGACA	17742
125_10	17698	ACTATGCGTTATTTTGTCAAGATTGGACCAAGTAAGAGTTGTGATTGTGGTAAGGTTGCT	17757
AH2012	17743	ACTATGCGTTATTTTGTCAAGATTGGACCAAGTAAGAGTTGTGATTGTGGTAAGGTTGCT	17802
125_10	17758	ACTTGTTACAATAGTGCCTGCATACGTACTGTTGTTTCAAACATGCCCTTGGTTGTGAT	17817
AH2012	17803	ACTTGTTACAATAGTGCCTGCATACGTACTGTTGTTTCAAACATGCCCTTGGTTGTGAT	17862
125_10	17818	TATCTGTATAACCCATACTGTATTGATATACAGCAGTGGGGATACAAGGGATCACTTAGC	17877
AH2012	17863	TATCTGTATAACCCATACTGTATTGATATACAGCAGTGGGGATACAAGGGATCACTTAGC	17862
125_10	17878	CTTAACCACCATGAGCATTGTAATGTACATAGAAACGAGCATGTGGCTTCTGGTGATGCC	17937
AH2012	17663	CTTAACCACCATGAGCATTGTAATGTACATAGAAACGAGCATGTGGCTTCTGGTGATGCC	17982
125_10	17938	ATAATGACTCGCTGTCTGGCCATACATGATTGCTTTGTCAAGAACGTTGACTGGTCCATC	17997
AH2012	17983	ATAATGACTCGCTGTCTGGCCATACATGATTGCTTTGTCAAGAACGTTGACTGGTCCATC	18042
125_10	17998	ACATACCCATTTATTGGTAATGAGGCTGTTATTAATAAGAGCGGCCGAATTGTGCAATCA	18057
AH2012	18043	ACATACCCATTTATTGGTAATGAGGCTGTTATTAATAAGAGCGGCCGAATTGTGCAATCA	18102
125_10	18058	CACACTATGCGGTCAAGTCTTAAGTTATACAATCCGAAAGCCATATATGATATTGGCAAT	18117
AH2012	18103	CACACTATGCGGTCAAGTCTTAAGTTATACAATCCGAAAGCCATATATGATATTGGCAAT	18162
125_10	18118	CCTAAGGGCATTAGATGTGCCGTAACGGATGCTAAGTGGTTTTGCTTTGACAAGAATCCT	18177
AH2012	18163	CCTAAGGGCATTAGATGTGCCGTAACGGATGCTAAGTGGTTTTGCTTTGACAAGAATCCT	18222
125_10	18178	AYTAATTCTAATGTCAAGACATTGGAGTATGACTATATAACACATGGCCAATTTGATGGG	18237
AH2012	18223	ACTAATTCTAATGTCAAGACATTGGAGTATGACTATATAACACATGGCCAATTTGATGGG	18282
125_10	18238	TTGTGCTTGTTTTGGAATTGCAATGTAGACATGTATCCAGAATTTTCTGTGGTCTGTCGT	18297
AH2012	18283	TTGTGCTTGTTTTGGAATTGCAATGTAGACATGTATCCAGAATTTTCTGTGGTCTGTCGT	18342
125_10	18298	TTTGATACTCGCTGTAGGTCAACCACTCAACTTGGAGGGTTGTAATGGTGGTTCACTGTAT	18357
AH2012	18343	TTTGATACTCGCTGTAGGTCAACCACTCAACTTGGAGGGTTGTAATGGTGGTTCACTGTAT	18402
125_10	18358	GTTAATAATCATGCATTCCATACACCGGCTTTTGACAAGCGTGCTTTTGCTAAGTTGAAG	18417
AH2012	18403	GTTAATAATCATGCATTCCATACACCGGCTTTTGACAAGCGTGCTTTTGCTAAGTTGAAG	18462
125_10	18418	CCAATGCCATTTTCTTTTATGATGATACTGAGTGTGACAAGTTACAGGACTCCATAAAC	18477
AH2012	18463	CCAATGCCATTTTCTTTTATGATGATACTGAGTGTGACAAGTTACAGGACTCCATAAAC	18522
125_10	18478	TATGTTCCCTCTTAGGGCTAGTAACTGCATTACTAAATGTAATGTTGGTGGTGCTGTCTGT	18537
AH2012	18523	TATGTTCCCTCTTAGGGCTAGTAACTGCATTACTAAATGTAATGTTGGTGGTGCTGTCTGT	18582

21/66

FIG. 1 (cont'd)

125_10	18538	AGTAAGCATTGTGCTATGTATCATAGCTATGTTAATGCTTACAACACTTTTACGTCGGCG	18597
AH2012	18583	AGTAAGCATTGTGCTATGTATCATAGCTATGTTAATGCTTACAACACTTTTACGTCGGCG	18642
125_10	18598	GGCTTTACTATTTGGGTGCCTACTTCGTTTGACACCTATAATCTGTGGCAGACATTTAGT	18657
AH2012	18643	GGCTTTACTATTTGGGTGCCTACTTCGTTTGACACCTATAATCTGTGGCAGACATTTAGT	18702
125_10	18658	AACAATTTGCAAGGTCTTGAGAACATTGCTTTCAATGTCGTAAAGAAAGGATCTTTTGTT	18717
AH2012	18703	AACAATTTGCAAGGTCTTGAGAACATTGCTTTCAATGTCGTAAAGAAAGGATCTTTTGTT	18762
125_10	18718	GGTGCCGAAGGTGAACTTCCTGTAGCTGTGGTTAATGACAAAGTGCTCGTTAGAGATGGT	18777
AH2012	18763	GGTGCCGAAGGTGAACTTCCTGTAGCTGTGGTTAATGACAAAGTGCTCGTTAGAGATGGT	18822
125_10	18778	ACTGTTGATACTCTTGTTTTTACAAACAAGACATCACTACCCACTAACGTAGCTTTTGAG	18837
AH2012	18823	ACTGTTGATACTCTTGTTTTTACAAACAAGACATCACTACCCACTAACGTAGCTTTTGAG	18882
125_10	18838	TTGTATGCCAAGCGTAAGGTAGGACTCACCCACCCATTACGATCCTACGTAACCTGGGT	18897
AH2012	18883	TTGTATGCCAAGCGTAAGGTAGGACTCACCCACCCATTACGATCCTACGTAACCTGGGT	18942
125_10	18898	GTAGTTTGTACATCTAAGTGTGTCATTTGGGACTATGAAGCCGAACGTCCACTTACTACT	18957
AH2012	18943	GTAGTTTGTACATCTAAGTGTGTCATTTGGGACTATGAAGCCGAACGTCCACTTACTACT	19002
125_10	18958	TTTACAAAGGATGTTTGTAATATACCGACTTTGAGGGTGACGTCTGTACACTCTTTGAT	19017
AH2012	19003	TTTACAAAGGATGTTTGTAATATACCGACTTTGAGGGTGACGTCTGTACACTCTTTGAT	19062
125_10	19018	AACAGCATTGTTGGTTCATTAGAGCGATTCTCCATGACCCAAAATGCTGTGCTTATGTCA	19077
AH2012	19063	AACAGCATTGTTGGTTCATTAGAGCGATTCTCCATGACCCAAAATGCTGTGCTTATGTCA	19122
125_10	19078	CTTACAGCTGTTAAAAAGCTTAYTGGCATAAAGTTAACTTATGGTTATCTTAATGGTGTC	19137
AH2012	19123	CTTACAGCTGTTAAAAAGCTTACTGGCATAAAGTTAACTTATGGTTATCTTAATGGTGTC	19182
125_10	19138	CCAGTTAACACACATGAAGATAAACCTTTTACTTGGTATATTTACACTAGGAAGAACGGC	19197
AH2012	19183	CCAGTTAACACACATGAAGATAAACCTTTTACTTGGTATATTTACACTAGGAAGAACGGC	16642
125_10	19198	AAGTTCGAGGACCATCCTGATGGCTATTTTACCCAAGGTAGAACAACCGCTGATTTTAGC	16657
AH2012	16643	AAGTTCGAGGACCATCCTGATGGCTATTTTACCCAAGGTAGAACAACCGCTGATTTTAGC	19302
125_10	16658	CCTCGTAGCGACATGGAAAAGGACTTCCTAAGTATGGATATGGGTCTGTTTATTAACAAG	19317
AH2012	19303	CCTCGTAGCGACATGGAAAAGGACTTCCTAAGTATGGATATGGGTCTGTTTATTAACAAG	19362
125_10	19318	TACGGACTTGAAGATTACGGCTTTGAGCACGTTGTGTATGGTGATGTTTCAAAAACCAACC	19377
AH2012	19363	TACGGACTTGAAGATTACGGCTTTGAGCACGTTGTGTATGGTGATGTTTCAAAAACCAACC	19422
125_10	19378	CTTGGTGGTTTGCATCTACTAATTTTCGCAGGTGCGTCTGGCCTGTATGGGTGTGCTCAAA	19437
AH2012	19423	CTTGGTGGTTTGCATCTACTAATTTTCGCAGGTGCGTCTGGCCTGTATGGGTGTGCTCAAA	19482
125_10	19438	ATAGACGAGTTTGTGTCTAGTAATGATAGCACGTTAAAGTCTTGTAAGTTACATATGCT	19497
AH2012	19483	ATAGACGAGTTTGTGTCTAGTAATGATAGCACGTTAAAGTCTTGTAAGTTACATATGCT	19542

22/66

FIG. 1 (cont'd)

125_10	19498	GATAACCCTAGTAGTAAGATGGTTTGTACGTATATGGATCTCCTGCTTGACGATTTTGTC	19557
AH2012	19543	GATAACCCTAGTAGTAAGATGGTTTGTACGTATATGGATCTCCTGCTTGACGATTTTGTC	19602
125_10	19558	AGCATTCTTAAATCTTTGGATTTGGGCGTTGTATCTAAAGTTCATGAAGTTATGGTCGAT	19617
AH2012	19603	AGCATTCTTAAATCTTTGGATTTGGGCGTTGTATCTAAAGTTCATGAAGTTATGGTCGAT	19662
125_10	19618	TGTAAATGTGGAGGTGGATGTTGTGGTGTAAGGATCATAAACTCCAGACATTTTATCCG	19677
AH2012	19663	TGTAAATGTGGAGGTGGATGTTGTGGTGTAAGGATCATAAACTCCAGACATTTTATCCG	19722
125_10	19678	CAACTTCAGGCCAGTGAATGGAAGTGTGGTTATTCCATGCCTTCTATTTACAAGATACAA	19737
AH2012	19723	CAACTTCAGGCCAGTGAATGGAAGTGTGGTTATTCCATGCCTTCTATTTACAAGATACAA	19782
125_10	19738	CGTATGTGTTTAGAACCTTGCAATCTCTACAACATGGTGCTGGTATTAAGTTACCTGAT	19797
AH2012	19783	CGTATGTGTTTAGAACCTTGCAATCTCTACAACATGGTGCTGGTATTAAGTTACCTGAT	19842
125_10	19798	GGCATTATGTTTAAACGTAGTTAAATACACACAGCTTTGTCAATATCTCAATAGCACCACA	19857
AH2012	19843	GGCATTATGTTTAAACGTAGTTAAATACACACAGCTTTGTCAATATCTCAATAGCACCACA	19902
125_10	19858	ATGTGTGTACCCCATCACATGCGTGTGCTACATCTTGGTGCTGGCTCCGACAAGGGTGTT	19917
AH2012	19903	ATGTGTGTACCCCATCACATGCGTGTGCTACATCTTGGTGCTGGCTCCGACAAGGGTGTT	19962
125_10	19918	GCACCTGGCACGGCTGTCTTACGACGTTGGTTGCCACTGGATGCCATTATAGTTGACAAT	19977
AH2012	19963	GCACCTGGCACGGCTGTCTTACGACGTTGGTTGCCACTGGATGCCATTATAGTTGACAAT	20022
125_10	19978	GATAGTGTGGATTACGTTAGCGATGCTGATTATAGTGTTACAGGAGATTGCTCTACCTTA	20037
AH2012	20023	GATAGTGTGGATTACGTTAGCGATGCTGATTATAGTGTTACAGGAGATTGCTCTACCTTA	20082
125_10	20038	TACCTGTCAGATAAGTTTGATTTAGTTATATCTGATATGTATGATGGTAAGATTAAGT	20097
AH2012	20083	TACCTGTCAGATAAGTTTGATTTAGTTATATCTGATATGTATGATGGTAAGATTAAGT	20142
125_10	20098	TGTGATGGGGAGAACGTGTCTAAAGAAGGCTTCTTTCCCTATATTAATGGTGTATCACC	20157
AH2012	20143	TGTGATGGGGAGAACGTGTCTAAAGAAGGCTTCTTTCCCTATATTAATGGTGTATCACC	20202
125_10	20158	GA-AAAGTTGGCACTTGGTGGTACTGTAGCTATTAAGGTGACGGAGTTTAGTTGGAATAA	20216
AH2012	20203	GACAAAGTTGGCACTTGGTGGTACTGTAGCTATTAAGGTGACGGAGCTTAGTTGGAATAA	20262
125_10	20217	GAAGTTGTATGAACTCATTCAGAGGTTTGAGTATTGGACAATGTTCTGTACCAGTGTTAA	20276
AH2012	20263	GAAGTTGTATGAACTCATTCAGAAGTTTGAGTATTGGACAATGTTCTGTACCAGTGTTAA	20322
125_10	20277	CACGTCATCGTCAGAGGCATTCTTAATTGGTGTTCACTATTTAGGTGATTTTGCAAGTGG	20336
AH2012	20323	CACGTCATCGTCAGAGGCATTCTTAATTGGTGTTCACTATTTAGGTGATTTTGCAAGTGG	20382
125_10	20337	CGCTGTGATTGACGGCAACACTATGCATGCCAATTATATCTTCTGGCGTAATTCCACAAT	20396
AH2012	20383	CGCTGTGATTGACGGCAACACTATGCATGCCAATTATATCTTCTGGCGTAATTCCACAAT	20442

23/66

FIG. 1 (cont'd)

125_10	20397	TATGACTATGTCTTACAATAGTGTACTTGATTTAAGCAAGTTCAATTGTAAGCATAAGGC	20456
AH2012	20443	TATGACTATGTCTTACAATAGTGTACTTGATTTAAGCAAGTTCAATTGTAAGCATAAGGC	20502
125_10	20457	TACAGTTGTCATTAATTTAAAAGATTCATCCATTAGTGATGTTGTGTTAGGTTTGTGAA	20516
AH2012	20503	TACAGTTGTCATTAATTTAAAAGATTCATCCATTAGTGATGTTGTGTTAGGTTTGTGAA	20562
125_10	20517	GAATGGTAAGTTGCTAGTGCGTAATAATGACGCCATTTGTGGTTTTCTAATCATTTGGT	20576
AH2012	20563	GAATGGTAAGTTGCTAGTGCGTAATAATGACGCCATTTGTGGTTTTCTAATCATTTGGT	20622
125_10	20577	CAACGTAAACAAATGAAGTCTTTAACCTACTTCTGGTTGTTCTTACCAGTACTTTCAACA	20636
AH2012	20623	CAACGTAAACAAATGAAGTCTTTAACCTACTTCTGGTTGTTCTTACCAGTACTTTCAACA	20682
125_10	20637	CTTAGCCTACCACAAGATGTCACCAGGTGCTCAGCTAACACTAATTTTAGGCGGTTCTTT	20696
AH2012	20683	CTTAGCCTACCACAAGATGTCACCAGGTGCTCAGCTAACACTAATTTTAGGCGGTTCTTT	20742
125_10	20697	TCAAAATTTAATGTTTCAGGCGCCTGCAGTTGTTGTACTGGGCGGTTATCTACCTATTGGT	20756
AH2012	20743	TCAAAATTTAATGTTTCAGGCGCCTGCAGTTGTTGTACTGGGCGGTTATCTACCTATTGGT	20802
125_10	20757	GAAAACCAGGGTGTCAATTCAACTTGGTACTGTGCTGGCCAACATCCAAGTCTAGTGGC	20816
AH2012	20803	GAAAACCAGGGTGTCAATTCAACTTGGTACTGTGCTGGCCAACATCCAAGTCTAGTGGC	20862
125_10	20817	GTTTCATGGTATCTTTGTTAGCCATATTAGAGGTGGTCATGGCTTTGAGATTGGCATTTCG	20876
AH2012	20863	GTTTCATGGTATCTTTGTTAGCCATATTAGAGGTGGTCATGGCTTTGAGATTGGCATTTCG	20662
125_10	20877	CAAGAGCCTTTTGACCCTAGTGGTTACCAGCTTTATTTACATAAGGCTACTAACGGTAAC	20936
AH2012	20663	CAAGAGCCTTTTGACCCTAGTGGTTACCAGCTTTATTTACATAAGGCTACTAACGGTAAC	20982
125_10	20937	ACTAATGCTACTGCGCGACTGCGCATTTGCCAGTTTCCTAGCATTAAACATTGGGCCCC	20996
AH2012	20983	ACTAATGCTACTGCGCGACTGCGCATTTGCCAGTTTCCTAGCATTAAACATTGGGCCCC	2662
125_10	20997	ACTGCTAATAATGATGTTACAATAGGTCGTAATTGCCTATTTAACAAAGCCATCCCAGCT	21056
AH2012	2663	ACTGCTAATAATGATGTTACAACAGGTCGTAATTGCCTATTTAACAAAGCCATCCCAGCT	21102
125_10	21057	CATATGAGTGAACATAGTGTTGTCGGCATAACATGGGATAATGATCGTGCTCACTGTCTTT	21116
AH2012	21103	CATATGAGTGAACATAGTGTTGTCGGCATAACATGGGATAATGATCGTGCTCACTGTCTTT	21162
125_10	21117	TCTGACAAGATCTATTATTTTTATTTTAAAAATGATTGGTCCCGTGTTGCGACAAAGTGT	21176
AH2012	21163	TCTGACAAGATCTATTATTTTTATTTTAAAAATGATTGGTCCCGTGTTGCGACAAAGTGT	21222
125_10	21177	TACAACAGTGGAGGTTGTGCTATGCAATATGTTTACGAACCCACCTATTACATGCTTAAT	21236
AH2012	21223	TACAACAGTGGAGGTTGTGCTATGCAATATGTTTACGAACCCACCTATTACATGCTTAAT	21282
125_10	21237	GTTACTAGTGCTGGTGAGGATGGTATTTCTTATCAACCCTGTACAGCTAATTGCATTGGT	21296
AH2012	21283	GTTACTAGTGCTGGTGAGGATGGTATTTCTTATCAACCCTGTACAGCTAATTGCATTGGT	21342
125_10	21297	TATGCTGCCAATGTATTTGCTACTGAGCCCAATGGCCACATACCAGAAGGTTTTAGTTTT	21356
AH2012	21343	TATGCTGCCAATGTATTTGCTACTGAGCCCAATGGCCACATACCAGAAGGTTTTAGTTTT	21402

24/66

FIG. 1 (cont'd)

125_10	21357	AATAATTGGTTTCTTTTGTCCAATGATTCCACTTTGGTGCATGGTAAGGTGGTTTCCAAC	21416
AH2012	21403	AATAATTGGTTTCTTTTGTCCAATGATTCCACTTTGGTGCATGGTAAGGTGGTTTCCAAC	21462
125_10	21417	CAACCATTGTTGGTCAATTGTCTTTTGGCCATTCTAAGATTTATGGACTAGGCCAATTT	21476
AH2012	21463	CAACCATTGTTGGTCAATTGTCTTTTGGCCATTCTAAGATTTATGGACTAGGCCAATTT	21522
125_10	21477	TTCTCCTTTAATCAAACGATCGATGGTGTGTGTAATGGAGCTGCTGTGCAGCGTGACCA	21536
AH2012	21523	TTCTCCTTTAATCAAACGATCGATGGTGTGTGTAATGGAGCTGCTGTGCAGCGTGACCA	21582
125_10	21537	GAGGCTCTGAGGTTTAATATTAATGACACCTCTGTCACTTCTTGCTGAAGGCTCAATTGTA	21596
AH2012	21583	GAGGCTCTGAGGTTTAATATTAATGACACCTCTGTCACTTCTTGCTGAAGGCTCAATTGTA	21642
125_10	21597	CTTCATACTGCTTTAGGAACAAATTTTTCTTTGTTTGCAGTAATTCCTCAAATCCTCAC	21656
AH2012	21643	CTTCATACTGCTTTAGGAACAAATTTTTCTTTGTTTGCAGTAATTCCTCAAATCCTCAC	21702
125_10	21657	TTAGCCACCTTCGCCATACCTCTGGGTGCTACCCAAGTACCTTATTATTGTTTTCTTAAA	21716
AH2012	21703	TTAGCCACCTTCGCCATACCTTTGGGTGCTACCCAAGTACCTTATTATTGTTTTCTTAAA	21762
125_10	21717	GTGGATACTTACAACCTCCACTGTTTATAAATTTTTGGCTGTTTACCTCCTACCGTCAGG	21776
AH2012	21763	GTGGATACTTACAACCTCCACTGTTTATAAATCTTGGCTGTTTACCTCCAACCGTCAGG	21822
125_10	21777	GAAATTGTCATCACCAAGTATGGTGATGTTTATGTCAATGGGTTTGGATACTTGCATCTC	21836
AH2012	21823	GAAATTGTCATCACCAAGTATGGTGATGTTTATGTCAATGGGTTTGGCTATTTGCATCTC	21882
125_10	21837	GGTTTGTGGATGCTGTCACAATTAATTTCACTGGTCATGGCACTGACGATGATGTTTCT	21896
AH2012	21883	GGTTTGTGGACGCTGTCACAATTAATTTCACTGGTCATGGCACTGACGATGACGTTTCA	21942
125_10	21897	GGTTTTTGGACCATAGCATCGACTAATTTTGTGATGCACTCATCGAAGTTCAAGGAACC	21956
AH2012	21943	GGTTTCTGGACCATAGCATCGACTAATTTTGTGATGCACTTATCGAAGTTCAAGGAACT	22002
125_10	21957	GCCATTGAGCGTATTCTTTATTGTGATGATCCTGTTAGCCAACCTCAAGTGTCTCAGGTT	22016
AH2012	22003	GCCATTGAGCGTATTCTTTATTGTGATGATCCTGTTAGCCAACCTCAAGTGTCTCAGGTT	22062
125_10	22017	GCTTTTGACCTTGACGATGGTTTTTACCCTATTTCTTCTAGAAACCTTCTGAGTCATGAA	22076
AH2012	22063	GCTTTTGACCTTGACGATGGTTTCTACCCTATTTCTTCTAGAAACCTTCTGAGTCATGAA	22122
125_10	22077	CAGCCAATTTCTTTTGTACTCTGCCATCATTTAATGATCATTCTTTTGTAAACATTACT	22136
AH2012	22123	CAGCCAATTTCTTTTGTACTTTGCCATCATTTAATGATCATTCTTTTGTAAACATTACT	22182
125_10	22137	GTATCTGCTTCCTTTGGTGGTCATAGTGGTGCCAACCTTATTGCATCTGACACTACTATC	22196
AH2012	22183	GTCTCTGCGTCCTTTGGTGGTCATAGTGGTGCCAACCTTATTGCATCTGACACTACTATC	22242
125_10	22197	AATGGGTTTAGTTCTTTCTGTGTTGACACTAGACAATTTACCATTTCACTGTTTTATAAC	22256
AH2012	22243	AATGGGTTTAGTTCTTTCTGTGTTGACACTAGACAATTTACCATTTCACTGTTTTATAAC	22302
125_10	22257	GTTACAAACAGTTATGGTTATGTGTCTAAATCACAGGACAGTAATTGCCCTTTCACCTTG	22316
AH2012	22303	GTTACAAACAGTTATGGTTATGTGTCTAAATCACAGGACAGTAATTGCCCTTTCACCTTG	22362

25/66

FIG. 1 (cont'd)

125_10	22317	CAATCTGTTAATGATTACCTGTCTTTTAGCAAATTTTGTGTTTCCACCAGCCTTTTGGCT	22376
AH2012	22363	CAATCTGTTAATGATTACCTGTCTTTTAGTAAATTTTGTGTTTCCACCAGCCTTTTGGCT	22422
125_10	22377	AGTGCCTGTACCATAGATCTTTTGGTTACCCTGAGTTTGGTAGTGGTGTTAAGTTTACG	22436
AH2012	22423	AGTGCCTGTACCATAGATCTTTTGGTTACCCTGATTTTGGTAGTGGTGTTAAGTTTACG	22482
125_10	22437	TCCCTTTACTTTCAATTACAAAGGGTGAGTTGATTACTGGCACGACTAAACCACTTGAA	22496
AH2012	22483	TCCCTTTACTTTCAATTACAAAGGGTGAGTTGATTACTGGCACGCCTAAACCACTTGAA	22542
125_10	22497	GGTGTCACGGACGTTTCTTTTATGACTCTGGATGTGTGTACCAAGTATACTATCTATGGC	22556
AH2012	22543	GGTGTCACGGACGTTTCTTTTATGACTCTGGATGTGTGTACCAAGTATACTATCTATGGC	22602
125_10	22557	TTTAAAGGTGAGGGTATCATTACCCTTACAAATTCTAGCTTTTGGCAGGTGTTTATTAC	22616
AH2012	22603	TTTAAAGGTGAGGGTATCATTACCCTTACAAATTCTAGCTTTTGGCAGGTGTTTATTAC	22662
125_10	22617	ACATCTGTTTCTGGACAGTTGTTAGCCTTTAAGAATGTCAGTAGTGGTGCTGTTTATTCT	22676
AH2012	22663	ACATCTGATTCTGGACAGTTGTTAGCCTTTAAGAATGTCAGTAGTGGTGCTGTTTATTCT	22722
125_10	22677	GTTACGCCATGTTCTTTTTCAGAGCAGGCTGCATATGTTGATGATGATATAGTGGGTGTT	22736
AH2012	22723	GTTACGCCATGTTCTTTTTCAGAGCAGGCTGCATATGTTGATGATGATATAGTGGGTGTT	22782
125_10	22737	ATTTCTAGTTTGTCTAGCTCCACTTTTAACAGTACTAGGGAGTTGCCTGGTTTCTTCTAC	22796
AH2012	22783	ATTTCTAGTTTGTCTAATTCCACTTTTAACAGTACTAGGGAGTTGCCTGGTTTCTTCTAC	22842
125_10	22797	CATTCTAATGATGGCTCTAATTGTACAGAGCCTGTGTTGGTGTATAGTAACATAGGTGTT	22856
AH2012	22843	CATTCTAATGATGGCTCTAATTGTACAGAGCCTGTGTTGGTGTATAGTAACATAGGTGTT	22902
125_10	22857	TGTAAATCTGGCAGTATTGGCTACGTCCCATCTCAGTCTGGCCAAGTCAAGATTGCACCC	22916
AH2012	22903	TGTAAATCTGGCAGTATTGGCTACGTCCCATCTCAGTCTGGCCAAGTCAAGATTGCACCC	22962
125_10	22917	ACGGTACTGGGAATATTAGTATTCCCACCAACTTTAGTATGAGTATTAGGACAGAATAT	22976
AH2012	22963	ACGGTACTGGGAATATTAGTATTCCCACCAACTTTAGTATGAGTATTAGGACAGAATAT	23022
125_10	22977	TTACAGCTTTACAACACGCCTGTTAGTGTTGATTGTGCCACATATGTTTGTAAATGGTAAC	23036
AH2012	23023	TTACAGCTTTACAACACGCCTGTTAGTGTTGATTGTGCCACATATGTTTGTAAATGGTAAC	23082
125_10	23037	TCTCGTTGTAAACAATTACTCACCCAGTACACTGCAGCATGTAAGACCATAGAGTCAGCA	23096
AH2012	23083	TCTCGTTGTAAACAATTACTCACCCAGTACACTGCAGCATGTAAGACCATAGAGTCAGCA	23142
125_10	23097	TTACRACTCAGCGCTAGGCTTGAGTCTGTTGAAGTTAACTCTATGCTTACTATTTCTGAA	23156
AH2012	23143	TTACAACTCAGCGCTAGGCTTGAGTCTGTTGAAGTTAACTCTATGCTTACTATTTCTGAA	23202
125_10	23157	GAGGCTCTACAGTTAGCTACCATTAGTTCGTTTAAATGGTGATGGATATAATTTTACTAAT	23216
AH2012	23203	GAGGCTCTACAGTTAGCTACCATCAGTTCGTTTAAATGGTGATGGATATAATTTTACTAAT	23262
125_10	23217	GTGCTGGGTGTTTCTGTGTATGATCCTGCAAGGGGCAGGGTGGTACAAAAAAGGTCTTTT	23276
AH2012	23263	GTGCTGGGTGTTTCTGTGTATGATCCTGCAAGTGGCAGGGTGGTACAAAAAAGGTCTTTT	23322

26/66

FIG. 1 (cont'd)

125_10	23277	ATTGAAGACCTGCTTTTTTAATAAAGTGGTTACTAATGGCCTTGGTACTGTTGATGAAGAC	23336
AH2012	23323	ATTGAAGACCTGCTTTTTTAATAAAGTGGTTACTAATGGCCTTGGTACTGTTGATGAAGAC	23382
125_10	23337	TATAAGCGCTGTTCTAATGGTCGCTCTGTGGCAGATCTAGTCTGTGCACAGTATTACTCT	23396
AH2012	23383	TATAAGCGCTGTTCTAATGGTCGCTCTGTGGCAGATCTAGTCTGTGCACAGTATTACTCT	23442
125_10	23397	GGTGTCATGGTACTACCTGGTGTTGTTGACGCTGAGAAGCTTCACATGTATAGTGCGTCT	23456
AH2012	23443	GGTGTCATGGTACTACCTGGTGTTGTTGACGCTGAGAAGCTTCACATGTATAGTGCGTCT	23502
125_10	23457	CTCATCGGTGGTATGGTGCTAGGAGGTTTTACTTCTGCAGCGGCATTGCCTTTTAGCTAT	23516
AH2012	23503	CTCATCGGTGGTATGGTGCTAGGAGGTTTTACTTCTGCAGCGGCATTGCCTTTTAGCTAT	23562
125_10	23517	GCTGTTCAAGCTAGACTCAATTATCTTGCTCTACAGACGGATGTTCTACAGCGGAACCAG	23576
AH2012	23563	GCTGTTCAAGCTAGACTCAATTATCTTGCTCTACAGACGGATGTTCTACAGCGGAACCAG	23622
125_10	23577	CAATTGCTTGCTGAGTCTTTTAACTCTGCTATTGGTAATATAACTTCAGCCTTTGAGAGT	23636
AH2012	23623	CAATTGCTTGCTGAGTCTTTTAACTCTGCTATTGGTAATATAACTTCAGCCTTTGAGAGT	23682
125_10	23637	GTTAAAGAGGCTATTAGTCAAACCTCCAAGGGTTTGAACACTGTGGCTCATGCGCTTACT	23696
AH2012	23683	GTTAAAGAGGCTATTAGTCAAACCTCCAAGGGTTTGAACACTGTGGCTCATGCGCTTACT	23742
125_10	23697	AAGGTTCAAGAGGTTGTTAACTCGCAGGGTGCAGCTTTGACTCAACTTACCGTACAGCTG	23756
AH2012	23743	AAGGTTCAAGAGGTTGTTAACTCGCAGGGTGCAGCTTTGACTCAACTTACCGTACAGCTG	23802
125_10	23757	CAACACAACCTCCAAGCCATTTCTAGTTCTATTGATGACATTTACTCTCGACTGGACATT	23816
AH2012	23803	CAACACAACCTCCAAGCCATTTCTAGTTCTATTGATGACATTTACACCCGACTGGACATT	23862
125_10	23817	CTTTCAGCCGATGTTTCAAGGTTGACCGTCTCATCACCGGCAGATTATCAGCACTTAATGCT	23876
AH2012	23863	CTTTCAGCCGATGTTTCAAGGTTGACCGTCTCATCACCGGCAGATTATCAGCACTTAATGCT	23662
125_10	23877	TTTGTGCTCAAACCCCTCACTAAGTATACTGAGGTTTCAAGGCTAGCAGGAAGTTAGCACAG	23936
AH2012	23663	TTTGTGCTCAAACCCCTCACTAAGTATACTGAGGTTTCAAGGCTAGCAGGAAGCTAGCACAG	23982
125_10	23937	CAAAAGGTTAATGAGTGCGTTAAATCGCAATCCCAGCGTTATGGTTTTTGTGGTGGTGAT	23996
AH2012	23983	CAAAAGGTTAATGAGTGCGTTAAATCGCAATCTCAGCGTTATGGTTTTTGTGGTGGTGAT	24042
125_10	23997	GGCGAGCACATTTTCTCTCTGGTACAGGCAGCACCTCAGGGCCTGCTGTTTTTACATACA	24056
AH2012	24043	GGCGATCACATTTTCTCTCTGGTACAGGCAGCACCTCAGGGCCTGCTGTTTTTACATACA	24102
125_10	24057	GTACTTGTACCGAGTGATTTTGTAGATGTTATTGCCATCGCTGGCTTATGCGTTAACGAT	24116
AH2012	24103	GTACTTGTACCGGGTGATTTTGTAGATGTTATTGCCATCGCTGGCTTATGCGTTAACGAT	24162
125_10	24117	GAAATTGCCTTGACTCTACGTGAGCCTGGCTTAGTCTTGTTTACGCATGAACTTCAAAAT	24176
AH2012	24163	GAAATTGCCTTGACTCTACGTGAGCCTGGCTTAGTCTTGTTTACGCATGAACTTCAAAAT	24222

27/66
FIG. 1 (cont'd)

125_10	24177	CATACTGCGACGGAATATTTTGTTCATCGCGACGTATGTTTGAACCTAGAAAACCTACC	24236
AH2012	24223	CATACTGCGACGGAATATTTTGTTCATCGCGACGTATGTTTGAACCTAGAAAACCTACC	24282
125_10	24237	GTTAGTGATTTTGTTCAAATTGAGAGTTGTGTGGTCACCTATGTCAATTTGACTAGAGAC	24296
AH2012	24283	GTTAGTGATTTTGTTCAAATTGAGAGTTGTGTGGTCACCTATGTCAATTTGACTAGAGAC	24342
125_10	24297	CAACTACCAGATGTAATCCCAGATTACATCGATGTTAACAAAACACTTGATGAGATTTTA	24356
AH2012	24343	CAACTACCAGATGTAATCCCAGATTACATCGATGTTAACAAAACACTTGATGAGATTTTA	24402
125_10	24357	GCTTCTCTGCCCAATAGAACTGGTCCAAGTCTTCCTTTAGATGTTTTTAATGCCACTTAT	24416
AH2012	24403	GCTTCTCTGCCCAATAGAACTGGTCCAAGTCTTCCTTTAGATGTTTTTAATGCCACTTAT	24462
125_10	24417	CTTAATCTCACTGGTGAAATTGCAGATTTAGAGCAGCGTTCAGAGTCTCTCCGTAATACT	24476
AH2012	24463	CTCAATCTCACTGGTGAAATTGCAAATTTAGAGCAGCGTTCAGAGTCTCTCCGTAATACT	24522
125_10	24477	ACAGAGGAGCTCCAAAGTCTTATATATAATATCAACAACACACTAGTTGACCTTGAGTGG	24536
AH2012	24523	ACAGAGGAGCTCCAAAGTCTTATACATAATATCAACAACACACTAGTTGACCTTGAGTGG	24582
125_10	24537	CTCAACCGAGTTGAGACATATATCAAGTGGCCGTGGTGGGTTTGGTTGATTATTTTCATT	24596
AH2012	24583	CTCAACCGAGTTGAGACATATATCAAGTGGCCGTGGTGGGTTTGGTTGTTATTTTATT	24642
125_10	24597	GTTCTCATCTTTGTTGTGTCATTACTAGTGTTCTGCTGCATTTCCACGGGTTGTTGTGGA	24656
AH2012	24643	GTTCTCATCTTTGTTGTGTCATTACTAGTGTTCTGCTGCATTTCCACGGGTTGTTGTGGA	24702
125_10	24657	TGCTGCGGCTGCTGCTGTGCTTGTCTCAGGTTGTTGTAGGGGTCCTAGACTTCAACCT	24716
AH2012	24703	TGCTGCGGCTGCTGCTGTGCTTGTCTCAGGTTGTTGTAGGGGTCCTAGACTTCAACCT	24762
125_10	24717	TACGAAGTTTTTGAAAAGGTCCACGTGCAGTGATGTTTCTTGGACTTTTTCAATACACGA	24776
AH2012	24763	TACGAAGTTTTTGAAAAGGTCCACGTGCAGTGATGTTTCTTGGACTTTTTCAATACACGA	24822
125_10	24777	TTGACACAGTTGTCAAAGATGTCTCAAAGTCTGCTAACTTGTCTTTGGATGCTGTCCAAG	24836
AH2012	24823	TTGACACAGTTGTCAAAGATGTCTCAAAGTCTGCTAACTTGTCTTTGGATGCTGTCCAAG	24882
125_10	24837	AGTTGGAGCTCAATGTAGTTCCAATTAGACAAGCTTCAAATGTGACGGGTTTTCTTTTCA	24896
AH2012	24883	AGTTGGAGCTCAATGTAGTTCCAATTAGACAAGCTTCAAATGTGACGGGTTTTCTTTTCA	24942
125_10	24897	CCAGTGTTTTTATCTACTTCTTTGCACTGTTTAAAGCGTCTTCTTTGAGGCGCAATTATA	24956
AH2012	24943	CCAGTGTTTTTATCTACTTCTTTGCACTGTTTAAAGCGTCTTCTTTGAGGCGCAATTATA	25002
125_10	24957	TTATGTTGGCAGCGCGTTTTGCTGTCATTGTTCTTTATTGCCCACTTTTATATTATTGTG	25016
AH2012	25003	TTATGTTGGCAGCGCGTTTTGCTGTCATTGTTCTTTATTGCCCACTTTTATATTATTGTG	25062
125_10	25017	GTGCATTTTTAGATGCAACTATTATTTGTTGCACACTTATTCAAAGTCGGTGGCAGGCTT	25076
AH2012	25063	GTGCATTTTTAGATGCAACTATTATTTGTTGCACACTTAT-----TGGCAGGCTT	25112
125_10	25077	TGTTTAGTCTGCTTTTACTCCTGGCGCTATAAAAATGCGCTCTTTATTATTTTAAATACT	25136
AH2012	25113	TGTTTAGTCTGCTTTTACTCCTGGCGCTATAAAAATGCGCTCTTTATTATCTTTAATACT	25172

28/66

FIG. 1 (cont'd)

125_10	25137	ACGACACTTTCTTTCCTCAATGGTAAAGCAGCTTATTATGACGGCAAATCCATTGTGATT	25196
AH2012	25173	ACGACACTTTCTTTCCTCAATGGTAAAGCAGCTTACTATGACGGCAAATCCATTGTGATT	25232
125_10	25197	TTAGAAGGTGGTGACCATTACATCACTTTTGGCAACTCTTTTGTTGCTTTTGTAGTAGC	25256
AH2012	25233	CTAGAAGGTGGTGACTATTACATCACTTTTGGGAAGCTTTTGTTGCTTTCGTTAGTAGC	25266
125_10	25257	ATCGACTTGTATCTAGCTATACGTGGGCGGCAAGAAGCTGACCTACAGCTGTTGCGAACT	25316
AH2012	25293	ATTGACTTGTATCTAGCTATACGTGGGCGGCAAGAAGCCGACCTACAGCTGTTGCGAACT	25352
125_10	25317	GTTGAGCTTCTTGATGGCAAGAAGCTTTATGTCTTTTCGCAACATCAAATTGTTGGCATT	25376
AH2012	25353	GTTGAGCTTCTTGATGGCAAGAAGCTTTATGTCTTTTCGCAACATCAAATTGTAGGCATT	25412
125_10	25377	ACTAATGCTGCATTTGACTCAATTCAACTAGACGAGTATGCTACAATTAGTGAATGATAA	25436
AH2012	25413	ACTAATGCTGCATTTGACTCAATTCAACTAGACGAGTATGCTACAATTAGTGAATGATAA	25472
125_10	25437	TGGTCTAGTAGTTAATGTTATACTTTGGCTTTTCGTAAGCTCTTTTCTGCTTATTATAAG	25496
AH2012	25473	TGGTCTAGTAGTTAATGTTATACTTTGGCTTTTCGTAAGCTCTTTTCTGCTTATTATAAG	25532
125_10	25497	CATTACTTTCGTCCAATTGGTTAATCTGTGCTTCACTTGTACCGGTTGTGAATAGCGC	25556
AH2012	25533	CATTACTTTCGTCCAATTGGTTAATCTGTGCTTCACTTGTACCGGTTGTGAATAGCGC	25566
125_10	25557	AGTTTACACACCTATAGGGCGTTTGTATAGAGTTTATAAGTCTTACATGCAAATAGACCC	25616
AH2012	25593	AGTTTACACACCTATAGGGCGTTTGTATAGAGTTTATAAGTCTTACATGCAAATAGACCC	25652
125_10	25617	CCTCCCTAGTACTGTTATTGACGTATAAACGAAATATGTCTAACGGTTCTATTCCCGTTG	25676
AH2012	25653	CCTCCCAGTACTGTTATTGACGTATAAACGAAATATGTCTAACGGTTCTATTCCCGTTG	25712
125_10	25677	ATGAGGTGATTCAACACCTTAGAACTGGAATTTACATGGAATATCATACTGACGATAC	25736
AH2012	25713	ATGAGGTGATTCAACACCTTAGAACTGGAATTTACATGGAATATCATACTGACGATAC	25772
125_10	25737	TACTTGTAGTGCTTCAGTATGGCCATTACAAGTACTCTGCGTTCTTGTATGGTGTCAAGA	25796
AH2012	25773	TACTCGTAGTGCTTCAGTATGGCCATTACAAGTACTCTGCGTTCTTGTATGGTGTCAAGA	25832
125_10	25797	TGGCTATTCTATGGATACTTTGGCCTCTTGTGTTAGCACTGTCACTTTTGTATGCATGGG	25856
AH2012	25833	TGGCTATTCTATGGATACTTTGGCCTCTTGTGTTAGCACTGTCACTTTTGTATGCATGGG	25866
125_10	25857	CTAGCTTTCAGGTCAATTGGGTCTTTTTTGCTTTGAGCATCCTTATGGCTTGCATCACTC	25916
AH2012	25893	CTAGCTTTCAGGTCAATTGGGTCTTTTTTGCTTTGAGCATCCTTATGGCTTGCATCACTC	25952
125_10	25917	TTATGCTGTGGATAATGTACTTTGTCAATAGCATTTCGGTTGTGGCGCAGGACACATTCTT	25976
AH2012	25953	TTATGCTGTGGATAATGTACTTTGTCAATAGCATTTCGGTTGTGGCGCAGGACACATTCTT	26012
125_10	25977	GGTGGTCTTTCAATCCTGAAACAGACGCGCTTCTCACTACTTCTGTGATGGGCCGACAGG	26036
AH2012	26013	GGTGGTCTTTCAATCCTGAAACAGACGCGCTTCTCACTACTTCTGTGATGGGCCGACAGG	26072

29/66

FIG. 1 (cont'd)

125_10	26037	TCTGCATTCCAGTGCTTGGAGCACCAACTGGTGTAACGCTAACACTCCTTAGTGGTACAT	26096
AH2012	26073	TCTGCATTCCAGTGCTTGGAGCACCAACTGGTGTAACGCTAACACTCCTTAGTGGTACAT	26132
125_10	26097	TGCTTGTAGAGGGCTATAAGGTTGCTACTGGCGTACAGGTAAGTCAATTACCTAATTTTCG	26156
AH2012	26133	TGCTTGTAGAGGGCTATAAGGTTGCTACTGGCGTACAGGTAAGTCAATTACCTAATTTTCG	26166
125_10	26157	TCACAGTCGCCAAGGCCACTACAACAATTGTCTACGGACGTGTTGGTCGTTCAAGTCAATG	26216
AH2012	26193	TCACAGTCGCCAAGGCCACTACAACAATTGTCTACGGACGTGTTGGTCGTTCAAGTCAATG	26252
125_10	26217	CTTCATCTGGCACTGGTTGGGCTTTCTATGTCCGGTCCAAACACGGCGACTACTCAGCTG	26276
AH2012	26253	CTTCATCTGGCACTGGTTGGGCTTTCTATGTCCGGTCCAAACACGGCGACTACTCAGCTG	26312
125_10	26277	TGAGTAATCCGAGTTCGGTTCTCACAGATAGTGAGAAAGTGCTTCATTTAGTCTAAACAG	26336
AH2012	26313	TGAGTAATCCGAGTTCGGTTCTCACAGATAGTGAGAAAGTGCTTCATTTAGTCTAAACAG	26372
125_10	26337	AAACTTTATGGCTTCTGTCAAGTTTTCAGGATCGTGGCCGCAAACGGGTGCCATTATCCCT	26396
AH2012	26373	AAACTTTATGGCTTCTGTCAAGTTTTCAGGATCGTGGCCGCAAACGGGTGCCATTATCCCT	26432
125_10	26397	CTATGCCCCCTTAGGGTTACTAATGACAAACCCCTTTCTAAGGTACTTGCAAATAATGC	26456
AH2012	26433	CTATGCCCCCTTAGGGTTACTAATGACAAACCCCTTTCTAAGGTACTTGCAAATAATGC	26466
125_10	26457	TGTACCCACTAATAAAGGAAATAAGGACCAGCAAATTGGATACTGGAATGAGCAAATTCG	26516
AH2012	26493	TGTACCCACTAATAAAGGAAATAAGGACCAGCAAATTGGATACTGGAATGAGCAAATTCG	26552
125_10	26517	CTGGCGCATGCGCCGTGGTGAGCGAATTGAACAACCTTCCAATTGGCATTCTACTACCT	26576
AH2012	26553	CTGGCGCATGCGCCGTGGTGAGCGAATTGAACAACCTTCCAATTGGCATTCTACTACCT	26612
125_10	26577	CGGAACAGGACCTCACGCCGACCTCCGCTATAGGACTCGTACTGAGGGTGTTTTCTGGGT	26636
AH2012	26613	CGGAACAGGACCTCACGCCGACCTCCGCTATAGGACTCGTACTGAGGGTGTTTTCTGGGT	26672
125_10	26637	TGCTAAAGAAGGCGCAAAGACTGAACCCACTAACCTGGGTGTCAGAAAGGCGTCTGAAAA	26696
AH2012	26673	TGCTAAAGAAGGCGCAAAGACTGAACCCACTAACCTGGGTGTCAGAAAGGCGTCTGAAAA	26732
125_10	26697	GCCAATTATTCCAAATTTCTCTCAACAGCTTCCCAGCGTAGTTGAGATTGTTGAACCTAA	26756
AH2012	26733	GCCTATCATTCCAAATTTCTCCCAACAGCTTCCCAGCGTAGTTGAGATTGTTGAACCTAA	26766
125_10	26757	CACACCTCCTACTTCACGTGCAAATTCACGTAGCAGGAGTCGTGGTAATGGCAACAACAG	26816
AH2012	26793	CACACCTCCCACTTCACGTTCAAATTCACGTAGCAGGAGTCGTGGTAATGGCAACAACAG	26852
125_10	26817	GTCCAGATCTCCAAGTAACAACAGAGGCAATAACCAGTCCCGCGGTAATTCACAGAATCG	26876
AH2012	26853	GTCCAGATCTCCAAGTAACAACAGAGGCAATAACCAGTCCCGCGGTAATTCACAGAATCG	26912
125_10	26877	TGGAAATAACCAGGGTCGTGGAGCTTCTCAGAACAGAGGAGGCAATAATAACAATAA	26936
AH2012	26913	TGGAAATAACCAGGATCGTGGAGCTTCTCAGAACAGAGGAGGCAATAATAACAATAA	26972

30/66

FIG. 1 (cont'd)

125_10	26937	CAAGTCTCGTAACCAGTCCAAGAACAGAAACCAGTCAAATGACCGTGGTGGTGTAAACATC	26996
AH2012	26973	CAAGTCTCGTAACCAGTCCAAGAACAGAAACCAGTCAAATGACCGTGGTGGTGTAAACATC	27032
125_10	26997	ACGCGATGATCTGGTGGCTGCTGTCAAGGATGCCCTTAAATCTTTGGGTATTGGCGAAAA	27056
AH2012	27033	ACGCGATGATCTGGTGGCTGCTGTCAAGGATGCCCTTAAATCTTTGGGTATTGGCGAAAA	27066
125_10	27057	CCCTGACAAGCTTAAGCAACAGCAGAAGCCCAAACAGGAAAGGTCTGACAGCAGCGGCAA	27116
AH2012	27093	CCCTGACAAGCTTAAGCAACAGCAGAAGCCCAAACAGGAAAGGTCTGACAGCAGCGGCAA	27152
125_10	27117	AAATACACCTAAGAAGAACAATCCAGAGCCACTTCGAAAGAACGTGACCTCAAAGACAT	27176
AH2012	27153	AAATACACCTAAGAAGAACAATCCAGAGCCACTTCGAAAGAACGTGACCTCAAAGACAT	27212
125_10	27177	CCCAGAGTGGAGGAGAATTCCCAAGGGCGAAAATAGCGTAGCAGCTTGCTTCGGACCCAG	27236
AH2012	27213	CCCAGAGTGGAGGAGAATTCCCAAGGGCGAAAATAGCGTAGCAGCTTGCTTCGGACCCAG	27272
125_10	27237	GGGAGGCTTCAAAAATTTTGGAGATGCGGAATTTGTCGAAAAAGGTGTTGATGCCTCAGG	27296
AH2012	27273	GGGAGGCTTCAAAAATTTTGGAGATGCGGAATTTGTCGAAAAAGGTGTTGATGCCTCAGG	27332
125_10	27297	CTATGCTCAGATCGCCAGTTTAGCACCAAATGTTGCAGCATTGCTCTTTGGTGGTAATGT	27356
AH2012	27333	CTATGCTCAGATCGCCAGTTTAGCACCAAATGTTGCAGCATTGCTCTTTGGTGGTAATGT	27366
125_10	27357	GGCTGTTTCGTGAGCTAGCGGACTCTTACGAGATTACATATAATTATAAAATGACTGTGCC	27416
AH2012	27393	GGCTGTTTCGTGAGCTAGCGGACTCTTACGAGATTACATATAATTATAAAATGACTGTGCC	27452
125_10	27417	AAAGTCTGATCCAAATGTAGAGCTTCTTGTTTCACAGGTGGATGCATTTAAAACTGGGAA	27476
AH2012	27453	AAAGTCTGATCCAAATGTAGAGCTTCTTGTTTCACAGGTGGATGCATTTAAAACTGGGAA	27512
125_10	27477	TGCAAAACCCAGAGAAAGAAGGAAAAGAAGAAYAAGCGTGAAACCACGCAGCAGCTGAA	27536
AH2012	27513	TGCAAAACCCAGAGAAAGAAGGAAAAGAAGAACAAGCGTGAAACCACGCAGCAGCTGAA	27572
125_10	27537	TGAAGAGGCCATCTACGATGATGTGGGTGTGCCATCTGATGTGACTCATGCCAATTTGGA	27596
AH2012	27573	TGAAGAGGCCATCTACGATGATGTGGGTGTGCCATCTGATGTGACTCATGCCAATTTGGA	27632
125_10	27597	ATGGGACACAGCTGTTGATGGTGGTGACACGGCCGTTGAAATTATCAACGAGATCTTCGA	27656
AH2012	27633	ATGGGACACAGCTGTTGATGGTGGTGACACGGCCGTTGAAATTATCAACGAGATCTTCGA	27666
125_10	27657	CACAGGAAATTAACAATGTTTGACTGGCTTATCCTGGCTATGTCCCAGGGTAGTGCCAT	27716
AH2012	27693	CACAGGAAATTAACAATGTTTGACTGGCTTATCCTGGCTATGTCCCAGGGTGGTGCCAT	27752
125_10	27717	TACACTGTTATTACTGAGTGTTTTTCTAGCGACTTGGCTGCTGGGCTATGGCTTTGCCCT	27776
AH2012	27753	TACACTGTTATTACTGAGTGTTTTTCTAGTGACTTGGCTGCTGGGCTATGGCTTTGCCCT	27812
125_10	27777	CTAACTAGCGGTCTTGGTCTTGACACAACGGTAAGCCAGTGGTAATGTCAGTGCAAGAA	27836
AH2012	27813	CTAACTAGCGGTCTTGGTCTTGACACAACGGTAAGCCAGTGGTAATGTCAGTGCAAGAA	27872
125_10	27837	GGATATTACCATAGCACTGTCATGAGGGGAACGCAGTACCTTTTCATCTAAACCTTTGCA	27896
AH2012	27873	GGATATTACCATAGCACTGTCATGAGGGGAACGCAGTACCTTTTCAACTAAACCTTTGCA	27932

FIG. 1 (cont'd)

125_10	27897	CGAGTAATCAAAGATCCGCTTGACGAGCCTATATGGAAGAGCGTGCCAGGTATTTGACTC	27956
AH2012	27933	CGAGTAATCAAAGATCCGCTTGACGAGCCTATATGGAAGAGCGTGCCAGGTATTTGACTC	27966
125_10	27957	AAGGACTGTTAGTAACTGAAGACCTGACGGTGTTGATAT	27995
AH2012	27993	AAGGACTGTTAGTAACTGAAGACCTGACGGTGTTGATAT	28031

32/66

FIG. 2

PEDV 1251-125-10 (125-10) near-complete genome (SEQ ID NO:1) aligned to closest North American PEDV G2a strain Colorado 2013 (US_Col) (GenBank Accn #: KF272660) (nucleotides 45 to 28031 of SEQ ID NO:11)

125_10	1	GACTCTTGTCTACTCAATTCAACTAAACGAAATTCTTGTCTTCCGGCCGCATGTCCAT	60
US_Col	45	GACTCTTGTCTACTCAATTCAACTAAACGAAATT--TTGTCTTCCGGCCGCATGTCCAT	102
125_10	61	GCTGCTGGAAGCTGACGTGGAATTTATTAGGTTTGCTTAAGTAGCCATCGCAAGTGCTG	120
US_Col	103	GCTGCTGGAAGCTGACGTGGAATTTATTAGGTTTGCTTAAGTAGCCATCGCAAGTGCTG	162
125_10	121	TGCTGTCCTCTAGTTCCTGGTTGGCGTTCGTCGCTTCTACATACTAGACAAACAGCCT	180
US_Col	163	TGCTGTCCTCTAGTTCCTGGTTGGCGTTCGTCGCTTCTACATACTAGACAAACAGCCT	222
125_10	181	TCCTCCGGTTCGCTGCGGGTTGTGTGGATAACTAGTTCGCTAGTTTGAAACCAGTA	240
US_Col	223	TCCTCCGGTTCGCTGCGGGTTGTGTGGATAACTAGTTCGCTAGTTTGAAACTAGTA	282
125_10	241	ACTGTCGGCTATGGCTAGCAACCATGTTACATTGGCTTTTGCCAATGATGCAGAAATTC	300
US_Col	283	ACTGTCGGCTATGGCTAGCAACCATGTTACATTGGCTTTTGCCAATGATGCAGAAATTC	342
125_10	301	AGCTTTTGGCTTTTGCACTGCTAGTGAAGCCGTCTCATACTATTCTGAGGCCGCCGCTAG	360
US_Col	343	AGCTTTTGGCTTTTGCACTGCTAGTGAAGCCGTCTCATACTATTCTGAGGCCGCCGCTAG	402
125_10	361	TGGATTTATGCAATGCCGTTTCGTGTCCTTCGATCTCGCTGACACTGTTGAGGGATTGCT	420
US_Col	403	TGGATTTATGCAATGCCGTTTCGTGTCCTTCGATCTCGCTGACACTGTTGAGGGATTGCT	462
125_10	421	TCCCGAAGACTATGTCATGGTGGTGGTGGCACTACCAAGCTTAGTGCGTATGTGGACAC	480
US_Col	463	TCCCGAAGACTATGTCATGGTGGTGGTGGCACTACCAAGCTTAGTGCGTATGTGGACAC	522
125_10	481	TTTTGGTAGCCGCCCAAAAACATTTGTGGTTGGCTGTTATTTTCTAACTGTAATTACTT	540
US_Col	523	TTTTGGTAGCCGCCCAAAAACATTTGTGGTTGGCTGTTATTTTCTAACTGTAATTACTT	582
125_10	541	CCTCGAAGAGTTAGAGCTTACTTTTGGTCGTGCTGGTGGTAACATCGTGCCAGTTGACCA	600
US_Col	583	CCTCGAAGAGTTAGAGCTTACTTTTGGTCGTGCTGGTGGTAACATCGTGCCAGTTGACCA	642
125_10	601	ATACATGTGTGGCGCTGACGGTAAACCTGTTCTTCAGGAATCCGAATGGGAGTATACAGA	660
US_Col	643	ATACATGTGTGGCGCTGACGGTAAACCTGTTCTTCAGGAATCCGAATGGGAGTATACAGA	702
125_10	661	TTTCTTTGCTGACTCCGAAGACGGTCAACTCAACATTGCTGGTATCACTTATGTGAAGGC	720
US_Col	703	TTTCTTTGCTGACTCCGAAGACGGTCAACTCAACATTGCTGGTATCACTTATGTGAAGGC	762
125_10	721	CTGGATTGTAGAGCGATCGGATGTCTCTTATGCGAGTCAGAATTTAACATCTATTAAGTC	780
US_Col	763	CTGGATTGTAGAGCGATCGGATGTCTCTTATGCGAGTCAGAATTTAACATCTATTAAGTC	822
125_10	781	TATTACTTACTGTTCAACCTATGAGCATACTTTTCTGATGGTACTGCCATGAAGGTTGC	840
US_Col	823	TATTACTTACTGTTCAACCTATGAGCATACTTTTCTGATGGTACTGCCATGAAGGTTGC	882

33/66

FIG. 2 (cont'd)

125_10	841	ACGTA	CTCCAAAGATTAAGAAGACTGTTGTCTTGTCTGAGCCACTTGCTACTATCTACAG	900
US_Col	883	ACGTA	CTCCAAAGATTAAGAAGACTGTTGTCTTGTCTGAGCCACTTGCTACTATCTACAG	942
125_10	901	GGAAAT	TGGTTCTCCTTTTGTGGATAATGGGAGCGATGCTCGTTCTATCATTAAGAGACC	960
US_Col	943	GGAAAT	TGGTTCTCCTTTTGTGGATAATGGGAGCGATGCTCGTTCTATCATTAAGAGACC	1002
125_10	961	AGTGTT	CCTCCACGCTTTTGTAAAGTGTAAGTGTGGTAGTTATCATTGGACTGTTGGTGA	1020
US_Col	1003	AGTGTT	CCTCCACGCTTTTGTAAAGTGTAAGTGTGGTAGTTATCATTGGACTGTTGGTGA	1062
125_10	1021	TTGGACT	TCCTATGTCTCCACTTGCTGTGGCTTTAAGTGTAAGCCAGTCCTTGTGGCTTC	1080
US_Col	1063	TTGGACT	TCCTATGTCTCCACTTGCTGTGGCTTTAAGTGTAAGCCAGTCCTTGTGGCTTC	1122
125_10	1081	ATGCTCT	GCTACGCCTGGTTCTGTTGTGGTTACGCGCGCTGGTGCTGGCACTGGTGTTAA	1140
US_Col	1123	ATGCTCT	GCTACGCCTGGTTCTGTTGTGGTTACGCGCGCTGGTGCTGGCACTGGTGTTAA	1182
125_10	1141	GTATTACA	AACAACATGTTCTGCGCCATGTGGCAGACATTGATGGGTTGGCATTCTGGCG	1200
US_Col	1183	GTATTACA	AACAACATGTTCTGCGCCATGTGGCAGACATTGATGGGTTGGCATTCTGGCG	1242
125_10	1201	AATTCTCA	AGGTGCAGTCCAAAGACGACCTCGCTTGCTCTGGTAAATTCCTTGAACACCA	1260
US_Col	1243	AATTCTCA	AGGTGCAGTCCAAAGACGACCTCGCTTGCTCTGGTAAATTCCTTGAACACCA	1302
125_10	1261	TGAGGAAG	GTTTACAGATCCTTGCTACTTTTTGAATGACTCGAGCATTGCTACTAAGCT	1320
US_Col	1303	TGAGGAAG	GTTTACAGATCCTTGCTACTTTTTGAATGACTCGAGCATTGCTACTAAGCT	1362
125_10	1321	CAAGTTT	GACATCCTTAGTGGCAAGTTTTCTGATGAAGTCAAACAAGCTATCTTTGCTGG	1380
US_Col	1363	CAAGTTT	GACATCCTTAGTGGCAAGTTTTCTGATGAAGTCAAACAAGCTATCTTTGCTGG	1422
125_10	1381	TCATGTT	GTTGTTGGCAGCGCGMTCGTTGACATTGTTGACGATGCACTGGGACAGCCTTG	1440
US_Col	1423	TCATGTT	GTTGTTGGCAGCGCGCTCGTTGACATTGTTGACGATGCACTGGGACAGCCTTG	1482
125_10	1441	GTTTATA	CGTAAGCTTGGTGACCTTGCAAGTGCAGCTTGGGAGCAGCTTAAGGCTGTCGT	1500
US_Col	1483	GTTTATA	CGTAAGCTTGGTGACCTTGCAAGTGCAGCTTGGGAGCAGCTTAAGGCTGTCGT	1542
125_10	1501	TAGAGGC	CCTTAACCTCCTGTCTGATGAGGTCGTGCTCTTTGGCAAAGACTTAGCTGTGC	1560
US_Col	1543	TAGAGGC	CCTTAACCTCCTGTCTGATGAGGTCGTGCTCTTTGGCAAAGACTTAGCTGTGC	1602
125_10	1561	CACTCTT	AGTATCGTTAACGGTGTTTTTGAGTTCATCGCCGAAGTGCCTGAGAAGTTGGC	1620
US_Col	1603	CACTCTT	AGTATCGTTAACGGTGTTTTTGAGTTCATCGCCGAAGTGCCTGAGAAGTTGGC	1662
125_10	1621	TGCGGCT	GTTACAGTTTTTGTCAACTTCTTGAATGAGCTTTTTGAGTCTGCCTGTGACTG	1680
US_Col	1663	TGCGGCT	GTTACAGTTTTTGTCAACTTCTTGAATGAGCTTTTTGAGTCTGCCTGTGACTG	1722
125_10	1681	CTTAAAG	GTCGGAGGTAAACCTTTAACAAGGTTGGCTCTTATGTTCTTTTTGACAACGC	1740
US_Col	1723	CTTAAAG	GTCGGAGGTAAACCTTTAACAAGGTTGGCTCTTATGTTCTTTTTGACAACGC	1782
125_10	1741	ATTGGTT	AAGCTTGTCAAGGCCAAAAGTTCGCGGCCACGACAGGCAGGTGTTTGTGAAGT	1800
US_Col	1783	ATTGGTT	AAGCTTGTCAAGGCCAAAAGTTCGCGGCCACGACAGGCAGGTGTTTGTGAAGT	1842

34/66

FIG. 2 (cont'd)

125_10	1801	TCGTTACACAAGCCTTGTTATTGGGAGTACTACCAAGGTGGTTTCCAAGCGCGTTGAAAA	1860
US_Col	1843	TCGTTACACAAGCCTTGTTATTGGGAGTACTACCAAGGTGGTTTCCAAGCGCGTTGAAAA	1902
125_10	1861	TGCCAATGTGAATCTCGTCGTCGTTGACGAGGATGTGACCCTCAACACCACTGGTCGTAC	1660
US_Col	1903	TGCCAATGTGAATCTCGTCGTCGTTGACGAGGATGTGACCCTCAACACCACTGGTCGTAC	1962
125_10	1661	AGTTGTTGTTGACGGACTTGCATTCTTCGAGAGTGACGGGTTTTACAGACATCTTGCTGA	1980
US_Col	1963	AGTTGTTGTTGACGGACTTGCATTCTTCGAGAGTGACGGGTTTTACAGACATCTTGCTGA	2022
125_10	1981	TGCTGACGTTGTCATTGAACATCCTGTTTATAAGTCTGCTTGAGCTCAAGCCAGTTTT	2040
US_Col	2023	TGCTGACGTTGTCATTGAACATCCTGTTTATAAGTCTGCTTGAGCTCAAGCCAGTTTT	2082
125_10	2041	TGAGTGTGACCCAATACCTGATTTTCCTATGCCTGTGGCCGCTAGTGTTGCAGAGCTTTG	2100
US_Col	2083	TGAGTGTGACCCAATACCTGATTTTCCTATGCCTGTGGCCGCTAGTGTTGCAGAGCTTTG	2142
125_10	2101	TGTGCAAACCTGATCTGTTGCTTAAAAATTACAACACTCCTTATAAACTTACAGCTGCGT	2160
US_Col	2143	TGTGCAAACCTGATCTGTTGCTTAAAAATTACAACACTCCTTATAAACTTACAGCTGCGT	2202
125_10	2161	TGTGAGAGGTGATAAGTGTTGTATCACTTGACCTTACATTTACAGCACCAAGTTATAT	2220
US_Col	2203	TGTGAGAGGTGATAAGTGTTGTATCACTTGACCTTACATTTACAGCACCAAGTTATAT	2262
125_10	2221	GGAGGCTGCTGCTAATTTTGTAGACCTCTGTACCAAGAACATTGGTACTGCTGGTTTTCA	2280
US_Col	2263	GGAGGCTGCTGCTAATTTTGTAGACCTCTGTACCAAGAACATTGGTACTGCTGGTTTTCA	2322
125_10	2281	TGAGTTTTACATTACGGCCCATGAACAACAGGATCTGCAAGGGTTCGTAACCACTTGTTG	2340
US_Col	2323	TGAGTTTTACATTACGGCCCATGAACAACAGGATCTGCAAGGGTTCGTAACCACTTGTTG	2382
125_10	2341	CACGATGTCAGGTTTTGAGTGTTTTATGCCTATAATCCCACAGTGTCAGCAGTGCTTGA	2400
US_Col	2383	CACGATGTCAGGTTTTGAGTGTTTTATGCCTATAATCCCACAGTGTCAGCAGTGCTTGA	2442
125_10	2401	AGAGATTGATGGTGGTAGCATCTGGCGGTCTTTTATCACTGGTCTTAATACAATGTGGGA	2460
US_Col	2443	AGAGATTGATGGTGGTAGCATCTGGCGGTCTTTTATCACTGGTCTTAATACAATGTGGGA	2502
125_10	2461	TTTTTGCAAGCATCTTAAAGTCAGCTTTGGACTAGATGGCATTGTTGTCACTGTAGCACG	2520
US_Col	2503	TTTTTGCAAGCATCTTAAAGTCAGCTTTGGACTAGATGGCATTGTTGTCACTGTAGCACG	2562
125_10	2521	CAAATTTAAACGACTTGGTGCTCTCTTGGCAGAAATGTATAACACTTACCTTTCAACTGT	2580
US_Col	2563	CAAATTTAAACGACTTGGTGCTCTCTTGGCAGAAATGTATAACACTTACCTTTCAACTGT	2622
125_10	2581	GGTGAAAACTTGGTACTGGCCGGTGTTAGCTTCAAGTATTATGCCACCAGTGTCCTTCA	2640
US_Col	2623	GGTGAAAACTTGGTACTGGCCGGTGTTAGCTTCAAGTATTATGCCACCAGTGTCCTTCA	2682
125_10	2641	AATTGTTTTGGGCTGTTGTTTTACAGTGTTAAAAGTGTTCTTGCAAGTGCCTTCCAGAT	2700
US_Col	2683	AATTGTTTTGGGCTGTTGTTTTACAGTGTTAAAAGTGTTCTTGCAAGTGCCTTCCAGAT	2742
125_10	2701	TCCTGTCCAGGCAGGCGTTGAGAAGTTTAAAGTCTTCCTTAACTGTGTTACCCTGTTGT	2760
US_Col	2743	TCCTGTCCAGGCAGGCGTTGAGAAGTTTAAAGTCTTCCTTAACTGTGTTACCCTGTTGT	2802

35/66

FIG. 2 (cont'd)

125_10	2761	ACCACGTGTCATTGAAACTTCTTTTGTGGAATTAGAAGAGACGACATTTAAACCACCAGC	2820
US_Col	2803	ACCACGTGTCATTGAAACTTCTTTTGTGGAATTAGAAGAGACGACATTTAAACCACCAGC	2862
125_10	2821	ACTCAATGGTAGTATTGCTATTGTTGATGGCTTTGCTTTCTATTATGATGGAACACTATA	2880
US_Col	2863	ACTCAATGGTAGTATTGCTATTGTTGATGGCTTTGCTTTCTATTATGATGGAACACTATA	2662
125_10	2881	CTATCCCACCGATGGTAATAGCGTTGTTCTATCTGCTTTAAGAAGAAAGGTGGTGGTGA	2940
US_Col	2663	CTATCCCACCGATGGTAATAGCGTTGTTCTATCTGCTTTAAGAAGAAAGGTGGTGGTGA	2982
125_10	2941	TGTCAAATTCTCTGATGAAGTCTCTGTTAAACCATTGACCCAGTTTATAAGGTCTCCCT	3000
US_Col	2983	TGTCAAATTCTCTGATGAAGTCTCTGTTAAACCATTGACCCAGTTTATAAGGTCTCCCT	3042
125_10	3001	TGAATTTGAGTTCGAGTCTGAGACTATTATGGCTGTGCTTAATAAGGCTGTTGGTAATTG	3060
US_Col	3043	TGAATTTGAGTTCGAGTCTGAGACTATTATGGCTGTGCTTAATAAGGCTGTTGGTAATTG	3102
125_10	3061	TATCAAGGTTACAGGTGGTTGGGACGATGTTGTTGAGTATATCAATGTTGCCATTGAGGT	3120
US_Col	3103	TATCAAGGTTACAGGTGGTTGGGACGATGTTGTTGAGTATATCAATGTTGCCATTGAGGT	3162
125_10	3121	TCTTAAAGATCACATCGATGTGCCTAAGTACTACATCTATGATGAGGAAGGTGGCACCGA	3180
US_Col	3163	TCTTAAAGATCACATCGATGTGCCTAAGTACTACATCTATGATGAGGAAGGTGGCACCGA	3222
125_10	3181	TCCTAATCTGCCCCGTAATGGTTTCTCAGTGGCCGTTGAATGATGACACGATCTCACAGGA	3240
US_Col	3223	TCCTAATCTGCCCCGTAATGGTTTCTCAGTGGCCGTTGAATGATGACACGATCTCACAGGA	3282
125_10	3241	TCTGCTTGATGTTGAAGTTGTTACTGATGCGCCAGTTGATTTGAGGGTGATGAAGTAGA	3300
US_Col	3283	TCTGCTTGATGTTGAAGTTGTTACTGATGCGCCAGTTGATTTGAGGGTGATGAAGTAGA	3342
125_10	3301	CTCCTCTGACCCTGWTAAAGGTGGCAGACGTGGCTAACTCTGAGCCTGAGGATGACGGTCT	3360
US_Col	3343	CTCCTCTGACCCTGATAAGGTGGCAGACGTGGCTAACTCTGAGCCTGAGGATGACGGTCT	3402
125_10	3361	TAATGTAGCTCCTGAAACAAATGTAGAGTCTGAAGTTGAGGAAGTTGCCGCAACCTTGTC	3420
US_Col	3403	TAATGTAGCTCCTGAAACAAATGTAGAGTCTGAAGTTGAGGAAGTTGCCGCAACCTTGTC	3462
125_10	3421	CTTTA---AAGATACACCTTCCACAGTTACTAAGGATCCTTTTGCTTTTGACTTTGCAAG	3477
US_Col	3463	CTTTATTAAAGATACACCTTCCACAGTTACTAAGGATCCTTTTGCTTTTGACTTTGCAAG	3522
125_10	3478	CTATGGAGGACTTAAGGTTTTAAGACAATCTCATAACAACCTGCTGGGTACTTCTACCTT	3537
US_Col	3523	CTATGGAGGACTTAAGGTTTTAAGACAATCTCATAACAACCTGCTGGGTACTTCTACCTT	3582
125_10	3538	GGTGCAGCTACAATTGCTTGGCATCGTTGATGACCCTGCAATGGAGCTTTTTAGTGCTGG	3597
US_Col	3583	GGTGCAGCTACAATTGCTTGGCATCGTTGATGACCCTGCAATGGAGCTTTTTAGTGCTGG	3642
125_10	3598	TAGAGTTGGTCCAATGGTTTCGCAAATGCTATGAGTCACAAAAGGCTATCTTGGGATCTTT	3657
US_Col	3643	TAGAGTTGGTCCAATGGTTTCGCAAATGCTATGAGTCACAAAAGGCTATCTTGGGATCTTT	3702

36/66

FIG. 2 (cont'd)

125_10	3658	GGGTGATGTGTCGGCTTGCCTAGAGTCTCTGACTAAGGACCTACACACACTTAAGATTAC	3717
US_Col	3703	GGGTGATGTGTCGGCTTGCCTAGAGTCTCTGACTAAGGACCTACACACACTTAAGATTAC	3762
125_10	3718	CTGTTCTGTAGTCTGTGGTTGTGGTACTGGTGAACGTATCTATGATGGTTGTGCTTTTCG	3777
US_Col	3763	CTGTTCTGTAGTCTGTGGTTGTGGTACTGGTGAACGTATCTATGATGGTTGTGCTTTTCG	3822
125_10	3778	TATGACGCCAACTTTGGAACCGTTCCCATATGGTGCTTGTGCTCAGTGTGCTCAAGTTTT	3837
US_Col	3823	TATGACGCCAACTTTGGAACCGTTCCCATATGGTGCTTGTGCTCAGTGTGCTCAAGTTTT	3882
125_10	3838	GATGCACACTTTTAAAAGTATTGTTGGCACC GG CATCTTTGTCGAGATACTACTGCTCT	3897
US_Col	3883	GATGCACACTTTTAAAAGTATTGTTGGCACC GG CATCTTTGTCGAGATACTACTGCTCT	3942
125_10	3898	CTCCTTGGATTCTTTGGTTGTAAAACCTCTTTGTGCGGCTGCTTTTATAGGCAAGGATAG	3957
US_Col	3943	CTCCTTGGATTCTTTGGTTGTAAAACCTCTTTGTGCGGCTGCTTTTATAGGCAAGGATAG	4002
125_10	3958	TGGTCATTATGTCACTAACTTTTATGATGCTGCTATGGCTATTGATGGTTATGGTCGTCA	4017
US_Col	4003	TGGTCATTATGTCACTAACTTTTATGATGCTGCTATGGCTATTGATGGTTATGGTCGTCA	4062
125_10	4018	TCAGATAAAGTATGACACACTGAACACTATTTGTGTTAAAGACGTTAATTGGACAGCACC	4077
US_Col	4063	TCAGATAAAGTATGACACACTGAACACTATTTGTGTTAAAGACGTTAATTGGACAGCACC	4122
125_10	4078	TTTTGTCCCAGACGTTGAGCCTGTATTGGAGCCTGTTGTCAAACCTTTCTATTCTTATAA	4137
US_Col	4123	TTTTGTCCCAGACGTTGAGCCTGTATTGGAGCCTGTTGTCAAACCTTTCTATTCTTATAA	4182
125_10	4138	GAATGTTGATTTTTACCAAGGAGATTTTAGTGACCTTGTTAAACTTCCATGTGATTTTGT	4197
US_Col	4183	GAATGTTGATTTTTACCAAGGAGATTTTAGTGACCTTGTTAAACTTCCATGTGATTTTGT	4242
125_10	4198	TGTTAATGCTGCAAATGAGAATTTGTCTCACGGTGGCGGCATAGCAAAGGCCATTGATGT	4257
US_Col	4243	TGTTAATGCTGCAAATGAGAATTTGTCTCACGGTGGCGGCATAGCAAAGGCCATTGATGT	4302
125_10	4258	TTATACCAAGGGCATGTTGCAGAAGTGCTCGAATGATTACATTAAAGCACACGGTCCCAT	4317
US_Col	4303	TTATACCAAGGGCATGTTGCAGAAGTGCTCGAATGATTACATTAAAGCACACGGTCCCAT	4362
125_10	4318	TAAAGTTGGACGTGGTGT CATGTTGGAGGCATTAGGTCTTAAGGTCTTTAATGTTGTTGG	4377
US_Col	4363	TAAAGTTGGACGTGGTGT CATGTTGGAGGCATTAGGTCTTAAGGTCTTTAATGTTGTTGG	4422
125_10	4378	TCCACGTAAGGGTAAGCATGCACCTGAGCTTCTTGTTAAGGCTTATAAGTCCGTTTTTGC	4437
US_Col	4423	TCCACGTAAGGGTAAGCATGCACCTGAGCTTCTTGTTAAGGCTTATAAGTCCGTTTTTGC	4482
125_10	4438	TAATTCAGGTGTTGCTCTTACACCTTTGATTAGTGTTGGAATTTT TAGTGTTCCTTTGGA	4497
US_Col	4483	TAATTCAGGTGTTGCTCTTACACCTTTGATTAGTGTTGGAATTTT TAGTGTTCCTTTGGA	4542
125_10	4498	AGAATCTTTATCTGCTTTTCTTG CATGTGTTGGTGATCGCCACTGTAAGTGCTTTTGTTA	4557
US_Col	4543	AGAATCTTTATCTGCTTTTCTTG CATGTGTTGGTGATCGCCACTGTAAGTGCTTTTGTTA	4602
125_10	4558	TAGTGACAAAGAGCGCGAGGCGATCATTAAATTACATGGATGGCTTGGTAGATGCTATTTT	4617
US_Col	4603	TAGTGACAAAGAGCGCGAGGCGATCATTAAATTACATGGATGGCTTGGTAGATGCTATTTT	4662

37/66

FIG. 2 (cont'd)

125_10	4618	CAAAGATGCACTTGTTGATACTACTCCTGTCCAGGAAGATGTTCAACAAGTTTCACAAAA	4677
US_Col	4663	CAAAGATGCACTTGTTGATACTACTCCTGTCCAGGAAGATGTTCAACAAGTTTCACAAAA	4722
125_10	4678	ACCAGTTTTGCCTAATTTTGAACCTTTT CAGGATTGAAGGTGCTCATGCTTTCTATGAGTG	4737
US_Col	4723	ACCAGTTTTGCCTAATTTTGAACCTTTT CAGGATTGAAGGTGCTCATGCTTTCTATGAGTG	4782
125_10	4738	CAACCCTGAAGGTTTGATGTCATTAGGTGCTGACAAGCTGGTGTTGTTTACAAATTCCAA	4797
US_Col	4783	CAACCCTGAAGGTTTGATGTCATTAGGTGCTGACAAGCTGGTGTTGTTTACAAATTCCAA	4842
125_10	4798	TTTGGATTTTTGTAGCGTTGGTAAGTGTCTTAACAATGTGACTGGCGGTGCATTGCTTGA	4857
US_Col	4843	TTTGGATTTTTGTAGCGTTGGTAAGTGTCTTAACAATGTGACTGGCGGTGCATTGCTTGA	4902
125_10	4858	AGCCATAAATGTATTTAAAAAGAGTAACAAAACAGTGCCTGCTGGCAACTGTGTTACTTT	4917
US_Col	4903	AGCCATAAATGTATTTAAAAAGAGTAACAAAACAGTGCCTGCTGGCAACTGTGTTACTTT	4962
125_10	4918	TGAGTGTGCAGATATGATTTCTATTACTATGGTAGTATTGCCATCTGACGGTGATGCTAA	4977
US_Col	4963	TGAGTGTGCAGATATGATTTCTATTACTATGGTAGTATTGCCATCTGACGGTGATGCTAA	5022
125_10	4978	TTATGACAAAAATTATGCACGCGCCGTCGTCAAGGTATCTAAGCTTAAAGGCAAGTTATT	5037
US_Col	5023	TTATGACAAAAATTATGCACGCGCCGTCGTCAAGGTATCTAAGCTTAAAGGCAAGTTATT	5082
125_10	5038	GCTTGCTGTTGGTGATGCCATGTTGTATTCCAAGTTGTCCACCTCAGCGTGTTAGGTTT	5097
US_Col	5083	GCTTGCTGTTGGTGATGCCATGTTGTATTCCAAGTTGTCCACCTCAGCGTGTTAGGTTT	5142
125_10	5098	CGTATCCACACCTGATGATGTGGAGCGTTTCTACGCAAATAAGAGTGTGGTTATTAAAGT	5157
US_Col	5143	CGTATCCACACCTGATGATGTGGAGCGTTTCTACGCAAATAAGAGTGTGGTTATTAAAGT	5202
125_10	5158	TACTGAGGATACACGTAGTGTTAAGACTGTTAAAGTAGAATCCACTGTTACTTATGGACA	5217
US_Col	5203	TACTGAGGATACACGTAGTGTTAAGACTGTTAAAGTAGAATCCACTGTTACTTATGGACA	5262
125_10	5218	ACAAATTGGACCTTGTCTTGTTAATGACACCGTTGTCACAGACAACAAACCTGTTGTTGC	5277
US_Col	5263	ACAAATTGGACCTTGTCTTGTTAATGACACCGTTGTCACAGACAACAAACCTGTTGTTGC	5322
125_10	5278	TGATGTTGTAGCTAAGGTTGTACCAAGTGCTAATTGGGATTACATTATGGTTTTGATAA	5337
US_Col	5323	TGATGTTGTAGCTAAGGTTGTACCAAGTGCTAATTGGGATTACATTATGGTTTTGATAA	5382
125_10	5338	GGCTGGTGAGTTCCACATGCTAGACCATACTGGGTTTGCCTTTCTAGTGAAGTTGTTAA	5397
US_Col	5383	GGCTGGTGAGTTCCACATGCTAGACCATACTGGGTTTGCCTTTCTAGTGAAGTTGTTAA	5442
125_10	5398	CGGTAGGCGTGTGCTTAAACACACAGATAATAACTGTTGGGTAAATGTTACATGTTTACA	5457
US_Col	5443	CGGTAGGCGTGTGCTTAAACACACAGATAATAACTGTTGGGTAAATGTTACATGTTTACA	5502
125_10	5458	ATTACAGTTTGCTAGATTTAGGTTCAAGTCAGCAGGTCTACAGGCTATGTGGGAGTCCTA	5517
US_Col	5503	ATTACAGTTTGCTAGATTTAGGTTCAAGTCAGCAGGTCTACAGGCTATGTGGGAGTCCTA	5562

38/66

FIG. 2 (cont'd)

125_10	5518	TTGTA	CTGGT	GATG	TTGCT	ATGTT	TGTC	ATTGG	TTGTA	CTGGC	TACTG	GTGTT	GACAA	5577
US_Col	5563	TTGTA	CTGGT	GATG	TTGCT	ATGTT	TGTC	ATTGG	TTGTA	CTGGC	TACTG	GTGTT	GACAA	5622
125_10	5578	AGGTC	CAGC	CTAG	TGATT	CAGAA	AATGC	ACTTA	ACATG	TTGT	GCTA	AGTAC	ATTG	5637
US_Col	5623	AGGTC	CAGC	CTAG	TGATT	CAGAA	AATGC	ACTTA	ACATG	TTGT	GCTA	AGTAC	ATTG	5682
125_10	5638	TGGTT	CTGT	CACTA	TGAA	CGTGT	CACGC	ATGAC	GGTTG	TTGTA	GTAAG	CGTGT	TGT	5697
US_Col	5683	TGGTT	CTGT	CACTA	TGAA	CGTGT	CACGC	ATGAC	GGTTG	TTGTA	GTAAG	CGTGT	TGT	5742
125_10	5698	CACTG	CACC	AGTT	TGTA	ATGCT	AGCG	TGTTG	AAGCT	TGGC	GTCG	AGGAT	GGTCT	5757
US_Col	5743	CACTG	CACC	AGTT	TGTA	ATGCT	AGCG	TGTTG	AAGCT	TGGC	GTCG	AGGAT	GGTCT	5802
125_10	5758	ACATG	GTCT	TAACT	AACAT	TGAC	AAAG	TGTTG	TAGTT	AAAG	GTA	CTACA	ATTG	5817
US_Col	5803	ACATG	GTCT	TAACT	AACAT	TGAC	AAAG	TGTTG	TAGTT	AAAG	GTA	CTACA	ATTG	5862
125_10	5818	TGTTG	GAAA	ACCT	GTAG	TGGC	ACCAT	CGCAC	CTCTT	CTTA	AGGG	TGTT	CCTAC	5877
US_Col	5863	TGTTG	GAAA	ACCT	GTAG	TGGC	ACCAT	CGCAC	CTCTT	CTTA	AGGG	TGTT	CCTAC	5662
125_10	5878	ATTC	CTAG	ATAA	TGGTA	ACGG	TGTG	CCGG	CCATT	ATACT	GTTTT	TGAT	CATG	5937
US_Col	5663	ATTC	CTAG	ATAA	TGGTA	ACGG	TGTG	CCGG	CCATT	ATACT	GTTTT	TGAT	CATG	5982
125_10	5938	TATGG	TGCAT	GATGG	AGAT	GTTTT	TGTAC	CAGG	TGAT	CTCA	ATGT	GTCT	CCTG	5997
US_Col	5983	TATGG	TGCAT	GATGG	AGAT	GTTTT	TGTAC	CAGG	TGAT	CTCA	ATGT	GTCT	CCTG	6042
125_10	5998	TGTTG	TCGT	CTCAG	AGCAG	ACGG	CTGTT	TGTGA	TAAAG	ACC	CTGT	GAAGA	AAAGT	6057
US_Col	6043	TGTTG	TCGT	CTCAG	AGCAG	ACGG	CTGTT	TGTGA	TAAAG	ACC	CTGT	GAAGA	AAAGT	6102
125_10	6058	AGAC	GCTA	CAAAG	CTGTT	AGAC	ACTAT	GAATT	TATGC	ATCG	GAAAG	ATTCT	TTTC	6117
US_Col	6103	AGAC	GCTA	CAAAG	CTGTT	AGAC	ACTAT	GAATT	TATGC	ATCG	GAAAG	ATTCT	TTTC	6162
125_10	6118	TGATT	TTTAT	GTCA	CGTA	AATTT	AATTAC	AGTG	TTTTT	TGTAC	ATCCT	TAGT	ATTTT	6177
US_Col	6163	TGATT	TTTAT	GTCA	CGTA	AATTT	AATTAC	AGTG	TTTTT	TGTAC	ATCCT	TAGT	ATTTT	6222
125_10	6178	CTGTT	TTTAG	GGCCT	TTTC	GTAAG	AGGG	ATGTT	AAAG	TCTAG	CTGG	TGTAC	CCCC	6237
US_Col	6223	CTGTT	TTTAG	GGCCT	TTTC	GTAAG	AGGG	ATGTT	AAAG	TCTAG	CTGG	TGTAC	CCCC	6282
125_10	6238	TGGTA	TATAT	TGCG	TAAAA	AGTGT	GCGCT	ATAAT	GCAA	AGG	CTTT	GGGT	GTCCT	6297
US_Col	6283	TGGTA	TATAT	TGCG	TAAAA	AGTGT	GCGCT	ATAAT	GCAA	AGG	CTTT	GGGT	GTCCT	6342
125_10	6298	GCTAA	AACT	TTTAT	TGGTT	CAAAG	TCTTG	GTAAG	TTTAG	TTTGG	TATTT	ATG	CATT	6357
US_Col	6343	GCTAA	AACT	TTTAT	TGGTT	CAAAG	TCTTG	GTAAG	TTTAG	TTTGG	TATTT	ATG	CATT	6402
125_10	6358	TGCAT	TACT	ATTC	ATG	ACA	ATAC	GCTTT	TAC	ACCT	ATAG	GTGG	CCCT	6417
US_Col	6403	TGCAT	TACT	ATTC	ATG	ACA	ATAC	GCTTT	TAC	ACCT	ATAG	GTGG	CCCT	6462
125_10	6418	TGTTG	CTGG	TTAT	GCTA	ATTCT	AGTTTT	TGACA	AGAAT	GAGT	ATTG	CAAC	AGTGT	6477
US_Col	6463	TGTTG	CTGG	TTAT	GCTA	ATTCT	AGTTTT	TGACA	AGAAT	GAGT	ATTG	CAAC	AGTGT	6522

39/66

FIG. 2 (cont'd)

125_10	6478	TAAGGTCTGTCTCTATGGGTACCAGGAACCTTCGGACTTCTCTCACACACAGGTAGTATG	6537
US_Col	6523	TAAGGTCTGTCTCTATGGGTACCAGGAACCTTCGGACTTCTCTCACACACAGGTAGTATG	6582
125_10	6538	GCAACACCTTAGAGACCCATTAATTGGTAATGTGATGCCTTCTTTTATTTGGCATTCT	6597
US_Col	6583	GCAACACCTTAGAGACCCATTAATTGGTAATGTGATGCCTTCTTTTATTTGGCATTCT	6642
125_10	6598	GGCAATTTTGGGGGTGTTTATGTAAAGGCTATTACTCTCTATTTTATTTTCCAGTATCT	6657
US_Col	6643	GGCAATTTTGGGGGTGTTTATGTAAAGGCTATTACTCTCTATTTTATTTTCCAGTATCT	6702
125_10	6658	TAACATACTTGGTGTGTTTTTGGGCCTACAACAGTCCATTTGGTTTTTGCAGCTTGCGC	6717
US_Col	6703	TAACATACTTGGTGTGTTTTTGGGCCTACAACAGTCCATTTGGTTTTTGCAGCTTGCGC	6762
125_10	6718	TTTTGATGTCTTTGGTGACGAGATCGTCGTCTTTTTCATCGTTACACGCGTATTGATGTT	6777
US_Col	6763	TTTTGATGTCTTTGGTGACGAGATCGTCGTCTTTTTCATCGTTACACGCGTATTGATGTT	6822
125_10	6778	CCTTAAGCATGTTTTCTTTGGCTGCGATAAGGCATCTTGTGTGGCTTGCTCTAAGAGTGC	6837
US_Col	6823	CCTTAAGCATGTTTTCTTTGGCTGCGATAAGGCATCTTGTGTGGCTTGCTCTAAGAGTGC	6882
125_10	6838	TCGCCTTAAGCGCGTTCCTGTCCAGACTATTTTTTCAGGGTACTAGCAAATCCTTCTACGT	6897
US_Col	6883	TCGCCTTAAGCGCGTTCCTGTCCAGACTATTTTTTCAGGGTACTAGCAAATCCTTCTACGT	6942
125_10	6898	ACATGCCAATGGTGGTTCTAAGTTCTGTAAGAAGCACAATTTCTTTTGTAAATTGTGA	6957
US_Col	6943	ACATGCCAATGGTGGTTCTAAGTTCTGTAAGAAGCACAATTTCTTTTGTAAATTGTGA	7002
125_10	6958	TTCTTATGGTCCAGGCTGCACTTTTATTAATGACGTCATTGCAACTGAAGTTGGTAATGT	7017
US_Col	7003	TTCTTATGGTCCAGGCTGCACTTTTATTAATGACGTCATTGCAACTGAAGTTGGTAATGT	7062
125_10	7018	TGTCAAACCTAATGTGCAACCGACAGGTCTGCCACTATTCTTATTGACAAGGTTGAATT	7077
US_Col	7063	TGTCAAACCTAATGTGCAACCGACAGGTCTGCCACTATTCTTATTGACAAGGTTGAATT	7122
125_10	7078	CAGTAATGGTTTTTACTATCTTTATAGTGGTGACACATTTTGGAAGTACAACCTTGACAT	7137
US_Col	7123	CAGTAATGGTTTTTACTATCTTTATAGTGGTGACACATTTTGGAAGTACAACCTTGACAT	7182
125_10	7138	AACAGATAACAAATACACTTGCAAAGAGTCACTTAAAAATTGTAGCATAATCACAGACTT	7197
US_Col	7183	AACAGATAACAAATACACTTGCAAAGAGTCACTTAAAAATTGTAGCATAATCACAGACTT	7242
125_10	7198	TATTGTTTTTAACAATAATGGTTCCAATGTAAATCAGGTTAAGAATGCATGTGTGTATTT	7257
US_Col	7243	TATTGTTTTTAACAATAATGGTTCCAATGTAAATCAGGTTAAGAATGCATGTGTGTATTT	7302
125_10	7258	TTCACAGATGCTTTGTAAACCTGTTAAGTTAGTGGACTCAGCGTTGTTGGCCAGTTTGTC	7317
US_Col	7303	TTCACAGATGCTTTGTAAACCTGTTAAGTTAGTGGACTCAGCGTTGTTGGCCAGTTTGTC	7362
125_10	7318	TGTTGATTTTGGTGCAAGCTTACATAGTGCTTTTGTAGTGTGTTGTGCAATAGTTTTGG	7377
US_Col	7363	TGTTGATTTTGGTGCAAGCTTACATAGTGCTTTTGTAGTGTGTTGTGCAATAGTTTTGG	7422

40/66

FIG. 2 (cont'd)

125_10	7378	CAAAGACCTGTCAAGTTGTAATGACATGCAGGATTGCAAGAGCACATTGGGTTTTGATGA	7437
US_Col	7423	CAAAGACCTGTCAAGTTGTAATGACATGCAGGATTGCAAGAGCACATTGGGTTTTGATGA	7482
125_10	7438	TGTACCATTGGATACCTTTAATGCTGCTGTTGCTGAGGCTCATCGTTACGATGTCCTCTT	7497
US_Col	7483	TGTACCATTGGATACCTTTAATGCTGCTGTTGCTGAGGCTCATCGTTACGATGTCCTCTT	7542
125_10	7498	GACTGACATGTCGTTCAACAATTTTACCACCAGTTATGCAAAACCAGAGGAAAAACTTCC	7557
US_Col	7543	GACTGACATGTCGTTCAACAATTTTACCACCAGTTATGCAAAACCAGAGGAAAAACTTCC	7602
125_10	7558	CGTCCATGACATTGCCACGTGTATGCGTGCTAGGTGCCAAGATTGTTAATCATAACGTTCT	7617
US_Col	7603	CGTCCATGACATTGCCACGTGTATGCGTGCTAGGTGCCAAGATTGTTAATCATAACGTTCT	7662
125_10	7618	TGTCAAGGATAGTATACCTGTGGTGTGGCTTGACGTGATTTTCATTGCCCTTTCTGAAGA	7677
US_Col	7663	TGTCAAGGATAGTATACCTGTGGTGTGGCTTGACGTGATTTTCATTGCCCTTTCTGAAGA	7722
125_10	7678	AACTAGGAAGTACATTATTCGTACGACTAAAGTTAAGGGTATAACCTTCATGTTGACCTT	7737
US_Col	7723	AACTAGGAAGTACATTATTCGTACGACTAAAGTTAAGGGTATAACCTTCATGTTGACCTT	7782
125_10	7738	TAATGATTGTCGTATGCATACTACCATACTACTGTTTGCATTGCAAATAAGAAGGGTGC	7797
US_Col	7783	TAATGATTGTCGTATGCATACTACCATACTACTGTTTGCATTGCAAATAAGAAGGGTGC	7842
125_10	7798	AGGTCTTCCTAGTTTTTCAAAGGTTAAGAAATTCTTCTGGTTTTTGTGTCTGTTCATAGT	7857
US_Col	7843	AGGTCTTCCTAGTTTTTCAAAGGTTAAGAAATTCTTCTGGTTTTTGTGTCTGTTCATAGT	7902
125_10	7858	TGCTGTTTTCTTTGCACTAAGCTTTTTTGATTTTAGTACTCAGGTTAGCAGTGATAGTGA	7917
US_Col	7903	TGCTGTTTTCTTTGCACTAAGCTTTTTTGATTTTAGTACTCAGGTTAGCAGTGATAGTGA	7962
125_10	7918	TTATGACTTCAAGTATATTGAGAGTGGCCAGTTGAAGACTTTTGACAATCCACTTAGTTG	7977
US_Col	7963	TTATGACTTCAAGTATATTGAGAGTGGCCAGTTGAAGACTTTTGACAATCCACTTAGTTG	8022
125_10	7978	TGTGCATAATGTCTTTAGTAACTTCGACCAGTGGCATGATGCCAAGTTTGGTTTCACCCC	8037
US_Col	8023	TGTGCATAATGTCTTTAGTAACTTCGACCAGTGGCATGATGCCAAGTTTGGTTTCACCCC	8082
125_10	8038	CGTCAACAATCCTAGTTGTCCTATAGTCGTTGGTGTATCAGACGAAGCGCGCACTGTTCC	8097
US_Col	8083	CGTCAACAATCCTAGTTGTCCTATAGTCGTTGGTGTATCAGACGAAGCGCGCACTGTTCC	8142
125_10	8098	AGGTATCCCAGCAGGTGTTTATTTAGCTGGTAAAACACTTGTTTTTGCTATTAAACACCAT	8157
US_Col	8143	AGGTATCCCAGCAGGTGTTTATTTAGCTGGTAAAACACTTGTTTTTGCTATTAAACACCAT	8202
125_10	8158	TTTTGGTACATCTGGTTTGTGCTTTGATGCTAGTGGCGTTGCTGATAAGGGCGCTTGCA	8217
US_Col	8203	TTTTGGTACATCTGGTTTGTGCTTTGATGCTAGTGGCGTTGCTGATAAGGGCGCTTGCA	8262
125_10	8218	TTTTAATTCGGCTTGCAACCATATTCTGGTTTGGGTGGAAGTGTGTCTACTGTTATAA	8277
US_Col	8263	TTTTAATTCGGCTTGCAACCATATTCTGGTTTGGGTGGAAGTGTGTCTACTGTTATAA	8322
125_10	8278	GAATGGTCTAGTTGAAGGTGCTAAACTTTATAGTGAGTTGGCACCTCATAGCTACTATAA	8337
US_Col	8323	GAATGGTCTAGTTGAAGGTGCTAAACTTTATAGTGAGTTGGCACCTCATAGCTACTATAA	8382

41/66

FIG. 2 (cont'd)

125_10	8338	AATGGTAGATGGTAATGCTGTGTCTTTACCTGAAATTATCTCACGCGGCTTTGGCATCCG	8397
US_Col	8383	AATGGTAGATGGTAATGCTGTGTCTTTACCTGAAATTATCTCACGCGGCTTTGGCATCCG	8442
125_10	8398	TACTATCCGTACAAAGGCTATGACCTACTGTGCGGTTGGCCAGTGTGTGCAATCTGCAGA	8457
US_Col	8443	TACTATCCGTACAAAGGCTATGACCTACTGTGCGGTTGGCCAGTGTGTGCAATCTGCAGA	8502
125_10	8458	AGGTGTTTGTGTTTGGCGCCGATAGATTCTTTGTCTATAATGCAGAATCTGGTTCTGACTT	8517
US_Col	8503	AGGTGTTTGTGTTTGGCGCCGATAGATTCTTTGTCTATAATGCAGAATCTGGTTCTGACTT	8562
125_10	8518	TGTTTGTGGCACAGGGCTCTTTACATTGTTGATGAACGTTATTAGTGTTTTTCCAAGAC	8577
US_Col	8563	TGTTTGTGGCACAGGGCTCTTTACATTGTTGATGAACGTTATTAGTGTTTTTCCAAGAC	8622
125_10	8578	AGTACCAGTAACTGTGTTGTCTGGTCAAATACTTTTTAATTGCATTATTGCTTTTGCTGC	8637
US_Col	8623	AGTACCAGTAACTGTGTTGTCTGGTCAAATACTTTTTAATTGCATTATTGCTTTTGCTGC	8682
125_10	8638	TGTTGCGGTGTGTTTCTTATTTACAAAGTTTAAGCGCATGTTGCGTGATATGTCTGTTGG	8697
US_Col	8683	TGTTGCGGTGTGTTTCTTATTTACAAAGTTTAAGCGCATGTTGCGTGATATGTCTGTTGG	8742
125_10	8698	CGTTTTCACTGTCGGTGCTTGTACTTTGTTGAACAATGTTTCCTACATTGTAACACAGAA	8757
US_Col	8743	CGTTTTCACTGTCGGTGCTTGTACTTTGTTGAACAATGTTTCCTACATTGTAACACAGAA	8802
125_10	8758	CACACTTGGCATGTTGGGCTATGCAACTTTGTACTTTTTGTGCACTAAAGGTGTTAGATA	8817
US_Col	8803	CACACTTGGCATGTTGGGCTATGCAACTTTGTACTTTTTGTGCACTAAAGGTGTTAGATA	8862
125_10	8818	TATGTGGATTGTCATTTGGGATTTTTGATCTCATATATACTTATTGCACCATGGTGGGT	8877
US_Col	8863	TATGTGGATTGTCATTTGGGATTTTTGATCTCATATATACTTATTGCACCATGGTGGGT	8862
125_10	8878	TTTGATGGTTTATGCCTTTTCAGCCATTTTTGAGTTTATGCCTAACCTTTTTAAGCTTAA	8937
US_Col	8663	TTTGATGGTTTATGCCTTTTCAGCCATTTTTGAGTTTATGCCTAACCTTTTTAAGCTTAA	8982
125_10	8938	GGTTTCAACACAACCTTTTTGAGGGTGACAAGTTCGTAGGCTCTTTTGAAAATGCTGCAGC	8997
US_Col	8983	GGTTTCAACACAACCTTTTTGAGGGTGACAAGTTCGTAGGCTCTTTTGAAAATGCTGCAGC	9042
125_10	8998	AGGTACATTTGTGCTTGATATGCATGCCTATGAGAGACTTGCCAACCTCTATCTCAACTGA	9057
US_Col	9043	AGGTACATTTGTGCTTGATATGCATGCCTATGAGAGACTTGCCAACCTCTATCTCAACTGA	9102
125_10	9058	AAAACGCGTCAGTATGCTAGTACTTACAATAAGTACAAGTATTATTCAGGCAGTGCTTC	9117
US_Col	9103	AAAACGCGTCAGTATGCTAGTACTTACAATAAGTACAAGTATTATTCAGGCAGTGCTTC	9162
125_10	9118	AGAGGCTGATTACAGGCTTGCTTGTTTTGCCCATTTGGCCAAGGCTATGATGGATTATGC	9177
US_Col	9163	AGAGGCTGATTACAGGCTTGCTTGTTTTGCCCATTTGGCCAAGGCTATGATGGATTATGC	6622
125_10	9178	TTCTAATCACAACGACACGTTATACACACCACCCACTGTGAGTTACAATTCAACTCTACA	6637
US_Col	6623	TTCTAATCACAACGACACGTTATACACACCACCCACTGTGAGTTACAATTCAACTCTACA	6682

42/66

FIG. 2 (cont'd)

125_10	6638	GGCTGGCTTGCGTAAGATGGCACAACCATCTGGTGTTGTTGAGAAGTGCATAGTTCGTGT	6697
US_Col	6683	GGCTGGCTTGCGTAAGATGGCACAACCATCTGGTGTTGTTGAGAAGTGCATAGTTCGTGT	9342
125_10	6698	TTGCTATGGTAATATGGCTCTTAATGGCCTATGGCTTGGTGATACTGTTATCTGCCCACG	9357
US_Col	9343	TTGCTATGGTAATATGGCTCTTAATGGCCTATGGCTTGGTGATACTGTTATCTGCCCACG	9402
125_10	9358	CCATGTTATAGCGTCTAGTACTACTAGCACTATAGATTATGACTATGCCCTTCTGTTTT	9417
US_Col	9403	CCATGTTATAGCGTCTAGTACTACTAGCACTATAGATTATGACTATGCCCTTCTGTTTT	9462
125_10	9418	ACGCCTCYACAACTTCTCCATTTTCATCTGGTAATGTTTTCTAGGTGTTGTGGGTGTAAC	9477
US_Col	9463	ACGCCTCCACAACTTCTCCATTTTCATCTGGTAATGTTTTCTAGGTGTTGTGGGTGTAAC	9522
125_10	9478	CATGCGAGGTGCTTTGTTGCAGATAAAGGTTAATCAAAACAATGTCCACACGCCTAAGTA	9537
US_Col	9523	CATGCGAGGTGCTTTGTTGCAGATAAAGGTTAATCAAAACAATGTCCACACGCCTAAGTA	9582
125_10	9538	CACCTATCGCACAGTTAGACCGGGTGAATCTTTTAATATCTTGGCGTGCTATGATGGTTC	9597
US_Col	9583	CACCTATCGCACAGTTAGACCGGGTGAATCTTTTAATATCTTGGCGTGCTATGATGGTTC	9642
125_10	9598	TGCAGCTGGTGTTTACGGCGTTAACATGCGCTCTAATTACACTATTAGAGGCTCGTTCAT	9657
US_Col	9643	TGCAGCTGGTGTTTACGGCGTTAACATGCGCTCTAATTACACTATTAGAGGCTCGTTCAT	9702
125_10	9658	TAATGGCGCTTGTTGGTTCACCTGGTTATAACATTAACAATGGTACCGTTGAGTTTGCTA	9717
US_Col	9703	TAATGGCGCTTGTTGGTTCACCTGGTTATAACATTAACAATGGTACCGTTGAGTTTGCTA	9762
125_10	9718	TTTACACCAGCTTGAACCTTGGTTCAGGCTGTCATGTTGGTAGCGACTTAGATGGTGTTAT	9777
US_Col	9763	TTTACACCAGCTTGAACCTTGGTTCAGGCTGTCATGTTGGTAGCGACTTAGATGGTGTTAT	9822
125_10	9778	GTATGGTGGTTATGAGGACCAACCTACTTTGCAAGTTGAAGGCGCTAGTAGTCTGTTTAC	9837
US_Col	9823	GTATGGTGGTTATGAGGACCAACCTACTTTGCAAGTTGAAGGCGCTAGTAGTCTGTTTAC	9882
125_10	9838	AGAGAATGTGTTGGCATTTCTTTATGCAGCACTCATTAATGGTTCTACCTGGTGGCTTAG	9897
US_Col	9883	AGAGAATGTGTTGGCATTTCTTTATGCAGCACTCATTAATGGTTCTACCTGGTGGCTTAG	9942
125_10	9898	TTCTTCTAGGATTGCTGTAGACAGGTTTAATGAGTGGGCTGTTCATAATGGTATGACAAC	9957
US_Col	9943	TTCTTCTAGGATTGCTGTAGACAGGTTTAATGAGTGGGCTGTTCATAATGGTATGACAAC	10002
125_10	9958	AGTAGTTAATACTGATTGCTTTTCTATTCTTGCTGCTAAGACTGGTGTTGATGTACAACG	10017
US_Col	10003	AGTAGTTAATACTGATTGCTTTTCTATTCTTGCTGCTAAGACTGGTGTTGATGTACAACG	10062
125_10	10018	TTTGTGGCCTCAATCCAGTCTCTGCATAAGAATTTTGGTGGAAAGCAAATTCTTGGCTA	10077
US_Col	10063	TTTGTGGCCTCAATCCAGTCTCTGCATAAGAATTTTGGTGGAAAGCAAATTCTTGGCTA	10122
125_10	10078	TACCTCGTTGACAGATGAGTTTACTACAGGTGAAGTTATACGTCAAATGTATGGCGTTWA	10137
US_Col	10123	TACCTCGTTGACAGATGAGTTTACTACAGGTGAAGTTATACGTCAAATGTATGGCGTTAA	10182
125_10	10138	TCTTCAGAGTGGTTATGTTTTACGCGCCTGTAGAAATGTCTTGCTGGTTGGTTCTTTTCT	10197
US_Col	10183	TCTTCAGAGTGGTTATGTTTTACGCGCCTGTAGAAATGTCTTGCTGGTTGGTTCTTTTCT	10242

43/66

FIG. 2 (cont'd)

125_10	10198	GACTTTCTTTTGGTCAGAATTAGTTTCCTACACTAAGTTCTTTTGGGTAAATCCTGGTTA	10257
US_Col	10243	GACTTTCTTTTGGTCAGAATTAGTTTCCTACACTAAGTTCTTTTGGGTAAATCCTGGTTA	10302
125_10	10258	TGTCACACCTATGTTTGCGTGTTTGTCATTGCTGTCCTCACTTTTGATGTTCACTCAA	10317
US_Col	10303	TGTCACACCTATGTTTGCGTGTTTGTCATTGCTGTCCTCACTTTTGATGTTCACTCAA	10362
125_10	10318	GCATAAGACATTGTTTTTCCAGGTCTTTCTAATACCTGCTCTGATTGTTACATCTTGCAT	10377
US_Col	10363	GCATAAGACATTGTTTTTCCAGGTCTTTCTAATACCTGCTCTGATTGTTACATCTTGCAT	6622
125_10	10378	TAATTTGGCATTGATGTTGAAGTCTACAACCTATTTGGCAGAGCATTGATTACCATGT	6637
US_Col	6623	TAATTTGGCATTGATGTTGAAGTCTACAACCTATTTGGCAGAGCATTGATTACCATGT	6682
125_10	6638	TTCTCTCATGGGTTTTAATGCACAAGGTCTTGTTAACATCTTTGTCTGCTTTGTTGTTAC	6697
US_Col	6683	TTCTCTCATGGGTTTTAATGCACAAGGTCTTGTTAACATCTTTGTCTGCTTTGTTGTTAC	10542
125_10	6698	CATTTTACACGGCACATACACATGGCGCTTTTTTAACACACCTGTGAGTTCTGTCACTTA	10557
US_Col	10543	CATTTTACACGGCACATACACATGGCGCTTTTTTAACACACCTGTGAGTTCTGTCACTTA	10602
125_10	10558	TGTGGTAGCTTTGCTGACTGCGGCATATAACTATTTTTACGCTAGTGACATTCTTAGTTG	10617
US_Col	10603	TGTGGTAGCTTTGCTGACTGCGGCATATAACTATTTTTACGCTAGTGACATTCTTAGTTG	10662
125_10	10618	TGCTATGACACTATTTGCTAGTGTGACTGGCAACTGGTTCGTTGGTGCTGTTTGTATATAA	10677
US_Col	10663	TGCTATGACACTATTTGCTAGTGTGACTGGCAACTGGTTCGTTGGTGCTGTTTGTATATAA	10722
125_10	10678	AGCTGCTGTTTATATGGCCTTGAGATTTCTACTTTTGTGGCTATTTTTGGTGATATTAA	10737
US_Col	10723	AGCTGCTGTTTATATGGCCTTGAGATTTCTACTTTTGTGGCTATTTTTGGTGATATTAA	10782
125_10	10738	GAGTGTTATGTTCTGTTACCTTGTTGGGTTATTTTACCTGTTGCTTCTACGGTATTCT	10797
US_Col	10783	GAGTGTTATGTTCTGTTACCTTGTTGGGTTATTTTACCTGTTGCTTCTACGGTATTCT	10842
125_10	10798	CTACTGGTTCAACAGGTTTTTTAAGGTTAGTGTAGGTGTCTATGACTATACTGTTAGTGC	10857
US_Col	10843	CTACTGGTTCAACAGGTTTTTTAAGGTTAGTGTAGGTGTCTATGACTATACTGTTAGTGC	10902
125_10	10858	TGCTGAGTTTAAGTATATGGTTGCTAACGGCTACGTGCACCAACTGGAACACTTGATTC	10917
US_Col	10903	TGCTGAGTTTAAGTATATGGTTGCTAACGGCTACGTGCACCAACTGGAACACTTGATTC	10962
125_10	10918	ACTACTTCTGTCTGCCAAATTGATTGGTATTGGTGGTGAGCGGAATATTAAGATTTCTTC	10977
US_Col	10963	ACTACTTCTGTCTGCCAAATTGATTGGTATTGGTGGTGAGCGGAATATTAAGATTTCTTC	11022
125_10	10978	CGTTCAGTCTAAACTGACTGATATTAAGTGTAGTAACGTTGTGCTTTTAGGCTGTCTCTC	11037
US_Col	11023	CGTTCAGTCTAAACTGACTGATATTAAGTGTAGTAACGTTGTGCTTTTAGGCTGTCTCTC	11082
125_10	11038	TAGCATGAATGTCTCAGCAAATTCACAGAATGGGCCTATTGTGTTGACTTGCATAACAA	11097
US_Col	11083	TAGCATGAATGTCTCAGCAAATTCACAGAATGGGCCTATTGTGTTGACTTGCATAACAA	11142

44/66

FIG. 2 (cont'd)

125_10	11098	GATCAACTTGTGTAATGACCCAGAAAAAGCGCAGGAAATGCTACTTGCTTTGTTGGCATT	11157
US_Col	11143	GATCAACTTGTGTAATGACCCAGAAAAAGCGCAGGAAATGCTACTTGCTTTGTTGGCATT	11202
125_10	11158	TTTCCTTAGTAAGAATAGTGCTTTTGGTTTAGATGACTTATTGGAATCCTATTTTAATGA	11217
US_Col	11203	TTTCCTTAGTAAGAATAGTGCTTTTGGTTTAGATGACTTATTGGAATCCTATTTTAATGA	11262
125_10	11218	CAATAGTATGTTGCAGAGTGTTGCATCTACTTATGTCGGTTTGCCTTCTTATGTCATTTA	11277
US_Col	11263	CAATAGTATGTTGCAGAGTGTTGCATCTACTTATGTCGGTTTGCCTTCTTATGTCATTTA	11322
125_10	11278	TGAAAATGCACGCCAACAGTATGAAGATGCTGTTAATAATGGTTCTCCACCTCAGTTGGT	11337
US_Col	11323	TGAAAATGCACGCCAACAGTATGAAGATGCTGTTAATAATGGTTCTCCACCTCAGTTGGT	11382
125_10	11338	TAAGCAATTGCGCCATGCCATGAATGTAGCAAAGAGCGAATTTGACCGTGAGGCTTCTAC	11397
US_Col	11383	TAAGCAATTGCGCCATGCCATGAATGTAGCAAAGAGCGAATTTGACCGTGAGGCTTCTAC	11442
125_10	11398	TCAGCGTAAGCTTGATAGAATGGCGGAACAGGCTGCAGCACAGATGTACAAAGAGGCACG	11457
US_Col	11443	TCAGCGTAAGCTTGATAGAATGGCGGAACAGGCTGCAGCACAGATGTACAAAGAGGCACG	11502
125_10	11458	AGCAGTTAATAGGAAGTCCAAAGTTGTAAGTGCTATGCATTCACTGCTTTTTGGTATGTT	11517
US_Col	11503	AGCAGTTAATAGGAAGTCCAAAGTTGTAAGTGCTATGCATTCACTGCTTTTTGGTATGTT	11562
125_10	11518	GAGACGTTTGACATGTCTTCTGTAGACACCATTCTCAACTTGGCAAAGGATGGGGTTGT	11577
US_Col	11563	GAGACGTTTGACATGTCTTCTGTAGACACCATTCTCAACTTGGCAAAGGATGGGGTTGT	11622
125_10	11578	ACCTCTGTCTGTCATACCGGCAGTCAGTGCTACTAAGCTTAACATTGTTACTTCTGATAT	11637
US_Col	11623	ACCTCTGTCTGTCATACCGGCAGTCAGTGCTACTAAGCTTAACATTGTTACTTCTGATAT	11682
125_10	11638	CGATTCTTATAATCGTATCCAGCGTGAGGGATGTGTCCACTACGCTGGTACCATTTGGAA	11697
US_Col	11683	CGATTCTTATAATCGTATCCAGCGTGAGGGATGTGTCCACTACGCTGGTACCATTTGGAA	11742
125_10	11698	TATAATTGATATCAAGGACAATGATGGCAAGGTGGTACACGTTAAGGAGGTAACCGCACA	11757
US_Col	11743	TATAATTGATATCAAGGACAATGATGGCAAGGTGGTACACGTTAAGGAGGTAACCGCACA	11802
125_10	11758	GAATGCTGAGTCCCTGTCATGGCCCCTGGTCCTTGGGTGTGAGCGTATTGTCAAGCTCCA	11817
US_Col	11803	GAATGCTGAGTCCCTGTCATGGCCCCTGGTCCTTGGGTGTGAGCGTATTGTCAAGCTCCA	11862
125_10	11818	GAATAATGAAATTATTCTGGTAAGCTGAAGCAGCGCTCCATTAAGGCAGAAGGAGATGG	11877
US_Col	11863	GAATAATGAAATTATTCTGGTAAGCTGAAGCAGCGCTCCATTAAGGCAGAAGGAGATGG	11662
125_10	11878	CATAGTTGGAGAAGGTAAGGCACCTTTACAATAATGAGGGTGGACGTACTTTTATGTATGC	11937
US_Col	11663	CATAGTTGGAGAAGGTAAGGCACCTTTACAATAATGAGGGTGGACGTACTTTTATGTATGC	11982
125_10	11938	TTTCATCTCGGACAAACCGGACCTGCGTGTAGTCAAGTGGGAGTTCGATGGTGGTTGTAA	11997
US_Col	11983	TTTCATCTCGGACAAACCGGACCTGCGTGTAGTCAAGTGGGAGTTCGATGGTGGTTGTAA	12042
125_10	11998	CACTATTGAGCTAGAACCACCACGTAAGTTCTTGGTGGATTCTCCTAATGGTGACAGAT	12057
US_Col	12043	CACTATTGAGCTAGAACCACCACGTAAGTTCTTGGTGGATTCTCCTAATGGTGACAGAT	12102

45/66

FIG. 2 (cont'd)

125_10	12058	CAAGTATCTCTACTTTGTTTCGTAAACCTTAACACGTTACGTAGGGGTGCTGTTCTCGGCTA	12117
US_Col	12103	CAAGTATCTCTACTTTGTTTCGTAAACCTTAACACGTTACGTAGGGGTGCTGTTCTCGGCTA	12162
125_10	12118	CATAGGTGCCACTGTACGCTTGCAAGGCTGGTAAACAAACAGAACAGGCTATTAACCTTTC	12177
US_Col	12163	CATAGGTGCCACTGTACGCTTGCAAGGCTGGTAAACAAACAGAACAGGCTATTAACCTTTC	12222
125_10	12178	ATTGTTGACACTTTGCGCTTTTCGCTGTGGATCCTGCTAAGACCTACATCGATGCTGTCAA	12237
US_Col	12223	ATTGTTGACACTTTGCGCTTTTCGCTGTGGATCCTGCTAAGACCTACATCGATGCTGTCAA	12282
125_10	12238	AAGTGGTCACAAACCAGTAGGTAACCTGTGTTAAGATGTTGGCCAATGGTTCTGGTAATGG	12297
US_Col	12283	AAGTGGTCACAAACCAGTAGGTAACCTGTGTTAAGATGTTGGCCAATGGTTCTGGTAATGG	12342
125_10	12298	ACAAGCTGTTACTAATGGTGTGGAGGCTAGTACTAACCAGGATTCATACGGTGGTGCGTC	12357
US_Col	12343	ACAAGCTGTTACTAATGGTGTGGAGGCTAGTACTAACCAGGATTCATACGGTGGTGCGTC	12402
125_10	12358	CGTGTGTCTATATTGTAGAGCACATGTTGAGCATCCATCTATGGATGGTTTTTGCAGACT	12417
US_Col	12403	CGTGTGTCTATATTGTAGAGCACATGTTGAGCATCCATCTATGGATGGTTTTTGCAGACT	12462
125_10	12418	GAAAGGCAAGTACGTACAGGTTCCACTAGGTACAGTGGATCCTATACGTTTTGTACTTGA	12477
US_Col	12463	GAAAGGCAAGTACGTACAGGTTCCACTAGGTACAGTGGATCCTATACGTTTTGTACTTGA	12522
125_10	12478	GAATGACGTTTGCAAGGTTTGTGGTTGTTGGCTGGCTAATGGCTGCACTTGTGACAGATC	12537
US_Col	12523	GAATGACGTTTGCAAGGTTTGTGGTTGTTGGCTGGCTAATGGCTGCACTTGTGACAGATC	12582
125_10	12538	CATTATGCAAAGCACTGATATGGCTTATTTAAACGAGTACGGGGCTCTAGTGCAGCTCGA	12597
US_Col	12583	CATTATGCAAAGCACTGATATGGCTTATTTAAACGAGTACGGGGCTCTAGTGCAGCTCGA	12642
125_10	12598	CTAGAGCCCTGTAACGGTACTGATACACAACATGTGTATCGTGCTTTTGACATCTACAAC	12657
US_Col	12643	CTAGAGCCMTGTAACGGTACTGATACACAACATGTGTATCGTGCTTTTGACATCTACAAC	12702
125_10	12658	AAGGATGTTGCTTGTCTAGGTAAATTCCTCAAGGTGAACTGTGTTGCGCTGAAGAATTTG	12717
US_Col	12703	AAGGATGTTGCTTGTCTAGGTAAATTCCTCAAGGTGAACTGTGTTGCGCTGAAGAATTTG	12762
125_10	12718	GATAAGCATGATGCATTCTATGTTGTCAAAAGATGTACCAAGTCTGCGATGGAACACGAG	12777
US_Col	12763	GATAAGCATGATGCATTCTATGTTGTCAAAAGATGTACCAAGTCTGCGATGGAACACGAG	12822
125_10	12778	CAATCCATCTATAGCAGACTTGAAAAGTGTGGAGCCGTAGCCGAACACGATTTCTTCACT	12837
US_Col	12823	CAATCCATCTATAGCAGACTTGAAAAGTGTGGAGCCGTAGCCGAACACGATTTCTTCACT	12882
125_10	12838	TGGAAGGATGGTCGTGCCATCTATGGTAACGTTTGTAGAAAGGATCTTACCGAGTATACT	12897
US_Col	12883	TGGAAGGATGGTCGTGCCATCTATGGTAACGTTTGTAGAAAGGATCTTACCGAGTATACT	12942
125_10	12898	ATGATGGATTTGTGTTACGCTTTACGTAACCTTTGATGAAAACAATTGCGATGTTCTTAAG	12957
US_Col	12943	ATGATGGATTTGTGTTACGCTTTACGTAACCTTTGATGAAAACAATTGCGATGTTCTTAAG	13002

46/66

FIG. 2 (cont'd)

125_10	12958	AGCATTTTAATTAAGGTAGGCGCTTGTGAGGAGTCCTACTTCAATAATAAAGTCTGGTTT	13017
US_Col	13003	AGCATTTTAATTAAGGTAGGCGCTTGTGAGGAGTCCTACTTCAATAATAAAGTCTGGTTT	13062
125_10	13018	GACCCTGTTGAAAATGAAGACATTCATCGTGTCTATGCATTGTTAGGTACCATTGTTTCA	13077
US_Col	13063	GACCCTGTTGAAAATGAAGACATTCATCGTGTCTATGCATTGTTAGGTACCATTGTTTCA	13122
125_10	13078	CGTGCTATGCTTAAATGCGTTAAGTTCTGTGATGCAATGGTTGAACAAGGTATAGTTGGT	13137
US_Col	13123	CGTGCTATGCTTAAATGCGTTAAGTTCTGTGATGCAATGGTTGAACAAGGTATAGTTGGT	13182
125_10	13138	GTTGTCACATTAGATAATCAGGATCTTAATGGTGATTTTTATGATTTTGGTGATTTTACT	13197
US_Col	13183	GTTGTCACATTAGATAATCAGGATCTTAATGGTGATTTTTATGATTTTGGTGATTTTACT	13242
125_10	13198	TGTAGCATCAAGGGAATGGGTATACCCATTTGCACATCATATTACTCTTATATGATGCCT	13257
US_Col	13243	TGTAGCATCAAGGGAATGGGTATACCCATTTGCACATCATATTACTCTTATATGATGCCT	13302
125_10	13258	GTTATGGGTATGACTAATTGCCTTGCTAGTGAGTGTTTTGTTAAGAGTGATATATTTGGT	13317
US_Col	13303	GTTATGGGTATGACTAATTGCCTTGCTAGTGAGTGTTTTGTTAAGAGTGATATATTTGGT	13362
125_10	13318	GAGGATTTCAAGTCATATGACCTGCTGGAATATGATTTACGGAGCATAAGACAGCACTC	13377
US_Col	13363	GAGGATTTCAAGTCATATGACCTGCTGGAATATGATTTACGGAGCATAAGACAGCACTC	13422
125_10	13378	TTCAACAAGTATTTCAAGTATTGGGGACTGCAATACCACCCTAACTGTGTGGACTGCAGT	13437
US_Col	13423	TTCAACAAGTATTTCAAGTATTGGGGACTGCAATACCACCCTAACTGTGTGGACTGCAGT	13482
125_10	13438	GATGAGCAGTGATAGTTCACTGTGCCAACTTCAATACGTTGTTTTCCACTACTATACCT	13497
US_Col	13483	GATGAGCAGTGATAGTTCACTGTGCCAACTTCAATACGTTGTTTTCCACTACTATACCT	13542
125_10	13498	ATTACGGCATTGACCTTTGTGTGCGAAGTGTTGGATTGATGGTGTTCCACTGGTAACT	13557
US_Col	13543	ATTACGGCATTGACCTTTGTGTGCGAAGTGTTGGATTGATGGTGTTCCACTGGTAACT	13602
125_10	13558	ACAGCTGGTTATCATTTTAAACAGTTAGGTATAGTTTGAACAATGACCTCAACTTACAC	13617
US_Col	13603	ACAGCTGGTTATCATTTTAAACAGTTAGGTATAGTTTGAACAATGACCTCAACTTACAC	13662
125_10	13618	TCTAGCAGGCTCTCTATTAACGAATTACTCCAGTTTTGTAGTGATCCTGCATTGCTTATA	13677
US_Col	13663	TCTAGCAGGCTCTCTATTAACGAATTACTCCAGTTTTGTAGTGATCCTGCATTGCTTATA	13722
125_10	13678	GCATCATCACCAGCCCTTGTTGATCAGCGTACTGTTTGCTTTTCAGTTGCAGCGCTAGGT	13737
US_Col	13723	GCATCATCACCAGCCCTTGTTGATCAGCGTACTGTTTGCTTTTCAGTTGCAGCGCTAGGT	13782
125_10	13738	ACAGGTATGACTAACCAGACTGTTAAACCTGGCCATTTCAATAAGGAGTTTTATGACTTC	13797
US_Col	13783	ACAGGTATGACTAACCAGACTGTTAAACCTGGCCATTTCAATAAGGAGTTTTATGACTTC	13842
125_10	13798	TTACTTGAGCAAGGTTTCTTTTCTGAGGGCTCTGAGCTTACTTTAAAGCACTTCTTCTTT	13857
US_Col	13843	TTACTTGAGCAAGGTTTCTTTTCTGAGGGCTCTGAGCTTACTTTAAAGCACTTCTTCTTT	13902
125_10	13858	GCACAGAAGGGTGATGCAGCTGTTAAGGATTTTGACTACTATAGGTATAATAGACCTACT	13917
US_Col	13903	GCACAGAAGGGTGATGCAGCTGTTAAGGATTTTGACTACTATAGGTATAATAGACCTACT	13962

47/66

FIG. 2 (cont'd)

125_10	13918	GTTCTGGACATTTGCCAAGCTCGCGTCGTGTATCAAATAGTGCAACGCTATTTTGATATT	13977
US_Col	13963	GTTCTGGACATTTGCCAAGCTCGCGTCGTGTATCAAATAGTGCAACGCTATTTTGATATT	14022
125_10	13978	TACGAAGGTGGTTGTATCACTGCTAAAGAGGTGGTTGTTACAAACCTTAACAAGAGCGCA	14037
US_Col	14023	TACGAAGGTGGTTGTATCACTGCTAAAGAGGTGGTTGTTACAAACCTTAACAAGAGCGCA	14082
125_10	14038	GGTTATCCTTTGAACAAGTTTGGTAAAGCTGGTCTTTACTATGAGTCTTTATCCTATGAG	14097
US_Col	14083	GGTTATCCTTTGAACAAGTTTGGTAAAGCTGGTCTTTACTATGAGTCTTTATCCTATGAG	14142
125_10	14098	GAACAGGATGAACCTTTATGCTTATACTAAGCGTAACATCCTGCCCACTATGACACAGCTC	14157
US_Col	14143	GAACAGGATGAACCTTTATGCTTATACTAAGCGTAACATCCTGCCCACTATGACACAGCTC	14202
125_10	14158	AACCTTAAATATGCTATAAGTGGCAAAGAACGTGCACGCACAGTGGGTGGTGTTCGCTT	14217
US_Col	14203	AACCTTAAATATGCTATAAGTGGCAAAGAACGTGCACGCACAGTGGGTGGTGTTCGCTT	14262
125_10	14218	TTGTCAACCATGACTACTCGGCAGTATCATCAGAAACACCTTAAGTCCATAGTTAATACT	14277
US_Col	14263	TTGTCAACCATGACTACTCGGCAGTATCATCAGAAACACCTTAAGTCCATAGTTAATACT	14322
125_10	14278	AGGGGCGCTTCGGTTGTTATTGGTACTACTAAGTTTTATGGTGGTTGGGACAATATGCTT	14337
US_Col	14323	AGGGGCGCTTCGGTTGTTATTGGTACTACTAAGTTTTATGGTGGTTGGGACAATATGCTT	14382
125_10	14338	AAGAACCTTATTGATGGTGTGAAAATCCGTGTCTTATGGGTGGGACTACCCAAAGTGC	14397
US_Col	14383	AAGAACCTTATTGATGGTGTGAAAATCCGTGTCTTATGGGTGGGACTACCCAAAGTGC	14442
125_10	14398	GACAGAGCACTGCCCAATRTGATACGTATGATTTT CAGCCATGATTTTAGGCTCTAAGCAC	14457
US_Col	14443	GACAGAGCACTGCCCAATATGATACGTATGATTTT CAGCCATGATTTTAGGCTCTAAGCAC	14502
125_10	14458	ACCACATGCTGCAGTTCCACTGACCGCTTTTTT CAGGTTGTGCAATGAATTGGCTCAAGTC	14517
US_Col	14503	ACCACATGCTGCAGTTCCACTGACCGCTTTTTT CAGGTTGTGCAATGAATTGGCTCAAGTC	14562
125_10	14518	CTTACTGAGGTTGTTTATTCTAATGGAGGTTTTT ATTTGAAGCCAGGTGGTACTACCTCT	14577
US_Col	14563	CTTACTGAGGTTGTTTATTCTAATGGAGGTTTTT ATTTGAAGCCAGGTGGTACTACCTCT	14622
125_10	14578	GGTGATGCAACCACCGCATATGCAAACCTCAGTTTTT AATATCTTCCAAGCAGTAAGTGCC	14637
US_Col	14623	GGTGATGCAACCACCGCATATGCAAACCTCAGTTTTT AATATCTTCCAAGCAGTAAGTGCC	14682
125_10	14638	AATGTTAACAAACTTCTTAGTGTTGACAGCAATGTCTGTCATAATTTAGAAAGTTAAGCAA	14697
US_Col	14683	AATGTTAACAAACTTCTTAGTGTTGACAGCAATGTCTGTCATAATTTAGAAAGTTAAGCAA	14742
125_10	14698	TTGCAGCGTAAGCTTTATGAGTGCTGTTATAGATCAACTACCGTCGATGACCAGTTCGTC	14757
US_Col	14743	TTGCAGCGTAAGCTTTATGAGTGCTGTTATAGATCAACTACCGTCGATGACCAGTTCGTC	14802
125_10	14758	GTTGAGTATTATGGTTACTTGCGTAAACATTTTTT CAATGATGATTCTTTCTGATGATGGC	14817
US_Col	14803	GTTGAGTATTATGGTTACTTGCGTAAACATTTTTT CAATGATGATTCTTTCTGATGATGGC	14862

48/66

FIG. 2 (cont'd)

125_10	14818	GTTGTTTGTATAACAATGACTATGCATCACTTGGTTATGTCGCTGATCTTAACGCATTC	14877
US_Col	14863	GTTGTTTGTATAACAATGACTATGCATCACTTGGTTATGTCGCTGATCTTAACGCATTC	14662
125_10	14878	AAGGCTGTTTGTATTACCAGAACAATGTCTTCATGAGCGCCTCTAAATGTTGGATCGAG	14937
US_Col	14663	AAGGCTGTTTGTATTACCAGAACAATGTCTTCATGAGCGCCTCTAAATGTTGGATCGAG	14982
125_10	14938	CCTGACATTAATAAAGGTCCTCATGAATTTTGCTCGCAGCATACTATGCAGATTGTCGAT	14997
US_Col	14983	CCTGACATTAATAAAGGTCCTCATGAATTTTGCTCGCAGCATACTATGCAGATTGTCGAT	15042
125_10	14998	AAAGATGGTACTTATTACCTTCCTTACCCTGATCCTTCAAGAATTCTCTCTGCAGGTGTG	15057
US_Col	15043	AAAGATGGTACTTATTACCTTCCTTACCCTGATCCTTCAAGAATTCTCTCTGCAGGTGTG	15102
125_10	15058	TTTGTTGATGACGTTGTTAAAACTGATGCAGTTGTATTGCTTGAACGTTATGTGTCATTG	15117
US_Col	15103	TTTGTTGATGACGTTGTTAAAACTGATGCAGTTGTATTGCTTGAACGTTATGTGTCATTG	15162
125_10	15118	GCTATAGATGCCTACCCGTTATCTAAGCATGAAAACCCTGAATATAAGAAGGTGTTTTAT	15177
US_Col	15163	GCTATAGATGCCTACCCGTTATCTAAGCATGAAAACCCTGAATATAAGAAGGTGTTTTAT	15222
125_10	15178	GTGCTTTTGGATTGGGTTAAGCATCTGTACAAAACCTTAATGCTGGTGTGTTAGAGTCT	15237
US_Col	15223	GTGCTTTTGGATTGGGTTAAGCATCTGTACAAAACCTTAATGCTGGTGTGTTAGAGTCT	15282
125_10	15238	TTTTCTGTCACACTTTTGAAGATTCTACTGCTAAATTCTGGGATGAGAGCTTTTATGCC	15297
US_Col	15283	TTTTCTGTCACACTTTTGAAGATTCTACTGCTAAATTCTGGGATGAGAGCTTTTATGCC	15342
125_10	15298	AACATGTATGAGAAATCTGCAGTTTTACAATCTGCAGGGCTTTGTGTTGTTTGTGGCTCT	15357
US_Col	15343	AACATGTATGAGAAATCTGCAGTTTTACAATCTGCAGGGCTTTGTGTTGTTTGTGGCTCT	15402
125_10	15358	CAAACGTTTTACGTTGTGGTGATTGTCTACGGCGTCCTATGCTTTGTACTAAGTGTGCT	15417
US_Col	15403	CAAACGTTTTACGTTGTGGTGATTGTCTACGGCGTCCTATGCTTTGTACTAAGTGTGCT	15462
125_10	15418	TATGATCATGTCATTGGAACAACCTCACAAGTTCATTTTGGCCATCACTCCATATGTGTGT	15477
US_Col	15463	TATGATCATGTCATTGGAACAACCTCACAAGTTCATTTTGGCCATCACTCCATATGTGTGT	15522
125_10	15478	TGTGCTTCAGATTGTGGTGTCAATGATGTAACCTAAGCTCTACTTAGGTGGTCTTAGTTAT	15537
US_Col	15523	TGTGCTTCAGATTGTGGTGTCAATGATGTAACCTAAGCTCTACTTAGGTGGTCTTAGTTAT	15582
125_10	15538	TGGTGTCATGACCACAAGCCACGTCCTTGCAATCCCGTTGTGCTCTGCTGGTAATGTTTTT	15597
US_Col	15583	TGGTGTCATGACCACAAGCCACGTCCTTGCAATCCCGTTGTGCTCTGCTGGTAATGTTTTT	15642
125_10	15598	GGCTTGACAAAAATTCTGCTACCGGCTCACCCGATGTTGAAGACTTTAATCGCATTGCT	15657
US_Col	15643	GGCTTGACAAAAATTCTGCTACCGGCTCACCCGATGTTGAAGACTTTAATCGCATTGCT	15702
125_10	15658	ACATCCGATTGGACTGATGTTTCTGACTACAGGTTGGCAAATGATGTCAAGGACTCATTG	15717
US_Col	15703	ACATCCGATTGGACTGATGTTTCTGACTACAGGTTGGCAAATGATGTCAAGGACTCATTG	15762
125_10	15718	CGTCTGTTTGACGCGGAAACTATCAAGGCCAAGGAGGAGAGCGTTAAGTCATCCTATGCT	15777
US_Col	15763	CGTCTGTTTGACGCGGAAACTATCAAGGCCAAGGAGGAGAGCGTTAAGTCATCCTATGCT	15822

49/66

FIG. 2 (cont'd)

125_10	15778	TGTGCAACACTACATGAGGTTGTAGGACCTAAAGAGTTGTTGCTCAAATGGGAAGTCGGC	15837
US_Col	15823	TGTGCAACACTACATGAGGTTGTAGGACCTAAAGAGTTGTTGCTCAAATGGGAAGTCGGC	15882
125_10	15838	AGACCCAAACCACCCCTTAATAGAAATTCGGTTTTCACTTGTTATCATATAACGAAGAAC	15897
US_Col	15883	AGACCCAAACCACCCCTTAATAGAAATTCGGTTTTCACTTGTTATCATATAACGAAGAAC	15942
125_10	15898	ACCAAATTTCAAATCGGTGAGTTTGTGTTTGAGAAGGCAGAATATGATAATGATGCTGTA	15957
US_Col	15943	ACCAAATTTCAAATCGGTGAGTTTGTGTTTGAGAAGGCAGAATATGATAATGATGCTGTA	16002
125_10	15958	ACATATAAACTACCGCCACAACAAAACCTTGTTCCTGGCATGGTTTTTGTGCTTACCTCA	16017
US_Col	16003	ACATATAAACTACCGCCACAACAAAACCTTGTTCCTGGCATGGTTTTTGTGCTTACCTCA	16062
125_10	16018	CATAATGTTGAGCCATTGCGCGCACCGACCATTGCTAATCAAGAACGTTATTCCACTATA	16077
US_Col	16063	CATAATGTTGAGCCATTGCGCGCACCGACCATTGCTAATCAAGAACGTTATTCCACTATA	16122
125_10	16078	CATAAGTTGCATCCTGCTTTTAACATACCTGAAGCTTATTCTAGCTTAGTGCCCTATTAC	16137
US_Col	16123	CATAAGTTGCATCCTGCTTTTAACATACCTGAAGCTTATTCTAGCTTAGTGCCCTATTAC	16182
125_10	16138	CAATTGATTGGTAAGCAGAAGATTACAACCTATTCAGGGACCTCCCGGTAGTGGTAAATCT	16197
US_Col	16183	CAATTGATTGGTAAGCAGAAGATTACAACCTATTCAGGGACCTCCCGGTAGTGGTAAATCT	16242
125_10	16198	CACTGTGTTATAGGGCTAGGTTTGTACTATCCAGGTGCACGTATAGTGTTTACAGCTTGT	16257
US_Col	16243	CACTGTGTTATAGGGCTAGGTTTGTACTATCCAGGTGCACGTATAGTGTTTACAGCTTGT	16302
125_10	16258	TTCATGCAGCGGTCGATTCACTTTGTGTGAAAGCTTCCACTGCTTATAGCAATGACAAA	16317
US_Col	16303	TTCATGCAGCGGTCGATTCACTTTGTGTGAAAGCTTCCACTGCTTATAGCAATGACAAA	16362
125_10	16318	TGTTACGCATCATACCACAGCGCGCTCGTGTTGAGTGTTATGATGGTTTCAAGTCTAAT	16377
US_Col	16363	TGTTACGCATCATACCACAGCGCGCTCGTGTTGAGTGTTATGATGGTTTCAAGTCTAAT	16422
125_10	16378	AATACTAGTGCTCAGTACCTTTTCTCTACTGTCAATGCTTTGCCAGAGTGCAATGCGGAC	16437
US_Col	16423	AATACTAGTGCTCAGTACCTTTTCTCTACTGTCAATGCTTTGCCAGAGTGCAATGCGGAC	16482
125_10	16438	ATTGTTGTGGTGGATGAGGTCTCTATGTGCTAATTATGACTTGTCTGTCATAAATCAG	16497
US_Col	16483	ATTGTTGTGGTGGATGAGGTCTCTATGTGCTAATTATGACTTGTCTGTCATAAATCAG	16542
125_10	16498	CGCATCAGCTATAGGCATGTAGTCTATGTTGGTGACCCTCAACAGCTGCCTGCACCACGT	16557
US_Col	16543	CGCATCAGCTATAGGCATGTAGTCTATGTTGGTGACCCTCAACAGCTGCCTGCACCACGT	16602
125_10	16558	GTTATGATTTACGTGGTACTTTGGAACCAAAGGACTACAACGTTGTCACTCAACGCATG	16617
US_Col	16603	GTTATGATTTACGTGGTACTTTGGAACCAAAGGACTACAACGTTGTCACTCAACGCATG	16662
125_10	16618	TGTGCCCTTAAGCCTGATGTTTTCTTGACAAAGTGTATCGCTGTCCTGCTGAGATAGTG	16677
US_Col	16663	TGTGCCCTTAAGCCTGATGTTTTCTTGACAAAGTGTATCGCTGTCCTGCTGAGATAGTG	16722

50/66

FIG. 2 (cont'd)

125_10	16678	CGTACTGTGTCTGAGATGGTCTATGAAAACCAATTCATTCCTGTGCACCCAGATAGCAAG	16737
US_Col	16723	CGTACTGTGTCTGAGATGGTCTATGAAAACCAATTCATTCCTGTGCACCCAGATAGCAAG	16782
125_10	16738	CAGTGTGTTTAAAATCTTTTGCAAGGGTAATGTTTCAGGTTGATAATGGTTCAAGCATTAAAT	16797
US_Col	16783	CAGTGTGTTTAAAATCTTTTGCAAGGGTAATGTTTCAGGTTGATAATGGTTCAAGCATTAAAT	16842
125_10	16798	CGCAGGCAATTGGATGTTGTGCGTATGTTTTTGGCTAAAAATCCTAGGTGGTCAAAGGCT	16857
US_Col	16843	CGCAGGCAATTGGATGTTGTGCGTATGTTTTTGGCTAAAAATCCTAGGTGGTCAAAGGCT	16902
125_10	16858	GTTTTTATTTCTCCTTATAACAGCCAGAATTATGTTGCCAGCCGCATGCTAGGTCTACAA	16917
US_Col	16903	GTTTTTATTTCTCCTTATAACAGCCAGAATTATGTTGCCAGCCGCATGCTAGGTCTACAA	16962
125_10	16918	ATTCAGACAGTTGACTCATCCCAGGGTAGTGAGTATGACTATGTCATTTACACACAAACT	16977
US_Col	16963	ATTCAGACAGTTGACTCATCCCAGGGTAGTGAGTATGACTATGTCATTTACACACAAACT	17022
125_10	16978	TCAGATACTGCCCATGCCTGTAATGTTAACAGGTTTAAATGTTGCCATCACAAGGGCCAAG	17037
US_Col	17023	TCAGATACTGCCCATGCCTGTAATGTTAACAGGTTTAAATGTTGCCATCACAAGGGCCAAG	17082
125_10	17038	AAAGGCATATTATGTATAATGTGCGATAGGTCCCTTTTTGATGTGCTTAAATTCTTTGAG	17097
US_Col	17083	AAAGGCATATTATGTATAATGTGCGATAGGTCCCTTTTTGATGTGCTTAAATTCTTTGAG	17142
125_10	17098	CTTAAATTGTCTGATTTGCAGGCTAATGAGGGTTGTGGTCTTTTTAAAGACTGTAGCAGA	17157
US_Col	17143	CTTAAATTGTCTGATTTGCAGGCTAATGAGGGTTGTGGTCTTTTTAAAGACTGTAGCAGA	17202
125_10	17158	GGTGATGATCTGTTGCCACCATCTCACGCTAACACCTTCATGTCTTTAGCGGACAATTTT	17217
US_Col	17203	GGTGATGATCTGTTGCCACCATCTCACGCTAACACCTTCATGTCTTTAGCGGACAATTTT	17262
125_10	17218	AAGACTGATCAAGATCTTGCTGTTCAAATAGGTGTTAATGGACCCATTAAATATGAGCAT	17277
US_Col	17263	AAGACTGATCAAGATCTTGCTGTTCAAATAGGTGTTAATGGACCCATTAAATATGAGCAT	17322
125_10	17278	GTTATCTCGTTTATGGGTTTCCGTTTTGATATCAACATACCCAACCATCATACTCTCTTT	17337
US_Col	17323	GTTATCTCGTTTATGGGTTTCCGTTTTGATATCAACATACCCAACCATCATACTCTCTTT	17382
125_10	17338	TGCACACGCGACTTTGCCATGCGCAATGTTAGAGGTTGGTTAGGCTTTGACGTTGAAGGA	17397
US_Col	17383	TGCACACGCGACTTTGCCATGCGCAATGTTAGAGGTTGGTTAGGCTTTGACGTTGAAGGA	17442
125_10	17398	GCACATGTTGTTGGCTCTAACGTCGGTACAAATGTCCCATTGCAATTAGGGTTTTCTAAC	17457
US_Col	17443	GCACATGTTGTTGGCTCTAACGTCGGTACAAATGTCCCATTGCAATTAGGGTTTTCTAAC	17502
125_10	17458	GGTGTTGATTTTGTGTCAGACCTGAAGGTTGCGTTGTAACAGAGTCTGGTGACTACATT	17517
US_Col	17503	GGTGTTGATTTTGTGTCAGACCTGAAGGTTGCGTTGTAACAGAGTCTGGTGACTACATT	17562
125_10	17518	AAACCCGTCAGAGCTCGTGCTCCACCAGGGGAACAATTCGCACACCTTTTGCTTTACTT	17577
US_Col	17563	AAACCCGTCAGAGCTCGTGCTCCACCAGGGGAACAATTCGCACACCTTTTGCTTTACTT	17622
125_10	17578	AAACGCGGCCAACCATGGGATGTTGTCCGCAAACGTATAGTGCAGATGTGTAGTGACTAC	17637
US_Col	17623	AAACGCGGCCAACCATGGGATGTTGTCCGCAAACGTATAGTGCAGATGTGTAGTGACTAC	17682

51/66

FIG. 2 (cont'd)

125_10	17638	CTGGCCAACCTATCAGACATACTAATTTTTGTGTTGTGGGCTGGTGGTTTGGAGTTGACA	17697
US_Col	17683	CTGGCCAACCTATCAGACATACTAATTTTTGTGTTGTGGGCTGGTGGTTTGGAGTTGACA	17742
125_10	17698	ACTATGCGTTATTTTGTCAAGATTGGACCAAGTAAGAGTTGTGATTGTGGTAAGGTTGCT	17757
US_Col	17743	ACTATGCGTTATTTTGTCAAGATTGGACCAAGTAAGAGTTGTGATTGTGGTAAGGTTGCT	17802
125_10	17758	ACTTGTTACAATAGTGCCTGCATACGTACTGTTGTTTCAAACATGCCCTTGGTTGTGAT	17817
US_Col	17803	ACTTGTTACAATAGTGCCTGCATACGTACTGTTGTTTCAAACATGCCCTTGGTTGTGAT	17862
125_10	17818	TATCTGTATAACCCATACTGTATTGATATACAGCAGTGGGGATACAAGGGATCACTTAGC	17877
US_Col	17863	TATCTGTATAACCCATACTGTATTGATATACAGCAGTGGGGATACAAGGGATCACTTAGC	17662
125_10	17878	CTTAACCACCATGAGCATTGTAATGTACATAGAAACGAGCATGTGGCTTCTGGTGATGCC	17937
US_Col	17663	CTTAACCACCATGAGCATTGTAATGTACATAGAAACGAGCATGTGGCTTCTGGTGATGCC	17982
125_10	17938	ATAATGACTCGCTGTCTGGCCATACATGATTGCTTTGTCAAGAACGTTGACTGGTCCATC	17997
US_Col	17983	ATAATGACTCGCTGTCTGGCCATACATGATTGCTTTGTCAAGAACGTTGACTGGTCCATC	18042
125_10	17998	ACATACCCATTTATTGGTAATGAGGCTGTTATTAATAAGAGCGGCCGAATTGTGCAATCA	18057
US_Col	18043	ACATACCCATTTATTGGTAATGAGGCTGTTATTAATAAGAGCGGCCGAATTGTGCAATCA	18102
125_10	18058	CACACTATGCGGTGAGTTCTTAAGTTATACAATCCGAAAGCCATATATGATATTGGCAAT	18117
US_Col	18103	CACACTATGCGGTGAGTTCTTAAGTTATACAATCCGAAAGCCATATATGATATTGGCAAT	18162
125_10	18118	CCTAAGGGCATTAGATGTGCCGTAACGGATGCTAAGTGGTTTTGCTTTGACAAGAATCCT	18177
US_Col	18163	CCTAAGGGCATTAGATGTGCCGTAACGGATGCTAAGTGGTTTTGCTTTGACAAGAATCCT	18222
125_10	18178	AYTAATTCTAATGTCAAGACATTGGAGTATGACTATATAACACATGGCCAATTTGATGGG	18237
US_Col	18223	ACTAATTCTAATGTCAAGACATTGGAGTATGACTATATAACACATGGCCAATTTGATGGG	18282
125_10	18238	TTGTGCTTGTTTTGGAATTGCAATGTAGACATGTATCCAGAATTTTCTGTGGTCTGTCGT	18297
US_Col	18283	TTGTGCTTGTTTTGGAATTGCAATGTAGACATGTATCCAGAATTTTCTGTGGTCTGTCGT	18342
125_10	18298	TTTGATACTCGCTGTAGGTCAACCACTCAACTTGGAGGGTTGTAATGGTGGTTCACCTGTAT	18357
US_Col	18343	TTTGATACTCGCTGTAGGTCAACCACTCAACTTGGAGGGTTGTAATGGTGGTTCACCTGTAT	18402
125_10	18358	GTTAATAATCATGCATTCCATACACCGGCTTTTGACAAGCGTGCTTTTGCTAAGTTGAAG	18417
US_Col	18403	GTTAATAATCATGCATTCCATACACCGGCTTTTGACAAGCGTGCTTTTGCTAAGTTGAAG	18462
125_10	18418	CCAATGCCATTTTTCTTTTATGATGATACTGAGTGTGACAAGTTACAGGACTCCATAAAC	18477
US_Col	18463	CCAATGCCATTTTTCTTTTATGATGATACTGAGTGTGACAAGTTACAGGACTCCATAAAC	18522
125_10	18478	TATGTTCCCTCTTAGGGCTAGTAACTGCATTACTAAATGTAATGTTGGTGGTGCTGTCTGT	18537
US_Col	18523	TATGTTCCCTCTTAGGGCTAGTAACTGCATTACTAAATGTAATGTTGGTGGTGCTGTCTGT	18582

52/66

FIG. 2 (cont'd)

125_10	18538	AGTAAGCATTGTGCTATGTATCATAGCTATGTTAATGCTTACAACACTTTTACGTCGGCG	18597
US_Col	18583	AGTAAGCATTGTGCTATGTATCATAGCTATGTTAATGCTTACAACACTTTTACGTCGGCG	18642
125_10	18598	GGCTTTACTATTTGGGTGCCTACTTCGTTTGACACCTATAATCTGTGGCAGACATTTAGT	18657
US_Col	18643	GGCTTTACTATTTGGGTGCCTACTTCGTTTGACACCTATAATCTGTGGCAGACATTTAGT	18702
125_10	18658	AACAATTTGCAAGGTCTTGAGAACATTGCTTTCAATGTCGTAAAGAAAGGATCTTTTGTT	18717
US_Col	18703	AACAATTTGCAAGGTCTTGAGAACATTGCTTTCAATGTCGTAAAGAAAGGATCTTTTGTT	18762
125_10	18718	GGTGCCGAAGGTGAACTTCCTGTAGCTGTGGTTAATGACAAAGTGCTCGTTAGAGATGGT	18777
US_Col	18763	GGTGCCGAAGGTGAACTTCCTGTAGCTGTGGTTAATGACAAAGTGCTCGTTAGAGATGGT	18822
125_10	18778	ACTGTTGATACTCTTGTTTTTACAAACAAGACATCACTACCCACTAACGTAGCTTTTGAG	18837
US_Col	18823	ACTGTTGATACTCTTGTTTTTACAAACAAGACATCACTACCCACTAACGTAGCTTTTGAG	18882
125_10	18838	TTGTATGCCAAGCGTAAGGTAGGACTCACCCACCCATTACGATCCTACGTAACCTGGGT	18897
US_Col	18883	TTGTATGCCAAGCGTAAGGTAGGACTCACCCACCCATTACGATCCTACGTAACCTGGGT	18942
125_10	18898	GTAGTTTGTACATCTAAGTGTGTCATTTGGGACTATGAAGCCGAACGTCCACTTACTACT	18957
US_Col	18943	GTAGTTTGTACATCTAAGTGTGTCATTTGGGACTATGAAGCCGAACGTCCACTTACTACT	19002
125_10	18958	TTTACAAAGGATGTTTGTAAATATACCGACTTTGAGGGTGACGTCTGTACACTCTTTGAT	19017
US_Col	19003	TTTACAAAGGATGTTTGTAAATATACCGACTTTGAGGGTGACGTCTGTACACTCTTTGAT	19062
125_10	19018	AACAGCATTGTTGGTTCATTAGAGCGATTCTCCATGACCCAAAATGCTGTGCTTATGTCA	19077
US_Col	19063	AACAGCATTGTTGGTTCATTAGAGCGATTCTCCATGACCCAAAATGCTGTGCTTATGTCA	19122
125_10	19078	CTTACAGCTGTTAAAAAGCTTAYTGGCATAAAGTTAACTTATGGTTATCTTAATGGTGTC	19137
US_Col	19123	CTTACAGCTGTTAAAAAGCTTACTGGCATAAAGTTAACTTATGGTTATCTTAATGGTGTC	19182
125_10	19138	CCAGTTAACACACATGAAGATAAACCTTTTACTTGGTATATTTACACTAGGAAGAACGGC	19197
US_Col	19183	CCAGTTAACACACATGAAGATAAACCTTTTACTTGGTATATTTACACTAGGAAGAACGGC	16642
125_10	19198	AAGTTCGAGGACCATCCTGATGGCTATTTTACCCAAGGTAGAACAAACCGCTGATTTTAGC	16657
US_Col	16643	AAGTTCGAGGACCATCCTGATGGCTATTTTACCCAAGGTAGAACAAACCGCTGATTTTAGC	19302
125_10	16658	CCTCGTAGCGACATGGAAAAGGACTTCCTAAGTATGGATATGGGTCTGTTTATTAACAAG	19317
US_Col	19303	CCTCGTAGCGACATGGAAAAGGACTTCCTAAGTATGGATATGGGTCTGTTTATTAACAAG	19362
125_10	19318	TACGGACTTGAAGATTACGGCTTTGAGCACGTTGTGTATGGTGATGTTTCAAAAACCAAC	19377
US_Col	19363	TACGGACTTGAAGATTACGGCTTTGAGCACGTTGTGTATGGTGATGTTTCAAAAACCAAC	19422
125_10	19378	CTTGGTGGTTTGCATCTACTAATTTTCGCAGGTGCGTCTGGCCTGTATGGGTGTGCTCAA	19437
US_Col	19423	CTTGGTGGTTTGCATCTACTAATTTTCGCAGGTGCGTCTGGCCTGTATGGGTGTGCTCAA	19482
125_10	19438	ATAGACGAGTTTGTGTCTAGTAATGATAGCACGTTAAAGTCTTGTAAGTTACATATGCT	19497
US_Col	19483	ATAGACGAGTTTGTGTCTAGTAATGATAGCACGTTAAAGTCTTGTAAGTTACATATGCT	19542

53/66

FIG. 2 (cont'd)

125_10	19498	GATAACCCTAGTAGTAAGATGGTTTGTACGTATATGGATCTCCTGCTTGACGATTTTGTC	19557
US_Col	19543	GATAACCCTAGTAGTAAGATGGTTTGTACGTATATGGATCTCCTGCTTGACGATTTTGTC	19602
125_10	19558	AGCATTCTTAAATCTTTGGATTTGGGCGTTGTATCTAAAGTTCATGAAGTTATGGTCGAT	19617
US_Col	19603	AGCATTCTTAAATCTTTGGATTTGGGCGTTGTATCTAAAGTTCATGAAGTTATGGTCGAT	19662
125_10	19618	TGTAAATGTGGAGGTGGATGTTGTGGTGTAAGGATCATAAACTCCAGACATTTTATCCG	19677
US_Col	19663	TGTAAATGTGGAGGTGGATGTTGTGGTGTAAGGATCATAAACTCCAGACATTTTATCCG	19722
125_10	19678	CAACTTCAGGCCAGTGAATGGAAGTGTGGTTATTCCATGCCTTCTATTTACAAGATACAA	19737
US_Col	19723	CAACTTCAGGCCAGTGAATGGAAGTGTGGTTATTCCATGCCTTCTATTTACAAGATACAA	19782
125_10	19738	CGTATGTGTTTAGAACCTTGCAATCTCTACAACATGGTGCTGGTATTAAGTTACCTGAT	19797
US_Col	19783	CGTATGTGTTTAGAACCTTGCAATCTCTACAACATGGTGCTGGTATTAAGTTACCTGAT	19842
125_10	19798	GGCATTATGTTTAAACGTAGTTAAATACACACAGCTTTGTCAATATCTCAATAGCACCACA	19857
US_Col	19843	GGCATTATGTTTAAACGTAGTTAAATACACACAGCTTTGTCAATATCTCAATAGCACCACA	19902
125_10	19858	ATGTGTGTACCCCATCACATGCGTGTGCTACATCTTGGTGCTGGCTCCGACAAGGGTGTT	19917
US_Col	19903	ATGTGTGTACCCCATCACATGCGTGTGCTACATCTTGGTGCTGGCTCCGACAAGGGTGTT	19962
125_10	19918	GCACCTGGCACGGCTGTCTTACGACGTTGGTTGCCACTGGATGCCATTATAGTTGACAAT	19977
US_Col	19963	GCACCTGGCACGGCTGTCTTACGACGTTGGTTGCCACTGGATGCCATTATAGTTGACAAT	20022
125_10	19978	GATAGTGTGGATTACGTTAGCGATGCTGATTATAGTGTTACAGGAGATTGCTCTACCTTA	20037
US_Col	20023	GATAGTGTGGATTACGTTAGCGATGCTGATTATAGTGTTACAGGAGATTGCTCTACCTTA	20082
125_10	20038	TACCTGTCAGATAAGTTTGATTTAGTTATATCTGATATGTATGATGGTAAGATTAAAAGT	20097
US_Col	20083	TACCTGTCAGATAAGTTTGATTTAGTTATATCTGATATGTATGATGGTAAGATTAAAAGT	20142
125_10	20098	TGTGATGGGGAGAACGTGTCTAAAGAAGGCTTCTTTCCCTATATTAATGGTGTCATCACC	20157
US_Col	20143	TGTGATGGGGAGAACGTGTCTAAAGAAGGCTTCTTTCCCTATATTAATGGTGTCATCACC	20202
125_10	20158	GAAAAGTTGGCACTTGGTGGTACTGTAGCTATTAAGGTGACGGAGTTTAGTTGGAATAAG	20217
US_Col	20203	GAAAAGTTGGCACTTGGTGGTACTGTAGCTATTAAGGTGACGGAGTTTAGTTGGAATAAG	20262
125_10	20218	AAGTTGTATGAACTCATTGAGAGGTTTGAGTATTGGACAATGTTCTGTACCAGTGTTAAC	20277
US_Col	20263	AAGTTGTATGAACTCATTGAGAGGTTTGAGTATTGGACAATGTTCTGTACCAGTGTTAAC	20322
125_10	20278	ACGTCATCGTCAGAGGCATTCTTAATTGGTGTTCACTATTTAGGTGATTTTGCAAGTGGC	20337
US_Col	20323	ACGTCATCGTCAGAGGCATTCTTAATTGGTGTTCACTATTTAGGTGATTTTGCAAGTGGC	20382
125_10	20338	GCTGTGATTGACGGCAACACTATGCATGCCAATTATATCTTCTGGCGTAATTCCACAATT	20397
US_Col	20383	GCTGTGATTGACGGCAACACTATGCATGCCAATTATATCTTCTGGCGTAATTCCACAATT	20442

54/66

FIG. 2 (cont'd)

125_10	20398	ATGACTATGTCTTACAATAGTGTACTTGATTTAAGCAAGTTCAATTGTAAGCATAAGGCT	20457
US_Col	20443	ATGACTATGTCTTACAATAGTGTACTTGATTTAAGCAAGTTCAATTGTAAGCATAAGGCT	20502
125_10	20458	ACAGTTGTCATTAATTTAAAAGATTCATCCATTAGTGATGTTGTGTTAGGTTTGTGAAG	20517
US_Col	20503	ACAGTTGTCATTAATTTAAAAGATTCATCCATTAGTGATGTTGTGTTAGGTTTGTGAAG	20562
125_10	20518	AATGGTAAGTTGCTAGTGCGTAATAATGACGCCATTTGTGGTTTTCTAATCATTTGGTC	20577
US_Col	20563	AATGGTAAGTTGCTAGTGCGTAATAATGACGCCATTTGTGGTTTTCTAATCATTTGGTC	20622
125_10	20578	AACGTAAACAAATGAAGTCTTTAACCTACTTCTGGTTGTTCTTACCAGTACTTTCAACAC	20637
US_Col	20623	AACGTAAACAAATGAAGTCTTTAACCTACTTCTGGTTGTTCTTACCAGTACTTTCAACAC	20682
125_10	20638	TTAGCCTACCACAAGATGTCACCAGGTGCTCAGCTAACACTAATTTTAGGCGGTTCTTTT	20697
US_Col	20683	TTAGCCTACCACAAGATGTCACCAGGTGCTCAGCTAACACTAATTTTAGGCGGTTCTTTT	20742
125_10	20698	CAAAATTTAATGTTTCAGGCGCCTGCAGTTGTTGTACTGGGCGGTTATCTACCTATTGGTG	20757
US_Col	20743	CAAAATTTAATGTTTCAGGCGCCTGCAGTTGTTGTACTGGGCGGTTATCTACCTATTGGTG	20802
125_10	20758	AAAACCAGGGTGTCAATTCAACTTGGTACTGTGCTGGCCAACATCCAAGTCTAGTGGCG	20817
US_Col	20803	AAAACCAGGGTGTCAATTCAACTTGGTACTGTGCTGGCCAACATCCAAGTCTAGTGGCG	20862
125_10	20818	TTCATGGTATCTTTGTTAGCCATATTAGAGGTGGTCATGGCTTTGAGATTGGCATTTCGC	20877
US_Col	20863	TTCATGGTATCTTTGTTAGCCATATTAGAGGTGGTCATGGCTTTGAGATTGGCATTTCGC	20662
125_10	20878	AAGAGCCTTTTGACCCTAGTGGTTACCAGCTTTATTTACATAAGGCTACTAACGGTAACA	20937
US_Col	20663	AAGAGCCTTTTGACCCTAGTGGTTACCAGCTTTATTTACATAAGGCTACTAACGGTAACA	20982
125_10	20938	CTAATGCTACTGCGCGACTGCGCATTTGCCAGTTTCCTAGCATTAACAAACATTGGGCCCCA	20997
US_Col	20983	CTAATGCTACTGCGCGACTGCGCATTTGCCAGTTTCCTAGCATTAACAAACATTGGGCCCCA	2662
125_10	20998	CTGCTAATAATGATGTTACAATAGGTCGTAATTGCCTATTTAACAAAGCCATCCCAGCTC	21057
US_Col	2663	CTGCTAATAATGATGTTACAACAGGTCGTAATTGCCTATTTAACAAAGCCATCCCAGCTC	21102
125_10	21058	ATATGAGTGAACATAGTGTTGTGCGCATAACATGGGATAATGATCGTGCTCACTGTCTTTT	21117
US_Col	21103	ATATGAGTGAACATAGTGTTGTGCGCATAACATGGGATAATGATCGTGCTCACTGTCTTTT	21162
125_10	21118	CTGACAAGATCTATTATTTTTATTTTAAAAATGATTGGTCCCGTGTGCGACAAAGTGTT	21177
US_Col	21163	CTGACAAGATCTATTATTTTTATTTTAAAAATGATTGGTCCCGTGTGCGACAAAGTGTT	21222
125_10	21178	ACAACAGTGGAGGTTGTGCTATGCAATATGTTTACGAACCCACCTATTACATGCTTAATG	21237
US_Col	21223	ACAACAGTGGAGGTTGTGCTATGCAATATGTTTACGAACCCACCTATTACATGCTTAATG	21282
125_10	21238	TTACTAGTGCTGGTGAGGATGGTATTTCTTATCAACCCTGTACAGCTAATTGCATTGGTT	21297
US_Col	21283	TTACTAGTGCTGGTGAGGATGGTATTTCTTATCAACCCTGTACAGCTAATTGCATTGGTT	21342
125_10	21298	ATGCTGCCAATGTATTTGCTACTGAGCCCAATGGCCACATACCAGAAGGTTTTAGTTTTA	21357
US_Col	21343	ATGCTGCCAATGTATTTGCTACTGAGCCCAATGGCCACATACCAGAAGGTTTTAGTTTTA	21402

55/66

FIG. 2 (cont'd)

125_10	21358	ATAATTGGTTTCTTTTGTCCAATGATTCCACTTTGGTGCATGGTAAGGTGGTTTCCAACC	21417
US_Col	21403	ATAATTGGTTTCTTTTGTCCAATGATTCCACTTTGGTGCATGGTAAGGTGGTTTCCAACC	21462
125_10	21418	AACCATTGTTGGTCAATTGTCTTTTGGCCATTCTAAGATTTATGGACTAGGCCAATTTT	21477
US_Col	21463	AACCATTGTTGGTCAATTGTCTTTTGGCCATTCTAAGATTTATGGACTAGGCCAATTTT	21522
125_10	21478	TCTCCTTTAATCAAACGATCGATGGTGTGTAATGGAGCTGCTGTGCAGCGTGACACCAG	21537
US_Col	21523	TCTCCTTTAATCAAACGATCGATGGTGTGTAATGGAGCTGCTGTGCAGCGTGACACCAG	21582
125_10	21538	AGGCTCTGAGGTTTAATATTAATGACACCTCTGTCAATTCTTGCTGAAGGCTCAATTGTAC	21597
US_Col	21583	AGGCTCTGAGGTTTAATATTAATGACACCTCTGTCAATTCTTGCTGAAGGCTCAATTGTAC	21642
125_10	21598	TTCATACTGCTTTAGGAACAAATTTTCTTTTGTGTCAGTAATCCCCAAATCCTCACT	21657
US_Col	21643	TTCATACTGCTTTAGGAACAAATTTTCTTTTGTGTCAGTAATCCTCAAATCCTCACT	21702
125_10	21658	TAGCCACCTTCGCCATACCTCTGGGTGCTACCCAAGTACCTTATTATTGTTTTCTTAAAG	21717
US_Col	21703	TAGCCACCTTCGCCATACCTCTGGGTGCTACCCAAGTACCTTATTATTGTTTTCTTAAAG	21762
125_10	21718	TGGATACTTACAACCTCACTGTTTATAAATTTTGGCTGTTTTACCTCCTACCGTCAGGG	21777
US_Col	21763	TGGATACTTACAACCTCACTGTTTATAAATTTTGGCTGTTTTACCTCCTACCGTCAGGG	21822
125_10	21778	AAATTGTCATCACCAAGTATGGTGATGTTTATGTCAATGGGTTTGGATACTTGCACTCTCG	21837
US_Col	21823	AAATTGTCATCACCAAGTATGGTGATGTTTATGTCAATGGGTTTGGATACTTGCACTCTCG	21882
125_10	21838	GTTTGTGGATGCTGTGACAATTAATTTCACTGGTCATGGCACTGACGATGATGTTTCTG	21897
US_Col	21883	GTTTGTGGATGCTGTGACAATTAATTTCACTGGTCATGGCACTGACGATGATGTTTCTG	21942
125_10	21898	GTTTTTGGACCATAGCATCGACTAATTTTGTGATGCACTCATCGAAGTTCAAGGAACCG	21957
US_Col	21943	GTTTTTGGACCATAGCATCGACTAATTTTGTGATGCACTCATCGAAGTTCAAGGAACCG	22002
125_10	21958	CCATTGAGCGTATTCTTTATTGTGATGATCCTGTTAGCCAACCTCAAGTGTCTCAGGTTG	22017
US_Col	22003	CCATTGAGCGTATTCTTTATTGTGATGATCCTGTTAGCCAACCTCAAGTGTCTCAGGTTG	22062
125_10	22018	CTTTTGACCTTGACGATGGTTTTTACCCTATTTCTTCTAGAAACCTTCTGAGTCATGAAC	22077
US_Col	22063	CTTTTGACCTTGACGATGGTTTTTACCCTATTTCTTCTAGAAACCTTCTGAGTCATGAAC	22122
125_10	22078	AGCCAATTTCTTTTGTACTCTGCCATCATTTAATGATCATTCTTTTGTAACTTACTG	22137
US_Col	22123	AGCCAATTTCTTTTGTACTCTGCCATCATTTAATGATCATTCTTTTGTAACTTACTG	22182
125_10	22138	TATCTGCTTCCTTTGGTGGTCATAGTGGTGCCAACCTTATTGCATCTGACACTACTATCA	22197
US_Col	22183	TATCTGCTTCCTTTGGTGGTCATAGTGGTGCCAACCTTATTGCATCTGACACTACTATCA	22242
125_10	22198	ATGGGTTTAGTTCTTTCTGTGTTGACACTAGACAATTTACCATTTCACTGTTTTATAACG	22257
US_Col	22243	ATGGGTTTAGTTCTTTCTGTGTTGACACTAGACAATTTACCATTTCACTGTTTTATAACG	22302

56/66

FIG. 2 (cont'd)

125_10	22258	TTACAAACAGTTATGGTTATGTGTCTAAATCACAGGACAGTAATTGCCCTTTCACCTTGC	22317
US_Col	22303	TTACAAACAGTTATGGTTATGTGTCTAAATCACAGGACAGTAATTGCCCTTTCACCTTGC	22362
125_10	22318	AATCTGTTAATGATTACCTGTCTTTTAGCAAATTTTGTGTTTCCACCAGCCTTTTGGCTA	22377
US_Col	22363	AATCTGTTAATGATTACCTGTCTTTTAGCAAATTTTGTGTTTCCACCAGCCTTTTGGCTA	22422
125_10	22378	GTGCCTGTACCATAGATCTTTTTGGTTACCCTGAGTTTGGTAGTGGTGTAAAGTTTACGT	22437
US_Col	22423	GTGCCTGTACCATAGATCTTTTTGGTTACCCTGAGTTTGGTAGTGGTGTAAAGTTTACGT	22482
125_10	22438	CCCTTTACTTTCAATTCACAAAGGGTGAGTTGATTACTGGCACGACTAAACCACTTGAAG	22497
US_Col	22483	CCCTTTACTTTCAATTCACAAAGGGTGAGTTGATTACTGGCACGCCTAAACCACTTGAAG	22542
125_10	22498	GTGTCACGGACGTTTCTTTTATGACTCTGGATGTGTGTACCAAGTATACTATCTATGGCT	22557
US_Col	22543	GTGTCACGGACGTTTCTTTTATGACTCTGGATGTGTGTACCAAGTATACTATCTATGGCT	22602
125_10	22558	TTAAAGGTGAGGGTATCATTACCCTTACAAATTCTAGCTTTTTGGCAGGTGTTTATTACA	22617
US_Col	22603	TTAAAGGTGAGGGTATCATTACCCTTACAAATTCTAGCTTTTTGGCAGGTGTTTATTACA	22662
125_10	22618	CATCTGTTTCTGGACAGTTGTTAGCCTTTAAGAATGTCACTAGTGGTGCTGTTTATTCTG	22677
US_Col	22663	CATCTGATTCTGGACAGTTGTTAGCCTTTAAGAATGTCACTAGTGGTGCTGTTTATTCTG	22722
125_10	22678	TTACGCCATGTTCTTTTTCAGAGCAGGCTGCATATGTTGATGATGATATAGTGGGTGTTA	22737
US_Col	22723	TTACGCCATGTTCTTTTTCAGAGCAGGCTGCATATGTTGATGATGATATAGTGGGTGTTA	22782
125_10	22738	TTTCTAGTTTGTCTAGCTCCACTTTTAACAGTACTAGGGAGTTGCCTGGTTTCTTCTACC	22797
US_Col	22783	TTTCTAGTTTGTCTAGCTCCACTTTTAACAGTACTAGGGAGTTGCCTGGTTTCTTCTACC	22842
125_10	22798	ATTCTAATGATGGCTCTAATTGTACAGAGCCTGTGTTGGTGTATAGTAACATAGGTGTTT	22857
US_Col	22843	ATTCTAATGATGGCTCTAATTGTACAGAGCCTGTGTTGGTGTATAGTAACATAGGTGTTT	22902
125_10	22858	GTAAATCTGGCAGTATTGGCTACGTCCCATCTCAGTCTGGCCAAGTCAAGATTGCACCCA	22917
US_Col	22903	GTAAATCTGGCAGTATTGGCTACGTCCCATCTCAGTCTGGCCAAGTCAAGATTGCACCCA	22962
125_10	22918	CGGTTACTGGGAATATTAGTATTCCCACCAACTTTAGTATGAGTATTAGGACAGAATATT	22977
US_Col	22963	CGGTTACTGGGAATATTAGTATTCCCACCAACTTTAGTATGAGTATTAGGACAGAATATT	23022
125_10	22978	TACAGCTTTACAACACGCCTGTTAGTGTTGATTGTGCCACATATGTTTGTAAATGGTAACT	23037
US_Col	23023	TACAGCTTTACAACACGCCTGTTAGTGTTGATTGTGCCACATATGTTTGTAAATGGTAACT	23082
125_10	23038	CTCGTTGTAAACAATTACTCACCCAGTACACTGCAGCATGTAAGACCATAGAGTCAGCAT	23097
US_Col	23083	CTCGTTGTAAACAATTACTCACCCAGTACACTGCAGCATGTAAGACCATAGAGTCAGCAT	23142
125_10	23098	TACGACTCAGCGCTAGGCTTGAGTCTGTTGAAGTTAACTCTATGCTTACTATTTCTGAAG	23157
US_Col	23143	TACAACTCAGCGCTAGGCTTGAGTCTGTTGAAGTTAACTCTATGCTTACTATTTCTGAAG	23202
125_10	23158	AGGCTCTACAGTTAGCTACCATTAGTTCGTTTAAATGGTGATGGATATAATTTTACTAATG	23217
US_Col	23203	AGGCTCTACAGTTAGCTACCATTAGTTCGTTTAAATGGTGATGGATATAATTTTACTAATG	23262

57/66

FIG. 2 (cont'd)

125_10	23218	TGCTGGGTGTTTCTGTGTATGATCCTGCAAGGGGCAGGGTGGTACAAAAAAGGTCTTTTA	23277
US_Col	23263	TGCTGGGTGTTTCTGTGTATGATCCTGCAAGTGGCAGGGTGGTACAAAAAAGGTCTTTTA	23322
125_10	23278	TTGAAGACCTGCTTTTTAATAAAGTGGTTACTAATGGCCTTGGTACTGTTGATGAAGACT	23337
US_Col	23323	TTGAAGACCTGCTTTTTAATAAAGTGGTTACTAATGGCCTTGGTACTGTTGATGAAGACT	23382
125_10	23338	ATAAGCGCTGTTCTAATGGTCGCTCTGTGGCAGATCTAGTCTGTGCACAGTATTACTCTG	23397
US_Col	23383	ATAAGCGCTGTTCTAATGGTCGCTCTGTGGCAGATCTAGTCTGTGCACAGTATTACTCTG	23442
125_10	23398	GTGTCATGGTACTACCTGGTGTTGTTGACGCTGAGAAGCTTCACATGTATAGTGCCTCTC	23457
US_Col	23443	GTGTCATGGTACTACCTGGTGTTGTTGACGCTGAGAAGCTTCACATGTATAGTGCCTCTC	23502
125_10	23458	TCATCGGTGGTATGGTGCTAGGAGGTTTTACTTCTGCAGCGGCATTGCCTTTTAGCTATG	23517
US_Col	23503	TCATCGGTGGTATGGTGCTAGGAGGTTTTACTTCTGCAGCGGCATTGCCTTTTAGCTATG	23562
125_10	23518	CTGTTCAAGCTAGACTCAATTATCTTGCTCTACAGACGGATGTTCTACAGCGGAACCAGC	23577
US_Col	23563	CTGTTCAAGCTAGACTCAATTATCTTGCTCTACAGACGGATGTTCTACAGCGGAACCAGC	23622
125_10	23578	AATTGCTTGCTGAGTCTTTTAACTCTGCTATTGGTAATATAACTTCAGCCTTTGAGAGTG	23637
US_Col	23623	AATTGCTTGCTGAGTCTTTTAACTCTGCTATTGGTAATATAACTTCAGCCTTTGAGAGTG	23682
125_10	23638	TTAAAGAGGCTATTAGTCAAACCTTCCAAGGGTTTGAACACTGTGGCTCATGCGCTTACTA	23697
US_Col	23683	TTAAAGAGGCTATTAGTCAAACCTTCCAAGGGTTTGAACACTGTGGCTCATGCGCTTACTA	23742
125_10	23698	AGGTTCAAGAGGTTGTAACTCGCAGGGTGCAGCTTTGACTCAACTTACCGTACAGCTGC	23757
US_Col	23743	AGGTTCAAGAGGTTGTAACTCGCAGGGTGCAGCTTTGACTCAACTTACCGTACAGCTGC	23802
125_10	23758	AACACAACCTTCCAAGCCATTTCTAGTTCTATTGATGACATTTACTCTCGACTGGACATTC	23817
US_Col	23803	AACACAACCTTCCAAGCCATTTCTAGTTCTATTGATGACATTTACTCTCGACTGGACATTC	23862
125_10	23818	TTTCAGCCGATGTTTCAGGTTGACCGTCTCATCACCGGCAGATTATCAGCACTTAATGCTT	23877
US_Col	23863	TTTCAGCCGATGTTTCAGGTTGACCGTCTCATCACCGGCAGATTATCAGCACTTAATGCTT	23662
125_10	23878	TTGTTGCTCAAACCCTCACTAAGTATACTGAGGTTTCAAGGCTAGCAGGAAGTTAGCACAGC	23937
US_Col	23663	TTGTTGCTCAAACCCTCACTAAGTATACTGAGGTTTCAAGGCTAGCAGGAAGTTAGCACAGC	23982
125_10	23938	AAAAGGTTAATGAGTGC GTTAAATCGCAATCCAGCGTTATGGTTTTTGTGGTGGTGATG	23997
US_Col	23983	AAAAGGTTAATGAGTGC GTTAAATCGCAATCTCAGCGTTATGGTTTTTGTGGTGGTGATG	24042
125_10	23998	GCGAGCACATTTTCTCTCTGGTACAGGCAGCACCTCAGGGCTGCTGTTTTTACATACAG	24057
US_Col	24043	GCGAGCACATTTTCTCTCTGGTACAGGCAGCACCTCAGGGCTGCTGTTTTTACATACAG	24102
125_10	24058	TACTTGTACCGAGTGATTTTGTAGATGTTATTGCCATCGCTGGCTTATGCGTTAACGATG	24117
US_Col	24103	TACTTGTACCGAGTGATTTTGTAGATGTTATTGCCATCGCTGGCTTATGCGTTAACGATG	24162
125_10	24118	AAATTGCCTTGACTCTACGTGAGCCTGGCTTAGTCTTGTTTACGCATGAACTTCAAAATC	24177
US_Col	24163	AAATTGCCTTGACTCTACGTGAGCCTGGCTTAGTCTTGTTTACGCATGAACTTCAAAATC	24222

58/66

FIG. 2 (cont'd)

125_10	24178	ATACTGCGACGGAATATTTTGTTCATCGCGACGTATGTTTGAACCTAGAAAACCTACCG	24237
US_Col	24223	ATACTGCGACGGAATATTTTGTTCATCGCGACGTATGTTTGAACCTAGAAAACCTACCG	24282
125_10	24238	TTAGTGATTTTGTTCAAATTGAGAGTTGTGTGGTCACCTATGTCAATTTGACTAGAGACC	24297
US_Col	24283	TTAGTGATTTTGTTCAAATTGAGAGTTGTGTGGTCACCTATGTCAATTTGACTAGAGACC	24342
125_10	24298	AACTACCAGATGTAATCCCAGATTACATCGATGTTAACAAAACACTTGATGAGATTTTAG	24357
US_Col	24343	AACTACCAGATGTAATCCCAGATTACATCGATGTTAACAAAACACTTGATGAGATTTTAG	24402
125_10	24358	CTTCTCTGCCCAATAGAACTGGTCCAAGTCTTCCTTTAGATGTTTTTAATGCCACTTATC	24417
US_Col	24403	CTTCTCTGCCCAATAGAACTGGTCCAAGTCTTCCTTTAGATGTTTTTAATGCCACTTATC	24462
125_10	24418	TTAATCTCACTGGTGAAATTGCAGATTTAGAGCAGCGTTCAGAGTCTCTCCGTAATACTA	24477
US_Col	24463	TTAATCTCACTGGTGAAATTGCAGATTTAGAGCAGCGTTCAGAGTCTCTCCGTAATACTA	24522
125_10	24478	CAGAGGAGCTCCAAAGTCTTATATATAATATCAACAACACACTAGTTGACCTTGAGTGGC	24537
US_Col	24523	CAGAGGAGCTCCAAAGTCTTATATATAATATCAACAACACACTAGTTGACCTTGAGTGGC	24582
125_10	24538	TCAACCGAGTTGAGACATATATCAAGTGGCCGTGGTGGGTTTGGTTGATTATTTTCATTG	24597
US_Col	24583	TCAACCGAGTTGAGACATATATCAAGTGGCCGTGGTGGGTTTGGTTGATTATTTTCATTG	24642
125_10	24598	TTCTCATCTTTGTTGTGTCATTACTAGTGTTCTGCTGCATTTCCACGGGTTGTTGTGGAT	24657
US_Col	24643	TTCTCATCTTTGTTGTGTCATTACTAGTGTTCTGCTGCATTTCCACGGGTTGTTGTGGAT	24702
125_10	24658	GCTGCGGCTGCTGCTGTGCTTGTCTCAGGTTGTTGTAGGGGTCCTAGACTTCAACCTT	24717
US_Col	24703	GCTGCGGCTGCTGCTGTGCTTGTCTCAGGTTGTTGTAGGGGTCCTAGACTTCAACCTT	24762
125_10	24718	ACGAAGTTTTTGAAAAGGTCCACGTGCAGTGATGTTTCTTGGACTTTTTCAATACACGAT	24777
US_Col	24763	ACGAAGTTTTTGAAAAGGTCCACGTGCAGTGATGTTTCTTGGACTTTTTCAATACACGAT	24822
125_10	24778	TGACACAGTTGTCAAAGATGTCTCAAAGTCTGCTAACTTGCTTTGGATGCTGTCCAAGA	24837
US_Col	24823	TGACACAGTTGTCAAAGATGTCTCAAAGTCTGCTAACTTGCTTTGGATGCTGTCCAAGA	24882
125_10	24838	GTTGGAGCTCAATGTAGTTCCAATTAGACAAGCTTCAAATGTGACGGGTTTTCTTTTCAC	24897
US_Col	24883	GTTGGAGCTCAATGTAGTTCCAATTAGACAAGCTTCAAATGTGACGGGTTTTCTTTTCAC	24942
125_10	24898	CAGTGTTTTTATCTACTTCTTTGCACTGTTTAAAGCGTCTTCTTTGAGGCGCAATTATAT	24957
US_Col	24943	CAGTGTTTTTATCTACTTCTTTGCACTGTTTAAAGCGTCTTCTTTGAGGCGCAATTATAT	25002
125_10	24958	TATGTTGGCAGCGCGTTTTGCTGTGCTTGTCTTTATTGCCCCACTTTTATATTATTGTGG	25017
US_Col	25003	TATGTTGGCAGCGCGTTTTGCTGTGCTTGTCTTTATTGCCCCACTTTTATATTATTGTGG	25062
125_10	25018	TGCATTTTTAGATGCAACTATTATTTGTTGCACACTTATTCAAAGTCGGTGCGCAGGCTTT	25077
US_Col	25063	TGCATTTTTAGATGCAACTATTATTTGTTGCACACTTAT-----TGGCAGGCTTT	25112

59/66

FIG. 2 (cont'd)

125_10	25078	GTTTAGTCTGCTTTTACTCCTGGCGCTATAAAAATGCGCTCTTTATTATTTTAACTA	25137
US_Col	25113	GTTTAGTCTGCTTTTACTCCTGGCGCTATAAAAATGCGCTCTTTATTATTTTAACTA	25172
125_10	25138	CGACACTTTCTTTCCTCAATGGTAAAGCAGCTTATTATGACGGCAAATCCATTGTGATTT	25197
US_Col	25173	CGACACTTTCTTTCCTCAATGGTAAAGCAGCTTATTATGACGGCAAATCCATTGTGATTT	25232
125_10	25198	TAGAAGGTGGTGACCATTACATCACTTTTGGCAACTCTTTTGTTGCTTTTGTAGTAGCA	25257
US_Col	25233	TAGAAGGTGGTGACCATTACATCACTTTTGGCAACTCTCTTGTTGCTTTTGTAGTAGCA	25266
125_10	25258	TCGACTTGTATCTAGCTATACGTGGGCGGCAAGAAGCTGACCTACAGCTGTTGCGAACTG	25317
US_Col	25293	TCGACTTGTATCTAGCTATACGTGGGCGGCAAGAAGCTGACCTACAGCTGTTGCGAACTG	25352
125_10	25318	TTGAGCTTCTTGATGGCAAGAAGCTTTATGTCTTTTCGCAACATCAAATTGTTGGCATT	25377
US_Col	25353	TTGAGCTTCTTGATGGCAAGAAGCTTTATGTCTTTTCGCAACATCAAATTGTTGGCATT	25412
125_10	25378	CTAATGCTGCATTTGACTCAATTCAACTAGACGAGTATGCTACAATTAGTGAATGATAAT	25437
US_Col	25413	CTAATGCTGCATTTGACTCAATTCAACTAGACGAGTATGCTACAATTAGTGAATGATAAT	25472
125_10	25438	GGTCTAGTAGTTAATGTTATACTTTGGCTTTTCGTA CTCTTTTCCTGCTTATTATAAGC	25497
US_Col	25473	GGTCTAGTAGTTAATGTTATACTTTGGCTTTTCGTA CTCTTTTCCTGCTTATTATAAGC	25532
125_10	25498	ATTACTTTCGTCCAATTGGTTAATCTGTGCTTCAC TTGTCACCGTTGTGTAATAGCGCA	25557
US_Col	25533	ATTACTTTCGTCCAATTGGTTAATCTGTGCTTCAC TTGTCACCGTTGTGTAATAGCGCA	25566
125_10	25558	GTTTACACACCTATAGGGCGTTTGTATAGAGTTTATAAGTCTTACATGCAAATAGACCCC	25617
US_Col	25593	GTTTACACACCTATAGGGCGTTTGTATAGAGTTTATAAGTCTTACATGCAAATAGACCCC	25652
125_10	25618	CTCCCTAGTACTGTTATTGACGTATAAACGAAATATGTCTAACGGTTCTATTCCCGTTGA	25677
US_Col	25653	CTCCCTAGTACTGTTATTGACGTATAAACGAAATATGTCTAACGGTTCTATTCCCGTTGA	25712
125_10	25678	TGAGGTGATTCAACACCTTAGAACTGGAATTTACATGGAATATCATACTGACGATACT	25737
US_Col	25713	TGAGGTGATTCAACACCTTAGAACTGGAATTTACATGGAATATCATACTGACGATACT	25772
125_10	25738	ACTTG TAGTGCTTCAGTATGGCCATTACAAGTACTCTGCGTTCTTGTATGGTGTCAAGAT	25797
US_Col	25773	ACTTG TAGTGCTTCAGTATGGCCATTACAAGTACTCTGCGTTCTTGTATGGTGTCAAGAT	25832
125_10	25798	GGCTATTCTATGGATACTTTGGCCTCTTGTGTTAGCACTGTCACTTTTTGATGCATGGGC	25857
US_Col	25833	GGCTATTCTATGGATACTTTGGCCTCTTGTGTTAGCACTGTCACTTTTTGATGCATGGGC	25866
125_10	25858	TAGCTTTCAGGTCAATTGGGTCTTTTTTGCTTTCAGCATCCTTATGGCTTGCATCACTCT	25917
US_Col	25893	TAGCTTTCAGGTCAATTGGGTCTTTTTTGCTTTCAGCATCCTTATGGCTTGCATCACTCT	25952
125_10	25918	TATGCTGTGGATAATGTACTTTGTCAATAGCATT CGGTTGTGGCGCAGGACACATTCTTG	25977
US_Col	25953	TATGCTGTGGATAATGTACTTTGTCAATAGCATT CGGTTGTGGCGCAGGACACATTCTTG	26012
125_10	25978	GTGGTCTTTC AATCCTGAAACAGACGCGCTTCTCACTACTTCTGTGATGGGCCGACAGGT	26037
US_Col	26013	GTGGTCTTTC AATCCTGAAACAGACGCGCTTCTCACTACTTCTGTGATGGGCCGACAGGT	26072

60/66

FIG. 2 (cont'd)

125_10	26038	CTGCATTCCAGTGCTTGGAGCACCAACTGGTGTAACGCTAACACTCCTTAGTGGTACATT	26097
US_Col	26073	CTGCATTCCAGTGCTTGGAGCACCAACTGGTGTAACGCTAACACTCCTTAGTGGTACATT	26132
125_10	26098	GCTTGTAGAGGGCTATAAGGTTGCTACTGGCGTACAGGTAAGTCAATTACCTAATTTTCGT	26157
US_Col	26133	GCTTGTAGAGGGCTATAAGGTTGCTACTGGCGTACAGGTAAGTCAATTACCTAATTTTCGT	26166
125_10	26158	CACAGTCGCCAAGGCCACTACAACAATTGTCTACGGACGTGTTGGTCGTTCAAGTCAATGC	26217
US_Col	26193	CACAGTCGCCAAGGCCACTACAACAATTGTCTACGGACGTGTTGGTCGTTCAAGTCAATGC	26252
125_10	26218	TTCATCTGGCACTGGTTGGGCTTTCTATGTCCGGTCCAAACACGGCGACTACTCAGCTGT	26277
US_Col	26253	TTCATCTGGCACTGGTTGGGCTTTCTATGTCCGGTCCAAACACGGCGACTACTCAGCTGT	26312
125_10	26278	GAGTAATCCGAGTTCGGTTCTCACAGATAGTGAGAAAGTGCTTCATTTAGTCTAAACAGA	26337
US_Col	26313	GAGTAATCCGAGTTCGGTTCTCACAGATAGTGAGAAAGTGCTTCATTTAGTCTAAACAGA	26372
125_10	26338	AACTTTATGGCTTCTGTCAAGTTTTCAGGATCGTGGCCGCAAACGGGTGCCATTATCCCTC	26397
US_Col	26373	AACTTTATGGCTTCTGTCAAGTTTTCAGGATCGTGGCCGCAAACGGGTGCCATTATCCCTC	26432
125_10	26398	TATGCCCCCTTAGGGTTACTAATGACAAACCCCTTTCTAAGGTACTTGCAAATAATGCT	26457
US_Col	26433	TATGCCCCCTTAGGGTTACTAATGACAAACCCCTTTCTAAGGTACTTGCAAATAATGCT	26466
125_10	26458	GTACCCACTAATAAAGGAAATAAGGACCAGCAAATTGGATACTGGAATGAGCAAATTCGC	26517
US_Col	26493	GTACCCACTAATAAAGGAAATAAGGACCAGCAAATTGGATACTGGAATGAGCAAATTCGC	26552
125_10	26518	TGGCGCATGCGCCGTGGTGAGCGAATTGAACAACCTTCCAATTGGCATTCTACTACCTC	26577
US_Col	26553	TGGCGCATGCGCCGTGGTGAGCGAATTGAACAACCTTCCAATTGGCATTCTACTACCTC	26612
125_10	26578	GGAACAGGACCTCACGCCGACCTCCGCTATAGGACTCGTACTGAGGGTGTTTTCTGGGTT	26637
US_Col	26613	GGAACAGGACCTCACGCCGACCTCCGCTATAGGACTCGTACTGAGGGTGTTTTCTGGGTT	26672
125_10	26638	GCTAAAGAAGGCGCAAAGACTGAACCCACTAACCTGGGTGTCAGAAAGGCGTCTGAAAAG	26697
US_Col	26673	GCTAAAGAAGGCGCAAAGACTGAACCCACTAACCTGGGTGTCAGAAAGGCGTCTGAAAAG	26732
125_10	26698	CCAATTATTCCAAATTTCTCTCAACAGCTTCCAGCGTAGTTGAGATTGTTGAACCTAAC	26757
US_Col	26733	CCAATTATTCCAAATTTCTCTCAACAGCTTCCAGCGTAGTTGAGATTGTTGAACCTAAC	26766
125_10	26758	ACACCTCCTACTTCACGTGCAAATTCACGTAGCAGGAGTCGTGGTAATGGCAACAACAGG	26817
US_Col	26793	ACACCTCCTACTTCACGTGCAAATTCACGTAGCAGGAGTCGTGGTAATGGCAACAACAGG	26852
125_10	26818	TCCAGATCTCCAAGTAACAACAGAGGCAATAACCAGTCCCGCGGTAATTCACAGAATCGT	26877
US_Col	26853	TCCAGATCTCCAAGTAACAACAGAGGCAATAACCAGTCCCGCGGTAATTCACAGAATCGT	26912
125_10	26878	GGAAATAACCAGGGTCGTGGAGCTTCTCAGAACAGAGGAGGCAATAATAACAATAAC	26937
US_Col	26913	GGAAATAACCAGGGTCGTGGAGCTTCTCAGAACAGAGGAGGCAATAATAACAATAAC	26972

61/66

FIG. 2 (cont'd)

125_10	26938	AAGTCTCGTAACCAGTCCAAGAACAGAAACCAGTCAAATGACCGTGGTGGTGTAAACATCA	26997
US_Col	26973	AAGTCTCGTAACCAGTCCAAGAACAGAAACCAGTCAAATGACCGTGGTGGTGTAAACATCA	27032
125_10	26998	CGCGATGATCTGGTGGCTGCTGTCAAGGATGCCCTTAAATCTTTGGGTATTGGCGAAAAC	27057
US_Col	27033	CGCGATGATCTGGTGGCTGCTGTCAAGGATGCCCTTAAATCTTTGGGTATTGGCGAAAAC	27066
125_10	27058	CCTGACAAGCTTAAGCAACAGCAGAAGCCCAAACAGGAAAGGTCTGACAGCAGCGGCAAA	27117
US_Col	27093	CCTGACAAGCTTAAGCAACAGCAGAAGCCCAAACAGGAAAGGTCTGACAGCAGCGGCAAA	27152
125_10	27118	AATACACCTAAGAAGAACAATCCAGAGCCACTTCGAAAGAACGTGACCTCAAAGACATC	27177
US_Col	27153	AATACACCTAAGAAGAACAATCCAGAGCCACTTCGAAAGAACGTGACCTCAAAGACATC	27212
125_10	27178	CCAGAGTGGAGGAGAATTCCCAAGGGCGAAAATAGCGTAGCAGCTTGCTTCGGACCCAGG	27237
US_Col	27213	CCAGAGTGGAGGAGAATTCCCAAGGGCGAAAATAGCGTAGCAGCTTGCTTCGGACCCAGG	27272
125_10	27238	GGAGGCTTCAAAAATTTTGGAGATGCGGAATTTGTGAAAAAGGTGTTGATGCCTCAGGC	27297
US_Col	27273	GGAGGCTTCAAAAATTTTGGAGATGCGGAATTTGTGAAAAAGGTGTTGATGCCTCAGGC	27332
125_10	27298	TATGCTCAGATCGCCAGTTTAGCACCAAATGTTGCAGCATTGCTCTTTGGTGGTAATGTG	27357
US_Col	27333	TATGCTCAGATCGCCAGTTTAGCACCAAATGTTGCAGCATTGCTCTTTGGTGGTAATGTG	27366
125_10	27358	GCTGTTTCGTGAGCTAGCGGACTCTTACGAGATTACATATAATTATAAAATGACTGTGCCA	27417
US_Col	27393	GCTGTTTCGTGAGCTAGCGGACTCTTACGAGATTACATATAATTATAAAATGACTGTGCCA	27452
125_10	27418	AAGTCTGATCCAAATGTAGAGCTTCTTGTTTACAGGTGGATGCATTTAAAACTGGGAAT	27477
US_Col	27453	AAGTCTGATCCAAATGTAGAGCTTCTTGTTTACAGGTGGATGCATTTAAAACTGGGAAT	27512
125_10	27478	GCAAAACCCAGAGAAAGAAGGAAAAGAAGAAYAAGCGTGAAACCACGCAGCAGCTGAAT	27537
US_Col	27513	GCAAAACCCAGAGAAAGAAGGAAAAGAAGAACAAGCGTGAAACCACGCAGCAGCTGAAT	27572
125_10	27538	GAAGAGGCCATCTACGATGATGTGGGTGTGCCATCTGATGTGACTCATGCCAATTTGGAA	27597
US_Col	27573	GAAGAGGCCATCTACGATGATGTGGGTGTGCCATCTGATGTGACTCATGCCAATTTGGAA	27632
125_10	27598	TGGGACACAGCTGTTGATGGTGGTGACACGGCCGTTGAAATTATCAACGAGATCTTCGAC	27657
US_Col	27633	TGGGACACAGCTGTTGATGGTGGTGACACGGCCGTTGAAATTATCAACGAGATCTTCGAC	27666
125_10	27658	ACAGGAAATTAACAATGTTTGACTGGCTTATCCTGGCTATGTCCCAGGGTAGTGCCATT	27717
US_Col	27693	ACAGGAAATTAACAATGTTTGACTGGCTTATCCTGGCTATGTCCCAGGGTAGTGCCATT	27752
125_10	27718	ACACTGTTATTACTGAGTGTTTTTCTAGCGACTTGGCTGCTGGGCTATGGCTTTGCCCTC	27777
US_Col	27753	ACACTGTTATTACTGAGTGTTTTTCTAGCGACTTGGCTGCTGGGCTATGGCTTTGCCCTC	27812
125_10	27778	TAACTAGCGGTCTTGGTCTTGACACACACGGTAAGCCAGTGGTAATGTCAGTGCAAGAAG	27837
US_Col	27813	TAACTAGCGGTCTTGGTCTTGACACACACGGTAAGCCAGTGGTAATGTCAGTGCAAGAAG	27872

FIG. 2 (cont'd)

125_10	27838	GATATTACCATAGCACTGTCATGAGGGGAACGCAGTACCTTTTCATCTAAACCTTTGCAC	27897
US_Co1	27873	GATATTACCATAGCACTGTCATGAGGGGAACGCAGTACCTTTTCATCTAAACCTTTGCAC	27932
125_10	27898	GAGTAATCAAAGATCCGCTTGACGAGCCTATATGGAAGAGCGTGCCAGGTATTTGACTCA	27957
US_Co1	27933	GAGTAATCAAAGATCCGCTTGACGAGCCTATATGGAAGAGCGTGCCAGGTATTTGACTCA	27966
125_10	27958	AGGACTGTTAGTAACTGAAGACCTGACGGTGTTGATAT	27995
US_Co1	27993	AGGACTGTTAGTAACTGAAGACCTGACGGTGTTGATAT	28030

63/66

FIG. 3

PEDV 1251-125-10 (125-10) spike protein (SEQ ID NO:14) aligned to closest Spike protein amino acid sequence from North American PEDV G2a Colorado strain (GenBank Accession No: AGO58664)(SEQ ID NO:12)

125-10	1	MKSLTYFWLFLPVLSTLSLPQDVTRCSANTNFRRFFSKFNVQAPAVVVLGGYLPIGENQG	180
		MKSLTYFWLFLPVLSTLSLPQDVTRCSANTNFRRFFSKFNVQAPAVVVLGGYLPIGENQG	
US_Co1	1	MKSLTYFWLFLPVLSTLSLPQDVTRCSANTNFRRFFSKFNVQAPAVVVLGGYLPIGENQG	60
125-10	181	VNSTWYCAGQHPTASGVHGFVSHIRGGHGFEIGISQEPFDPSTGYQLYLHKATNGNTNAT	360
		VNSTWYCAGQHPTASGVHGFVSHIRGGHGFEIGISQEPFDPSTGYQLYLHKATNGNTNAT	
US_Co1	61	VNSTWYCAGQHPTASGVHGFVSHIRGGHGFEIGISQEPFDPSTGYQLYLHKATNGNTNAT	120
125-10	361	ARLRICQFPSIKTLGPTANNDVTIGRNCLFNKAIPAHMSEHSVVGITWDNDRVTVFSDKI	540
		ARLRICQFPSIKTLGPTANNDVT GRNCLFNKAIPAHMSEHSVVGITWDNDRVTVFSDKI	
US_Co1	121	ARLRICQFPSIKTLGPTANNDVTTGRNCLFNKAIPAHMSEHSVVGITWDNDRVTVFSDKI	180
125-10	541	YYFYFKNDWSRVATKCYNSGGCAMQYVVEPTYMYMLNVTSAEDGISYQPCTANCIGYAAN	720
		YYFYFKNDWSRVATKCYNSGGCAMQYVVEPTYMYMLNVTSAEDGISYQPCTANCIGYAAN	
US_Co1	181	YYFYFKNDWSRVATKCYNSGGCAMQYVVEPTYMYMLNVTSAEDGISYQPCTANCIGYAAN	240
125-10	721	VFATEPNGHIPEGFSFNNWFLLSNDSTLVHGKVVSNQPLLVCNLLAIPKIYGLGQFFSFN	900
		VFATEPNGHIPEGFSFNNWFLLSNDSTLVHGKVVSNQPLLVCNLLAIPKIYGLGQFFSFN	
US_Co1	241	VFATEPNGHIPEGFSFNNWFLLSNDSTLVHGKVVSNQPLLVCNLLAIPKIYGLGQFFSFN	300
125-10	901	QTIDGVCNGAAVQRAPEALRFNINDTSVILAEGSIVLHTALGTNFSFVCSNSPNPHLATF	1080
		QTIDGVCNGAAVQRAPEALRFNINDTSVILAEGSIVLHTALGTNFSFVCSNS NPHLATF	
US_Co1	301	QTIDGVCNGAAVQRAPEALRFNINDTSVILAEGSIVLHTALGTNFSFVCSNSSNPHLATF	360
125-10	1081	AIPLGATQVPYYCFLKVDTYNSTVYKFLAVLPPTVREIVITKYGDVYVNGFGYLHLGLLD	1260
		AIPLGATQVPYYCFLKVDTYNSTVYKFLAVLPPTVREIVITKYGDVYVNGFGYLHLGLLD	
US_Co1	361	AIPLGATQVPYYCFLKVDTYNSTVYKFLAVLPPTVREIVITKYGDVYVNGFGYLHLGLLD	420
125-10	1261	AVTINFTGHGTDDDVSGFWTIASTNFVDALIEVQGTAIQRILYCDDPVSQLKCSQVAFDL	1440
		AVTINFTGHGTDDDVSGFWTIASTNFVDALIEVQGTAIQRILYCDDPVSQLKCSQVAFDL	
US_Co1	421	AVTINFTGHGTDDDVSGFWTIASTNFVDALIEVQGTAIQRILYCDDPVSQLKCSQVAFDL	480
125-10	1441	DDGFYPISSRNLLSHEQPISFVTLPSTFNDHSFVNITVSASFSGHSGANLIASDTTNGFS	1620
		DDGFYPISSRNLLSHEQPISFVTLPSTFNDHSFVNITVSASFSGHSGANLIASDTTNGFS	
US_Co1	481	DDGFYPISSRNLLSHEQPISFVTLPSTFNDHSFVNITVSASFSGHSGANLIASDTTNGFS	540
125-10	1621	SFCVDTRQFTISLFYNVTNSYGYVSKSQDSNCPFTLQSVNDYLSFSKFCVSTSLLASACT	1800
		SFCVDTRQFTISLFYNVTNSYGYVSKSQDSNCPFTLQSVNDYLSFSKFCVSTSLLASACT	
US_Co1	541	SFCVDTRQFTISLFYNVTNSYGYVSKSQDSNCPFTLQSVNDYLSFSKFCVSTSLLASACT	600
125-10	1801	IDLFGYPEFGSGVKFTSLYFQFTKGELITGTTPLEGVTDVSFMTLDVCTKYTIYGFKE	1980
		IDLFGYPEFGSGVKFTSLYFQFTKGELITGT KLEGVTDVSFMTLDVCTKYTIYGFKE	
US_Co1	601	IDLFGYPEFGSGVKFTSLYFQFTKGELITGTPKLEGVTDVSFMTLDVCTKYTIYGFKE	660
125-10	1981	GIITLTNSSFLAGVYYTSVSGQLLAFKNVTSGAVYSVTPCSFSEQAAYVDDDIVGVISSL	2160
		GIITLTNSSFLAGVYYTS SGQLLAFKNVTSGAVYSVTPCSFSEQAAYVDDDIVGVISSL	
US_Co1	661	GIITLTNSSFLAGVYYTSDSGQLLAFKNVTSGAVYSVTPCSFSEQAAYVDDDIVGVISSL	720

64/66


FIG. 3 (cont'd)

125-10	2161	SSSTFNSTRELPGFFYHSNDGSNCTEPVLVYSNIGVCKSGSIGYVPSQSGQVKIAPTVTG	2340
		SSSTFNSTRELPGFFYHSNDGSNCTEPVLVYSNIGVCKSGSIGYVPSQSGQVKIAPTVTG	
US_Col	721	SSSTFNSTRELPGFFYHSNDGSNCTEPVLVYSNIGVCKSGSIGYVPSQSGQVKIAPTVTG	780
125-10	2341	NISIPTNFSMSIRTEYLQLYNTPVSVDCATYVCNGNSRCKQLLTQYTAACKTIESALXLS	2520
		NISIPTNFSMSIRTEYLQLYNTPVSVDCATYVCNGNSRCKQLLTQYTAACKTIESAL LS	
US_Col	781	NISIPTNFSMSIRTEYLQLYNTPVSVDCATYVCNGNSRCKQLLTQYTAACKTIESALQLS	840
125-10	2521	ARLESVEVNSMLTISEEALQLATISSFNGDGYNFTNVLGVSVDPAARGRVVQKRSFIEDL	2700
		ARLESVEVNSMLTISEEALQLATISSFNGDGYNFTNVLGVSVDPA GRVVQKRSFIEDL	
US_Col	841	ARLESVEVNSMLTISEEALQLATISSFNGDGYNFTNVLGVSVDPASGRVVQKRSFIEDL	900
125-10	2701	LFNKVVTNGLGTVDEEDYKRCNSGRSVADLVCAQYYSGVMVLPGVVDAEKLHMYASLIGG	2880
		LFNKVVTNGLGTVDEEDYKRCNSGRSVADLVCAQYYSGVMVLPGVVDAEKLHMYASLIGG	
US_Col	901	LFNKVVTNGLGTVDEEDYKRCNSGRSVADLVCAQYYSGVMVLPGVVDAEKLHMYASLIGG	960
125-10	2881	MVLGGFTSAAALPFSYAVQARLNYLALQTDVLQRNQQLLAESFNSAIGNITSAFESVKEA	3060
		MVLGGFTSAAALPFSYAVQARLNYLALQTDVLQRNQQLLAESFNSAIGNITSAFESVKEA	
US_Col	961	MVLGGFTSAAALPFSYAVQARLNYLALQTDVLQRNQQLLAESFNSAIGNITSAFESVKEA	1020
125-10	3061	ISQTSKGLNTVAHALTKVQEVVNSQGAALTQLTVQLQHNFQAISSSIDDIYSRLDILSAD	3240
		ISQTSKGLNTVAHALTKVQEVVNSQGAALTQLTVQLQHNFQAISSSIDDIYSRLDILSAD	
US_Col	1021	ISQTSKGLNTVAHALTKVQEVVNSQGAALTQLTVQLQHNFQAISSSIDDIYSRLDILSAD	1080
125-10	3241	VQVDRLITGRLSALNAFVAQTLTKYTEVQASRKLAQQKVNCEVKSQSQRYGFCGGDGEHI	3420
		VQVDRLITGRLSALNAFVAQTLTKYTEVQASRKLAQQKVNCEVKSQSQRYGFCGGDGEHI	
US_Col	1081	VQVDRLITGRLSALNAFVAQTLTKYTEVQASRKLAQQKVNCEVKSQSQRYGFCGGDGEHI	1140
125-10	3421	FSLVQAAPQGLLFLHTVLVPSDFVDVIAIAGLCVNDEIALTLREPGLVLFTHQLNHTAT	3600
		FSLVQAAPQGLLFLHTVLVPSDFVDVIAIAGLCVNDEIALTLREPGLVLFTHQLNHTAT	
US_Col	1141	FSLVQAAPQGLLFLHTVLVPSDFVDVIAIAGLCVNDEIALTLREPGLVLFTHQLNHTAT	1200
125-10	3601	EYFVSSRRMFEPKPTVSDFVQIESCVVTVYNLTRDQLPDVIPDYIDVNKTLDEILASLP	3780
		EYFVSSRRMFEPKPTVSDFVQIESCVVTVYNLTRDQLPDVIPDYIDVNKTLDEILASLP	
US_Col	1201	EYFVSSRRMFEPKPTVSDFVQIESCVVTVYNLTRDQLPDVIPDYIDVNKTLDEILASLP	1260
125-10	3781	NRTGPSLPLDVFNATYLNLTGEIADLEQRSESLRNTTEELQSLIYNINNTLVDLEWLN RV	3960
		NRTGPSLPLDVFNATYLNLTGEIADLEQRSESLRNTTEELQSLIYNINNTLVDLEWLN RV	
US_Col	1261	NRTGPSLPLDVFNATYLNLTGEIADLEQRSESLRNTTEELQSLIYNINNTLVDLEWLN RV	1320
125-10	3961	ETYIKWPWWVWLIIFIVLIFVVSLLVFCCISTGCCGCCGCCACFSGCCRGPRLPYEVF	4140
		ETYIKWPWWVWLIIFIVLIFVVSLLVFCCISTGCCGCCGCCACFSGCCRGPRLPYEVF	
US_Col	1321	ETYIKWPWWVWLIIFIVLIFVVSLLVFCCISTGCCGCCGCCACFSGCCRGPRLPYEVF	1380
125-10	4141	EKVHVQ	4158
		EKVHVQ	
US_Col	1381	EKVHVQ	1386

65/66

FIG. 4

Group least square mean $\pm$ standard error anti-PEDV-IgG S:P ratios for D-1, 14, 28 and 49.



66/66

FIG. 5

Group least square mean $\pm$ standard error anti-PEDV-IgA S:P ratios for D-1, 14, 28 and 49.

